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i 
 
Abstract 
 
 
Article 27.3(b) of the Agreement on Trade-related Aspects of Intellectual Property Rights 
1994 allows its Signatories to exclude „animals‟ from patent protection within national patent 
laws. While the exclusion of „animal varieties‟ is contained in s13(1)(b) of the Malaysian 
Patents Act 1983, the meaning of the term which represents the exclusion, and, therefore, the 
excluded subject matter, is unclear. A question arises as to how the country should interpret 
the exclusionary provision in the context of the flexibility under Article 27.3(b). This thesis 
answers the question in the light of the growing demand for animal protein-based food from 
Malaysians, which proves difficult to meet from within existing production methods. 
Therefore, animal biotechnology has been identified by the Malaysian Government as a 
pertinent tool to reduce costly imports of livestock products. Underpinned by doctrinal 
approach, the thesis assesses two models of interpretation within the international patent law 
framework: the permissive and restrictive approaches. The former arises from narrowly 
construing the term „animal varieties‟ under Article 53(b) of the European Patent Convention 
which results in permissively enabling patenting for animal inventions which would be 
excluded under a broad legislative construction arising from the interpretation of the term 
„invention‟ under s2 of the Canadian Patent Act 1985. The implications of both approaches 
on the livestock industry are assessed so as to identify a suitable model which would promote 
the progression of the Malaysian animal biotechnology sector, and ultimately secure the 
supply of the livestock products for the population. Underpinned by the argument that patent 
protection is a pertinent factor in encouraging innovation and investment, this thesis argues 
that the permissive approach is the most practical approach for Malaysia to adopt for 
interpreting the exclusion of animal inventions under s13(1)(b). This thesis provides a test 
case for other developing countries which also exclude animal inventions within their 
national patent laws, and have a similar economic template to Malaysia, enabling them to 
appreciate how the exclusion can be construed in pursuing their economic priorities.  
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1 
 
INTRODUCTION 
 
This thesis focuses on the unpatentability of animal inventions. Under patent law, an 
invention is patentable if it is new, if it involves an inventive step, and if it is industrially 
applicable (the patentability criteria). In addition an invention must not fall under any 
excluded categories recognised by the patent system. Within the international patent law 
framework, Article 27.1 of the Agreement on Trade-related Aspects of Intellectual Property 
Rights 1994 (the TRIPs Agreement)
1
 spells out the rule of patentability whereas Article 27.3 
provides a list of subject matter which may not be patentable.
2
 In particular, Article 27.3(b) 
allows Signatories to the TRIPS Agreement to exclude animal inventions under their national 
patent laws.
3
 Nevertheless, the TRIPs Agreement does not define the term „animals‟ which 
represents the exclusion. As a result, a Signatory has a wide discretion to determine the 
meaning of the term which is adopted in the exclusionary provision, and therefore, whether or 
not animal inventions are patentable under its patent system. 
 
In particular, this thesis studies the exclusion of animal inventions from the Malaysian patent 
protection legislation, specifically s13(1)(b) of its Patents Act 1983 (Malaysian Patents Act 
1983).
4
 Malaysia is a Signatory to the TRIPs Agreement, hence its status as a Member State 
                                                          
1
  Available at: WTO, http://www.wto.org/english/docs_e/legal_e/legal_e.htm#TRIPs (Accessed: 8 April 
2011).  
2
  See Appendix 4. 
3
  Other matters which may be excluded by Member States are diagnostic, therapeutic and surgical methods for 
the treatment of humans or animals, and plants. While also being living matter, micro-organisms are 
patentable due to the recognition of their ability to fulfil the patentability criteria. Other subject matters 
mentioned here are, however, not covered by this thesis.  
4
Act 291. Available at: World Intellectual Property Organization (WIPO), 
http://www.wipo.int/wipolex/en/text.jsp?file_id=128826 (Accessed: 28 March 2012). Section 13(1) states: 
„Notwithstanding the fact that they may be inventions within the meaning of section 12, the following shall 
not be patentable: (b) plant or animal varieties or essentially biological processes for the production of plants 
or animals, other than man-made living micro-organisms, micro-biological processes and the products of 
such micro-organism processes; Provided that this paragraph shall not apply to products used in any such 
methods.‟ In turn, s12 provides the meaning for an „invention‟ as: „an idea of an inventor which permits in 
practice the solution to a specific problem in the field of technology.‟ 
2 
 
of the World Trade Organization (WTO), since 1 January 1995.
5
 In this respect, the existence 
of the exclusion of animal inventions in s13(1)(b) of the Malaysian Patents Act 1983 
corresponds with Article 27.3(b) of the TRIPs Agreement. This thesis is motivated by the fact 
that while „animal varieties‟ are excluded from patent protection under s13(1)(b), but the term 
is not defined by the Malaysian Patents Act 1983. So far, the exclusion has yet to be 
interpreted by the Intellectual Property Organisation of Malaysia (MyIPO) or the Malaysian 
courts. Consequently, within the context of national patent law, it is not clear what subject 
matter is excluded by the exclusionary term, nor what implications arise from any intended 
construction.  
 
Yet as far as Malaysia and other Signatories are concerned the flexibility under Article 27.3(b) 
necessitates an answer as to how to construe the exclusion while observing their international 
obligations under Article 27.1, which also requires that patents be made available to any 
inventions which fulfil the patentability criteria irrespective of the fields of technology. In the 
context of international patent law, a Signatory which is deemed to be failing to accord 
protection to animal inventions, may be considered in breach of its obligations under Article 
27.1, notwithstanding that there is no definitive international standard of interpretation with 
regard to the exclusion of animal inventions. This implication is particularly relevant in view 
of potential bilateral agreements which maybe entered into between Signatories to the TRIPs 
Agreement where a country may impose a condition on the other contracting country that 
patent protection be made available to animal inventions irrespective of the flexibility under 
Article 27.3(b).
6
 As a result, the „failure‟ of the latter country may expose it to trade sanctions 
which arise from the dispute settlement mechanism, used by the WTO so as to promote 
international compliance with trade-related rules, including patent law principles such as 
                                                          
5
  WTO: Members and observers, http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm (Accessed: 
1 April 2011). 
6
  This point is elaborated further in sub-section 2.2.3 of chapter 2. 
3 
 
Article 27.1.
7
 In view of this adverse consequence, it is pertinent that a Signatory such as 
Malaysia should be able to justify its decision on how the exclusion is to be interpreted within 
national patent law. 
 
In this Introduction chapter the following aspects are identified, and justification for each is 
advanced: the research questions of the thesis, the methodological approach to answer the 
questions, the context of assessment of the questions, the two opposite legal approaches 
which are adopted and assessed to answer the questions, the relevance of the European and 
Canadian materials to the questions, the audience of the thesis, the contribution of the thesis, 
the limitations of the thesis, and potential future work. The chapter ends with an overview of 
the organisation of the thesis where pertinent points argued by each chapter of the thesis, so 
as to answer the research questions set forth, are highlighted. 
 
Given the vague aspects identified in the context of the Malaysian patent law, and the 
importance of clarifying the issues, this thesis aims to answer the following two questions: 
firstly, how can the exclusion of animal varieties under s13(1)(b) of the Malaysian Patents 
Act 1983 be construed; and secondly, which of the existing approaches within the 
international patent law framework, either (1) the permissive approach; or (2) the restrictive 
approach, is the most practical for Malaysia to adopt in the light of the problems and needs of 
its livestock industry. 
 
The research questions are answered by assessing two opposite legal approaches, which are 
identified as being relevant to Malaysia by their effect on the industry that they regulate. In 
essence, this thesis adopts a doctrinal approach (specifically, a comparative methodological 
                                                          
7
WTO, Understanding the WTO – settling disputes, 
http://www.wto.org/english/thewto_e/whatis_e/tif_e/disp1_e.htm (Accessed: 15 June 2012). 
4 
 
approach based in an industry impact analysis). Primary and secondary sources are engaged 
to analyse the benefits and disadvantages of the interpretations to existing legal provisions 
relating to the exclusion of animal inventions, and to identify their impact on the livestock 
industry.  
 
Overall, the endeavour to answer the research questions of this thesis is underpinned by an 
enquiry-based learning (EBL) approach.
8
 In essence, driven by a process of enquiry, the 
approach emphasises the gathering, understanding and evaluating of relevant information 
relating to an issue which is to be investigated. The knowledge obtained is then applied to the 
identified issue or problem in order to achieve a reasonable solution.
9
 As there is no one 
solution to the problem, the EBL allows a researcher to present his or her conclusions based 
on a range of evidence which support his or her views.
10
 These key features of the EBL are 
utilised by this thesis in reaching the conclusions at the end of the study. 
 
The focus on the Malaysian livestock industry (agricultural) as the context of assessment of 
the law is for a number of reasons. In the light of the growing number of (and demand from) 
the population, developing countries place great emphasis on increasing production, and 
improving quality, of agricultural products (including livestock) for the purpose of feeding 
their inhabitants.
11
 Agricultural research has, therefore, been one of the main tools to achieve 
these aims.
12
 Being a developing country, Malaysia has a similar emphasis. In this respect, 
                                                          
8
  For detailed information about the EBL approach, see for instance, T. Barrett, I.M. Labhrainn and H. Fallon 
(eds), Handbook of enquiry and problem based learning, http://www.aishe.org/readings/2005-
2/contents.html (Accessed: 28 March 2012); T. Deignan, Enquiry-based learning: perspectives in practice 
(2009) 14 Teaching in Higher Education, 1, 13-28.  
9
  ibid. 
10
  ibid. 
11
  Food and Agriculture Organization of the United Nations (FAO), What should be the role and focus of 
biotechnology in the agricultural research agendas of developing countries? 
http://www.fao.org/biotech/C8doc.htm (Accessed: 28 March 2012). 
12
  ibid. 
5 
 
the Malaysian National Biotechnology Policy 2005
13
 explicitly underlines agricultural 
biotechnology for development, as agriculture has been the backbone of the country‟s 
economy since long before its independence.
14
 Livestock has itself been an important 
commodity which contributes to the country‟s income and is a source of protein for the 
population. In tandem with the National Biotechnology Policy, animal biotechnology 
applications have been widely utilised in research involving livestock animals in higher 
learning and public research institutions in the country. The research aims at increasing the 
output and enhancing the quality of the livestock. The effort is underpinned by the aspiration 
of the Malaysian Government to reduce the country‟s dependency on imports so as to meet 
the growing demand of the population due to the insufficiency of the main livestock products. 
Imports cost the government a substantial expense, and are increasing every year. For these 
reasons, any implications arising from the interpretation of s13(1)(b) which involve animal 
inventions (including livestock obtained from modern animal biotechnology) are particularly 
significant, given the need to: (1) adequately supply animal protein-based food to Malaysians; 
and (2) develop relevant technology and products. 
 
While Malaysia has the liberty to formulate its own interpretation, this must be done in 
consequence of an understanding of the options available. This thesis engages two 
international models of interpretation for analysis: the permissive approach (which is adopted 
by the European patent system), and the restrictive approach (which is adopted by the 
Canadian patent system). According to Article 53(b) of the European Patent Convention 2010 
                                                          
13
Available at: Malaysian Biotechnology Information Centre, 
http://www.bic.org.my/?action=localscenario&do=policy (Accessed: 3 December 2009). For full details of 
the Policy, see Appendix 1. 
14
  Healthcare and bioremediation are two other sectors for development under the Policy. „Bioremediation‟ 
means: „the use of biological agents, such as bacteria or plants, to remove or neutralize contaminants, as in 
polluted soil or water‟. See http://www.thefreedictionary.com/bioremediation (Accessed: 14 June 2012). 
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(EPC),
15
 European patents shall not be granted to „animal varieties or essentially biological 
processes for the production of animals‟.16 Nevertheless, „microbiological processes and the 
products thereof‟ are not excluded from patentability. 17  Notwithstanding the prohibition 
against animal varieties, patent claims for animal inventions have been allowed by the 
European Patent Office (EPO) through the only „animal variety‟ case to date, namely the 
Harvard/Onco-mouse.
18
 Underpinning the decision is that Article 53(b) is an exception to the 
general rule of patentability
19
 (that an invention is patentable if it fulfils the patentability 
criteria), which should be given a very narrow application.
20
 Adopting this rule, the EPO 
decided in the case that the transgenic mice, which had been genetically engineered to make 
them susceptible to cancer, were not a „variety‟ within the meaning of the exception, thus the 
invention was patentable. Conversely, the Canadian patent system chooses to take a different 
stand in dealing with the patentability of living things. In the case of Harvard College v 
Canada (Commissioner of Patents) (Harvard Mouse)
21
 (similarly being the only case within 
the country‟s patent law jurisdiction where the patentability of animal inventions was at 
issue), the claim to patent the transgenic mouse was refused by the Canadian Supreme Court. 
The genetically engineered mouse was held not to be patentable because, unlike inanimate 
matter which can be invented by an inventor, higher life forms were deemed to be incapable 
                                                          
15
  Available at: EPO, http://www.epo.org/law-practice/legal-texts/epc.html (Accessed: 3 June 2011). 
16
  ibid. See Appendix 5.  
17
  ibid. 
18
  Transgenic Animals/Harvard, T 315/03, Decision of Technical Board of Appeal, 6 July 2004; Onco-
mouse/Harvard, Decision of the Opposition Division 7 November 2001, Official Journal of the EPO, 
October 2003, 473; Harvard V 0006/92, Examining and Opposition Divisions, Official Journal of the EPO 
1992, 589; Harvard T 0019/90, Technical Board of Appeal, Official Journal of the EPO 1990, 476; Harvard 
V 0004/89, Examining and Opposition Division, Official Journal of the EPO 1989, 451.  
19
  Article 52(1) of the EPC. 
20
  This rule is elaborated further in sub-sections 3.2 and 3.3 of chapter 4. 
21
  [2003] 5 LRC 330; [2002] SCC 76; [2002] 4 SCR 45; [2000] 4 FC 528; [1998] 3 FC 510; Decision of the 
Commissioner of Patents dated 4 August 1995. Available at Canadian Intellectual Property Office (CIPO), 
http://brevets-patents.ic.gc.ca/opic-
cipo/comdec/eng/decision/933/summary.html?query=933+%3cin%3e+comdecnumber&start=1&num=10  
(Accessed: 4 May 2010). 
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of constituting an „invention‟ within the meaning of the term „invention‟ under s2 of the 
Canadian Patent Act 1985 (Canadian Patent Act 1985).
22
  
 
In the context of Article 27.3(b) which allows Signatories to the TRIPs Agreement to exclude 
animal inventions under their national patent laws, the converse approach demonstrates how 
Signatories to the Agreement have, so far, decided on the implementation of the flexibility. 
Therefore, in essence, the term „permissive approach‟ used throughout this thesis refers to the 
position adopted by the EPO. It denotes the ease with which an inventor may obtain patent 
protection for animal inventions (as products) in the EPC Member States, notwithstanding the 
explicit exclusion of animal varieties under Article 53(b) of the Convention. Conversely, the 
term „restrictive approach‟ is exemplified in the context of the position adopted under the 
Canadian Patent Act 1985. It refers to the unpatentability of animal inventions under 
Canadian patent law, despite the absence of express statutory exclusion. The focus on the two 
approaches is because they represent the archetypal polar opposite approaches which has 
been explored both judicially and legislatively, providing invaluable guidance on how 
Malaysia could construe its s13(1)(b).  
 
While it was mentioned earlier that this thesis focuses on the food industry, it is notable that 
the permissive and restrictive approaches arise from the decisions which pertain to a health-
related invention. This thesis adopts the view that both of the approaches are extendable to 
livestock animals derived from modern biotechnology for two reasons: (1) Article 53(b) of 
the EPC and s2 of the Canadian Patent Act 1985 (within which the patentability of animal 
inventions is interpreted) are general patent law provisions;
23
and (2) the decisions of the 
                                                          
22
  Patent Act, R.S.C, 1985, c.P-4. Available at: Department of Justice Canada, http://laws-
lois.justice.gc.ca/eng/acts/P-4/index.html (Accessed: 13 October 2011). 
23
  M.W. Tvedt, Patent protection in the field of animal breeding (2007) 57 Acta Agriculturae Scand Section  A, 
106. 
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Harvard/Onco-mouse and Harvard Mouse were reached from an extensive consideration of 
patent law principles relating to animal patenting. Therefore, notwithstanding the specific 
subject matter which was at issue in the cases, arguably the two approaches derived from 
them are similarly applicable to farm animals.
24
 In addition, it is worth noting that there is not 
so far any decision involving farm animals per se.   
 
The relevance of the European and Canadian materials to the research questions requires 
some explanation. Malaysia is not a Member State of the EPC. However, its patent law 
originated from the UK‟s patent system. Being a Member State of the EPC, the UK courts are, 
in principle, constrained to adopt the decisions of the EPO in interpreting the unpatentability 
of „variety of animal‟ in paragraph 3(f) of Schedule A2 of the UK Patents Act 1977.25 
Therefore, based on the principle of judicial precedence, the European materials become 
relevant to Malaysia through the adoption of the EPO decision by the UK courts. As regards 
the Canadian materials, similar to Malaysia, Canada is a commonwealth country whose 
system of law derived from English Law. Therefore, while not binding, the materials are also 
of highly persuasive value to the Malaysian courts in construing the exclusion of animal 
varieties in s13(1)(b).
26
 
 
While the exclusion of animal inventions was adopted by Article 27.3(b) at the conclusion of 
the General Agreement on Tariffs and Trade (GATT) Uruguay Round Meeting (Uruguay 
Round Meeting),
27
 it was the subject of review within the WTO four years after the TRIPs 
Agreement came into effect in 1995. Underpinning the review is the continuing contrasting 
                                                          
24
  ibid. 
25
  Available at: UK Intellectual Property Office (UKIPO), http://www.ipo.gov.uk/patentsact1977.pdf 
(Accessed: 30 May 2011). For the provision see Appendix 9. Prior to the amendment in 2000, the provision 
was contained in s1(3) of the Act. The relationship between the jurisprudence of the UK and European 
Board is further discussed in sub-section 3.1.1 of chapter 5. 
26
  This point is further elaborated in chapters 3, 4 and 5 of the thesis. 
27
  The Meeting spans the period from 1986 to 1994. 
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perception of developed and developing countries as to the patentability of the invention.
 28
 
So far, the review has not yet achieved any definite answer as to whether the exclusion of 
animal inventions should remain in, or otherwise be removed from, the TRIPs Agreement. 
This situation shows the importance of the issue, and also the complexities of the problem to 
be resolved. As already identified, while the issue of the unpatentability of animal inventions 
has been legally developed at the international patent law level, the implications of the 
existing interpretation to a given industry have not yet been explored in Malaysia. As such 
this thesis is also important in identifying the issues that Malaysia has to take into 
consideration in construing s13(1)(b) in the light of the minimum requirement  to grant patent 
protection under Article 27.1. Therefore, its decision on how narrowly or broadly to construe 
the exclusionary provision is informed by current international legal developments, and thus 
can be firmly defended. For these reasons, the thesis also analyses pertinent issues debated 
during the review process of Article 27.3(b), namely the patentability of life forms (including 
animal inventions), access and transfer of technology, and the requirement to disclose the 
source, and country of origin of genetic material used in animal inventions. In the context of 
the research questions, the analysis allows an evaluation as to whether or not developing 
countries such as Malaysia should consider allowing patent protection to animal inventions 
based on at least three factors: (1) the country‟s technological development; (2) the nature of 
the country being a technology-user (rather than exporter); and (3) the socio-economic impact 
arising from the lack of protein-based animal products. The assessment also identifies the 
implications of the mandatory disclosure requirement to a patent applicant and, more broadly, 
the progress of the animal biotechnology and livestock industry.
29
  
 
 
                                                          
28
  Issues relating to the review process are dwelt upon in detail in chapter 2. 
29
  ibid. 
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The central aspect of the thesis is that it analyses the implications of the permissive, and 
restrictive approaches to the development of animal biotechnology applications and the 
livestock industry so as to permit the identification of a suitable model which would promote 
the industrial development determined to be most appropriate in Malaysia. The assessment 
discloses that the political, economic and industrial perspective of the comparable regions 
(Europe and Canada) toward animal patenting conforms to the approach which each has 
adopted. In the context of the research questions, the approach which allows the progression 
of research and development (R&D) activities, animal biotechnology and livestock industry 
is proposed for adoption by Malaysia. 
 
While the interpretation of the term „animal varieties‟ under s13(1)(b) directly benefits 
Malaysian judicial authorities and patent examiners in deciding the patentability of animal 
inventions, the thesis aims at a broader audience. Firstly, Malaysian policy makers and 
drafters of the law need to know the implications of the legal term used and whether or not it 
carries the purpose of the exclusion intended by legislature. The thesis provides an appraisal 
if any amendment is necessary to the existing provision. Secondly, clarification of aspects 
relating to the term „animal varieties‟ is also useful to legal practitioners in advising their 
clients who intend to file a patent application with the MyIPO. Finally, the creation of the 
inventions involves inventors and investors. As the process to develop inventions is time-
consuming and requires huge investment, these parties would be interested to know if their 
inventions will be protected or their investment could be recouped under the Malaysian 
patent system.  
 
It was identified earlier that this thesis builds on the existing construction of the permissive 
and restrictive approaches, rather than developing a novel interpretation to answer the 
11 
 
research questions. The EPO and some critics have argued their points on how the term 
„animal varieties‟ under Article 53(b) of the EPC is to be construed. In turn, the Canadian 
Supreme Court has adopted a purely legal approach to decide on the unpatentability of animal 
inventions. However, so far no one has tested the existing construction within an 
exclusionary provision in national patent law and economic policy pertaining to the livestock 
industry of a particular country. This thesis fills this gap in two respects. By analysing the 
EPO and Canadian Supreme Court decisions, and the critics of the respective decisions, the 
thesis identifies the strengths and weaknesses of the previous arguments, so as to assess their 
defensibility and implications for the specific national and economic policies of a country. 
Practically, while the context of Malaysia is being studied, the thesis provides guidance for 
other developing countries which similarly exclude „animal varieties‟ or „animals‟ in their 
national patent laws, but have not decided how the exclusion is to be legally interpreted.
 30
 In 
particular, the thesis provides a test case for those countries which have a similar economic 
template to Malaysia with which to appreciate how the exclusionary provision can be 
construed in pursuing their economic priorities. 
 
Of necessity, this thesis has certain limitations. Firstly, while the unpatentability of animal 
varieties in s13(1)(b) is being studied, the narrower focus of this thesis is on product patents 
rather than process patents.
 31
 This is because process patents are not an issue within patent 
                                                          
30
  For instance, see s62(b) of the Sri Lanka Intellectual Property Act No 36 of 2003; s3(j) of the Indian Patents 
Act 1970 (39 of 1970); Article 25 of the China Patent Law of the People's Republic of China 1984; and 
s22.4 of the Intellectual Property Code of the Philippines 1997 (Republic Act No 2893). All the statutes are 
available at: WIPO, http://www.wipo.int/wipolex/en/ (Accessed: 28 March 2012). 
31
  A patent could be described in a number of ways depending on how it is perceived: (1) it may be described 
by authorities issuing the patent. For instance, in Europe, there are two types of patents namely the European 
patent which has a national patent effect (including in non-European Union (non-EU) countries) and the 
Community patent which will be effective only in all EU countries once it is implemented; (2) they may be 
classified based on the subject matter that they protect, such as a biotechnological patent (inventions related 
to the biotechnology sector) or a technological patent (which relates to mechanical inventions); and (3) by 
looking at the nature of the interest that is protected. In this way patents can be divided into three types 
namely a process patent, a product patent and a product-by-process patent. A process patent gives protection 
to activities or actions (methods, processes or uses). It can either be methods or processes involved in the 
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law in Malaysia or in most countries, since processes are explicitly recognised as patentable 
subject matter. As a result, patents are normally allowed by patent offices for their intrinsic 
ability to fulfil the patent qualification criteria.  
 
Secondly, ethical issues which are highly debated when animal patenting is discussed are 
beyond the scope of the thesis. Intrinsically, this is because the unpatentability of animal 
inventions under s13(1)(b) relates to the question of whether or not animal inventions are 
patentable subject matter. These are different from the question of whether animal inventions 
ought to be patentable or not on ethical grounds. In support of this contention, s13(1)(b) is 
distinct from the moral-related legal provision contained in s31(1) of the Malaysian Patents 
Act 1983.
32
  
 
Finally, this thesis confines its assessment to the implications of the two adopted approaches 
being analysed for the livestock industry‟s food production. The implications for other 
sectors where animal biotechnology is also involved (such as healthcare and bioremediation) 
are not considered. This limitation is based on the fact that each industry involves distinct and 
unique challenges, problems and issues to be solved. Consequently, it is beyond the scope of 
this work, which is directed to providing value for policy makers and the legislature to assess 
the most practical interpretation of the legal exclusion of animal inventions from patent 
protection in the context of the livestock industry (specifically as food). This aims to 
                                                                                                                                                                                    
production of an invention, or methods of using products. The latter is also known as a method of use patent 
(an example of this could be a claim to a new use using something which is already known). A product 
patent as the name suggests, gives protection to the product that is produced (and this includes „selection 
patents‟ on chemicals). A product-by-process patent gives protection to a product which can only be 
described by its method of production. See the detailed account on this in L. Bently and B. Sherman, 
Intellectual property law (Oxford University Press, 2009) 365-368.  
32
  Section 31(1) states: „The grant of a patent shall not be refused and a patent shall not be invalidated on the 
ground that the performance of any act in respect of the claimed invention is prohibited by any law or 
regulation, except where the performance of that act would be contrary to public order or morality‟. Similar 
moral-related provisions are provided in Article 27.2 of the TRIPs Agreement and Article 53(a) of the EPC. 
See Appendices 4 and 5, respectively, for the provisions. The Canadian Patent Act has no moral-related 
provision. 
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determine if it is necessary for the law to be amended, or for any provisions in the existing 
patent law related documentation or guidelines to be introduced, so as to clarify the law. In 
future work, empirical research to investigate (for instance): (1) the perceptions of Malaysian 
scientists and animal biotechnology companies on the importance of patenting animal 
inventions for the development of R&D activities; and (2) the views of industrial 
stakeholders on the implications of the exclusion for the interests of investors in the 
Malaysian animal biotechnology sector, are the aspects which would be useful for expanding 
the understanding of the law. 
 
This thesis consists of six chapters. Chapter One reviews the industrial context of the thesis. 
It identifies the need to secure animal-protein based sources for the growing demand from 
Malaysians, but the long-term problem of self-sufficiency level for main livestock products. 
Modern animal biotechnology applications and animal biotechnology food have been 
identified as a pertinent tool to solve the problem. However, it is unclear how the technology 
and product are to be legally regulated in the context of the exclusion of animal varieties 
under s13(1)(b) of the Malaysian Patents Act 1983. Chapter Two assesses the flexibility to 
exclude animal inventions from national patent law within the international patent law 
framework as underlined by Article 27.3(b) of the TRIPs Agreement. Mainly, it identifies 
issues and implications which are pertinent for a Signatory (including Malaysia) to consider 
in interpreting the relevant national exclusionary provision. Chapter Three assesses s13(1)(b) 
of the Malaysian Patents 1983. It identifies the ambiguity, minimal development and 
application of the provision within the Malaysian patent law, and therefore, the justification 
for the research. Chapter Four analyses the first model of construing the exclusion of animal 
varieties namely the permissive approach and its implications on the livestock industry. 
Chapter Five analyses the second model of construing the exclusion of animal varieties 
14 
 
namely the restrictive approach and its implications on the livestock industry. In the light of 
the needs and problems faced by the Malaysian livestock industry (identified in chapter 1), 
the Discussion and Conclusion chapter evaluates the permissive and restrictive approach so 
as to identify the legal approach which would resolve the problem and permit the 
development of animal biotechnology and products. The approach is proposed to Malaysia 
for adoption so as to construe the exclusion of animal varieties under s13(1)(b). Pertinent 
points argued by each chapter toward answering the research questions are highlighted here. 
  
Chapter One examines and assesses the global and Malaysia‟s livestock industries, and 
animal biotechnology applications to enhance the industry. The focus is on identifying the 
development, challenges and expectations that Malaysia has toward its animal biotechnology, 
and livestock sector. It is identified that animal biotechnology applications have a huge 
potential to increase production and high quality output which are the aims of developing 
countries, including Malaysia. While there are concerns from consumers pertaining to the 
safety of animal biotechnology food
33
 for human health and the environment, the chapter 
demonstrates that there is ample scientific evidence to refute the concern. Most importantly, 
the chapter identifies that Malaysia is facing a long-term problem in achieving a self-
sufficiency level for all main livestock commodities, notwithstanding the on-going efforts to 
meet the growing demand and specific needs of the population. Mainly, this is due to 
challenges which are beyond human control, such as livestock and aquatic diseases, and 
constraints of animal and fish feed. Notably, the Malaysian Government has made it explicit 
that animal biotechnology applications are to be fully utilised in order to develop the 
livestock industry, hence, fulfilling the relevant demand and need. The chapter argues that 
animal biotechnology and animal biotechnology food provide Malaysia with a solution to 
                                                          
33
  Throughout this thesis, the term „animal biotechnology food‟ refers to animals which are intended to be used  
for food and produced through modern animal biotechnology techniques including genetic engineering and 
cloning. 
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resolve the problem identified here. Therefore, the question as to how the exclusion of animal 
inventions under s13(1)(b) of the Malaysian Patents Act 1983 is to be construed (either 
narrowly or broadly), is to be guided by this parameter. 
 
Chapter Two examines Article 27.3(b) of the TRIPs Agreement with two aims. Firstly, to 
identify the rationale underpinning the flexibility for Signatories either to exclude animal 
inventions under the national patent system, or not. Secondly, to identify and assess the 
international issues relating to the exclusion under the review process of the provision. It is 
disclosed that the flexibility is the result of the different perspectives of the negotiating 
countries toward the patentability of animal inventions, due to their diverse technological and 
economic development. Developed countries such as the US, Japan and Australia have been 
of the view that patent protection is necessary for the dissemination of knowledge, for 
encouraging innovation and for increasing trade.
34
 Conversely, developing countries consider 
animals as unpatentable on the grounds that they are discoveries rather than inventions. The 
chapter contends that the retention of the exclusion under Article 27.3(b) is necessary and 
important so as to allow developing countries to interpret the flexibility according to their 
national priorities which they wish to pursue. This includes a decision on how narrowly or 
broadly the exclusion is to be construed. Nevertheless, in the context of the thesis, the chapter 
asserts that patent protection for animal inventions should be considered by developing 
countries which intend to exploit animal biotechnology applications in enhancing their 
livestock industry for the purpose of securing the supply of livestock products for the 
population. This is provided that the countries have the technological ability to adapt the 
technology transfer from developed countries. In this respect, developing countries are 
                                                          
34
  See for instance GATT, „Draft Agreement on the Trade-Related Aspects of IPRs: Communication from the 
US‟, Document MTN.GNG/NG11/W/70 (11 May 1990) Article 23, 9; WTO, „Review of the provisions of 
Article 27.3(b): Summary of issues raised and points made‟, Document IP/C/W/369/Rev.1 (9 March 2006) 4. 
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contrasted with the least-developed countries (LDCs) which would struggle to benefit from 
strengthening their patent protection due to low technological development.  
 
One of the pertinent arguments of developing countries during the review process was that 
the disclosure of the source and country of origin of genetic material used in animal 
inventions is to be made mandatory under Article 27.3(b). The chapter identifies the potential 
burden to patent applicants to fulfil the condition due to the difficulties in ascertaining the 
two aspects which are caused mainly by the prevalent practice of the trans-boundary 
movement of animal livestock. This would pose an unnecessary hurdle to obtain patent 
protection for animal inventions, discourage interest to innovate, and adversely affect the 
progression of technology. Finally, while there is no definitive rule as to how the exclusion of 
animal inventions under national patent laws is to be construed, the chapter argues that the 
examination and assessment of the permissive and restrictive approaches (in chapters 4 and 5, 
respectively) is the most appropriate way of dealing with the issue. Since the existing two 
models for interpreting the exclusion of animal inventions are within the international patent 
law framework, any choice of interpretation made by a Signatory (including Malaysia) 
cannot be easily challenged. 
 
Chapter Three examines s13(1)(b) of the Malaysian Patents Act 1983 which contains the 
exclusion of animal varieties so as to identify the clarity and legal development of the 
provision. Examination of the legislative history of the provision discloses that the exclusion 
was included under the Malaysian Patents Act 1983 mainly to bring the country‟s patent law 
as close as possible to the provisions of international patent law text. This is important given 
the aim of the country being to participate in the international patent law arena (by becoming 
a signatory and a member state of patent law conventions and organizations, such as the Paris 
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Convention, and the World Intellectual Property Organization (WIPO), respectively. This 
aim is designed to ensure that the commercial interest of local inventors is secured globally, 
in view of the country‟s shift of economy from agriculture to industry between the 1980s and 
the mid-1990s. Nevertheless, the parliamentary proceedings of the Malaysian Patents Bill 
1983 disclose that the exclusion was not extensively debated or thoroughly considered. The 
minimal deliberation leads to the conclusion that the meaning of „animal varieties‟ was not at 
all weighed by the legislature in the light of scientific advancement to create animal 
inventions. This, together with the absence of application of the exclusion so far by the 
MyIPO or judicial authorities, renders the legal position of the exclusion in the country vague. 
Therefore, this research is justified. In the context of the thesis, the chapter contends that any 
interpretation to be given to s13(1)(b) is to be guided by the needs and problems of the 
country‟s livestock industry identified in chapter 1. 
 
Chapter Four examines and assesses the first model of interpretation adopted by the thesis, 
namely the European-wide permissive approach. It exemplifies the narrow construction of an 
exclusionary provision which results in permissively enabling patenting for animal inventions 
that would be excluded under a broad legislative construction. The chapter shows that the 
exclusion of animal varieties under Article 53(b) of the EPC is largely influenced by the 
existence of the same exclusion in its predecessor; Article 2(b) of the Convention on the 
Unification of Certain Points of Substantive Law on Patents for Invention 1963 (Strasbourg 
Convention).
 35
 In turn, the need for consistency between the two Conventions is underpinned 
by the aim of creating a unified patent system for the European Union (EU) Member States. 
Through this, the EU aspires to compete economically with the US and Japan, which are the 
two key players in the international patent law scene. Notwithstanding the long existence of 
                                                          
35
  Available at: Council of Europe (COE), http://conventions.coe.int/Treaty/en/Treaties/Html/047.htm 
(Accessed: 30 June 2011). 
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the exclusion of animal varieties in the European Patent Convention the intended meaning, 
purpose, and subject matter of the exclusion are all unclear. As Article 53(b) relates to the 
question of whether or not animal inventions fall under the term „animal varieties‟ 
(unpatentable), its interpretation becomes pertinent. In the final decision on the case of the 
Harvard/Onco-mouse it was held that the exclusion is to be narrowly construed. In particular, 
only species are to be excluded. Genetically engineered animals, being classified as sub-
species, are not barred from patent protection. The chapter asserts that underpinning the 
narrow construction is the recognition that animal inventions which could fulfil patent 
qualification criteria should be given the necessary patent protection. This is logical given the 
fact that, unlike plant varieties, which are similarly excluded from the patent system under 
Article 53(b), but which would be entitled to a sui generis
36
 protection under the International 
Convention for the Protection of New Varieties of Plants (UPOV Convention),
37
 animal 
inventions would be without any legal protection if a patent is not granted to them. 
Eventually, the development of the technology (and thereby the growth of the livestock 
industry) will be adversely affected as there would be a lack of incentive to inventors to 
innovate. In the context of the thesis, the chapter argues that the permissive approach 
develops animal biotechnology applications and the livestock industry. This is because, 
through patent protection for livestock animals derived from modern biotechnology, investors 
would be attracted to invest in the technology, and the relevant R&D activities. The 
regulatory framework to assess the pre-market safety of animal biotechnology food which are 
already in place in Europe support the advancement of the technology further through the 
potential marketability of the products in the region.  
                                                          
36
 Latin expression which means: „of its own kind‟. See http://www.thefreedictionary.com/sui+generis 
(Accessed: 17 August 2009). 
37
  The Convention was adopted in Paris on 2 December 1961 and came into force on 10 August 1968. It has 
been revised on 10 November 1972, 23 October 1978 and 19 March 1991. Available at: International Union 
for the Protection of New Varieties of Plants, http://www.upov.int/index_en.html (Accessed:  11 April 2011). 
The Convention gives protection to plant varieties which are new, distinct, homogenous and stable.  
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Chapter Five examines and assesses the second model of interpretation adopted by the thesis 
namely the Canadian restrictive approach, in comparison with the permissive approach 
adopted in Europe. Contrary to the EU policy which aims to promote animal biotechnology 
applications to ensure the sustainable production of livestock production, Canada has adopted 
a more pessimistic view. This is evidenced by the country‟s negative political stance toward 
animal patenting as disclosed during the negotiations of the TRIPs Agreement and the 
reluctance of the government to regulate the marketability of animal biotechnology food. It 
has also been identified that while some animal biotechnology applications have been 
adopted in R&D activities involving livestock animals in Canada, none is directed toward the 
creation of transgenic livestock animals. Pessimistic consumers‟ opinion toward the product 
has been identified both in Europe and Canada. Nevertheless, unlike in Europe where the 
decision to utilise animal biotechnology in full is based on its importance to secure food 
production, the public view has been a pertinent impetus toward the Canadian Government‟s 
unenthusiastic policy. From the legal perspective, the chapter shows that the Canadian 
Supreme Court decision to refuse patent protection to the transgenic mouse in the case of 
Harvard Mouse (for its failure to qualify under any of the categories of invention under s2 of 
the Canadian Patent Act 1985), conforms to the government policy on the issue. Specifically, 
it is demonstrated that the Supreme Court decision shows a lack of legal reasoning because of 
the Court‟s own recognition that patent prerequisites are met, and that the transgenic mouse 
(or animal inventions generally) can be categorised under the term „art‟, „manufacture‟ or 
„composition of matter‟ under s2. Underpinned by the argument that patent protection is a 
pertinent factor in encouraging innovation and investment, it is contended that the lack of 
patent protection for animal inventions per se in Canada adversely affects animal 
biotechnology, and consequently the livestock industry. 
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The Discussion and Conclusion chapter concludes the whole thesis. Bringing forward the 
analyses in the foregoing chapters, an evaluation is made of whether Malaysia should adopt 
the permissive or restrictive approach in construing the exclusion of animal varieties in 
s13(1)(b) of the Malaysian Patents Act 1985. The thesis argues that in order for Malaysia to 
resolve the problem of a self-sufficiency level of all main livestock products, and in the light 
of the aspirations and investment made by the government to develop the animal 
biotechnology sector, it should adopt the permissive approach. Through an evaluation of the 
restrictive approach, the chapter stresses certain points. Firstly, only the permissive approach 
can secure the investment and technology transfer which is required by Malaysia to develop 
its animal biotechnology and livestock industry. Secondly, Malaysia‟s national policies 
relating to the technology are in tandem with the EU policies which warrant the adoption of 
the latter‟s legal approach. Thirdly, the permissive approach corresponds with the 
international obligations imposed by Article 27.3(b) of the TRIPs Agreement on its 
Signatories where an invention which fulfils patent qualification criteria is to be patentable. 
Fourthly, the granting of patent to animal inventions does not prejudice Malaysia‟s interests 
under other international conventions such as the Convention on Biological Diversity 1992 
(CBD)
38
 which it ratified. Fifthly, the refusal to grant patents to animal inventions would 
leave such inventions without any legal protection, which would adversely affect the progress 
of the technology. Sixthly, patent protection to animal inventions per se is pertinent as other 
forms of protection would not adequately protect the commercial interests of an inventor. 
Finally, in the context of animal biotechnology relating to the livestock industry, an argument 
that the licensing of patents would hinder technology transfer to developing countries is 
determined to be premature for Malaysia to consider, as more advanced applications are still 
                                                          
38
  Available at: CBD, http://www.cbd.int/doc/legal/cbd-en.pdf (Accessed: 31 March 2012). 
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at the research stage. Conversely, the refusal to allow patents on animal inventions would 
cause a more crucial socio-economic problem as animal-protein based food for the population 
cannot be secured. The chapter ends by a proposal that there is no requirement that s13(1)(b) 
of the Malaysian Patents Act 1983 be amended. The exclusion of „animal varieties‟ in the 
exclusionary provision is to be narrowly interpreted so as not to exclude transgenic or cloned 
animals for food purposes from patent protection. Section 12 of the Malaysian Patents Act 
1983 on the meaning of the term „invention‟ supports this construction. Nevertheless, it is 
suggested that the Guidelines for Patent Examination of MyIPO clarify the Malaysian legal 
position by introducing two provisions. Firstly, a provision which allows patent protection be 
granted, not only to the process of production of an animal invention, but also to the product 
itself. Secondly, a provision to the effect that an animal invention is patentable provided it 
meets the patentability criteria. 
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CHAPTER ONE 
 
THE MALAYSIAN LIVESTOCK INDUSTRY AND ANIMAL BIOTECHNOLOGY 
APPLICATIONS: EXPECTATIONS AND CHALLENGES 
 
1. Introduction 
      
The world food-price crisis between 2007 and 2008 demonstrates the far-reaching 
implications of an inconsistency between production and demand for food by the world‟s 
population. The crisis has caused economic concerns at national level where costs of major 
crops such as rice, wheat, corn and soybean, increased drastically.
1
 Socially, food-related 
riots and demonstrations took place in many countries across the globe such as Haiti, Egypt, 
Philippines, Cameroon and others.
2
 Various factors accumulatively contributed to the crisis. 
Among others are the rapid increases of oil and energy prices, bad weather which caused low 
harvests
3
 and the decrease of global grain stockpiles caused by growing demand for animal 
feed.
4
 The last of these has been associated with the global growing consumption of livestock 
products such as beef, pork, poultry, eggs and dairy products, especially in developing 
countries.  
 
Livestock and its products are closely related to human lives and have been contributing to 
human livelihood for decades as sources of food, income, employment and various other 
purposes. With the growth of the human population which is projected by the United Nations 
                                                          
1
  Cereals prices rose 21% in the International Monetary Fund (IMF) market indices in 2006, 31% by 2007 and 
49% by the first half of 2008. See World Food Programme, Food out of reach: pathway to the financial crisis, 
http://www.wfp.org/photos/gallery/food-crisis-timeline (Accessed: 22 November 2010). 
2
Global crisis as food prices soar, The Star, 14 April 2008, 
http://thestar.com.my/news/story.asp?file=/2008/4/14/focus/20942898&sec=focus (Accessed: 22 November 
2010). 
3
  In 2005, crops in Russia and Ukraine were reportedly struck by drought while Australia underwent its worst 
dry season in many years. See World Food Programme, n 1 above. 
4
  ibid. 
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(UN) to reach 9.2 billion by 2050,
5
 the livestock sector worldwide is facing constant 
challenges to meet the increasing demand. For many countries in the world, especially 
developing and LDCs, the key challenge facing their national livestock industry is how to 
increase the livestock output to meet the population‟s needs. Conversely, the focus of 
industrialised countries has been moving toward producing quality livestock products
6
 rather 
than meeting self-sufficiency levels.  
 
Human intervention in the livestock industry has aimed to achieve two most important 
objectives, namely high production and quality yields. Commencing with traditional selection 
methods, advances in biotechnology have brought a new revolution to the industry. Modern 
breeding technologies such as artificial insemination,
7
 multiple ovulations followed by 
embryo transfer,
8
deoxyribonucleic acid (DNA)-based marker-assisted selection
9
 and 
synchronisation of oestrus
10
 have allowed the production of larger numbers of offspring and a 
greater rate of precision in fertilisation.
11
 Apart from these breeding techniques, there is 
                                                          
5
  Food and Agriculture Organization of the United Nations (FAO), The state of food and agriculture: livestock 
in the balance, 2009, http://www.fao.org/docrep/012/i0680e/i0680e.pdf (Accessed: 26 November 2010) vi. 
The world‟s population in 2010 is 6.9 billion. See UN, World population prospects: the 2008 revision 
population database, http://esa.un.org/unpp/p2k0data.asp (Accessed: 26 November 2010). 
6
  M. Mazzocchi, C. Brasili and E. Sandri, Trends in dietary patterns and compliance with World Health 
Organization recommendations: a cross-country analysis (2007) 11 Public Health Nutrition, 5, 539. 
7
  Means: „introduction of semen into the uterus or oviduct by other than natural means‟. See 
http://www.merriam-webster.com/dictionary/artificial%20insemination (Accessed: 25 March 2011). 
8
  The process involves: (1) treating female livestock animals with hormones to increase the number of eggs at 
ovulation; (2) artificial insemination of the cow; (3) the flushing of the embryos (non-surgically, using a 
catherer placed into the uterus); and (4) the implantation of the embryos in recipient livestock animals. See 
http://www.biotopics.co.uk/edexcel/biotechnol/supovu.html (Accessed: 25 March 2011). 
9
  DNA is an abbreviation for Deoxyribonucleic acid. It means „a nucleic acid which carries the genetic 
information in the cell of all organisms‟. See http://www.thefreedictionary.com/DNA (Accessed: 15 March 
2011).  
10
  Means: the synchronisation of mating interest in livestock animals by methods such as injection of hormones. 
See http://medical-dictionary.thefreedictionary.com/Estrus+synchronization (Accessed: 25 March 2011). 
11
  M.B. Wheeler, Agricultural applications for transgenic livestock (2007) 25 Trends in biotechnology, 5, 204-
210; J.F. Garcia, M.R.S. Fortes, L.R. Porto-Neto and P.J. Boettcher, Achievement of research in the field of 
molecular genetics: recent molecular genetics achievements and unfolding applications to livestock, 53-62 in 
A. Rosati, A. Tewolde and C. Mosconi (eds), WAAP Book of the year 2007: a review on developments and 
research in livestock systems (Wageningen Academic Publishers, 2009); R.H. Phipps and A. Cockburn, GM 
technology: a tool to benefit livestock production, 247-257 in E. Owen, T. Smith, M.A. Steele, S. Anderson, 
A.J. Duncan, M. Herrero, J.D. Leaver, C.K. Reynolds, J.I. Richards, J.C. Ku-Vera (eds), Responding to the 
livestock revolution (Nottingham University Press, 2004). 
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considerable research and practical evidence which have shown the potential of genetic 
engineering
12
 and somatic cell nuclear transfer (SCNT) (cloning)
13
 techniques in producing 
yields of intended traits involving animals of different species. This is a fundamental 
achievement which was not possible before from the use of traditional breeding. As a result, 
modern biotechnology is one of the tools which, has been identified
14
 as able to play an 
important role in assisting the livestock industry, not only to increase production, but also to 
improve genetic traits to produce livestock of high quality. The dual ability of modern 
biotechnology could fulfil the objectives of the livestock industry in countries worldwide.  
 
The difference between traditional and modern breeding lies in the techniques involved. In 
traditional breeding, livestock animals are „genetically altered‟ through crossbreeding and 
selection techniques.
15
 Crossbreeding involves the mating of animals which belong to 
different breeds, whereas selection technique entails the selection of superior parents to 
produce generations of similar or even better quality, such as livestock with superior fertility 
and better adaptation to environmental changes. While both methods involve natural breeding 
processes, they differ from the fact that human intervention is involved in the latter. 
Comparing the selection technique with genetic engineering methods, while humans play a 
                                                          
12
  Modern biotechnology began in 1970s with the two basic techniques of recombinant DNA technology 
(genetic engineering) and hybridoma technology. In genetic engineering technology, also referred to as gene 
splicing, genetic material from an external source is inserted into a cell in such a way that it causes the 
production of desired protein by the cell. In hybridoma technology, different type of immune cell are fused 
together to form a hybrid cell line producing monoclonal antibodies. See P. Grubb, Patents for chemicals, 
pharmaceuticals and biotechnology: fundamentals of global law, practice and strategy (Oxford: Oxford 
University Press, 1999) 225. 
13
  Cloning in livestock animals was introduced in livestock breeding programmes in the 1980s. The SCNT 
process has been successfully performed in livestock species such as cattle, sheep, pigs and goats. The most 
well-known livestock animal produced using this method is perhaps „Dolly the sheep‟. See A.L. van 
Eenennaam, What is the future of animal biotechnology (2006) 60 California Agriculture, 3, 133. 
14
  ibid. The promises of modern biotechnology for food security have also been recognised by many critics 
from developing countries. See for instance, N.J. Tonukari and D.G. Omotor, Biotechnology and food 
security in developing countries (2010) 5 Biotechnology and Molecular Biology Reviews, 1, 13-23; N. Ozor 
and E.M. Igbokwe, Roles of agricultural biotechnology in ensuring food security in developing societies 
(2007) 6 African Journal of Biotechnology, 14, 1597-1602. 
15
  A. Christie and N. Peace, Intellectual property protection for the products of animal breeding (1996) 18 
European Intellectual Property Review, 4, 214. 
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significant role in both, the manipulation of genetic traits at molecular level in the latter 
technique signifies a more fundamental involvement of humans in determining the output of 
the process. Notwithstanding the underlying promises, biotechnology has raised various 
concerns. It is interesting to note that scientists, being practitioners of the technology, are not 
all agreed about the advantages of biotechnology. Due to the „invasive‟ procedures which are 
involved, products of the technology have been associated with various issues, which call for 
regulatory frameworks at national and international level. Of particular importance are the 
potential environmental hazards and risks to human health. At the international level, these 
aspects have been regulated by the Cartagena Protocol on Biosafety to the Convention on 
Biological Diversity 2000 (Cartagena Protocol).
16
  
 
This chapter identifies the expectations of the Malaysian livestock industry and highlights the 
challenges that have been limiting the industry in meeting the population‟s demand. Based on 
the analyses of the two aspects, a solution to resolve the on-going problem of self-sufficiency 
levels for the main livestock products, within the country, will be proposed. While Malaysia‟s 
context is the one that is being examined, the global dimension will be considered in giving a 
comparative situation for relevant aspects under discussion.      
 
Towards this end, this chapter is divided into seven sections. Section 2 explains the 
importance of the livestock industry to Malaysia and the aspiration of the government to 
maximise the use of animal biotechnology applications to develop the industry. In addition, 
biotechnological applications which have so far been adopted by the industry will be 
examined in order to identify whether all methods, or only certain ones, have been applied. 
The section gives the background to the country‟s expectations of the industry and 
                                                          
16
  Available at: Convention on Biological Diversity (CBD), http://bch.cbd.int/protocol/text/ (Accessed: 3 June 
2011). 
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technology. The extent of the technological application further demonstrates the level of 
knowledge and expertise currently available in the country. Notwithstanding the application 
of animal biotechnology, there have been various concerns arising from it. Therefore, since 
the success of any technology would ultimately depend on consumers‟ willingness to invest 
their money, public concerns about the products of biotechnology at international level, and 
in Malaysia, will be examined in section 3. As regards Malaysia, it will be seen if the 
concerns have led to opposition to the technology and its products. Apart from that, as 
livestock animals (including those genetically altered) are subject to trans-boundary 
movement for various purposes, the problems and benefits of the Cartagena Protocol which 
governs issues relating to the movement will be assessed. Despite the concerns that 
consumers may have, similar to the global trend, the Malaysian livestock industry has to meet 
the growing and specific demands from its population. Therefore, section 4 examines the 
trends in consumption and production, and the changing trend of consumers‟ and nations‟ 
preference for livestock products. This is followed by section 5 which investigates some of 
the challenges faced by the livestock industry and the implications which they have caused to 
Malaysia. Based on the information contained in the preceding sections, section 6 will 
identify the potential of animal biotechnology applications to resolve the problem (faced by 
Malaysia) as identified in section 5. Section 7 concludes the chapter. 
 
This chapter sets the context to the thesis. An understanding of how animal biotechnology 
applications could assist Malaysia to meet the demands of its consumers and resolve the 
problems of its livestock industry is important. It functions as a guiding parameter for the 
country (and also other developing countries with similar economic interests) in deciding 
how the law on the patenting of animal inventions should be regulated. Since the application 
27 
 
of animal biotechnology in the Malaysian livestock industry is pertinent to this thesis, its 
development should be first understood. 
 
2. The Malaysian animal biotechnology industry: aspirations and development 
 
Agriculture has been the backbone of Malaysia‟s economy since long before its independence 
on the 31
st
 August 1957. Although between the 1980s and the mid-1990s, the country‟s 
economy experienced a shift from an agricultural to an industrial basis, agriculture remains 
one of the key economic drivers. There are various national policies which have been in place 
to support the industry. Of particular importance is the Third National Agricultural Policy 
(Malaysian Agricultural Policy) which broadly aims to maximise the country‟s income by 
optimal usage of resources in the sector.
 17
 A specific objective of the Policy includes the 
increase of food production (in view of the growth in demand), reduction of imports and 
increase of exports. To this end, numerous efforts have been planned and adopted by the 
government to develop the livestock and fisheries industries.  
 
While the initial decision to develop the biotechnology field in Malaysia was announced in 
1991, the earnest intention to develop the sector could be said to be fairly new. The 
Malaysian National Biotechnology Policy
18
 evidenced the government‟s commitment to 
promote the technology as a key new economic sector. In this regard, three areas of 
development have been identified: (1) agricultural biotechnology; (2) healthcare 
biotechnology; and (3) industrial biotechnology.
19
 The importance of the first of these is 
explicable by the fact that the agricultural sector has been one of the main sources of income 
                                                          
17
  Ministry of Agriculture and Agro-Based Industry Malaysia, Third National Agricultural Policy (1992-2010), 
http://moa.gov.my/web/guest/dpn3 (Accessed: 3 December 2010). 
18
  See Appendix 1. 
19
  ibid. 
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for the country for a long time. Within this, „Thrust 1‟ of the Policy aims at „total utilisation 
of biotechnology to transform and enhance the value creation of the agricultural sector‟.20  
 
Animal biotechnology research in Malaysia has been undertaken by various research and 
higher learning institutions for decades. In tandem with the aspiration to harness 
biotechnology for the development of the agricultural sector (including the livestock and 
fisheries industries), the Malaysian animal biotechnology industry is working towards this 
end. The progress of animal biotechnology in Malaysia can be divided into two stages: (1) the 
application stage; and (2) the research stage. The application of animal biotechnology in 
Malaysia‟s livestock sector is limited. The country has not yet produced any transgenic 
livestock or fisheries products, as developed countries have. This is not surprising given that 
research in animal science in developed countries started more than 200 years ago, compared 
to only a few decades ago in developing countries.
21
 As regards modern breeding techniques, 
unlike most North American and western European countries which have widely applied 
technologies such as embryo transfer and molecular genetics technologies, the only technique 
which has been widely applied in Malaysia is artificial insemination.
22
 The method is 
particularly important in increasing the usefulness of superior sires, hence, a greater number 
of offspring can be produced within the same period, compared to natural breeding methods. 
Nevertheless, the use of other reproductive biotechnological techniques such as gamete and 
                                                          
20
  ibid. 
21
  A. Waters-Bayer and W. Bayer, Research to alleviate poverty in the face of industrialisation of livestock 
production, in E. Owen et al, n 11 above, 191. 
22
  This practice corresponds with the practice by other developing countries due to the affordability of the 
technology compared to other modern breeding techniques. In fact, the technique has been the most 
popularly used in all regions in the world: Africa, Asia, Europe, Latin America and the Caribbean, Near and 
Middle East, North America and Southwest Pacific (55% to 100% usage), compared to two other 
biotechnologies namely embryo transfer (10% to 100%) and molecular genetics technologies (11% to 100%). 
See D. Pilling, R. Cardellino, M. Zjalic, B. Rischkowsky, K.A. Tempelman and I. Hoffmann, The use of 
reproductive and molecular biotechnology in animal genetic resource management – a global overview 
(2007) Animal Genetic Resources Information, 40, 3; FAO, The state of capacities in animal genetic 
resources management: reproductive and molecular biotechnology, 2007, 
ftp://ftp.fao.org/docrep/fao/010/a1250e/a1250e.pdf  (Accessed: 17 December 2010) 265-266. 
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gene manipulation for the production of sexed embryos,
23
 embryo transfer and embryo 
cryopreservation are already at the research stage.
24
 Other focuses include molecular markers 
for identification of important traits such as disease resistance and heat stress tolerance, 
production of cheaper livestock feed and seed production techniques for the aquaculture 
industry.
25
 
 
In Malaysia, the application of animal biotechnology and its commercialisation is most 
notable in the production of several vaccines against livestock diseases such as Newcastle 
and Fowl Pox diseases for the poultry industry.
26
 In order to promote innovation, the 
government has been encouraging research institutions and individual scientists to apply for 
patent protection for newly developed biotechnological inventions.
27
 It is pertinent to note 
that some higher learning institutions and public research institutes have been filing patent 
applications, locally and internationally, (for example) for DNA sequences encoding for 
various proteins and vaccines, and animal feed. Some of the applications have been granted 
while others are awaiting examination.
28
  
  
                                                          
23
  Means: „the determination of the sex of an embryo before birth‟. FAO, http://www.fao.org/glossary/spec-
term-n.asp?id_glo=4151&id_lang=TERMS_E (Accessed: 14 April 2012). 
24
  K. Yusoff, Biotech R&D scenario in Malaysia, http://www.eumbio.org/papers/BFS/R&D%20Scenario.pdf 
(Accessed: 17 December 2010); Malaysian Biotechnology Corporation, Overview: Malaysian agricultural 
biotechnology, http://biotechcorp.inventgw.com/wp-
content/uploads/2011/11/publications/White_Paper_Agricultural.pdf (Accessed: 17 December 2010); 
Malaysian Biotechnology Information Centre, Biotechnology in Malaysia, 
http://www.bic.org.my/?action=localscenario&do=biotechnology (Accessed: 17 December 2010). 
25
  ibid. 
26
  Putra University of Malaysia, Commercialized products, http://www.vet.upm.edu.my/eresearch5.html 
(Accessed: 17 December 2010). 
27
  More local inventions: scientists and researchers to get good payouts from Government, The Star, 23 June 
2009, http://thestar.com.my/news/story.asp?file=/2009/6/23/nation/4175423&sec=nation (Accessed: 17 
December 2010). 
28
  Science University of Malaysia, http://cserver.cs.usm.my/patent/Search_Patent.aspx (Accessed: 17 
December 2010); Putra University of Malaysia, Faculty of Agriculture: Facts and figures, 
http://www.rmc.upm.edu.my/upmip/index.php?content=faculty&fac=1 (Accessed: 9 January 2012); 
Malaysian Agricultural Research and Development Institute, IP status, http://www.mardi.my/web/guest/ip-
status (Accessed: 9 January 2012). 
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It can be concluded from this section that Malaysia has the technological knowledge and 
ability to utilise modern animal biotechnology. For this reason, it has been actively 
encouraging and embarking upon various biotechnology techniques in diverse areas of 
animal research. While the production of transgenic
29
 livestock animals, as already achieved 
by international animal biotechnology research, is still a long way off, the country‟s 
expectations from its animal biotechnology sector are at least clear; they should contribute 
toward the enhancement of food production so as to reduce the country‟s dependence on 
imports of food.  
 
Notwithstanding this aim, consumers‟ acceptance of genetically modified (GM) livestock and 
their products is paramount for the products to reach the market. Owing to this, the following 
section identifies concerns of consumers in order to appreciate the challenges embracing the 
technology and products. Similar to livestock animals derived from traditional breeding, their 
GM counterparts are subject to trans-boundary movement. Internationally, the implications of 
the movement for the environment and human health are regulated by the Cartagena Protocol. 
Therefore, the next section will also analyse the problems and benefits of the Protocol in 
regulating the subject matter. It will be shown that the various concerns of consumers are 
refutable by evidence of the safe use of animal biotechnology food. If any, the concern is 
adequately addressed by the Cartagena Protocol. The discussion is important to the research 
questions so as to show the position of animal biotechnology food within the society and to 
appreciate whether or not concern arising from its potential use is justifiable. 
 
 
 
                                                          
29
  Means: „an organism which has had genes from another organism in its genome through genetic engineering 
techniques‟. See http://www.biology-online.org/dictionary/Transgenic (Accessed: 25 March 2011). 
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3. Animal biotechnology food: consumers‟ concerns and protection of interest 
 
3.1 Concern about animal biotechnology food: the opposing views 
 
Consumers‟ concerns about animal biotechnology food are two-fold: their effects on health 
and the environment. As regards the former, the safety for consumption of products of cloned 
livestock products has been the focus of many studies. For instance, in a study
30
 on 
perceptions of consumers toward cloned cows‟ milk, it was discovered that in the first 
instance, consumers showed similar interest for the branded full-priced product and the 25-
percent-discount product which used a biotechnology process. However, the purchase interest 
dropped for the latter when consumers were informed that the product came from cloned 
cows. However, the study also made an important conclusion that consumers‟ scepticism 
could be improved by education and information as to its benefit.
31
 In a recent collaborative 
study by a group of scientists,
32
 it has been concluded that cloned cattle show no biological or 
biochemical differences in their meat and milk composition compared to non-cloned cattle. 
Notably, the US Food and Administration (USFDA)
33
 had also recently published that meat 
and milk from cloned cattle, pigs and goats, and the offspring of all clones are as safe to eat 
as food from conventionally bred animals. The conclusion is achieved based on data obtained 
from rigorous risk assessment pertaining to implication of the food to human health.
34
 
                                                          
30
  L.J. Butler, M.M. Wolf and S. Bandoni, Consumer attitudes toward milk products produced from cloned 
cows (2008) 39 Journal of Food Distribution Research, 1, 35. 
31
  ibid. 
32
  X. Yang, X.C. Tian, C. Kubota, R. Page, J. Xu, J. Cibelili and G. Suidal Jr, Risk assessment of meat and 
milk from cloned animals (2007) 25 Nature Biotechnology, 1, 82. 
33
  US Department of Health and Human Services, FDA issues documents on the safety of food from animal 
clones, 15 January 2008,  
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116836.htm (Accessed: 12 
March 2012). 
34
  ibid. The USFDA had earlier called for a voluntary prohibition on the marketing of milk or meat from 
cloned livestock animals and their offspring, despite the report from the Food and Drug Administration 
(FDA) Centre for Veterinary Medicine which indicated their safety for consumption. It had been reported 
that further data relating to the composition of meat and milk from clones and their progeny and also the 
32 
 
 
One of the potential uses of genetic engineering is the alteration of animals‟ growth rate. In 
the aquaculture sector, the technology has been applied to the production of Atlantic salmon. 
The growth hormone from Chinook salmon and eel-like ocean pout which was inserted into 
an Atlantic salmon enabled it to grow the whole year. The modification means the transgenic 
fish can grow faster than its non-transgenic counterpart of the same age, which normally 
stops growing in the winter. So it needs a shorter time to reach the market. While concerns 
over their safety for human health are also relevant for this product, opposition has been 
mainly on the threat that they could pose to the survival of native salmon due to the high 
possibility that they would escape from farms and pens. The concern is not without basis as 
studies have pointed in this direction. For example, a study by Purdue University, on the fast-
growing of Japanese Medaka, a fish species which is used as a research model, has reported 
three important findings:
35
 (1) the four-fold higher mating rate from its smaller-sized 
competitors could result to rapid domination of the altered genes in place of the wild stocks; 
(2) the 30% non-surviving potential of the transgenic fish before reaching sexual maturity; 
and (3) due to production of non-surviving offspring, it only requires 0.001% of the 
transgenic fish to eradicate the population of 60,000 wild fish.
36
 In view of possible risks of 
these nature, Aqua Bounty Farms, the applicant in the case of transgenic Atlantic Salmon, has 
given repeated assurances that the risks could be overcome by farming the transgenic fish in 
inland pools, and that only sterile females would be sold,
37
 hence avoiding cross-breeding.  
 
                                                                                                                                                                                    
health status of the progeny has been required, in order to convince consumers. See A.L.van Eenennaam, n 
13 above, 132. 
35
  W.M. Muir and R.D. Howard, Fitness components and ecological risks of transgenic release: a model using 
Japanese Medaka (Oryzias latipes) (2001) 158 The American Naturalist, 1, 11-13. 
36
  ibid.  
37
  ibid. 
 
33 
 
Similar concern involving transgenic Atlantic salmon has been observed in the UK, where 
Scotland is the largest producer of farmed Atlantic salmon in the EU.
38
 In 1995, a pilot scale 
growth trial project for breeding transgenic Atlantic salmon
39
 was held at Loch Fyne. This 
trial caused considerable controversy. In a debate concerning the potential and risks of GM 
crops in the UK‟s Parliament in 1999, concern over the probable risks that the transgenic 
Salmon would cause to the wild populations was highlighted.
40
 Due to the concerns, all the 
transgenic fish at Loch Fyne were destroyed at the end of the trial period, with no further 
trials since then. Subsequently, the use of transgenic fish in Scotland‟s aquaculture industry 
was forbidden by the Code of Good Practice for Scottish Finfish Aquaculture 2006.
41
 A 
similar rejection of its production has been voiced by the Scottish Salmon Producers‟ 
Organization and the International Salmon Farmers‟ Association. 42  In relation to this, 
opposition in the US to the marketing of transgenic fish from restaurant owners, consumers‟ 
associations, and environmentalists have also been reported.
43
 
 
Notwithstanding the concerns and opposition demonstrated here, salmon has notably been 
cited as one of the favourite fish in developed countries, apart from tuna and striped bass.
44
 
Unfortunately, according to the World Wide Fund (WWF),
45
 the number of salmon has 
significantly reduced from 800,000 to 80,000 over the last 25 years. Over-fishing has been 
identified as one of the factors which have been contributing to the decrease in the supply of 
                                                          
38
  North Atlantic Salmon Conservation Organization (NASCO), „Focus area report: aquaculture, introductions 
and transfers, and transgenics, United Kingdom (Scotland)‟, 2010, 4. 
39
  ibid. 8. 
40 UK Parliament: Lords Hansard, „Genetic Modification in Agriculture: ECC Report‟, 
http://www.publications.parliament.uk/pa/ld199899/ldhansrd/vo990527/text/90527-08.htm (Accessed: 19 
November 2010). 
41
  ibid. 
42
  NASCO, n 38 above, 8. 
43
  R. Black, Push to have GM salmon approved, BBC News, 24 March 2004, 
http://news.bbc.co.uk/1/hi/sci/tech/3565041.stm (Accessed: 18 November 2010). 
44
  D. Cressey, Future fish, Nature, 2009, 458, 399. 
45
A. Kirby, Atlantic salmon in short supply, BBC News, 31 May 2000, 
http://news.bbc.co.uk/1/hi/sci/tech/769646.stm (Accessed: 20 December 2010). 
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fisheries worldwide.
 46
 Improvements to many aspects of fisheries production have long been 
practised worldwide; these include the use of modern equipment for finding fish and 
sophisticated trawls and fishing nets.
47
 While these methods are effective in increasing 
fisheries production, each would require considerable cost, and if ineffectively managed may 
cause substantial damage to the environment. In the context of these potential issues, 
increasing the growth rate of the fish appears to be a viable option. 
 
Concerns for human health through consumption of GM fish include the potential production 
of toxins or allergens due to the insertion of foreign genes and transfer of pathogens. 
Nevertheless, there is not yet any conclusive evidence in terms of the potential risks of the 
transgenic salmon to human health.
48
 Notably, the risk of biotechnological aquaculture to 
human health has been described by the Food and Agriculture Organization of the United 
Nations (FAO)
49
 as „circumscribed and minor‟ because, in the fisheries sector, the most 
common gene construct involves a growth hormone gene derived from fish, hence avoiding 
allergic problems caused by a foreign gene.
50
 Many other studies have concluded that the 
consumption of transgenic fish shows no adverse implications for health.
51
 For instance, a 
study
52
 has reported that mice which were feed with transgenic fish, demonstrated no 
negative implications for growth performance, reproduction capacity and biochemical 
analysis of blood.  
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FAO, Overfishing on the increase in Asia-Pacific seas, 2004, 
http://www.fao.org/newsroom/en/news/2004/49367/index.html (Accessed: 22 March 2011). 
47
  ibid. 
48
  See for instance observation in R.S. Rasmussen and M.T. Morrissey, Biotechnology in aquaculture: 
transgenics and polyploidy (2007) 6 Comprehensive Reviews in Food Science and Food Safety, 12; P. Aerni, 
Risk, regulation and innovation: the case of aquaculture and transgenic fish (2004) 66 Aquatic Science, 335. 
49
  FAO, The state of world fisheries and aquaculture, 2000, 
http://www.fao.org/DOCREP/003/X8002E/x8002e05.htm#P30 (Accessed: 22 March 2011) 74. 
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  ibid. 
51
  See for instance G. Wu, Y. Sun and Z. Zhu, Growth hormone gene transfer in common carp (2003) 16 
Aquatic Living Resources, 418-419; R.S. Rasmussen et al, n 48 above, ibid. 
52
  G. Wu et al, ibid. 419. 
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It has been widely accepted that environmental stewardship is pertinent to maintain the 
world‟s biodiversity. However, the contention that GM fish would adversely affect the 
ecology should not be generalised given that there has been evidence to the contrary.
53
 The 
minimal risks to ecology are supported by the observation that transgenic Atlantic salmon are 
less careful in avoiding predators.
 54
  As a result, they are less likely to survive in the wild.
55
 
It has been concluded in a study
56
 that the risks to ecology brought about by transgenic coho 
salmon would depend on the availability of food in the wild environment. The study shows 
that, only when there is an abundance in food due to the low density of the population could 
the transgenic fish, which is stronger, affect its wild counterpart.
57
 Nevertheless, in case of 
low availability of food, it is their inability to stand long periods of starvation caused by the 
growth hormone which could result in their elimination. For these reasons, the potential harm 
caused by GM fish should not be exaggerated, and their potential should not be rejected 
outright. The two most important concerns relating to the transgenic fish, namely its possible 
escape to the open sea and mating with its wild counterparts can be addressed by the 
approving authority. They include imposing mandatory compliance with the relevant 
conditions such as requiring the breeding process to be made onshore and the sterilization of 
the GM fish, as already undertaken by Aquabounty. Logically, compliance with the inland 
breeding requirement would automatically address the mating issue. If these conditions could 
be fulfilled by an applicant, there is no reason why the potential of animal biotechnology 
should be wasted in assisting the growing demand of livestock and aquaculture products from 
the world‟s population. 
                                                          
53
  See for instance T. Reichhardt, Will souped salmon sink or swim? (2000) 406 Nature, 12; R.H. Devlin, M. 
D‟Andrade, M. Uh and C.A. Biagi, Population effects of growth hormone transgenic coho salmon depending 
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In the case of Malaysia, one might argue that it is premature to anticipate the Malaysian 
perceptions of animal biotechnology food when efforts to produce them are not yet on the 
Malaysian animal biotechnology agenda. Nevertheless, in the light of the country‟s serious 
commitment to exploit animal biotechnology applications,
 
and the approval already granted 
to transgenic crops
58
 the possibility of producing animal biotechnology food in the future 
would make the discussion relevant.  
 
In the absence of any animal biotechnology food produced in the country so far, some 
responses from the public to the use of biotechnology involving plants and hormone could 
shed some light as to their attitude toward this increasingly important field of science.  
Malaysians‟ perceptions of three biotechnology applications have been assessed in a study.59 
They are GM soy beans,
60
 GM insulin,
61
 and GM palm oil.
62
 In terms of perceived benefit 
and risks, the study found that the last of these was regarded as the most beneficial and the 
least risky, followed by GM insulin and GM soybean. While all applications clearly involve 
human manipulation, the study suggested that GM palm oil was regarded as having the least 
impact since there was no intra- or inter-species gene transfer.
63
 When comparing GM palm 
oil with GM soybean (where both relate to human consumption) the higher acceptance of the 
former could be based on the perception of a product‟s direct benefit to their health. The 
disease-resistant feature of GM soybean appears not to fall into this category. Nevertheless, 
                                                          
58
  In Malaysia, there are five approved transgenic products namely Roundup Ready soybean, MON 810 maize, 
MON 863 maize and NK 603 maize for use in food, feed and processing, as well as ice structuring protein 
derived from a GM yeast, for use in ice-cream. See Malaysia Biosafety Clearing House, Country‟s decision, 
http://www.biosafety.nre.gov.my/country_decision.shtml (Accessed: 21 December 2010).  
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modern biotechnology applications, Proceedings of the 6
th
 WSEAS International Conference on 
Environment, Ecosystems and Development, 2008, 60-61. 
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  Which involve the transfer of human genes into the bacteria. 
62
  Which involve the modification of oil palm genes to reduce its saturated content. 
63
  L. Amin et al, n 59 above, 60. 
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in another study,
64
 it was reported that respondents who generally accept the promises of 
modern biotechnology perceive GM soybean as „more familiar, of low risks, beneficial and to 
be encouraged.‟ As far as Malaysians are concerned, the studies demonstrate two important 
points: (1) the public are not totally against modern biotechnology and its products; and (2) 
their acceptance would increase with their familiarity of the technology. In the context of the 
thesis, therefore, the Malaysian Government and industrial stakeholders should take 
advantage of these facts, by effectively educating the consumers of the benefits of animal 
biotechnology food. 
 
Malaysians perceptions to biotechnological products can also be inferred from the recent 
decision by the government to approve the trial release of genetically engineered sterile male 
Aedes aegypti mosquitoes in two areas in the country. The transgenic mosquitoes are meant 
to combat dengue disease by carrying a „fatal‟ gene, which, when they mate with female 
mosquitoes, would lead to unviable offspring. Notwithstanding the potential of this 
innovation, the public remains sceptical of this new proposed method of tackling the disease. 
Notably, criticisms have come from consumers‟ associations and environment-based non-
governmental organisations (NGOs). Most of the concerns relate to the efficiency of the 
control measures adopted by the applicant (the Institute for Medical Research Malaysia)
65
 in 
order to ensure complete removal of all the released mosquitoes and larvae at the end of the 
trial period. The opposition argued that failure to control this would mean adverse health and 
safety implications for humans.
66
 The concern could be understood, as bad handling of GM 
organism could have disastrous implications. For example, in the 1950s, researchers in Brazil 
imported African bees in their effort to create a hybrid population of bees which could 
                                                          
64
  L. Amin, J. Md Jahi, A.R. Md Nor, M. Osman and N.M. Mahadi, Uncovering factors influencing Malaysian 
public attitude towards modern biotechnology (2006) 14 Asia-Pacific Journal of Molecular Biology and 
Biotechnology, 2, 36. 
65
  A research institute under the Ministry of Health Malaysia. 
66
  ibid. 
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improve honey production and better adapt to tropical conditions.
67
 Unfortunately, some of 
the African bees were accidentally released from their confined environment and mated with 
European (local) bees, producing Africanized honey bees which are more aggressive than 
their local counterparts. The hybrid bees have spread since then from Brazil to many regions 
in the US, displacing European honey bees which have been bred for many years. As a result 
of their aggressiveness, they have been posing risks to the populations‟ health and safety.68 
 
Focussing back on the case of genetically altered mosquitoes in Malaysia, notwithstanding 
the concerns which arise, the potential of the technology involved is evidenced by the fact 
that similar experiments are currently on-going in many countries worldwide such as 
Colorado (the US), Thailand, Brazil and India, albeit all still at the stage of contained use 
experiments.
69
 It has been reported that Singapore and Vietnam are reviewing the same 
technology.
70
 The use of transgenic mosquitoes in Malaysia points to a pertinent direction. It 
indicates the seriousness of the issue at hand, and the less effective methods adopted so far.
71
 
According to the Malaysian Department of Biosafety, current efforts
72
 only manage to 
control 80% of dengue fever. 
73
 In evidence, between January and October 2010, 38,330 
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  G. Cambray, African bees – a solution to North America‟s bee problems? 
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  S. Param, GM mosquitoes could help save many lives, The Star, http://www.thestar.com.my (Accessed: 21 
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72
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73
  Ministry of Natural Resources and Environment Malaysia, Permohonan untuk kelulusan uji kaji lapangan 
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people were infected with dengue and 117 deaths were reported.
 74
 This was an increase from 
32,560 cases and 72 deaths over the same period in 2009.
75  
In view of these alarming 
statistics, the decision of the Government of Malaysia to approve the field trials is reasonable, 
in particular since the approval for the field trials was made without compromising the safety 
issues. It is important to note the strict terms and conditions for the certificate of approval. 
They include the requirements for consent from the relevant local councils where the release 
is to take place, an isolated location for the release sites, strict sex sorting procedures for the 
genetically and non-GM mosquitoes to ensure only male mosquitoes were released.
76
 Further, 
the Department of Biosafety was: (1) satisfied with the success of the laboratory trials and 
assurances of the safety of the trial by strict compliance with the committee‟s guidelines;77 
and that (2) the concerns (either scientific views or otherwise) voiced by all the NGOs
78
 
consulted prior to the field trial have been fully considered by the government before the 
decision to approve the same.  
 
This brings the discussion to another aspect of GM livestock animals and fish (which also 
relates to consumers‟ concern) namely the implications for the environment and human 
health due to their trans-boundary movement. The following sub-section analyses the 
problems and benefits of the Cartagena Protocol in regulating the potential risk. 
 
                                                          
74
  Buzz of GM mosquitoes still feared, http://www.asiaone.com (Accessed: 21 December 2010). 
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  ibid. 
76
  See detailed terms and conditions of the approval in National Biosafety Malaysia Board Decision, 
Application for approval for limited mark-release-capture of Aedes aegypti wild type and aedes aegypti 
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  Aedes mosquito experiment: too many risks involved, The New Straits Times, 6 September 2010. Malaysia 
has in place the Biosafety Act 2007 (Act 678) and the Biosafety (Approval and Notification) Regulations 
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3.2 The Cartagena Protocol: problems and benefits in regulating any potential risk to the 
environment and human health  
 
The Cartagena Protocol was negotiated with GM crops in mind.
79
 However, due to the 
general definition of the term „living modified organisms‟(LMOs) 80  the Protocol covers 
genetically engineered animals
81
 (including innovations
82
 such as GM livestock animals and 
fish). In recognition that LMOs may have an adverse effect on the conservation and 
sustainable use of biological diversity, including human health,
83
 the Protocol focuses on the 
trans-boundary movement of the LMOs.
 
It aims to ensure that they are safely transferred, 
handled and used.
84
 There are four categories of LMOs which are subject to the Protocol 
namely, LMOs: (1) intended for intentional introduction into the environment of the 
importing Party;
85
 (2) intended for direct use as food or feed, or for processing (LMOs-
FFP);
86
 (3) in transit; and (4) destined for contained use. Notwithstanding its noble objective, 
the Protocol has been subject to criticism. Therefore, pertinent aspects of the Protocol will be 
discussed, and their relevance to animal biotechnology food will be analysed. 
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  J.M. Marshall, The Cartagena Protocol and genetically modified mosquitoes (2010) 28 Nature 
Biotechnology, 9, 896. 
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  LMOs for intentional release to environment include seeds for planting, fish for release, and micro-
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modern biotechnology, (2001) 27 CANOPY International, 5, 7. 
86
  LMOs-FFP includes corn, soybeans, wheat or other grains, and animals meant to feed humans or animals. 
See G. Jaffe, n 81 above, 301. 
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3.2.1 The Advanced Informed Agreement Procedure (AIA Procedure)  
 
The AIA Procedure is the central feature of the Protocol. It is underpinned by the principle 
that the trans-boundary movement of LMOs from one country to another can take place only 
with the prior informed consent of the importing Party (to the Protocol). The principle 
reflects that the sovereign right of an individual Party over its territorial sea and land is 
recognised by the Protocol.
87
 In essence, the AIA Procedure requires the Party of export to 
notify its intention by providing required minimum information relating to the relevant 
LMOs.
88
 The importing Party has to acknowledge receipt of the notification in writing.
89
 
Failure to acknowledge should not be taken as consent.
90
 Any decision of the importing Party 
shall be in accordance with risk assessment procedures prescribed by the Protocol.
91
 The 
Party has options either to allow or refuse the import, or to request further information before 
making any decision.
92
 Where any condition is attached to a decision, reasons should be 
given for this.
93
 Again, failure of the importing Party to communicate its decision after 
evaluating the evidence of the potential risks of the LMOs does not constitute its consent to 
the intended trans-boundary movement.
94
  
 
One of the issues which have been identified by critics
95
 is the narrow application of the AIA 
Procedure as the Protocol seems to „exclude rather than include‟. This is because the Protocol 
prescribes different procedures for the four categories of LMOs identified earlier. The AIA 
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  Article 2(3) of the Protocol. 
88
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89
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  A. Warren-Jones, n 82 above, 201; H. Meyer, The Cartagena Protocol on Biosafety (2000) 43 Biotechnology 
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(2001) 12 The Fordham Environmental Law Journal, 408-409. 
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Procedure discussed here is only applicable to LMOs intended for deliberate release into the 
environment of the importing Party. The other three categories of LMOs are not subject to the 
procedure. Based on the recognition by the Protocol itself that all LMOs have potential risks 
for the environment and human health, criticism on this ground is not surprising. As regards 
the LMOs-FFP, while not covered by the AIA Procedure, they are subject to the notification 
procedure of the Protocol
96
 which is to be governed by a national regulatory framework.
97
 
Critics
98
 have argued that the notification procedure prescribed by the Protocol is a weaker 
form of the AIA procedure as the requirement of prior informed consent is absent. 
Nevertheless, by comparing the AIA, with the notification procedure, it is equally possible to 
argue that the implications of the two procedures are the same. This is because while the 
requirement of prior written notification of intent to export is absent, import of LMOs-FFP 
remains impossible without explicit agreement from the importing Party.
99
 As regards  
developing countries or a Party with an economy in transition (which has no domestic 
regulatory framework), the Protocol expressly provides that the countries may require the 
exporting Party to undertake the risk assessment procedure at its own expense,
100
 before any 
decision to import is made.
101
 Similarly, the failure of the importing Party to communicate its 
decision could not be taken as giving consent to the import.
102
 
 
The exclusion of LMOs in transit
103
 and for contained used
104
 from the AIA Procedure 
appears to be based on the perception of reduced potential risk that they may cause compared 
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  Article 11 of the Protocol. 
97
  Article 11(4) of the Protocol. 
98
  H. Meyer, n 95 above, ibid. 
99
  Article 11(7) of the Protocol. 
100
  Articles 15(2) and (3) of the Protocol. 
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to the case where LMOs are introduced to the environment of the Party of import.
105
 Their 
exclusion from the procedure has, however, led to the criticism
106
 that exporters may easily 
evade the procedure by declaring that the LMOs fall under the category of contained use by 
postponing field releases.
107
 It should be noted that the Cartagena Protocol only provides a 
minimum standard which needs to be included in national legislations. Parties would need to 
adapt the provisions of the Protocol which suit national biosafety policies provided that the 
objective of the Protocol is achieved.
108
 In this respect, the Protocol explicitly underlines that 
a Party is not restricted from providing more protective provisions in national legislation than 
those provided by the Protocol,
109
 including subjecting all LMOs to a risk assessment prior to 
a decision about import. This rule similarly applies to LMOs in transit and in contained use. 
As regards the former, a Party of transit may regulate the transport of LMOs through its 
territory,
110
 whereas the latter may be regulated by the standards of the Party of import.
111
 
There have been countries which impose a more restrictive procedure for LMOs-FFP, LMOs 
in transit and for contained use, than the minimum requirements by the Protocol. For instance, 
according to the Malaysian Biosafety Act 2007,
112
 the AIA procedure is applicable to all 
release activities and import activities involving LMOs. This includes the LMOs-FFP and 
LMOs for field trials, and products thereof (all of which are not covered by the AIA 
procedure of the Protocol).
113
 More strict provisions (than the Protocol‟s) are also observed in  
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  G. Jaffe, n 81 above, 302. 
106
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the biosafety laws and regulations of countries such as Norway
114
 and China.
115
 
 
While currently animal biotechnology food is largely at the research stage, trans-boundary 
movement of the animals at later stages is imminent as research collaboration and trading 
between Parties to the Protocol ensues.
116
 In terms of consent for importation and risk 
assessment, it is argued that the Protocol adequately covers GM livestock animals and fish. 
This is because, depending on the stages of development, animal biotechnology food may fall 
under all categories of LMOs governed by the Protocol, and hence be subject to the AIA or 
the notification procedure, and the risk assessment requirement. Illustratively, inventions 
such as the Atlantic Salmon may constitute LMOs for contained use or intentional release to 
environment during the research stage, whereas the same would later constitute the LMOs-
FFP when it is to be marketed for human consumption. The product could also constitute 
LMOs in transit in both stages of development. As argued earlier, Parties may also impose 
relevant conditions in national biosafety legal framework so as to address the concern that 
may arise from the movement of the LMOs. 
 
As regards LMOs in transit and for contained use, it appears difficult to refute the fear that 
GM livestock animals and fish may escape notwithstanding the short period of transit or even 
where used in a controlled environment such as a laboratory or confined storage facilities. 
                                                          
114
  Section 7(c) of Act of 2 April 1993 No. 38 Relating to the Production and Use of Genetically Modified 
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This problem has been identified, at least, for seeds where GM corn has been discovered in a 
remote region of Mexico where its planting had not been approved.
117
 Investigation showed 
that the source of the transgene was potentially from „imported transgenic grain that is 
shipped to rural communities for planting by small-scale farmers.‟ 118  Nevertheless, it is 
argued that the problem is more crucial with seeds and micro-organisms where their 
proliferation with natural counterparts is difficult to control, thus the potential harm to the 
environment and human health may be disastrous. Conversely, similar risks are almost absent 
for genetically altered animals for food purpose,
 119
 or, at least the risks are easily managed 
and controlled. For example, as regards the Atlantic Salmon, the inland breeding method will 
address any concern about its potential risks to the environment. With respect to other GM 
livestock animals such as cows with, increased quantity of milk produce or, leaner meat, and 
poultry with disease-resistant traits, it is argued that the environmental risk is much less an 
issue and more manageable due the breeding practices which take place in controlled areas.
120
 
Even in the case of potential escape from confined enclosures, it is difficult to envisage any 
harm that GM farm animals (such as double-breasted chickens) could pose to human health. 
The only effect will be the creation of additional quantities of quality poultry meat which 
would eventually benefit consumers. In addition, due to the practice in international transfer 
where animals are normally placed in special carriers or storage, the potential for escape 
during transit in any country is arguably negligible.  
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3.2.2 Identification of LMOs, and documentation accompanying their shipment 
 
Another key issue covered by the Protocol is the identification of LMOs which are subject to 
trans-boundary movement. Again, the Protocol prescribes different rules for distinct 
categories of LMOs. Documentation accompanying LMOs: (1) for contained use;
121
 and (2) 
intended for intentional introduction into the environment of the importing Party,
122
 should be 
clearly identified as LMOs. In addition, any requirements for their safe handling, storage, 
transport and use, and the relevant traits and/or characteristics of the LMOs should also be 
specified.
123
 For the purpose of identification and documentation, no rule is provided for 
LMOs in transit. This can be expected given that they would be subject to the relevant 
provisions depending on the end purpose of the LMOs (under the respective categories of 
Article 18). Nevertheless, criticism has surrounded the identification of LMOs-FFP as the 
Protocol only requires that the documentation accompanying their shipment should identify 
that they: (1) may contain LMOs; and (2) are not intended for international introduction into 
the environment.
124
 This particular issue is further elaborated here. 
 
The distinction between LMOs for intentional release into the environment and those which 
are not has been described as „a legal fiction‟.125 This is because the purpose of LMOs could 
easily change, irrespective of the intention of the exporter. For instance, it has been identified 
that developing countries normally import grain for food purposes, but the same are used as 
seeds during a food crisis.
126
 This is among the reasons which led to further negotiations 
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  Article 18(2)(b) of the Protocol. 
122
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among Parties to the Protocol to determine the „detailed requirements‟ of Article 18(2)(a).127 
In the recent decision of the Conference of the Parties,
128
 Parties to the Protocol are required 
to ensure that documentation accompanying the LMOs-FFP states: „(1) in cases where the 
identity of the LMOs is known through means such as identity preservation systems, that the 
shipment contains LMOs-FFP; and (2) in cases where the identity of the LMOs is not known 
through means such as identity preservation systems, that the shipment may contain one or 
more LMOs-FFP‟. 129  Unfortunately, the decision has been the subject to a range of 
criticism.
130
 Firstly, it has been argued that compliance with the decision will unnecessarily 
increase the cost of trade as it will require a large investment to monitor and test international 
shipments as they leave exporting Parties and enter importing Parties.
131
 This would 
eventually increase the price of GM crops such as maize and soybeans.
132
 Secondly, it has 
also been argued that it is impractical for exporters (being at the end of the export chain, who 
take ownership of the GM crops from farm to importing country) to know the LMOs content 
of their cargoes.
133
 Thirdly, the possibility to identify LMOs in an export cargo through an 
identity preservation system is rather limited, and the system can only identify the absence of 
LMOs and not their presence.
134
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  The further negotiations are mandated by the Article itself where it states: „The Conference of the Parties 
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necessary for the implementation of the Protocol. 
129
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Protocol on Biosafety (COP-MOP 3) – Meeting decision  BS-III/10, „Handling, transport, packaging and 
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for presentation at the Agricultural and Applied Economics Association‟s, 2010, 1-26; J. Huang, D. Zhang, J. 
Yang, S. Rozelle and N. Kalaitzandonakes, Will the Biosafety Protocol hinder or protect the developing 
world: learning from China‟s experience, (2008) 33 Food Policy, 1-12. 
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  ibid. 
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  ibid. 
133
  J. Huang et al, n 130 above, 4. 
134
  ibid. 
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With respect to animal biotechnology food, notwithstanding the critique identified here, it is 
argued that the decision is reasonable and will not overly burden the stakeholders. This is 
because the options underlined by the Protocol demonstrate its recognition of the challenges 
that stakeholders may have to fully implement the LMOs-tracing-system. The options may be 
seen by critics as a discretion which would eventually impair the effectiveness of the Protocol. 
Nevertheless, it is further argued that being an internationally imposed obligation, the 
measure is an important milestone so as to enhance consumers‟ acceptance and confidence in 
consuming the products, hence the development of the technology.  
 
3.2.3 Liability and redress for damage arising out of the trans-boundary movement of 
LMOs 
 
Article 27 (on „liability and redress‟) is another pertinent aspect of the Protocol which has 
been subject to much deliberation during the Conference of the Parties and the issue as to the 
type of liability that would be imposed to Parties has only recently been resolved. Within the 
negotiations, developed countries proposed an administrative approach which relies upon the 
competence of national authority to monitor and address cases of damage or threats of 
damage caused by LMOs.
135
 Conversely, developing countries which lack capacity to 
implement the approach proposed by developed countries, had been in favour of an 
international regime based on civil liability, administered by the existing court system.
136
 The 
adopted Article 12 of the Supplementary Protocol on Liability and Redress to the Cartagena 
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  S. Jungcurt and N. Schabus, Liability and redress in the context of the Cartagena Protocol on Biosafety, 
(2010) 19, Review of the European Community and International Environmental Law, 2, 201; G.S. Nijar, S. 
Lawson-Stopps and G.P. Fern, liability and redress under the Cartagena Protocol on Biosafety: a record of 
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Protocol on Biosafety
137
 appears to consider the claims of both categories of Parties where 
three options for implementation are given: „(1) to apply their existing domestic law, 
including, where applicable, general rules and procedures on liability; (2) to apply or develop 
civil liability rules and procedures specifically for this purpose; or (3) to apply or develop a 
combination of both.‟138  
 
While critics
139
 have precisely identified that there is no international obligation to implement 
the civil liability system
140
 (due to the operative wording of „parties may as appropriate‟ 
preceding the options) the alternatives are important from some perspectives. Developing 
countries are satisfied that the enabling reference to civil liability was secured.
141
 Intrinsically, 
where the Supplementary Protocol comes into force,
142
 they are able to resort to the option 
without opposition from developed countries. Apart from that, the monitoring of potential 
hazards from LMOs can be pursued by the countries‟ existing judicial system without much 
additional cost compared to the development of a new or additional administrative framework. 
The options should also be able to alleviate the concerns of consumers concerning the use of 
animal biotechnology food.  
 
3.2.4 Non-parties to the Protocol 
 
Another significant feature of the Protocol is that, while the document only binds Parties 
which ratify it, the obligations of non-Parties are also given due weight by the negotiators. 
                                                          
137
  Available at: CBD, http://bch.cbd.int/protocol/supplementary/ (Accessed: 22 March 2012). The Nagoya-
Kuala Lumpur Supplementary Protocol on Liability and Redress to the Cartagena Protocol on Biosafety was 
finalised and adopted in the Conference of the Parties in Nagoya on 15
th
 October 2010.  
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  ibid. 
139
  S. Jungcurt et al, n 135 above, 203. 
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  ibid. 
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  Under Article 18, the Supplementary Protocol is to enter into force on the ninetieth day after the date of 
deposit of the fortieth instrument ratification. As of 23 March 2012, there are fifty one Signatories and two 
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Intrinsically, this is because LMOs have been developed in many countries worldwide as the 
promise of biotechnology is increasingly recognised. As a result, Article 24 of the Protocol 
explicitly spells out that „trans-boundary movement of LMOs between Parties and non-
Parties shall be consistent with the objective of the Protocol‟. Further, the provision states 
that: „the Parties may enter into bilateral, regional and multilateral agreements and 
arrangements with non-Parties regarding such movement‟.143 Notwithstanding this, critics 
may argue that Article 24 remains less influential due to the non-binding legal effect of the 
Protocol on non-Parties. Nevertheless, in terms of animal biotechnology food, the willingness 
of non-Parties to similarly observe the provisions of the Protocol can be expected. This is 
because any likely risk in one country can impact on another due to the possible trans-
boundary movement of the animals. Consequently, the credence of the provision cannot be 
taken lightly. 
 
The concerns of international and national consumers toward animal biotechnology food 
shown in this section illustrate the challenges experienced by the products in proving their 
potential contribution to society. Despite the concerns, evidence of their safety in the 
environment and human health should not be deemed trivial. Therefore, animal 
biotechnology food should be given an equal opportunity to prove its potential for the benefit 
of society. In Malaysia, it can be concluded that consumers‟ confidence in their use could be 
nurtured and enhanced provided that the benefits of the products are thoroughly explained. It 
has been further shown that, if any, the concerns of Malaysian (and international) consumers 
are adequately addressed by the Cartagena Protocol, and biosafety legislations and 
regulations which are already in place in many countries worldwide. 
                                                          
143
  More broadly, for instance, the US which is not a Party to the Protocol has agreed to ensure that its data 
including import or use of LMOs into the country be made available on the Biosafety Clearing House (BCH). 
See J. Kinderler, The Cartagena Protocol on Biosafety (2008) 4 Collection of Biosafety Reviews, 41. Article 
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Irrespective of the concerns of consumers which have been identified in this section, an 
appreciation of the trends of the global livestock industry (and in Malaysia) in terms of 
demand and specific requirements from the populations is particularly important. This aspect 
will be the focus of the next section. The discussion will facilitate an appropriate 
understanding of the factual situation that needs to be dealt with by a particular country in 
deciding if modern animal biotechnology and its products are crucial for consideration in 
order to secure a food supply for its population.  
 
4.  Demands of consumers for livestock and fisheries products 
 
4.1 The importance of the livestock industry and products to the economy 
 
The livestock industry has been one of the main contributors to the world‟s agricultural 
economy. According to the World Bank,
144
 as of 2009, livestock already constituted 40% of 
the global value of agricultural output, and 30% of the agricultural Gross Domestic 
Production (GDP) in developing countries. The FAO statistical data shows that the world‟s 
trade in livestock products
145
 increased significantly between 1995 and 2006. Since the 1980s, 
the industry has been undergoing a process which is termed by Delgado
146
 as „livestock 
revolution‟, in particular, due to the increase in demand for livestock products from 
developing countries.
 
In Malaysia, agriculture has been an important sector which contributes 
to the country‟s economy and continues to be given special attention under the Tenth 
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http://siteresources.worldbank.org/INTARD/Resources/FinalMindingtheStock.pdf (Accessed: 26 November 
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revolution (2003) The Journal of Nutrition, 133, 3907S. 
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Malaysian Plan (2010-2015). The sector is expected to contribute 2% of the GDP by 2015, 
compared to its 1% contribution in 2009.
147
 Since the First Malaysia Plan (1966-1970), 
livestock has been listed among the important commodities which represent the backbone of 
Malaysia‟s agricultural industry apart from rubber, palm oil, rice, pepper and other crops. The 
following sub-sections will discuss three aspects which relate to the industry: (1) trends of 
production and consumption of livestock products; (2) changing trends of consumers‟ 
preference for livestock products; and (3) preference of some nations based on geographical 
location and religious obligation. 
 
4.2 Trends in the consumption and production of livestock products 
  
Notwithstanding the fact that the livestock revolution is due to the increase in demand from 
developing countries, per capita consumption of livestock products in developed countries is 
still significantly higher than in developing countries and is also increasing, albeit at a more 
modest rate.
148
 For the period between 1980 and 2005, there was an increase in per capita 
consumption of livestock products of meat and milk, respectively, from 76.3kg to 82.1kg and 
197.6kg to 207.7kg in developed countries. Nevertheless, a higher rate of growth was 
experienced by developing countries for the same period. Meat consumption increased from 
14.1kg to 30.9kg, whereas milk consumption increased from 33.9kg to 50.5kg. With regard 
to the per capita consumption of eggs, developed countries recorded a decrease from 14.3kg 
to 13.0kg, whereas per capita consumption of eggs for developing countries grew threefold 
from 2.5kg to 8.0kg for the same period.
149
 Regionally, among developing countries, East and 
Southeast Asia was reported to have experienced the greatest increase in livestock 
                                                          
147
Economic Planning Unit Malaysia, Tenth Malaysia Plan (2011-2015), 
http://www.epu.gov.my/html/themes/epu/html/RMKE10/rmke10_english.html (Accessed: 26 October 2010) 
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consumption. Malaysia is one of the countries which have shown a significant increase in the 
Southeast Asia region, apart from the Democratic People‟s Republic of Korea and 
Vietnam.
150
 Per capita consumption of poultry meat in Malaysia has been the highest. In 
evidence, for the ten year period from 2000 to 2010, there was an increase from 27.3kg to 
35.04kg compared to beef, mutton and pork which rose only from 4.75kg to 7.96kg.
151
 
 
Economists associate the rapid growth of the consumption of livestock products in 
developing countries with two factors: (1) urbanisation; and (2) increasing income. Recently, 
the influence of prices and income on demand for agriculture in the five largest developing 
and emerging economies: Brazil, Russia, India, Indonesia and China (the so-called „BRIIC‟) 
was studied by the Organisation for Economic Co-operation and Development (OECD).
 152
 
One of the findings revealed in the report was that, whereas demand for most agricultural 
products namely cereals, fruits and vegetables, sugar, fats and oil has been declining despite 
an increase in income, there was an exception with regard to the demand for meat and dairy 
products.
153
  
 
In the Malaysian context, the findings of researchers who studied the patterns of urbanisation, 
nutrition and health transition, and demand systems for foods, have supported the economists‟ 
view. The percentage of urban population in Malaysia was increasing at a greater rate from 
1980 to 2000 (35.8% to 61.8%), compared to the period between 1957 and 1970 (26.8% in 
1970).
154
 At least two reasons contributed to this trend: (1) between 1957 and 1970, the 
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country was undergoing an „adjustment period‟ after gaining its independence from the 
British; and (2) starting from 1980, there was a shift in the government‟s economic policy 
from agriculture to industry, which meant more opportunities for employment were offered in 
urban areas.
155
 In this regard, research
156
 has shown that the increase in the income of 
Malaysians corresponds with the demand for meat, fish, vegetables and fruits which was 
higher than for other energy-source foods such as rice, bread and other cereals.
 
 
 
The output of livestock products, worldwide and in Malaysia, is responding to this 
consumption pattern. At an international level, the production of livestock products has been 
championed by countries such as China, Brazil and India.
 157
 They emerged as new key 
players for livestock production, replacing developed countries such as the US and the EU 
Member States which were the main producers before 1995.
158
 The production of pigs, 
poultry, cattle and sheep and goats either doubled or tripled in developing countries for the 
ten year period from 1987 to 1997. Comparatively, in developed countries, only the 
production of pigs and poultry was increasing for the same period, whereas the production of 
cattle, sheep and goats was declining.
159
 Production of livestock products was similarly 
increasing in Malaysia. For the period from 1985 to 2005, the increase in production of 
livestock products was: beef (from 17,000 tonnes to 40,000 tonnes), mutton (from 6,000 
tonnes to 8,000 tonnes), pork (from 164,000 tonnes to 183,000 tonnes), poultry (from 
251,000  tonnes  to  1.3  million tonnes),  eggs (from 3.4 million units to 10 million units) and  
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milk (from 24 million litres to 65 million litres).
160
 
 
The consumption of livestock products will continue to increase in future as the size, and 
income, of the population increase. While the latter implies a better quality of life for a 
greater number of people in the population, the livestock industry, globally and in Malaysia, 
needs to be able to cope with the increasing demand. In tandem with the increasing pattern in 
consumption, and, as consumers become more knowledgeable, their awareness of health 
issues are developing. The implications of this will be appreciated in the following sub-
section. It is important that the specific requirements of consumers from livestock products 
are understood as they could pose a new challenge to the livestock industry. 
 
4.3 Changing trend of consumers’ preference for livestock products  
 
In developed countries, where incomes are generally high and basic dietary needs have long 
been more than satisfied, consumers often look for more variety in their diets.
161
 In this 
context, demand for livestock products corresponding to income growth, is less responsive in 
high-income countries compared to lower-income countries.
162
 Consumers in developed 
countries such as within Europe, Japan and the US are increasingly demanding food with 
specific  features.
163
  These include  healthy  and  good  quality food
164
  for consumption, and  
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food that is safe for the environment.
165
 
 
Non-communicable diseases mainly cardiovascular disease, cancers, diabetes and chronic 
respiratory disease, have been presenting a major challenge to global public health.
166
 While 
matters such as nutrition and diet have long been one of the important health agenda items for 
the World Health Organization (WHO), it is worth noting the ever-increasing growth of cases 
of non-communicable diseases. The diseases constitute the world‟s largest killers, causing an 
estimated 35 million deaths each year (60% of all deaths globally).
167
 The trend, which, in the 
past, has been commonly associated with affluent societies in developed countries, is 
currently being experienced by developing countries and LDCs. In Malaysia, in 2009 for 
instance, heart and lung disease have been recorded as the main cause of death in government 
hospitals which amounted to 16.9%.
168
 The WHO has acknowledged two leading causes 
which led to this phenomenon: (1) an unhealthy diet; and (2) lack of physical activity.
169
 As 
regards the former, high consumption of energy-dense foods that are high in fat has been 
specifically identified as one of the factors which increase the health risks for all 
consumers.
170
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Notwithstanding the similar health problems troubling countries worldwide, developed 
countries have made notable improvements toward adhering to the WHO recommended 
dietary pattern.
171
 The recommendations indicated certain lower and upper limits for calorie 
intake from seven categories of sources of energy: fats, proteins, carbohydrates, saturated fats, 
trans-fats, raw sugar, and fruit and vegetables.
 172
 Using the WHO recommendation as the 
basis of their study, research
173
 has
 
concluded that developed countries were regularly 
improving their dietary habits towards the „ideal diet‟ and were the closest to the 
recommendations. A similar trend was observed among developing countries, albeit at a 
marginal rate. Almost no improvement was found for LDCs.
174
 This study supports the 
contention that consumers in developed countries choose quality of food as their main 
consideration. 
 
An important sector which has been specifically identified by the WHO as being able to play 
a fundamental role is the manufacturing industry.
175
 Responding to the global dietary strategy 
as advocated by the WHO, the market health services and nutritionists in five European 
countries which make up 80% of the processed meat market in Western Europe have been 
putting pressure on the meat and food industry to reduce the amount of saturated fats in their 
products.
176
 Nevertheless, with taste being the most decisive factor for the success of 
processed meat products,
177
 the challenge facing the meat industry is how to produce 
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reduced-fat products and maintain the taste. Modern animal biotechnology has the potential 
to address this challenge and will be discussed further in the final section of this chapter. 
 
In line with the WHO‟s recommendation to maintain a healthy diet in order to reduce the risk 
of heart attack and stroke, the consumption of lean meat and fish has been specifically 
mentioned and encouraged.
178
 In this regard, consumers‟ preference for lean meat in western 
countries has been studied. In a study involving participating consumers of four European 
countries namely, Germany, Spain, France and the UK, their perception of the healthy 
qualities of beef was explored.
179
 The study revealed that, while generally the participating 
consumers consider beef as a healthy food product, fresh lean beef is perceived as more 
healthy compared to processed and packaged beef. Notably, the study also found that 
consumers prefer improvement to produce leaner beef during the production phase (for 
instance by adjusting the feed to influence the fatty acids composition of beef), rather than the 
processing phase (for instance marinating to reduce the formation of carcinogenic compounds 
during grilling).
180
 This shows that consumers are prompting a change in animal physiology, 
rather than in the meat processing industry, which can be more effectively achieved through 
modern biotechnology. The preference of Malaysian consumers for meat has also been 
studied
181
 where it was concluded that while demand from domestic consumers is for a 
greater quantity of beef products, demand for the quality of beef (higher-value hybrid or 
imported beef) is notable among people with higher incomes.  
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This sub-section has shown that the healthy quality in beef has become an increasingly 
important factor to consumers worldwide. The awareness of the benefits of leaner meat is 
more prevalent within developed countries. Nevertheless, people from developing countries 
are catching up by consuming better quality meat. Therefore, while currently, requiring 
leaner meat seems to be a very specific feature for the purpose of developed countries, 
arguably the trend will develop in the near future in developing countries as the level of 
income and education of the population increases. Another pertinent aspect for consideration 
is the specific preference for livestock products among some of the nations, which is 
discussed in the next sub-section. This has become a factor which contributes to the focus on 
the consumption of some types of animal-protein based products.  
 
4.4 Preferences for livestock and fisheries products among nations: geographical 
location and religious obligations  
 
Geographical location is an aspect which has influenced consumption patterns across 
countries around the globe.
182
 In South Asia, including India for example, per capita 
consumption of livestock products has increased progressively, except for meat.
183
 This is 
due to the fact that the majority of the population continues to practise a vegetarian diet, even 
though the younger generation has been more open to a western meat-based diet.
184
 In Japan, 
higher levels of fish consumption replace lower levels of livestock products consumption.
185
 
As regards Malaysia, the country‟s population comprises many ethnic groups. Malays (who 
profess the Muslim religion) constitute the majority of the population, while others include 
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Chinese, Indian and various indigenous ethnics, such as the natives of Sabah (Kadazans and 
Bajaus)  and  Sarawak (Ibans).  Due  to  religious obligations, Muslim consumers in Malaysia  
can only consume „halal‟ (permissible) products.186 Muslims are forbidden to consume pork 
and animals which are not slaughtered in accordance with Islamic principles. Therefore, pork 
is consumed only by non-Muslim consumers. Other livestock products such as beef, mutton, 
poultry, milk and eggs are generally consumed by all other ethnic groups, including Malays.  
 
Where Malaysians‟ choice of animal-protein intake is discussed, the consumption of fish 
must be mentioned, as fish is a popular part of the Malaysian (and broadly, Asian) daily diet. 
It is not suggested that fish is consumed less by populations in developed countries. In fact, 
according to the FAO,
 187
 the per capita consumption of fish in developing countries is only 
half than that of developed countries. In evidence, in 2005, per capita consumption of fish in 
developed countries was 29.3kg whereas per capita consumption in Asia was 17.9kg.
188
 
Nevertheless, similar to the trend in consumption for livestock products, the rate of growth in 
per capita consumption of fish is higher in developing countries than in developed 
countries.
189
 The generally accepted lower health risk implications resulting from 
consumption of fish may have contributed to the popularity of fish among consumers where 
Omega-3 essential fatty acids found in fish have been known for various health benefits in 
helping to reduce inflammation, to heal dry skin, to control high cholesterol level and 
others.
190  
The consumption of fish among Malaysians has been much higher than that of meat. 
For the period from 1985 to 2003 per capita consumption of fish increased from 45.44kg to 
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56.39kg, whereas, meat consumption increased from 29.4kg to 48.5kg.
191
 Further, in a cross-
country study involving nine countries in Asia, it was revealed that for the period from 2001 
to 2004, Malaysian‟s allocation of consumption expenditure for fish (from total budget) was 
the highest among the participating countries.
192
  
 
This section has shown the increasing trends in consumption and the myriad needs of 
consumers pertaining to livestock and fisheries products. A country should be able to cope 
with the relevant aspects in order to ensure adequate supplies to, and meet specific demand of, 
the population. Geographical location and religious obligations are some of the factors which 
distinguish the preference for livestock and fisheries products among nations. They also 
explain the different challenges that a country has, compared to others, in terms of 
requirements for certain types of protein-based products. The appreciation of the aspects are 
key in assisting a particular country to make an informed assessment of whether or not 
current national practice of the animal livestock and fisheries industry could meet the trends. 
The next section will look at the specific challenges of the industry and implications arising 
from them. As regards Malaysia, it aims to identify the on-going and crucial problems which 
require solution.  
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5.  Challenges facing livestock and fisheries production, and, its implications for 
Malaysia 
 
5.1 Constraints confronting the livestock and fisheries industries 
 
There are many issues, which hinder attempts by the livestock and fisheries industries to 
achieve production targets set at a global or national level. The lack of financial capacity to 
build basic or extended infrastructure facilities, weaknesses in management and marketing 
strategy and lack of legal or regulatory framework are some of them. Nevertheless, for the 
purpose of this section, three factors will be examined. They are: (1) a shortage of breeding 
stock and fish seed; (2) the risk of livestock and aquatic diseases; and (3) constraints of feed. 
They are specifically chosen as they are „beyond human control‟, and relevant in the context 
of this thesis, being factors to which the application of modern animal biotechnologies has 
mainly been directed.  
 
5.1.1 Shortage of productive breeding stock and fish seed 
 
The importance of animal genetic resources for the sustainability of the world‟s food security, 
agriculture, and nutritional and rural development, is recognised and evidenced by the 
adoption of the Interlaken Declaration of Animal Genetic Resources 2007 (Interlaken 
Declaration‟) by 109 countries worldwide.193 Having adequate animal genetic resources is a 
significant requirement for the livestock industry in order to ensure continuing supply. Not 
surprisingly livestock has been described as „farmers‟ most essential input‟.194  
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Unfortunately for Malaysia‟s ruminant industry (which includes livestock such as cattle, 
buffalo, goat and sheep), the shortage of productive breeding stock has long been identified 
as a major problem.
195
 In contrast, the poultry and pig industry does not experience the same 
problem. Two reasons contribute to this distinction: (1) the nature of poultry and pigs which 
have high reproductive rates; and (2) the short generation interval of poultry and pigs 
compared to ruminants.
196
 Lack of breeding stock will put the Malaysian livestock industry in 
a challenging situation especially when the existing stock is facing increasing demand from 
consumers and also due to the risk of livestock diseases. Slow progress in generating 
indigenous breeds and breeding stocks
197
 has resulted in the Malaysian Government 
importing high quality cattle for breeding purposes and applying artificial insemination 
procedures
198
 to generate increased production. Many quality breeds have been brought into 
the country for commercial purposes, namely Anglo Nubian (from England), Boer (South 
Africa) and Jamnapari (India and Pakistan) for goat breeds; Brahman (India), Charollais 
(France), Droughtmaster (Australia) and Jersey (England) for cattle breeds; and Damara (East 
Asia and Egypt) and Dorper (South Africa) for sheep breeds.
199
 
 
On a similar note, constraints of fish seed for the aquaculture sector remain a problem 
worldwide. In particular, aquaculturists who rely on wild-caught fry to be cultured, such as 
yellowtail, grouper, or yellow fin tuna face more problems than those who breed species such 
as carp, shrimp and salmon. This is because the latter groups can already be produced using 
artificial reproduction.
200
 For the Malaysian fisheries industry, one would assume that 
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constraints of seed causes fewer problems to the country‟s fisheries industry since the 
industry focuses heavily on capture fisheries rather than aquaculture. In evidence, in 2010, 26% 
of the country‟s fish production was contributed by capture fisheries (from coastal and deep 
sea fisheries), while only 7.93% comes from aquaculture.
201
 Nevertheless, as its aquaculture 
sector also includes finfish species such as tilapia, and grouper
202
 (which have not been able 
to use artificial reproduction techniques) similar problems would apply to the country. 
 
5.1.2 Risk of livestock and aquatic diseases 
 
Livestock diseases have caused global concerns for at least two main reasons: (1) 
implications for food security and the economy; and (2) implications for human health. It is 
useful to look at the timeline of some livestock diseases which have affected the globe. For 
instance, Newcastle disease was discovered in 1926, Bovine Spongiform Encephalopathy 
(BSE, or Mad Cow disease) in 1984, the Henipavirus (Nipah virus) in 1998 and the Influenza 
A (H1N1) virus, the strain which is better known as „swine flu‟ in 2009. This timeline 
evidences the long repeatable threats which have affected livestock animals and caused 
economic loss to industry and farmers.  
 
The economic implications of these diseases for developing and developed countries are 
massive. It was estimated that the total costs caused by the disease in the UK amounted to 
US$18 to US$25 billion between 1999 and 2002.
203
 The 2009 Pandemic H1N1 Influenza, 
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caused Mexico an estimated economic cost of over US$2 billion.
204
 In the case of developing 
countries, the Avian Influenza (H5N1) disease which affected poultry industries has caused 
adverse implication on prices and the amount of poultry meat sold in the major markets of 
affected developing countries.
205
 It was shown that prices fell by 8% to 75% in countries such 
as Cambodia, Indonesia, Vietnam, Egypt and Bangladesh. The drop in the volume of poultry 
meat traded was in the range of 33% to 90%. These drops were mainly due to consumer 
apprehension about the risk of contracting the Avian Influenza disease by consuming the 
poultry meat.
206
  
 
Malaysia is not exempt from the livestock diseases mentioned above. The following 
discussion highlights the economic implications of the Nipah virus outbreak to the country.
207
 
Economically, the outbreak caused excessive economic trade loss to the country‟s pig 
industry and the farmers. Approximately 1.1 million pigs were destroyed during the outbreak 
period, causing an estimated loss of US$97 million.
208
 The number destroyed accounted for 
nearly half of the country‟s pig population (2.4 million) prior to the outbreak. This caused a 
drastic decrease of pig meat production from 283,000 tonnes in 1995 to only 150,000 tonnes 
in 2000.
209
 Prior to the outbreak, Malaysia exported pigs to Singapore and Hong Kong. In 
1999, the ban on imports due to the outbreak caused an estimated trade loss of US$120 
million.
210
 Other indicators pointed in the same direction. For instance, self-sufficiency levels 
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for pig meat decreased drastically from 104% in 1995 to 80% in 2000.
211
 In the context of the 
domestic market, the outbreak caused a drop of 80% in consumption, causing an estimated 
loss of US$124 million to local farmers during the outbreak period. In terms of management 
costs, the country spent an estimated US$136 million to bring the outbreak under control.
212
   
 
Moving on to the fisheries industry, aquatic diseases has been described by aquaculture 
experts as a very significant threat to sustainable production and trade.
213
 Generally, they are 
caused by an imbalance of the ecological environment due to factors such as increased 
urbanisation, growth of new industries and changes in industrial practices. The practices in 
aquaculture which include the removing of live aquatic animals from their natural 
environment (such as freshwater and offshore) to high density captivity and also the trans-
boundary movement from one country to another have been widely recognised as the main 
factors which cause the spread of aquatic pathogens.
214
 The economic implications of aquatic 
diseases are a major problem for countries around the world. Of all aquaculture sectors, prawn 
farming has been the most remarkably affected. Since more than 90% of prawn farming is 
based in Asia and Latin America, it means major losses have been experienced by most 
developing countries. To illustrate this point, in 1993 China reported a loss of US$20 million 
in a single season, and in 2002 India‟s estimated loss was more than US$250 million, that is 
60% of the national production.
215
 Fisheries industries in industrialised countries have been 
similarly affected. For instance, salmon-farming industries in Europe and North America 
experienced serious losses due to infectious salmon anaemia (ISA) in 1984. By 1999, the 
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fisheries industries in Norway, Scotland and Canada were estimated to have lost US$60 
million due to the same disease.
216
 
 
5.1.3 Constraints of animal and fish feed  
 
Animal feed is one of the determining factors for the amount of production and quality of 
livestock and fisheries products. According to the OECD-FAO
217
  projections, from 2009 to 
2018, the demand for feed such as wheat, coarse grain and oilseed meal, mainly from 
developing countries, will be increasing. Demand for these resources for livestock feed has to 
compete with at least two other factors: (1) increasing human consumption; and (2) 
production of bioproducts such as biofuel, bioethanol, biodiesel and biogas, which have been 
encouraged due to their environmental friendly and energy saving features. This competition 
would inevitably mean high costs for the inputs. In this regard, the OECD-FAO projected (for 
instance) an increase of 3% for wheat prices by 2019 from the average price in 2007-2009 
(during the world food-price crisis) and also an increase for coarse grain rice.
218
  
 
In order to meet the increasing local demand for animal feed, efforts have been continuously 
undertaken by the Malaysian Government to improve the supply and quality of foodstuffs for 
ruminant and non-ruminant animals. Locally available feed ingredients such as tapioca waste 
and rice bran are encouraged to be utilised either as compound feed for feeding livestock 
together with ground maize and soybean meal, or as a single feed. Of particular importance is 
the use of local palm kernel cake
219
 which has proved to be of nutritional value for dairy 
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cattle
220
 and fish such as tilapia and catfish
221
 in Malaysia. Notwithstanding all these efforts, 
crucially, a large amount of animal feed is still imported. The high cost of feed ingredients 
means Malaysia has to spend a huge amount of money for the importation of soybean meal, 
corn flour and wheat flour for this purpose. According to the Ministry of Agriculture and 
Agro-Based Industry Malaysia,
 222
 the value of imports of animal feed has been gradually 
increasing from RM2.1 billion in 2003 to RM3.8 billion in 2007. The Ninth Malaysia Plan 
projected a further increase of imports to RM4.3 billion in 2010.
223
 
 
The FAO has identified that feed perhaps is the best-known constraint for the aquaculture 
industry.
 224
 In the sector, fish has a dual function: (1) as a source of food for human 
consumption; and (2) as a source of food for fish itself. As regards the latter, fish feed 
consists of fishmeal, fish oil and trash fish
225
 which themselves originate from a few fish 
species (called „bait fish‟ or „industrialised fish‟) which are less suitable for human 
consumption. Some critics
226
 have argued that claims that increasing demand for aquafeeds 
will destroy the stocks of „bait fish‟ were not supported by evidence, since catches for the last 
two decades have been stable. Nevertheless, as it is doubtful that the catch would increase, 
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the need for substitute feed has been recognised.
227
 This precautionary measure is the reason 
why research into substitute fish feed has become increasingly focussed worldwide.  
 
The complete substitution of fishmeal has been achieved mainly for herbivorous and 
omnivorous fish (such as silver perch), and it has also been possible for very small species of 
carnivorous fish (such as barramundi).
228
 Two-thirds substitution is already possible for 
prawns. Replacement proteins include grains (such as soybean meal, peas and beans and 
wheat products) and terrestrial animal meals (such as meat meal and poultry meal).
229
 
Unfortunately, there has been less success with substitution for most carnivorous fish which 
cannot survive without fish as a major component of their diet. Of particular importance are 
salmonids which significantly rely on fish oil.
230
 The problems include aspects such as 
digestibility, acceptance and changes in the fatty acid profiles of fish.
231
 In the light of the 
intensification of aquaculture, the continuing supply of fishmeal and fish oil for aquaculture 
feed (which in turn is based on the bait fish catch) is risky and might become critical in the 
near future. The situation may be exacerbated, for instance, by competition for the use of fish 
oil from other sectors such as the pharmaceutical industry.
232
 
 
This sub-section has shown pertinent continuing challenges facing the Malaysian livestock 
and fisheries industries. As already shown, the problems identified are similarly experienced 
by other developing and developed countries. However, for developing countries, each of 
these problems would pose a greater challenge in the light of the growth of demand for 
livestock products, as compared to developed countries in which demand has become 
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stagnant. The following sub-section highlights the implication arising from the challenges to 
Malaysia so as to assess whether or not the problem can be resolved in near future, without 
any support from new technologies.  
 
5.2 The on-going efforts adopted in the Malaysian livestock and fisheries industries, and 
the problem of the self-sufficiency level  
 
The Malaysian Government has handled the challenges facing the livestock and fisheries 
industries by developing infrastructure and research activities.
233
 A huge amount of money 
has been allocated to research ways of improving livestock and fisheries production, both in 
terms of quantity and quality. Educational programmes have also been arranged and 
implemented in order to expose the farmers and fishermen to all aspects of good husbandry 
practices including farm or fisheries management and marketing strategies. As far as 
livestock animals are concerned, grazing reserves are continuously being developed in many 
parts of the country. Improvement has also been made to abattoirs, aiming to produce a better 
quality of products that comply with various health regulations, and hence an increase in 
production. With regard to the prevention of animal diseases, research into the production of 
vaccines for specific livestock diseases such as foot and mouth, Newcastle disease
234
 and 
avian influenza has been undertaken. Ways have also been adopted to improve animal health 
through veterinary services. In addition to these, specific efforts for the fisheries industry 
include improvement of fishing equipment, the establishment of cold rooms and processing 
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facilities, training for the extensive use of modern fishing and conservation of fisheries stocks 
in marine parks.
235
  
 
Unfortunately, notwithstanding these and years of efforts by the government to develop the 
industry, stories relating to the rising price of livestock products are still common. Headings 
of articles such as „No reason to increase meat prices‟, 236  „Conspiracy to raise price of 
chicken‟237 and „Government to check on festive price hikes‟238 have become common annual 
phenomena in local newspapers particularly when festive seasons are approaching. Whereas 
these „one-off‟ scenarios could not be taken as suggesting inadequate local supplies of 
livestock products, statistical evidence will show that Malaysia is in fact facing problems in 
meeting local demand in both livestock and fisheries products.  
 
In Malaysia, similar to other major food commodities such as rice, fruit and vegetables, the 
self-sufficiency level of livestock products has been increasing for the past ten years (2000-
2010) due to the various efforts by the government. The increase of percentage levels for 
livestock products are: beef (from 15% to 28%), mutton (6% to 10%), pork (100% to 132%), 
poultry (113% to 122%) and milk (3% to 5%).
239
 Self-sufficiency levels for eggs have 
similarly increased (110.3% to 152.5%, from 1995 to 2005).
240
 These statistics show that 
Malaysia is self-sufficient only in some livestock products. Despite the low percentage levels 
for beef and mutton, the goal of achieving self-sufficiency is pursued. The Ministry of 
Agriculture and Agro-Based Industry Malaysia targeted a 40% self-sufficiency level for these 
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two products by 2015.
241
 Currently, in order to meet the population‟s demand, Malaysia 
depends on 80% imports from countries such as India, Australia, New Zealand, Uruguay, 
Argentina and Brazil.
242
 A similar challenge has been encountered with Malaysia‟s fish 
supply. The production of fish has increased from 1.5 million tonnes in 2000,
243
 to 1.7 
million tonnes in 2009.
244
 Yet Malaysia has been continuously dependent on imported fish 
from countries such as Thailand and Indonesia,
245
 to fulfil local demand. The value of 
imports was RM1.1 billion in 2000, and it increased to RM 2.2 billion in 2007.
246
  
 
This section has shown the specific challenges facing the livestock and fisheries industries, 
and its implication for Malaysia. The problems have continued to persist notwithstanding the 
numerous efforts which have been adopted by the government. The self-sufficiency levels for 
three main livestock products in Malaysia namely, beef, mutton and milk is very critical. A 
similar problem is burdening the fisheries industry. For these products, much more effort is 
needed to increase the self-sufficiency levels to at least 50%, hence, alleviating the heavy 
dependency on imported products. A shortage in the supply of livestock and fisheries 
products may eventually lead to some further problems such as increased prices and lack of 
protein-based sources. Therefore, it is timely for Malaysia to look for a new option to 
overcome the problems. This contention will be further discussed in the next section which 
identifies the potential of modern biotechnology to assist the country in meeting the demands 
and needs of its population. 
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6. Animal biotechnology applications and animal biotechnology food as a catalyst for 
Malaysia 
 
It has been shown in section 5 that the needs of Malaysian consumers in terms of the quantity 
of livestock and fisheries products are not being met. Following on from the experience in 
developed countries, once the problems of quantity are resolved, consumers will concentrate 
more on problems of quality. Animal biotechnology is able to assist with both of these issues. 
Therefore, in addition to the potential of the genetic engineering technique identified in sub-
section 3.1, other possible contributions of animal biotechnology applications are further 
assessed below.  
 
Animal biotechnology can improve the physiological aspects of livestock animals and fish 
such as feed efficiency and disease resistance qualities, which results in higher yields. The 
introduction of certain enzymes using transgenic technology to the gut of livestock animals 
such as pigs and poultry can help to increase feed efficiency, and reduce the amount of feed 
required.
247
 In the context of Malaysia, the decrease of the amount of feed required by the 
GM livestock would eventually mean less government expenditure on imported feed. As a 
result, relevant funds may be channelled to R&D activities in order to speed up the various 
animal biotechnology applications which are at the research stages. In a broader context, 
there is competing demand for feed resources, such as wheat and coarse grain rice for 
livestock animals, between human consumption and the production of bioproducts. The use 
of GM livestock can contribute to reduce the price of the crops, hence, ensuring the 
affordable consumption by consumers worldwide. Apart from this, the increased pressure 
caused to eco-systems and natural resources, such as land and water, due to intensive 
                                                          
247
  M.B. Wheeler n 11 above, 205; R.H. Phipps et al, n 11 above, 247. 
74 
 
production of livestock can, ultimately, be reduced. Increased feed efficiency has been further 
associated with potential improvements to the environmental condition, where it can decrease 
methane production which contributes to global warming and climate change.
248
 In evidence, 
Enviropig (the genetically altered pig which has been developed in Canada) can better absorb 
phosphorus from its food, hence reducing environmental pollution caused by that 
substance.
249
  
 
With respect to the alteration of genetic material to increase disease resistance, the production 
of mastitis-free cattle has been highlighted.
250
 Mastitis is an infectious disease of the 
mammary gland that causes decreased milk production. By producing antibodies in the 
mammary glands, such a disease can be prevented. In addition, the ability of the technology 
to produce BSE-free livestock in the future has also been anticipated.
251
 For the aquaculture 
industry, the quality of disease-resistance from bacterial infection has been specifically 
identified. For instance, research
252
 has reported that transgenic Channel catfish shows 
improved disease resistance and survival rate compared to the non-transgenic individuals 
when challenged with pathogenic bacteria.
253
 The production of disease-resistant livestock 
animals and fish provides an alternative to dependency on the use of vaccines in dealing with 
the continuous problems on livestock diseases. While vaccines have been effective in treating 
diseases, they are not without limit. Taking catfish as an example, it has been reported that 
common catfish disease, including enteric septicaemia, has no accurate effective treatment.
254
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In the long run, resistance to livestock and aquatic diseases means the increase of breeding 
stock which is fundamental for Malaysia.   
 
In terms of quality of livestock and fisheries products, it has been anticipated
255
 that genetic 
engineering could improve carcass composition by using certain knockout genes to increase 
the lean quality of meat. This is done by altering the metabolism or uptake of cholesterol and 
or the fatty acids to lower the fat and cholesterol content of meats, eggs and cheeses. In 
addition, the ability of genetic engineering in modifying milk composition and properties for 
several purposes has also been projected.
256
 An example for this is the increase of casein
257
 
components in milk that could enhance the value of milk in manufacturing yogurt or cheese 
or producing better-tasting low-fat cheese.
258
 Related to this, in 1993, the USFDA approved 
recombinant bovine somatotropin (BST) after satisfying itself over its safety for human 
health.
 259
 The hormone, which is derived from genetically engineered bacteria, is a product 
of genetic engineering that is currently being used throughout the US‟ dairy industry.260 The 
protein increases milk production in lactating cows.
261
 Leaner quality of meat, and reduced 
cholesterol rate in livestock and dairy products, are clear promise of modern biotechnology 
applications which could improve the health quality of Malaysians.  
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7.  Conclusion 
 
The livestock and fisheries industries have contributed largely toward the world‟s and 
Malaysia‟s economy. In tandem with the growth of the population, demand for livestock and 
fisheries products has been increasing. While this trend can be observed in developed and 
developing countries, the rate of growth in the latter is more notable particularly because of 
the increasing income of the population, which helps them to purchase and consume the 
products. The two most important objectives of livestock and fisheries industry are high 
volume and quality of outputs. The focus of developing countries has been on increasing the 
production whereas the main consideration of developed countries is on the quality of the 
products, including their implications for human health and the environment.  
 
The development of the livestock and fisheries industries in Malaysia and throughout the 
world is progressing rapidly in line with the explosion of demand. Nevertheless, the world 
food-price crisis between 2007 and 2008 made it explicit that the world‟s livestock and 
fisheries industries production is very vulnerable due to various factors which are beyond 
human control. Important challenges which have been identified include the shortage of 
productive breeding stock and fish seed, the risks of livestock and aquatic diseases and 
constraints of animal and fish feed. These are also the challenges that have been recognised 
worldwide as restricting the performance of the livestock and fisheries industries to produce 
optimal outputs.  
 
Advances in molecular biology have brought a new dimension to the livestock industry. 
Scientific findings have proven that animal biotechnology applications are able to assist the 
industry in achieving the objectives of developing and developed countries. For developing 
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countries, the technology helps to develop livestock animals and fish which are disease-
resistant, with improved digestive systems and growth rates. It therefore, produces increased 
yields. In the context of developed countries animal biotechnology has the potential to 
produce output which is richer in nutritional quality, has leaner meat, and is environmentally 
friendly. As it is anticipated that the healthy criterion of livestock products will become an 
important factor for the populations of developing countries as their income and knowledge is 
enhanced, modern animal biotechnology will similarly benefit them.  
 
Notwithstanding the promises of the technology, animal biotechnology food is not without 
challenge. Notably, consumers are concern about the implications for their health and for the 
environment. As a result, many studies focus on these two aspects. Ample scientific evidence 
has been published as to the safety of animal biotechnology food for human health. In 
particular it has been shown that the meat and milk of cloned cattle is no different than the 
non-cloned variety, based on rigorous risk assessment of the potential risk of the products to 
human health. An important fact which has been identified is that consumer‟s scepticism 
toward animal biotechnology food could be improved by education and information about its 
benefits. This finding has been reported in several empirical research papers involving 
consumers globally and similar conclusions can be made for Malaysians who are not totally 
against modern biotechnology and its products. This is evidenced by the acceptance of 
products such as GM soybean, palm oil and insulin. Therefore, it is important for the 
Malaysian Government and industrial stakeholders to educate consumers about the benefits 
of animal biotechnology food.  
 
At the international level, potential risks arising from the trans-boundary movement of LMOs 
(including GM livestock animals and fish) is addressed by the Cartagena Protocol. In addition 
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to the evidence for the safety of animal biotechnology food, this chapter has also argued that 
the concern of consumers, if any, relating to the potential risk to the environment and to 
human health, is adequately addressed by the Protocol. In particular this is achieved by four 
factors: (1) subjecting the transgenic animals to prior informed consent and notification 
procedures before the intended trans-boundary movement; (2) their compulsory identification 
in international shipments (if the identity of the LMOs is known); (3) the ability of Parties to 
the Protocol to claim damages caused by the LMOs using civil liability laws; and (4) the 
encouragement that non-Parties similarly observe the provisions of the Protocol.  
 
Malaysia is self-sufficient in poultry, pork and eggs. However, the country is heavily 
dependent on imports for beef, mutton and fisheries products to meet the populations‟ 
growing demand. The import value of these products is very significant and increasing every 
year. In addition, the government is also spending a huge amount of money to import animal 
feeds. These problems are persistent notwithstanding the government‟s endeavours to 
enhance the livestock industry, including, increasing grazing reserves, exposing farmers and 
fishermen to good husbandry practice and improving marketing strategies. There are in hand 
two choices that can be considered; either continuing to rely on various efforts which have 
been adopted to develop the industry over recent years, or venturing into modern animal 
biotechnology which has the potential to assist the industries. As already identified, the first 
choice has not succeeded in generating a sufficiently increased food supply in all livestock 
commodities for the country. Therefore, Malaysia has made a pertinent decision by opting to 
utilise modern animal biotechnology to this end. So far the most notable application of the 
technology in the country is the modern breeding techniques of artificial insemination. 
Nevertheless, it has been shown that efforts to apply animal biotechnology in a wider area of 
research involving livestock animals and fish are already in place. This is made possible by 
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the clear vision of the government as contained in the country‟s National Biotechnology 
Policy which states that animal biotechnology is to be utilised in full in order to maximise the 
value of livestock and fisheries industries. In tandem with this are the explicit aims of the 
National Agricultural Policy to increase food (including livestock) production and exports, 
and reduce imports. This chapter argues that animal biotechnology applications can assist 
Malaysia to increase the self-sufficiency level in all main livestock and fisheries products, 
and improve the health quality of the population.  
 
In order to promote innovation in biotechnological inventions the government has 
specifically encouraged local research institutions and individual scientists to apply for patent 
protection to protect their commercial interest. So far patents have been secured locally and 
internationally for products such as DNA sequence encoding for various proteins and 
vaccines and animal feed. Animal biotechnology food could constitute an invention within 
the patent law sense. However, the legal protection which is covered by s13(1)(b) of the 
Malaysian Patents Act 1983 (where „animal varieties‟ are excluded from patent protection) is 
unclear. Article 27.3(b) of the TRIPs Agreement allows Signatories (such as Malaysia) to 
exclude „animals‟ from national patent protection. Nevertheless, what is required in Malaysia 
is an answer as to how this flexibility could be construed. In the context of the thesis, the 
interpretation is to be assessed in the context of two pertinent points already identified in this 
chapter: (1) the long-term problem faced by Malaysia in achieving self-sufficiency in all 
main livestock products; and (2) the aspiration and commitment of the government to harness 
animal biotechnology applications to develop its livestock industry and increase its products 
in order to meet the various increasing requirements of consumers.  
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The next chapter will discuss the exclusion of animal inventions under Article 27.3(b) of the 
TRIPs Agreement. Central to the discussion is an examination of the rationale underpinning 
the flexibility for the exclusion and assessment of issues pertaining to the exclusion under the 
TRIPs Agreement. The chapter contributes to the research questions by highlighting to a 
Signatory to the TRIPs Agreement (including Malaysia), the rights which it has and 
obligations which are expected from it within the international patent law framework in 
interpreting its exclusionary provision.  
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CHAPTER TWO 
 
THE EXCLUSION OF ANIMAL INVENTIONS UNDER ARTICLE 27.3(b) OF THE  
TRIPs AGREEMENT 1994: THE PAST, PRESENT AND FUTURE 
 
1. Introduction 
 
The TRIPs Agreement lays down an international minimum standard of patent protection 
which needs to be implemented by its Signatories. Article 27.1 of the TRIPs Agreement 
requires Signatories to grant patent protection for any inventions, whether products or 
processes, irrespective of their field, provided the patentability criteria are fulfilled. 
Notwithstanding this broad requirement for patentability, the treaty provides for some 
flexibility in the implementation of patent protection for living organisms. The flexibility is 
very important in view of such a complex multilateral agreement which involves negotiating 
countries with different levels of economic background and with diverse levels of 
technological development. Fundamentally, the flexibility seeks to ensure that all 
participating countries feel able to take on board various obligations that need to be included 
into their national patent laws, and ultimately implemented, should they decide to ratify the 
TRIPs Agreement. 
 
As a result, irrespective of the obligation under Article 27.1 of the TRIPs Agreement, 
Signatories are allowed to exclude „animals‟ from patent protection. Article 27.3(b) states: 
 
Members may also exclude from patentability: 
Plants and animals other than micro-organisms, and essentially biological 
processes for the production of plants or animals other than non-biological and 
micro-biological processes. However, Members shall provide for the protection of 
plant varieties either by patents or by an effective sui generis system or by any 
combination thereof. The provisions of this subparagraph shall be reviewed four 
years after the date of entry into force of the WTO Agreement. (emphasis added) 
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Whereas the TRIPs Agreement came into force in 1995, the „unsettled‟ nature of Article 
27.3(b) (which is indicated by the last sentence in the provision) quickly becomes apparent. 
The provision, which is subject to review (also often referred to as the „built-in‟ agenda) 
arose from, and is evidenced by, the complexities of reaching an agreement between the 
negotiating countries at the conclusion of the Uruguay Round Meeting. The crux of the 
problem lies within the different perspectives held by the negotiating countries on the 
purposes and implications of the exclusion. More than a decade has lapsed. The review, 
which started in December 1998, has not yet achieved any specific understanding among the 
negotiating parties including the basic issue of what „review‟ should mean. 1  These 
divergences on basic points will be shown to be similarly relevant to the issue on patent 
protection for animal inventions. Consequently, while Signatories remain obliged to give 
effect to Article 27.1 and retain the flexibility to exclude „animals‟ under Article 27.3(b), they 
are left with much uncertainty as to how the latter should be applied.  
 
This chapter aims to understand the reason why different Signatories to the TRIPS 
Agreement have adopted diverse approaches to interpret the exclusion of animal inventions. 
It also intends to examine the development within the WTO of issues relating to the exclusion. 
In order to achieve these aims, this chapter is divided into five sections. Section 2 examines 
the past history of the exclusion. This contains an examination of the basis and purpose for 
having the exclusion in the TRIPs Agreement and the grounds underpinning the adoption of 
the final version of the exclusion. The negotiation process of the TRIPs Agreement will be 
examined to see if the reasons for the exclusion were made explicit, and to appreciate the 
                                                          
1
  On the one hand, developed countries hold the view that it means only a „review of implementation‟. On the 
other hand, developing countries argue that the revision of the content of the provision itself is crucial. See 
C.M. Correa, Review of the TRIPs Agreement: fostering the transfer of technology to developing countries, 
946, http://www.twnside.org.sg/title/foster.htm (Accessed: 10 August 2010). 
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reasons leading to the flexibility to implement the exclusion. Section 3 discusses the present 
status of Article 27.3(b) arising from the review process of the provision during the Doha 
Development Agenda (DDA).
 2
 In this section issues relating to the patentability of life forms 
and the Convention on Biological Diversity 1992 (CBD)
3
 will be analysed so as to 
understand the current debate between developed and developing countries on the issues. 
Grounds for favouring or opposing the elimination of the exclusion, under the review will 
also been assessed. In the absence of any specific resolution of the review of the exclusion, 
section 4 will discuss the future of the exclusion, in terms of its application in Malaysia, 
which has chosen to exclude animal varieties under its national patent law. Suggestions on 
how Malaysia can proceed to interpret the exclusion will be made. Section 5 concludes the 
chapter. 
 
In relation to the previous chapter, this chapter will add emphasis to the fact that the needs of 
a developing country (such as Malaysia) and its national priorities play an important role in 
determining the interpretation of the exclusion. Having identified the needs of the livestock 
industry in Malaysia, this chapter places the debate in its international context, to identify 
factors which affect Signatories such as Malaysia in adopting a specific approach to construe 
the exclusion of animal inventions within national patent law. As this chapter will argue, due 
to the flexibility under Article 27.3(b), any interpretation for the exclusion of animal 
inventions would not undermine a Signatory‟s obligation under the TRIPs Agreement. 
                                                          
2
  The Doha Declaration is the WTO Ministerial Declaration which was adopted on 14 November 2001 at the 
Fourth Session of the Ministerial Conference. Through Article 19 of the Declaration (which underpins the 
Doha Development Agenda within the WTO), the Ministerial Declaration instructed the TRIPs Council „to 
examine, under the review of Article 27.3(b), inter alia, the relationship between the TRIPs Agreement and 
the CBD.‟ The Declaration, together with other Declarations similarly adopted by the Ministerial Conference 
(including the Ministerial Declaration on the TRIPs Agreement and public health) are available at: 
http://www.wto.org/english/tratop_e/dda_e/texts_contents_e.htm (Accessed: 22 June 2012). 
3
  Available at: CBD, http://www.cbd.int/doc/legal/cbd-en.pdf (Accessed: 31 March 2012). 
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Nevertheless, the issues debated within the review process are relevant to be considered by 
the Signatory in implementing the flexibility.  
 
2. The Past: the historical overview of the exclusion of animal inventions under the 
negotiation of the TRIPs Agreement 
 
2.1 The inclusion of intellectual property rights (IPRs) in the negotiations 
 
IPRs which cover intangible objects as opposed to tangible goods have been under the 
exclusive territory and expertise of the WIPO.
4
 Prior to the inclusion of IPRs under the trade 
regime (since the Uruguay Round Meeting), the WIPO had been functioning as standard-
setter and decision-maker in the field of intellectual property protection.
5
 As regards to patent 
rights, the function of the Organisation was implemented through one of its important 
administered Conventions, namely the Paris Convention for the Protection of Industrial 
Property 1883 (Paris Convention).
6
 As far as the decision-making function is concerned, the 
WIPO does not have a formalised dispute settlement procedure, but only Alternative Dispute 
Resolution (ADR).  Article 28 of the Paris Convention provides for the possibility of bringing 
                                                          
4
  It is a specialised agency of the United Nations (UN) which has been mandated with the promotion of 
intellectual property throughout the world through co-operation among Member States and where 
appropriate, in collaboration with any other international organisation. The WIPO was established by the 
WIPO Convention in 1967. The Organisation administers the Paris Convention and the Berne Convention 
(for copyright protection). See WIPO, What is WIPO?  http://www.wipo.int/about-
wipo/en/what_is_wipo.html (Accessed: 9 February 2010).  
5
  D.D. Bièvre and L. Thomann, Forum shopping in the global intellectual property regime, Arbeitspapiere - 
Working Papers, Nr. 132, (Mannheimer Zentrum für Europäische Sozialforschung, 2010) 15.                         
6
  The Act of Stockholm of 14 July 1967. The Convention provides for general guidelines for the protection of 
a range of subjects that are considered to be „industrial property‟ under the Convention. The rights available 
for protecting this subject matter include patent, trademarks, trade names, industrial designs, and utility 
models. As far as the international patent framework is concerned, the Paris Convention plays an important 
role in the internationalisation of patent protection. Its difference with the TRIPs Agreement is that the latter 
is tied down to the international trade obligations of Member States of the World Trade Organisation (WTO). 
In order to be a WTO‟s Member State, a country must be a Signatory to the TRIPs Agreement. 
85 
 
disputes before the International Court of Justice (ICJ).
7
 However, there is no specific 
reference to how disputes between party states are to be settled. 
8
  
 
The insertion of IPRs under trade regimes aptly raises a question: what led to the shift in 
regulatory regime for IPRs from WIPO to GATT, which has dealt mainly with trade in 
tangible goods since 1948?
9
 One of the factors which led to the shift of the forum for 
regulating certain international issues from one regulatory institution to another is a concept 
known as „forum or venue shopping‟. Countries engage in forum shopping where there is an 
alternative and better venue to pursue and achieve their specific policy objectives.
10
 In the 
context of international IPRs, it has been pointed out
11
 that the main reason which leads states 
to forum shop is the „differing degrees of judicialisation‟.12  
 
The inclusion of IPRs on the agenda of the Uruguay Round Meeting was mooted by the US
13
 
which has been known as the world‟s major trading power. However, in the 1970s and 1980s, 
the country‟s economic supremacy in manufacturing and technology was threatened by the 
catching up process from countries such as Japan and some other Asian newly industrialised 
                                                          
7
   WIPO, n 4 above, ibid. 
8
  D.D. Bièvre et al, n 5 above, ibid. 
9
  WTO, Understanding the WTO, http://www.wto.org/english/thewto_e/whatis_e/tif_e/understanding_e.pdf 
(Accessed: 8 February 2010). The WTO replaced the GATT as an international organisation, but the GATT 
still exists as the WTO‟s umbrella treaty for trade in goods, updated as a result of the Uruguay Round 
Negotiations. 
10
  See for instance D.D. Bièvre et al, n 5 above; S.K. Sell, From forum-shifters to shape-shifters: rulemaking 
and enforcement in intellectual property, Paper presented at the annual meeting of the International Studies 
Association‟s (ISA) 50th Annual Convention „Exploring the past, anticipating the future‟, New York City, 15 
February 2009, 
http://www.allacademic.com//meta/p_mla_apa_research_citation/3/1/0/4/2/pages310424/p310424-1.php 
(Accessed: 29 March 2011). 
11
  Other reasons why states forum shop are: (1) diverging actor (country) preferences; (2) power and 
capabilities; and (3) government agency specialisation. D.D. Bièvre et al, n 5 above, 3. 
12
  ibid. 
13
  M. Blakeney, Trade related aspects of intellectual property rights: a concise guide to the TRIPs Agreement 
(London: Sweet and Maxwell, 1996) 2. 
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countries (NICs).
 14
 One of the factors which weakened the US competitive performance in 
the world‟s trading arena was the ineffective IPRs in developing countries.15 This system 
enabled its economic competitors to take advantage of the innovations developed by US 
inventors by copying and trading counterfeit goods, causing the loss of substantial revenues 
to its domestic industries.
16
 Illustratively, annual losses of the video industry were reported to 
be approximately US$6 billion in 1983 and the counterfeiting of spare parts was estimated to 
cause the automotive industry an approximate loss of US$12 billion.
17
  
 
These adverse economic implications have been used by the affected key players in the 
industries such as computer software and microelectronics, chemicals, pharmaceuticals and 
biotechnology,
18
 to convince the US Government of the need to restrict competition by 
connecting IPRs to trade.
19
 It is in the pursuance of this economic interest that in 1982, during 
the preparatory work for the GATT ministerial meeting, the proposal to consider IPRs to be 
included in the agenda of the Meeting was submitted. The importance of having IPRs in the 
agenda of the Uruguay Round Meeting was due to the value of those rights, and this was 
evidenced by the strategy adopted by the US to assure that this aim was achieved. In the 
words of Edmund T. Pratt, chairman of Pfizer, who initiated the process in 1984: 
 
[w]e must also work to get more broadly based economic organizations such as the 
OECD [Organization for Economic Co-operation and Development] and the 
GATT, to develop intellectual property rules, because intellectual property 
protection is essential for the continued development of international trade and 
investment.
20
 
                                                          
14
  C.M. Correa, Implementing the TRIPs Agreement: general context and implications for developing countries 
(Third World Network: 1998) 5-6. 
15
  M. Blakeney, n 13 above, ibid. 
16
  ibid. 
17
  ibid. 
18
  A.O. Adede, Origins and history of the TRIPS negotiations in C. Bellmann, G. Dutfield and R. Melendez-
Ortiz (eds), Trading in knowledge: development perspectives on TRIPS, trade and sustainability (London: 
Earthscan, 2003) 24.  
19
  ibid. 
20
  A.O. Adede, n 18 above, 24.  
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The US‟ insistence for IPRs to be brought under the trade regime (GATT) was primarily due 
to its dissatisfaction with the performance of the WIPO in revising the Paris Convention for 
stronger standards of protection of international IPRs in view of the substantial losses caused 
to its industries.
21
 The feature of the GATT forum that provided for effective enforcement of 
agreements through its dispute settlement mechanism was another reason for this. The 
mechanism is seen as an important enforcement tool with which the US can protect its highly 
technological industries‟ interests worldwide. This weapon is missing from the WIPO and the 
Paris Convention.
22
  
 
The proposal to shift the regulatory regime received strong objections from developing 
countries led by Brazil and India, mainly due to the WIPO-World Trade Organization (WTO) 
expertise issue. Subsequent negotiations with regard to the issue of whether IPRs were to be 
shifted within GATT‟s jurisdiction were led by the Swiss and Colombian Ambassadors. 23  
Their proposal argued that negotiations on IPRs issues within the GATT Meeting would not 
prejudice other complementary initiatives that might be taken in the WIPO and elsewhere.
24
 
As a result, IPRs were finally included in the Uruguay Round Meeting.  
 
The decision by the GATT meeting to incorporate IPRs in the Uruguay Round Meeting in the 
light of the proposal championed by the US can be interpreted in two ways. On the one hand, 
it reflects the increasing recognition by the GATT Agreement of the relationship between 
IPRs, which themselves are underpinned by commercial elements, and international trade. 
                                                          
21
  See for instance A.O. Adede, n 18 above, 25; M. Matsushita, T.J. Schoenbaum and P.C. Mavroidis, The 
World Trade Organization: law, practice and policy (Oxford: The Oxford International Law Library, 2003) 
398 and 677. 
22
  ibid. 
23
  T.P. Stewart (ed), The GATT Uruguay Round: a negotiating history (1986-1992), Volume II: commentary 
(Deventer: Kluwer Law and Taxation Publishers, 1993) 2263. 
24
  ibid. 
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Bringing the rights under common international rules was seen as the best way to achieve the 
aim of introducing more consistency in trading regulations,
25
 which is obviously part of the 
functions of the international Agreement such as GATT. On the other hand, since IPRs, in 
particular patent rights, depend heavily on the technological progress of a given country, it 
has been asserted
26
 that the decision was only to fulfil the interests of the industrialised 
countries such as the US and Japan. With a strong economic ability, robust investments in 
scientific research and ultimately, technological advancement, the inclusion of IPRs into the 
realm of GATT has put these countries in a far better position to utilise the system to pursue 
their economic interests, compared to their developing counterparts.
27
 
 
Two factors underpinned the divergence of views between developed and developing 
countries during the Uruguay Round Meeting: (1) a difference of objectives that each 
category of countries intended to achieve by participating in the negotiations; and (2) 
divergence of views as to the importance of IPRs in economic development. On the one hand, 
industrialised countries such as the US entered into the negotiations with a clear and strong 
objective to secure their economic interests worldwide.
28
 One of the most important aspects 
being negotiated during the Uruguay Round Meeting was the scope and standard of IPRs 
protection to be adhered to by the negotiating countries. With strong demand for enforcing 
IPRs from the private sector, which is the key investor in R&D (compared to the public 
sector), it is important for developed countries to ensure that the aspect is agreed upon in 
accordance with the industries‟ interests. It has been widely emphasised 29  that IPRs, in 
                                                          
25
  WTO, n 9 above. 
26
  See for instance observation in H. Adolf, Trade-related aspects of intellectual property rights and developing 
countries (2001) The Developing Economies, 76. 
27
  ibid. 
28
  For objectives set out by the US proposal for negotiation of the TRIPs Agreement, see P.K. Yu, The 
objectives and principles of the TRIPs Agreement (2009) 46 Houston Law Review, 4, 984. 
29
  K.W. McCabe, The January 1999 review of Article 27 of the TRIPs Agreement: diverging views of 
developed and developing countries toward the patentability of biotechnology (1998) Journal of Intellectual 
Property Law, 47. 
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particular patent rights, are an important instrument for industrialised countries to recoup 
enormous amounts of investments involved in developing a particular product and bringing it 
to the market. In evidence, it was estimated by the Pharmaceutical Research and 
Manufacturers of America that it takes ten to twelve years and over US$350 million to bring 
a single pharmaceutical product to market.
30
 Specifically on animal inventions, US$15 
million was invested by Du Pont to finance the transgenic onco-mouse research which could 
assist in the detection of cancer.
31
  
 
On the other hand, while the participation of developing countries in the Uruguay Round 
Meeting was also motivated by economic interests, their objectives and expectations from the 
process were different from their developed counterparts. The protection of innovation was at 
that time not yet on the economic agenda of developing countries.
32
 In fact, IPRs had not 
been given much importance prior to the Uruguay Round Meeting, in particular due to the 
lack  of  technological  progress  and  the  existence  of  only  small-scale  industries  in  these 
countries, hence a lack of investment for research.
33
 This state of affairs led to the absence of 
a legal framework at national level for IPRs since there was no need to protect the interest of 
inventors or to enforce their rights.
34
 Notwithstanding this, it is not suggested that IPRs were 
not important to developing countries or that they were absolutely against their 
implementation. The point is that their protection was not the motivation for participating in 
the Meeting. Nevertheless, the awareness of developing countries of the importance of IPRs 
had been improved by participating in the Meeting. From that point onwards, developing 
                                                          
30
  ibid. 48. 
31
  See Harvard College v Canada (Commissioner of Patents) [2003] 5 LRC 330, 344. For another instance, the 
regulatory costs to commercialise animal vaccine was estimated at US$242,000 to US$469,000. See OECD, 
The bioeconomy to 2030: designing a policy agenda, 2009, 
http://www.oecd.org/dataoecd/5/24/42837897.pdf (Accessed: 5 April 2011) 11. 
32
  H. Adolf, n 26 above, 49. 
33
  ibid. 
34
  ibid. 
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countries started to rationalise how the system could be utilised to their benefit, within their 
economic strength and technological development. This change of perception was 
particularly relevant during the „second round of negotiations‟ that is during the review 
process of Article 27.3(b), as will be shown in section 3 of this chapter. 
 
The main reason that prompted developing countries to negotiate in the Uruguay Round 
Meeting was their anticipation of gains from other trade areas which were concurrently being 
negotiated during the Meeting.
35
 Developing countries are major producers of commodities 
such as agricultural goods, textiles and clothing. The negotiations were seen as a gateway to 
international market opportunities for these products which could assist the growth of their 
economies.
36
 In this way, it can be concluded that the focus of developing countries during 
the Meeting was on the success of other Agreements attached to the WTO Agreement, rather 
than the TRIPs Agreement which was the focal point for developed countries. As regards the 
TRIPs Agreement, due to their lack of capital and technological expertise,
37
 much hope was 
put by developing countries on the potential of technology transfer
38
 (being the „Objective‟ of 
the Agreement),
39
 to obtain necessary technologies to develop their economies.  
 
Since the negotiations involved the major economic players in the world where highly 
technological industries are mainly located, developing countries could already foresee the 
                                                          
35
  The Agreement was an Annexe to the Agreement Establishing the World Trade Organisation (WTO 
Agreement) together with 13 Multilateral Agreements on Trade in Goods. The Multilateral Agreement on 
Trade are; General Agreement on Tariffs and Trade 1994 and Agreements on Agriculture, Application of 
Sanitary and Phytosanitary Measures, Textiles and Clothing, Technical Barriers to Trade, Trade-Related 
Investment Measures, Implementation of Articles VI and VII of the General Agreement on Tariffs and Trade, 
Preshipment Inspection, Rules of Origin, Import Licensing Procedures, Subsidies and Countervailing 
Measures and Safeguards. See M. Blakeney, n 13 above, 7. These other Agreements will however, not to be 
discussed further in this thesis. 
36
  A.O. Adede, n 18 above, 31. 
37
  A.M. Pacon, What will TRIPs do for developing countries? in F.K. Beier and G. Schricker (eds), From 
GATT to TRIPS – the Agreement on Trade-related Aspects of IPRs (New York: Max Planck Institute for 
Foreign and International Patent, Copyright and Competition Law, 1996) 343. 
38
  A. Howard and J. Reinbothe, The state of play in the negotiations on TRIPs (GATT/Uruguay Round) (1991) 
13 European Intellectual Property Review, 5, 158. 
39
  Article 7 of the TRIPs Agreement. 
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high standard of protection that would be required from them in order to protect the interests 
of developed countries. This led to their opposition to a prescribed scope and standard of 
protection for patent rights. Such a standard has been viewed by developing countries as 
creating an imbalance in benefits and a greater economic gap between them and developed 
countries.
40
 Whereas they would be obliged to accord protection to innovations which are 
mostly developed by industrialised countries, they anticipated the unequal benefits that they 
could obtain from the imposed standard, due to their weaker capability in economic and 
technological development. In evidence, in the late 1980s developing countries held only 
about 1% of all patents in biotechnology, and by 2005 that figure has increased but to only 
4%.
41
 Consequently, it has been developing countries‟ consistent stance that the regulation of 
IPRs affects the „sovereign rights of all countries‟42 and therefore, needs to be made on the 
basis of their own national standards and requirements.
 
 
 
The differences in objectives and expectations of developed and developing countries are also 
relevant in the context of the shift of regulatory regime discussed earlier. For developed 
countries which prefer strong enforcement for IPRs globally, the GATT is the most 
appropriate forum to achieve this aim. However, for developing countries, their lack of 
technological development was the basis for their argument that IPRs should remain under 
the WIPO, rather than being placed under the GATT. Allowing IPRs to be moved under the 
GATT, where strict enforcement mechanisms are available, would expose them to economic 
trade sanctions if they failed to accommodate the economic interests of developed countries. 
Notwithstanding the diverse views between developed and developing countries, the TRIPs 
                                                          
40
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  G.K. Rosendal, Balancing access and benefit sharing and legal protection of innovations from 
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Development, 4, 432. 
42
  H. Adolf, n 26 above, 57. 
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Agreement was concluded in 1994 and came into effect a year later. On the one hand, for 
developed countries, this conclusion marked their achievement in getting developing 
countries to agree on the various IPRs rules prescribed by the TRIPs Agreement. Most 
importantly it was for securing the enforcement of the rights under the international trade 
regime. On the other hand, for developing countries, accepting the TRIPs Agreement as a 
package of the negotiations has been described by critics
43
  as a „price that they had to pay‟ in 
the exchange for concessions in issues salient to them such as market access in agricultural 
and textile trade.  
 
After this review of the diverse expectations and interests of developed and developing 
countries on the general aspect of international IPRs, the next sub-section will focus on their 
views on patent protection involving biotechnological inventions, in particular animal 
inventions. As the discussion will demonstrate, the negotiators had different views as to the 
need to protect animal inventions under the patent regime. The final adopted version of 
Article 27.3(b) will be analysed to show how this divergence was „reconciled‟ at the end of 
the Meeting. The analysis will reveal that, the solution has only aimed at the „speedy‟ 
conclusion of the TRIPs Agreement, which eventually led to the review of Article 27.3(b) 
within the WTO.  
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2.2 Patent protection for animal inventions during the negotiation period 
 
2.2.1 Proposals from the negotiators 
 
Negotiating countries were divided in their proposals as far as the exclusion of animal 
inventions was concerned. The proposals could be broadly divided into two categories: (1) 
the countries which proposed their inclusion within the patent regime; and (2) the countries 
which suggested their exclusion. Proposals for the first category came from negotiating 
countries such as the US,
44
 Switzerland,
45
 Japan
46
 and Australia.
47
 These countries generally 
urged for broad patent coverage without any exclusion for inventions involving living 
matter.
48
  Proposals for the second category came from three groups of negotiating countries. 
The first proposal came from the European Community (which later became the EU)
49
 and 
the second was communicated by the Negotiating Group of the Nordic countries.
50
 The final 
proposal came from fourteen countries from developing world, which comprised Argentina, 
Brazil, Chile, China, Colombia, Cuba, Egypt, India, Nigeria, Pakistan, Peru, Tanzania, 
Uruguay
 
and Zimbabwe.
51
 These proposals reflected the adopted nature of the patent law and 
biotechnology policies already practised by the negotiating countries. In the context of 
                                                          
44
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Related Aspects of IPRs‟, Document MTN.GNG/NG11/W/36 (10 July 1989) 1-2. 
51
  GATT, „Communication from Argentina, Brazil, Chile, China, Colombia, Cuba, Egypt, India, Nigeria, Peru, 
Tanzania, Uruguay‟, Document MTN.GNG/NG11/W/71 (14 May 1990) Article 4(1), 8.  
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international negotiations such as the Uruguay Round Meeting it would normally have been 
the intention of each negotiating country, to seek to ensure that that the Meeting would adopt 
the proposal that each had forwarded. This is because, assuming that the Meeting adopted a 
different principle from the one forwarded by a negotiating country, the relevant country 
would need to amend its national law to suit the requirement under the concluded agreement. 
It is beneficial that the development of patent protection involving living matter in some of 
the negotiating countries be discussed at this juncture so as to understand their laws, policies 
and practices relating to the subject matter.  
 
It is pertinent to note that, traditionally, the grant of patent protection was limited to technical, 
mechanical and chemical inventions. §101 of the 35
th
 Title US Code (§101 35 USC)
52
 
provides for a broad range of matter that could be patentable. Nevertheless, in practice, 
despite the granting of patent by the US Patent and Trademark Office (USPTO) to Louis 
Pasteur in 1873, the patent office consistently refused claims to life forms as not being 
patentable subject matter.
53
 It has been observed
54
  that the key precedent discouraging the 
patenting of life in the US was the decision  given by the patent office in the case of Ex Parte 
Latimer,
55
 which later formed the basis of the principle known as the „product of nature‟ 
doctrine. In that case, the Commissioner of the USPTO in refusing a patent application which 
covered a fibre identified in the needles of a pine tree said that, „it would be unreasonable and 
impossible to allow patents upon the trees of the forest and the plants of the earth.‟56 Based 
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Available at: US Patent and Trademark Office (USPTO), 
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53
  P. Grubb, Patents for chemicals, pharmaceuticals and biotechnology: fundamentals of global law, practice 
and strategy (Oxford: Oxford University Press, 1999) 227. 
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  D.J. Kevles, A history of patenting life in the US with comparative attention to Europe and Canada 
(Luxembourg: Office for Official Publications of the European Communities, 2002) 1. 
55
  (1889) Dec. Com. Pat., 123. 
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on this doctrine, life forms such as plants, animals and micro-organisms have been 
consistently held to be unpatentable. 
 
As regards animals and micro-organisms, the long-held „product of nature‟ doctrine was 
radically changed in 1980 due to the US Supreme Court‟s decision in the case of Diamond v 
Chakrabarty (the Chakrabarty case).
57
 In the case, the patentability of a bacterium capable of 
breaking down multiple components of crude oil which was developed by the applicant was 
at issue. The USPTO refused the application in the first instance, since the claimed micro-
organisms were a „product of nature‟.58  However, the Supreme Court granted the patent 
sought for and made an important ruling where it was held that the patentability of an 
invention did not depend on the question whether it related to animate or inanimate matter, 
but rather whether or not the invention is made by man.
59
 This finding has led to the 
evolution of the principle that „anything under the sun manufactured by man is patentable‟, 
which allows patent examiners to consider the patentability of life forms, provided they meet 
the usual patentability criteria.
60
  
 
While patent protection is territorial in nature, economic competition is key to the 
international patent law framework. In Japan, which is another major player of the world‟s 
economy, there has also been a consistent move toward enabling patent law to protect life 
forms. Starting with five categories originally excluded in the Patent Act 1959, the list 
became thinner with only products which are „likely to disturb public order or morals or to be 
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  Diamond, Commissioner of Patents and Trademarks v Chakrabarty [1980] 447 US 303; 100 SCt 2204. 
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  ibid. 305. 
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  ibid. 312. 
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injurious to public health‟ to be excluded. 61 While living organisms have never specifically 
been on the excluded list, micro-organisms and genetic materials became patentable in 1979 
with the amendment to the patent examiners‟ guidelines by the Japan Patent Office (JPO).62  
 
Moving on to Australia, under the Australian Patents Act 1990,
63
 genetically modified 
organisms (GMOs) are patentable unless the use of the claimed invention is contrary to law 
under s51(1) or where it falls under the „general inconvenience‟ exception under s18(1).64 
The phrase „contrary to law‟ is limited to the instance where the use of the invention will be a 
criminal offence and, as far as the „general inconvenience‟ exception is concerned, it has been 
used in Australia to deny patent claims only for subject matter to which the public expects 
free access, such as a method of operating a computer.
65
 
 
Principally, the above developed countries‟ stance as to the patentability of life forms is that 
the policy of not excluding anything from being the subject matter of a patent or from patent 
protection is necessary in order to encourage innovation, help disseminate ideas and increase 
trade. Furthermore, since they are the nations which are already the most advanced in 
technology, these countries have the most to gain in terms of finance and power from the 
broad protection of biotechnological inventions. 
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  The Patent Act is available at: Japan Patent Office, http://www.cas.go.jp/jp/seisaku/hourei/data/PA.pdf 
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The proposals to exclude animal inventions by the EU and the Nordic countries can be 
understood by looking at the historical background and perceptions of their own patent laws. 
Their proposals were fundamentally influenced by the existence of a similar provision which 
had been included long before in Article 2(b) of the Strasbourg Convention and Article 53(b). 
This was further evidenced by an admission to this effect made by the representative of this 
group when the reason for proposing this exclusion was requested by other negotiators during 
the Uruguay Round Meeting.
66
 Having the exclusion in the two European Patent Conventions, 
it was therefore, to be expected that the EU would forward a proposal which contained a 
similar exclusion. 
 
The patentability of an invention involving living matter started to become relevant in the EU 
Member States as early as 1969, where in the case of Rote Taube,
67
 the German Federal 
Supreme Court held that a method for breeding better quality doves was patentable, provided 
that it fulfilled the repeatability requirement. In the course of its judgement, the court made 
an important ruling when it stated that, in principle, the possibility of patenting is not 
excluded by the fact that living matter is involved.
 68
 This decision seems to suggest that the 
door to allowing patent protection for inventions involving living matter in Europe is 
permitted provided the patent qualification criteria are met. However, it will be shown in 
chapter 4 that the rule is not that straight forward, when Article 53(b) which excludes animal 
varieties is analysed.  
 
                                                          
66
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The basis of the proposal from developing countries was that potential Signatories should be 
given the freedom to exclude certain subject matter from patentability. The built-in flexibility 
was averred
69
 to be necessary in view of various issues that required due consideration. This 
includes differences in the economic level of the negotiating countries and the need to take 
into account particular national interests
70
 such as socio-economic needs, technological 
advancement,
71
 ethical, and environmental issues. The uncertainty with regard to the 
economic consequences that could be caused by research activities in biotechnology
72
 were 
also among the concerns of developing countries. As will be shown in sub-section 2.2.2 
below, the drafts of the provision relating to the protection for animal inventions during the 
Uruguay Round Meeting similarly reflect the diverse views and national practice among the 
negotiating countries.  
 
2.2.2 The drafts of the exclusionary provisions  
 
As the negotiations developed, the drafts containing the exclusion of animal inventions 
during the Uruguay Round Meeting were contained in three documents: (1) the Anell Draft; 
(2) the Dunkel Draft; and (3) the Brussels Draft. The prepared drafts were essentially a 
compilation of the options for the various legal commitments as they had emerged from the 
process of informal consultations.  
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The Anell Draft
 73
 was the first draft of the TRIPs Agreement which was prepared by the 
Ambassador Lars E. R. Anell (Chairman of the Negotiation Group) in his administrative 
capacity, with the aim of expediting the business of the meeting toward the conclusion of the 
TRIPs Agreement. Under this Draft, as far as animal inventions were concerned, the options 
of exactly what was to be excluded were still left open. Two questions which then became an 
issue were: (1) whether the exclusion of the invention was to be made mandatory or 
permissive; and (2) whether the term „animals‟ or „animal varieties‟ was to be adopted to 
represent the exclusion of animal inventions from patent protection. There is however, no 
documented evidence in the Negotiating Group‟s papers to show that the wording of the 
provision (relating to animal inventions) was debated. 
 
The Anell Draft remained under discussion by the Negotiation Groups for four months until 
the emergence of the Draft Final Act Embodying the Results of the Uruguay Round of 
Multilateral Trade Negotiations
 74
 that was submitted to the Ministerial Meeting in Brussels 
(Brussels Draft) in December 1990. In the Brussels Draft, the relevant exclusionary provision 
was expanded to provide a number of other versions to be considered. Whereas there was still 
no conclusive decision with regard to the term that should represent the exclusion, at this 
stage, an agreement had been obtained for the exclusion to be made optional rather than 
mandatory. 
 
The Brussels Ministerial Meeting was supposed to conclude the Uruguay Round Meeting,
75
 
including the provision which contained the exclusion of animal inventions. However, due to 
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the „undecided‟ position (as demonstrated by the availability of the options for the term to 
represent the exclusion) this provision (together with many other key areas of negotiations)
76
 
was sent back to the Trade Negotiations Committee (TNC) for further consideration. The 
Brussels Draft became the working text for the TNC (under the chairmanship of Mr Arthur 
Dunkel)
77
 until the finalisation of the document prepared for the purpose of concluding the 
Uruguay Round.
78
 The exclusionary provision contained in the final document (Dunkel 
Draft), which formed the final text of the TRIPs Agreement, showed that a decision had 
finally been made that the term „animals‟ should be adopted by the Agreement. However, 
there was again no information available as to why the final text was chosen by the TNC. 
 
2.2.3 The „compromise solution‟ 
 
The developments of the exclusion of animal inventions as discussed in sub-sections 2.2.1 
and 2.2.2 above pointed in the direction of a „compromise solution‟. Whereas the original 
proposals by the three groups of the negotiating countries to exclude animal varieties and the 
broad protection sought by developed countries had both been compromised, the exclusion of 
animal inventions was principally accepted by the negotiating countries. Nevertheless, the 
proposal by the EU and developing countries to secure the exclusion seems to have prevailed 
over the proposal of their developed counterparts which required broad protection to be 
explicitly recognised by the TRIPs Agreement.  
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The biggest compromise must have come from the US. As noted by Straus:
 79
 „the US was 
originally categorically opposed to an exclusion for plants and animals. It finally concurred 
because the provision only provides for an optional exclusion which need not be 
implemented by the US‟.  Notably, one of the principles agreed upon by all the negotiating 
countries in the Ministerial Declaration on the Uruguay Round
80
 was that developed 
contracting parties should not seek, nor should developing contracting parties be required to 
make, concessions which were inconsistent with, their development, and financial and trading 
needs.
81
 This general principle governing the negotiations seems to have been the basis for 
the flexibility granted to the negotiating countries which have different levels of economic 
and technological growth.  
 
The decision to allow the negotiating countries to exclude animal inventions was indeed an 
inevitable step. It was meant to ensure that the countries which have divergent views on the 
patentability of biotechnological inventions came together, to agree to become Signatories to 
such a complex multilateral Agreement. Consequently, any provision which was included in 
the TRIPs Agreement must be seen as having considered the interests of developed and 
developing countries. In this context, the WTO could be seen as a „moderator‟ which 
balances the interests of negotiating countries. Conversely, it can equally be concluded that 
such flexibility does not necessarily mean a balance of interests. In this respect, critics
82
 have 
urged that developing countries should maximise the use of the flexibility under Article 
27.3(b) in view of their progress in economy and technology. However, the practical 
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application may not be without problems. The subjectivity of what is meant by „minimum 
standard‟ of protection could inevitably put developing countries under pressure to strengthen 
the IPRs protection as intended by developed countries. Evidentially, bilateral agreements 
have been used by the US for this purpose.
83
 Moreover, the general rule of patentability under 
Article 27.1 could also be used by industrialised countries to press for broad patent 
protection
84
 because this very general principle is capable of narrowing down or overriding 
the flexibility given by Article 27.3(b). The situation may be different altogether if there were 
a specific provision in the TRIPs Agreement, stating that the option by any Signatory to 
exercise such flexibility is conclusive.  
 
While having broad protection for living matter is important for developed countries, getting 
as many countries as possible to agree to become Signatories to such an international trade-
based Agreement is arguably of greater achievement to their economy. Through the TRIPs 
Agreement, various other aspects of patenting such as terms of protection and licensing of 
patent products and processes are able to be internationally regulated and any non-
compliance with these other issues could be effectively enforced.
85
 Intrinsically, an important 
area which was left undecided by the negotiation process of the Uruguay Round Meeting is 
the subject matter excluded under Article 27.3(b). The decision to adopt the term „animals‟, 
rather than the term „animal varieties‟, as proposed by a small group of countries to represent 
the exclusion remains unclear. The minutes of the various proceedings, either in the 
documents forwarded by those countries proposing the exclusion or by the representatives in 
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discussing the form of the exclusion, show that no attempt was made to define what these 
terms mean. Therefore, as the term „animals‟ has not been defined anywhere in the TRIPs 
Agreement, Signatories can exercise their discretion to determine the subject matter of the 
exclusion. 
 
This section has shown how the exclusion of animal inventions was included in the TRIPs 
Agreement. It arose from the differences in national practice and perspectives of the 
negotiating countries toward the patentability of inventions involving living matter, which 
each country has tried to pursue at the international level. Notably, this is underpinned by 
different technological and economic development of the negotiating countries. The 
conclusion of the Uruguay Round Meeting in view of various international trade regulations 
contained therein was a paramount objective of GATT. As regards the exclusion under 
Article 27.3(b), assuming any decision was made in favour of any particular negotiating 
country, the success of concluding the TRIPs Agreement would be seriously prejudiced. The 
outcome of the Uruguay Round Meeting, by providing the negotiating countries with 
flexibility to exclude animal inventions from patent protection is therefore expected. 
Nevertheless, the achievement of the „compromised solution‟ as contained in Article 27.3(b) 
marked the beginning of another episode of debate under the international IPRs regime.  
 
In this respect, as explained by critics,
86
 whereas an international agreement was concluded, 
the forum shopping does not necessarily end. During the review process of an agreement, 
countries would utilise the given regulatory regime to either argue in favour of adding a new 
issue to, or removing an existing issue from, the concluded agreement.
87
 This rule precisely 
explains the current development in the review process of Article 27.3(b) which is the focus 
                                                          
86
  D.D. Bièvre et al, n 5 above, 3. 
87
  ibid. 
104 
 
of the following section. The discussion will show that the flexibility granted to the 
Signatories to exclude animal inventions, has subjected Article 27.3(b) to greater 
complexities during the review process. Central to the discussion is an assessment of the 
issues which have been debated between developed and developing countries, and 
suggestions as to how the latter countries could advance their technology and economy by 
allowing patent protection to animal inventions while observing their rights and interests 
under the CBD. The discussion is relevant to the research question so as to inform a 
Signatory (including Malaysia) of international patent law issues pertaining to the exclusion 
of animal inventions which requires consideration in construing the relevant exclusionary 
provision within its national patent law.  
 
3. The Present: the on-going review process of Article 27.3(b)  
 
At the commencement of the review, the focus was mainly on issues pertaining to the subject 
matter of the exclusion under Article 27.3(b). This includes the question of whether or not the 
exclusion of animal inventions should remain in, or be deleted from the Article, and the 
clarification of some terms adopted by the Article: animals, micro-organisms, and patentable 
and non-patentable processes. While this agenda is still relevant, the review of Article 27.3(b) 
has, since 2001, included broader policy issues, which relate the implications of patenting 
living matter to the national interests of the negotiating parties. The inclusion of the new 
agenda depicts the increasing recognition within the WTO of the challenges faced by 
developing countries in implementing the provisions of the TRIPs Agreement.  
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 3.1 The general perspectives of the negotiating countries  
 
The term „biotechnological invention‟, including animal inventions, in the context of patent 
rights triggers different perspectives „in the mind‟ of developed and developing countries. For 
developed countries, the focus is primarily on commercial value and hence the question of 
how investments devoted to develop them could be recouped. This view can be easily 
appreciated if one looks into the amount of investments (in term of financial and 
technological expertise) spent in developing an invention.
88
 Therefore, it is not surprising
 
that 
developed countries are reluctant to enter into R&D, technology transfer, or licensing 
agreements in respect of their biotechnological inventions unless they are guaranteed 
exclusive rights.
89 
 
 
In contrast, for developing countries, the term „biotechnological invention‟ has far reaching 
implications, and should not be purely assessed on its economic value. Developing countries 
have been known as important providers of biological resources
90
 which are required for the 
development of research by life-science industries in developed world. As a result, they have 
claimed that their contribution should be equally recognised within the international IPRs 
framework. Patent protection for biotechnological inventions has been perceived by 
developing countries as a powerful tool that would allow developed countries to manipulate 
their genetic resources without appropriate economic return. In the long term, they argue that 
this practice would hinder technological development in their countries where the protection 
will be used to block access and the transfer of technology. Consequently, they require the 
term „biotechnological invention‟ to be associated with other aspects including the value and 
sustainable development of biological resources, recognition of traditional knowledge which 
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has been developed for generations by their populations, and equal sharing of commercial 
profits arising from the manipulation of the genetic resources.
91
 These divergences of 
perspective have created considerable tensions hence complicate the interpretation and 
application of the exclusion of animal inventions under Article 27.3(b). The following 
discussion will assess pertinent aspects which have been debated during the review process. 
They can be broadly categorised under: (1) patentability of life forms; and (2) issues relating 
to the CBD.  
 
3.2 Pertinent issues debated between developed and developing countries 
 
3.2.1 Patentability of life forms 
 
3.2.1.1 Progress of the review  
 
So far, there are mixed views as to whether the exclusion of animals under Article 27.3(b) 
should be retained or deleted.
92
 Specifically, the views can be assigned to four categories: (1) 
that the exclusion is unnecessary and animal inventions should be patentable; (2) that the 
exclusion should be maintained as it is, with no lowering of the level of protection; (3) that 
the exclusion should be retained, but clarification or definitions of certain terms used are to 
be provided; and (4) that the exclusion should be amended or clarified to the effect that it 
should prohibit the patenting of all life forms, including their parts and natural processes 
which produce them.
93
 The proponents to the first and second views are technologically-
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developed countries such as the US, Singapore, Australia, Canada, China, Korea, the EU, 
Japan, Singapore and Switzerland. Underpinning their views is that life forms can constitute 
inventions and their exclusion would hinder R&D activities, hence affecting economic 
advancement.
94
 Conversely, countries which fall under the two latter categories are 
developing countries such as Brazil, India, Peru, Thailand, Kenya (on behalf of the African 
Group), Zimbabwe and Bangladesh.
95
 This latter group of countries are primarily of the view 
that life forms are discoveries rather than inventions.
96
 The main issues relating to these 
opposing views are elaborated further in sub-sections 3.2.1.2, 3.2.1.3 and 3.2.1.4 below. 
 
3.2.1.2 Meaning of the terms adopted in Article 27.3(b) 
 
There have been varying interpretations among critics as what could be excluded under 
Article 27.3(b). For instance, it has been contended
97
 that the exclusion of „animals‟ suggests 
the exclusion of even genetically altered animals. This construction appears to demonstrate 
the „exclude all‟ rule. A question which may arise is: what is the difference between the term 
„animals‟ under Article 27.3(b) of the TRIPs Agreement and the term „animal varieties‟ under 
Article 53(b) of the EPC, with respect to the subject matter excluded under both provisions? 
While at a brief glance, they both seem to be linguistically similar, it has been suggested that 
the subject matter of exclusion carried by the terms is different, due to the construction of the 
provision. Some critics
98
 have asserted that the term „animals‟ has a broader meaning than 
„animal varieties‟. In the context of Article 53(b),99 the contention is based on an analogy 
with the term „plants‟ (which means plants in general) and „plant varieties‟ (which means a 
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particular classification of plant in the plant kingdom), when they are contained in the same 
provision.
100
 A few cases decided by the EPO such as Ciba-Geigy/Propagating Material
101
 
and Lubrizol/Hybrid Plants
102
 have established this principle.
103
 As such, it has been 
argued
104
  that, on the one hand, Article 27.3(b) is to be interpreted broadly, and with regard 
to „animals‟, the exclusion may cover transgenic animals and animal races.105 On the other 
hand, based on the non-definitive flexibility suggested by Article 27.3(b), it has also been 
argued
106
 that Signatories may also opt to exclude from patentability only certain categories 
of plant and animal inventions. A justification for construing the term „animals‟ narrowly 
arises from the fact that Article 27.3(b) is an exception to the general rule of patentability 
under Article 27.1.
 107
 As a matter of fact, this narrow interpretation has been adopted by the 
EPO in construing term „animal varieties‟ to mean only certain categories of animals and not 
animals per se. 
 
For Signatories, most of which are developed countries,
108
 which choose not to exclude 
animal inventions from their national patent law, intricacies as to the meaning, and therefore 
the subject matter of the exclusion as illustrated above, will not arise. Nevertheless, for 
countries which adopt the exclusion in their national patent laws (many of which are 
developing countries),
109
 Article 27.3(b) would inevitably invite various possible 
interpretations. It may amount to „all animal inventions are unpatentable‟ or „only certain 
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animal inventions are unpatentable‟. The latter seems to invite more potential arguments than 
the former, since there will be a need for a clear guideline within the national patent laws or 
the patent examiners‟ guidelines of a list of what could constitute patentable animal 
inventions and what could not. Yet the existence of the list could not be said to resolve the 
matter. As science and technologies progress rapidly, the list would need constant revision. A 
definition which is relevant this year might not be relevant in five years time. Bearing in 
mind that patent applications may take nearly five years to be granted,
110
 a specific definition 
is likely to prejudice an applicant in various aspects. An applicant may need to amend the 
specification attached to an application in order to ensure that the claim falls within the 
patentable subject matter. Consequently, this would cause additional costs to the applicant. 
The matter is exacerbated if translations to documentation are required by the relevant patent 
office.
111
 On the administrative aspect of a national patent system, this could lead to endless 
amendments to the national patent laws or patent offices‟ guidelines which would burden the 
legislature and patent offices.  
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3.2.1.3 Should the terms under Article 27.3(b) be defined? 
 
The absence of an exact meaning for the terms has been a concern which was raised by a 
group of developing countries in international forums.
112
 This can be surmised since it relates 
to their international obligation to provide a „minimum standard‟ of protection required by 
the TRIPs Agreement. So far, there is no hard evidence to show that the deviation in terms of 
interpretation from the standard set out by the main granting office could cause a particular 
country which chooses to depart from such a standard, to be subject to any international 
enforcement procedures such as the WTO‟s.113 Nevertheless, when international patent law 
with regard to the exclusion of animal inventions is evaluated, the interpretation given by a 
particular main granting office (in particular in developed countries) could become relevant 
to the case. The narrow interpretation of the term „animal varieties‟ under Article 53(b), is an 
illustration. Since the excluded subject matter is determined by the EPO, which is the main 
patent-granting office for a significant number of developed countries
114
 and which was one 
of the driving forces behind the introduction of the WTO,
115
 it cannot easily be ignored by 
other Signatories to the TRIPs Agreement which have a similar exclusion. It has been 
highlighted
116
 that where a provision has an existing jurisprudence (such as that applied by 
the EPO in respect of Article 53(b)) and this was known at the time the TRIPs Agreement 
came into being, then this should, at least, be taken into account when determining if a 
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Signatory has reached that minimum standard. In this respect, the subject matter which other 
countries might wish to exclude would require careful consideration as any „deviation‟ from 
the decided „standard protection‟ might attract criticism and the countries might be regarded 
as in breach of their obligations under the WTO law (including the TRIPs Agreement).
117
  
 
Due to the ambiguity of Article 27.3(b), developing countries such as India, Kenya (on behalf 
of the African Group), Pakistan and Zimbabwe, have suggested during the review process 
that the provision be made clear by excluding all life forms and biological materials such as 
cells, cell lines, genes and genomes.
118
 These countries argued that the latter are not 
patentable since they cannot qualify as micro-organisms, being the only category that is 
mandatorily patentable under Article 27.3(b). In particular, the African Group
119
 asserted that 
there is only an „artificial distinction‟ between animals and micro-organisms, since there is no 
scientific basis for this division and allowing patents for these materials contravenes the basic 
principle of patent law, in which only invention (and not discovery) can be patentable. 
Opposing this view, developed countries have averred that the meaning of the terms used in 
Article 27.3(b) need not be defined and that the distinctions made in Article 27.3(b) are in 
accordance with the generally accepted scientific classification of organisms and widely 
accepted in existing international agreements.
120
 
 
There is little doubt that a precise meaning to the terms in Article 27.3(b) would assist a 
Signatory to implement their obligation where any decision either to allow or refuse animal 
inventions could be made on a firm basis. In other words, any ambiguity could at least be 
guided by the Agreement. Yet, subjectivity is still the rule, and therefore any argument for 
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interpreting a particular term remains possible. This point can be illustrated by the fact that in 
many national legislations even though there is normally a section for „definition‟ or 
„interpretation‟ of terms used in the statute, thousands of cases have landed in courts merely 
due to interpretational problems. Assuming the terms are defined, this would contradict 
developing countries‟ stance during the Uruguay Round Meeting, where they were against 
any prescribed scope and standard of patent protection. Moreover, in a situation where a term 
is defined differently in a Signatory‟s patent law, compared to the one underlined by the 
TRIPs Agreement, this could be argued by another Signatory as non-compliance with the 
treaty. Consequently, this may cause the dispute settlement mechanism to be invoked against 
the relevant Signatory, which would cause an adverse effect politically and economically to 
the same country.
121
   
 
3.2.1.4 Could animal inventions be patentable?  
 
The suggestion of developing countries that all life forms be excluded from the patent regime 
amounted to arguing that the patentability of life forms which have been well accepted in 
developed countries since the 1980s be reversed. As aptly observed by critics
122
 this would 
require developed countries to overturn all their jurisprudence on the subject matter. It seems 
unrealistic for the US and Europe (for instance) to agree to this proposal through the revision 
of Article 27.3(b),
123
 in view of the value of patents of biotechnological inventions to 
developed countries. As expected, the suggestion by developing countries has been strongly 
opposed by developed countries during the review process. They maintained that 
biotechnological inventions (including animal inventions) should be accorded adequate 
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patent protection in the same way as inventions in other fields of technology.
124
 Intrinsically, 
this argument echoed Article 27.1 of the TRIPs Agreement.  
 
Underpinning the contrasting view of developing and developed countries as to whether 
animal inventions should be patentable at all is the question of whether they can be 
considered as inventions or are discoveries. This relates the question to the ability of the 
inventions to fulfil the patent qualification criteria, where the discussion now turns. In the 
context of this thesis, livestock animals which are produced through animal biotechnology 
applications such as cattle with increased amount of milk and leaner meat (discussed in 
chapter 1), can meet the requirement of industrial application without much hurdle. This is 
because they are created with the aim of being used in the animal husbandry industry. 
Showing this purpose in a patent claim is therefore sufficient for an applicant for the purpose 
of satisfying the prerequisite.
125
  
 
Since living matter is involved, novelty and inventive step are two patent conditions which 
are more crucial. Patent protection is a tool to recognise the intellectual contribution of an 
inventor. The protection creates a right of exclusivity for the inventor, which he can legally 
enforce. The concept of novelty for the purpose of patent protection has been specifically 
defined as something which has not been disclosed in prior art. An inventive step under 
patent law means the invention must not be obvious to „the person skilled in the art‟. i.e. it 
must not follow plainly or logically from what is already known. Animal inventions as the 
term suggests are the result of human manipulation, and can be achieved in three ways:  
 
(1) direct transgenic alteration of the animal by injecting „foreign‟ DNA into 
freeze-dried sperm, before inserting the recombined sperm into an ovum; (2) 
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transporting recombined DNA into an animal‟s embryonic stem cells; and (3) 
treating the animal at the adult stage by injecting it with transgenically altered 
DNA.
126
 
 
These procedures involve fundamental human intervention at a micro level to alter an 
animal‟s attributes. Animal resources which have not been manipulated in any of these ways 
(in other words, mere discoveries) are clearly beyond the ambit of patent protection. 
Therefore, based on the principle of patentability, it is argued that animal inventions which 
can fulfil these two other conditions are patentable. 
 
Yet another challenging question would arise from the above: are the three above-mentioned 
ways of alteration sufficient for animal inventions to be treated as having attained novelty and 
inventive step? The general principle under patent law states that life forms in their natural 
state would not satisfy the criteria of patentability in the TRIPs Agreement. However, patent 
jurisprudence and guidelines for patent examiners in developed countries such as the US, 
Japan and Europe have explicitly provided a certain degree of flexibility to the general rule. 
For instance, under Article 3.2 of the EU Directive on the Legal Protection of 
Biotechnological Inventions (EU Biotechnology Directive),
127
 „biological material which is 
isolated from its natural environment or produced by means of a technical process may be the 
subject of an invention even if it previously occurred in nature.‟ Similarly, paragraph 2.3, Part 
C-IV of the Guidelines of Examination of the European Patent Office
128
 provides that „a 
substance found in nature is patentable if it is isolated from its surrounding and a process for 
obtaining it is developed.‟  
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As the TRIPs Agreement does not prescribe the exact threshold of novelty and inventive step 
that an animal invention needs to achieve, it is too subjective for a precise answer. Therefore, 
it appears that Signatories are at liberty to impose any threshold on the patentability criteria. 
Notably, it has been emphasised
129
 that due to the lack of consensus on fundamental 
principles relating to biotechnological inventions such as the degree of novelty, utility, non-
obviousness and disclosure, it seems unlikely that a Signatory could use the WTO framework 
to compel other Signatory to adopt high levels of patent protection for such inventions in the 
near future. This is why some Signatories in the Andean Community have utilised the 
flexibility under Article 27.3(b) by including in their patent laws exclusions of 
biotechnological inventions with specific conditions attached to them. For example, Article 
10.IX of the Brazilian Industrial Property Code 1996 excludes: 
 
all or part of natural living beings and biological materials found in nature, even if 
isolated therefrom, including the genome or germplasm of any natural living being, 
and the natural biological processes.
 130
 
 
Similarly, Article 7(b) of the Argentina Invention Patents and Utility Models Act excludes 
from patentability: 
 
all biological and genetic material existing in nature or derived therefrom in 
biological processes associated with animal, plant and human reproduction, 
including genetic processes applied to the said material that are capable of bringing 
about the normal, free duplication thereof in the same way as in nature.
 131
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Appreciating the current development in the review process, the chances of reaching a 
definite meaning for the term „animals‟ adopted under Article 27.3(b) that would satisfy the 
perception of all the negotiation parties, are negligible. On the one hand, as far as developing 
countries are concerned, the provision would be best left as it stands since this is the basis of 
the flexibility achieved at the end of the Uruguay Round. The non-definitive meaning to the 
term allows them to interpret the aspect in accordance with their national socio-economic 
situations and needs. On the other hand, the suggestion of developed countries for the 
deletion of the exclusion of animal inventions under Article 27.3(b) seems difficult to attain, 
at least not in the near future. The deletion will invite prevalent criticism since the WTO has 
itself explicitly recognised the „demand‟ of developing countries in its negotiation forum. 
This can be demonstrated by the agreement of the Organisation for the review process of 
Article 27.3(b) to also consider issues relating to the CBD within the WTO, which is a result 
of strong pressure from developing countries before the beginning of the review process.
132
 
 
3.2.2 Issues relating to the CBD 
 
3.2.2.1 Progress of the review 
 
It has been widely accepted that developing countries are the source of the world‟s biological 
diversity. However, advanced technology, and the expertise to develop the resources to 
produce beneficial products, often lies with developed countries. It is this strength and 
constraint of both developing and developed countries which underpins the three 
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requirements concerning the access and benefit-sharing of genetic resources under Article 15 
of the CBD:  
 
(1) the access must be preceded by prior informed consent by the producer 
countries;
133
 (2) there shall be full participation in scientific research by the 
producer countries;
134
 and (3) there shall be benefit-sharing of research results and 
commercialisation between the Contracting Parties.
135
  
 
So far, issues relating to the CBD within the review of Article 27.3(b) have not been resolved. 
The most important point where developing and developed countries have different views is 
with regard to the question of whether Article 27.3(b) is compatible with the CBD 
requirements. It is important to bear in mind the different primary objectives that the TRIPs 
Agreement and the CBD have. The former sets a minimum standard of IPRs protection, 
whereas the concern of the latter is the regulation and utilisation of biodiversity for 
sustainable development. It has been the concern of the countries which are Signatories to 
both treaties (in particular developing countries) that, since under Article 27.3(b) 
biotechnological inventions may be patentable, it undermines the recognition given by the 
CBD that a state has a sovereign right to its natural resources, including animal genetic 
resources.
136
 According to these countries, Article 27.3(b) is not compatible with the CBD 
and unless the treaties are reconciled, their commitments under both treaties are problematic. 
Consequently, it has been argued that Article 27.3(b) should be amended to include all the 
CBD requirements. This argument has been vehemently opposed by developed countries 
which are of the view that Article 27.3(b) and the CBD are mutually supportive: there is no 
incompatibility between them; there is no necessity to amend to Article 27.3(b), as proposed 
by developing countries; and that the issues relating to the CBD would best be addressed 
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within the relevant national laws rather than the TRIPs Agreement. These opposing views 
will be discussed and analysed further in sub-section 3.2.2.3. But before that, sub-section 
3.2.2.2 below will assess the issue on access and transfer of technology, an aspect which has 
also been discussed in connection with the protection of life forms during the review of 
Article 27.3(b). It is a prerequisite to be considered by a Signatory in assessing the need and 
extent of allowing patent protection to animal inventions within its national patent law.  
 
3.2.2.2 Access and transfer of technology 
 
The efficiency of strict patent protection in ensuring the flow of technology from developed 
to developing countries as a result of the implementation of the TRIPs Agreement has been 
seen in different lights. Foreign direct investment (FDI), technology transfer and strict 
intellectual property protection have been perceived by developed countries as a recipe for 
technological growth and industrialisation.
137
 Proponents of the principle have contended
138
 
that strict patent protection, including that for biotechnological inventions, could promote 
private sector investment in R&D activities in fields such as agriculture, health and 
environment. Social welfare benefits from these fields are said to be meant not only for the 
populations in developed countries, but also those in developing countries.
139
 It has been 
further contended 
140 
that strict patent protection serves as an attractive tool that would lead to 
transfer of technology to developing countries which means the enhancement of their national 
technological knowledge, and ultimately the development of their economy.
 
Intrinsically, this 
is because it is unlikely for developed countries to invest in R&D activities in countries 
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which lack patent protection for biotechnological inventions.
141
 Nevertheless, input from 
developing countries during the review process of Article 27.3(b) has been very sceptical 
about these views. Many of those countries have conversely perceived that giving exclusive 
rights to patent holders could in fact prevent the effective dissemination of technology to their 
countries.
142
 This concern stems from the considerable costs that they have to bear due to the 
licensing of the technology for having access to the relevant technologies.
143
 
 
Pessimistic views as to the interface between strict IPRs and transfer of technology has been 
similarly highlighted in research. For instance, a survey by the United Nations University on 
the FDI and technology transfer concluded that IPRs did not play a significant role in 
influencing the pattern of FDI and technology transfer.
144
 From the perspective of developing 
countries, it has been argued
145
 that patents on biotechnological inventions would act as a 
barrier to the transfer of technology. Consequently, it leads to a disincentive for local research 
agencies, since their ability to utilise the necessary technology becomes limited.
 146
 These 
concerns are not without basis especially if assessed in the context of the type of technologies 
at issue, where a distinction has been made between technologies which have reached 
„maturity‟ stage and new technologies.147 Mature technologies are relatively easy for users to 
acquire by users, whereas it has been observed that there are considerable difficulties for 
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developing countries to obtain technologies that fall under the latter, including modern 
biotechnology. This is because these technologies are still changing and profitable.
148
 
 
To take sides with any one of the opposing views of the negotiating countries during the 
review or any views of the critics would not be reasonable without assessing them in the light 
of the context of the focus of the thesis; namely the importance of animal biotechnology 
applications to develop the livestock industry of developing countries. While the problem of 
expensive technology due to the licensing agreement may be circumvented if patent 
protection is not granted to animal inventions, arguably the socio-economic implications for 
developing countries are more crucial. In this regard, it has been observed that there are three 
factors which could influence the effect of IPRs on the flow of FDI into a country.
149
 They 
are: (1) the market size of the host country;
150
 (2) the nature of the product itself; and (3) 
whether or not the industry is export-based.
151
 The last of these has been identified
152
 as 
directly relevant to the issue of intellectual property protection, thus requiring further 
elaboration. As already shown in chapter 1, developing countries are importers of livestock 
products so as to meet the growing demands and needs of the population. Notably, while 
animal biotechnology applications have been applied in the countries to assist with the 
development of their livestock industry, they are mostly at the research stage. According to 
economists, stronger intellectual property protection could, in theory, either promote or 
restrict economic growth.
 153
 Nevertheless, they have also observed two important aspects: (1) 
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the strong and positive impact of patents on investments and R&D spending;
154
 and (2) IPRs 
(including patents) as an important factor influencing the international transfer of 
technology.
155
 Therefore, it is argued that for both users and importers of modern 
biotechnologies,
156
 patent protection is necessary in developing countries so as to attract 
research collaboration, and hence transfer of technology from their developed counterparts. 
Eventually, a supply of livestock products to meet the demand can be secured. 
 
Developing countries themselves can be categorised further as those which are more 
economically developed than others. For instance, for the „BRIIC‟ (Brazil, Russia, India, 
Indonesia and China), which are the world‟s developing and emerging economies the need 
for transfer of technology to develop their industries may be less pressing than for other 
developing countries. It has, however, been identified
157
 that in order to ensure effective 
technology transfer to developing countries, it is pertinent that they develop an indigenous 
scientific and technological capacity and have the ability to absorb knowledge from other 
countries for the purpose of adaption to their interests.
158
 Intrinsically, transfer of technology 
to countries where the facilitating factors are absent will serve no purpose. In this respect, a 
more specific distinction appears necessary between the LDCs which have no technological 
capabilities to utilise modern biotechnologies in any of their industries and developing 
countries which have the ability to do so. The former would not be able to reap the benefits of 
patent protection because the cost of reforming or creating the patent system outweighs the 
benefits they could achieve from it,
159
 and it would be unlikely for them to adapt and absorb 
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the technology into domestic industry
160
 (including, animal biotechnology). Consequently, it 
is argued that for developing countries, which have started to develop their biotechnological 
industries or have the technological ability to achieve this end, allowing patent protection to 
biotechnological inventions is a pertinent matter for consideration. This would assist the 
countries to enhance their R&D activities by having the necessary technologies to develop 
the relevant fields further. Overall, it is also possible to argue that the need to provide patent 
protection to biotechnological inventions will increase as a particular country transforms its 
developmental policy toward promoting technology-based industries.  
 
3.2.2.3 The disclosure requirements 
 
Developing countries in their communication to the WTO during the review of Article 27.3(b) 
proposed that the TRIPs Agreement should include all the three aspects underlined by Article 
15 of the CBD (as identified in sub-section 3.2.2.1 above). Specifically it was proposed that 
information as to the source and country of origin of the genetic materials and associated 
traditional knowledge used in developing an invention claimed in a patent application should 
be disclosed. The information should include the evidence of prior informed consent and 
evidence of a benefit-sharing agreement (the disclosure requirements).
161
  Two options have 
been proposed by developing countries: (1) which is by way of an amendment to Article 27 
of the TRIPs Agreement, that Signatories should be allowed to exclude from patentability, 
products or processes which have not included information of prior informed consent, 
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sources and origin of genetic resources and a benefit-sharing agreement;
162
 and (2) which is 
by way of an amendment to Article 29,
163
  that, where appropriate, Signatories shall require 
the disclosure of origin and legal provenance in the patent applications to be submitted.
164
  
 
Developing countries‟ concern, which led to the proposals, has been mainly on the grant of 
patents to inventions involving turmeric and hoodia plants, and the neem tree patent which 
originate from developing countries.
 165
 These plant genetic resources have been used for 
centuries as medicines, appetite suppressant and insecticide. In the turmeric patent for 
instance, the patent has been revoked by the USPTO after it was proved that the use of 
turmeric powder to heal wounds has for a long time been common in India.
166
 It has been 
argued by developing countries
167
 that the cost of revocation of an erroneously granted patent 
is more expensive and burdensome than including the disclosure requirements in a patent 
application. It is for the avoidance of the granting of an inappropriate patent that developing 
countries have been pressing for the disclosure requirements to be considered within the 
TRIPs Agreement.
168
 Opposing the proposals and the views, the US
169
 has been advocating 
the argument that implementing the disclosure requirements within the TRIPs Agreement 
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would  lead  to  „legal  uncertainty  and  other  negative  consequences‟  since  the  access and 
benefit-sharing system are new to many Signatories. It has also been contended
170
 that the 
disclosure of sources and origin of genetic resources in patent applications is rarely relevant 
to avoid the granting of inappropriate patent. This is due to the fact that the patentability of an 
invention would only be subject to the fulfilment of the relevant qualifications; where novelty 
and the inventiveness of an invention would depend on the state of prior art. According to the 
US,
 171
 the more suitable options to deal with the issue include the use of organized and 
searchable databases and the use of effective post-grant opposition or re-examination systems. 
Other than this, it has also been pointed out that since many of the plant genetic resources are 
grown in many countries, it would be difficult to determine the exact origin or source of 
genetic material.
172
 This would burden the applicants, hence discouraging innovations. 
Developing countries do not share these views. They highlighted the limitations in organised 
databases in protecting traditional knowledge and genetic resources.
173
 It was asserted
174
 that 
the disclosure requirements would function as a check and balance tool to ensure that patent 
protection is granted only to proper applications without denying the rights of the provider of 
the genetic resources. Moreover, the disclosure requirements are not overly burdensome 
because a simple statement by the patent applicant to comply with the requirement is 
sufficient.
175
  
 
Another proposal from developed countries is that a national contract-based system is the 
best way to deal with issues relating to prior informed consent, access and benefit-sharing of 
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genetic resources. In this respect, apart from the proposals from the US, Switzerland
176
 has 
proposed that the disclosure requirements be regulated through a WIPO-administered 
mechanism: the Patent Co-operation Treaty 1970 (PCT). Specifically it was suggested that an 
amendment to the Treaty should be made so that domestic laws may require inventors to 
disclose the source of genetic resources and traditional knowledge when they apply for 
patents. Failure to meet the requirement could delay a patent being granted, or, when done 
with fraudulent intent could entail a granted patent being invalidated.
177
 The EU
178
 in its 
latest communication has indicated its willingness to support the inclusion of the disclosure 
obligation within the TRIPs Agreement. Nevertheless, two limitations were mentioned: (1) 
the disclosure is restricted to the origin of genetic materials which is known to the patent 
applicants, or have reason to know; and (2) penalties for non-compliance are to be left outside 
the patent system.
179
  
 
It is important that the opposing views of developing and developed countries be assessed so 
as to appreciate their advantages, disadvantages, and implications. While the implications for 
failure to comply with the disclosure as proposed by Switzerland seem promising to 
developing countries, the fact that the penalties are to be contained in the PCT or outside the 
patent system would still be seen as an attempt to circumvent the built-in dispute settlement 
mechanisms under the TRIPs Agreement. The PCT is a treaty which concerns procedures of 
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application and granting of patents. It does not yet possess compliance enforcement 
procedures. Hence, how the non-compliance should be enforced is very uncertain. Moving on 
to the EU‟s proposal, the proposed methods of enforcing the non-compliance for disclosure 
are through civil law or administrative law.
180
 These national measures have less powerful 
implications compared to the dispute settlement mechanisms under the TRIPs Agreement 
which could carry international trade sanctions. Notably, this strategy is used by negotiators 
who oppose a particular regulatory arrangement which could compromise the interests they 
are pursuing.
181
 Consequently, while a national contract-based system is undeniably an option 
for implementing the proposed disclosure requirements, the inclusion of the requirements 
within the TRIPs Agreement would have greater prospects for being enforced and generating 
international compliance, compared to other methods or forums for application. 
 
In this respect, there is little doubt that disclosing the information about the sources and 
origins of genetic resources will not guarantee the non-granting of patent protection to 
inappropriate applications. The mere presence of the information in patent applications would 
not necessarily trigger patent examiners‟ suspicion of the illegal possession of the genetic 
materials used in biotechnological inventions. Nevertheless, the requirement for the 
information may emphasise the transparency of the patent system which underpins the 
demand of developing countries. It would allow the relevant patent office to request further 
information should any need arise to verify the legality of the sources. In the context of the 
limited number of traditional knowledge databases worldwide (currently available only in 
India and China)
182
 the disclosure requirements as proposed by developing countries are not 
unreasonable. 
                                                          
180
  ibid. paragraph 55. 
181
  D.D. Bièvre et al,  n 5 above, 9.  
182
  EPO, India‟s traditional knowledge digital library (TKDL): a powerful tool for patent examiners, 
http://www.epo.org/news-issues/issues/traditional.html (Accessed: 31 March 2011). 
127 
 
 
After many years of negotiations, the future of including the disclosure requirements within 
the TRIPs Agreement seems politically challenging, since there are so far, no indications that 
technologically-developed parties will accept the mandatory disclosure requirements as 
proposed by developing countries. While the disclosure requirements debated during the 
review closely relate to plant genetic resources, they would also be applicable to livestock 
animals derived from modern biotechnology (for similarly being biotechnological inventions). 
Therefore, if capable of being fulfilled, the requirements would ideally benefit the community 
in developing countries in at least two ways. Firstly, they give recognition to farmers‟ 
associated knowledge in developing particular breeds of livestock animals which are 
involved in scientific research. Secondly, in case patents are granted to related inventions, it 
could ensure an economic return to the farmers.  
 
The various conflicting views arising within the review process are in the light of many 
patent disputes involving plant genetic resources, which are located mainly within developing 
countries. For this reason, the proposed mandatory disclosure requirements may be seen as 
leading to an unequal distribution of benefit in terms of the potential beneficiary. The 
disclosure requirements would seem to impose one-sided obligations or additional burdens on 
developed countries where most life-sciences companies are located, albeit „unfortunately‟ 
for the benefit of developing countries. Consequently, the response of the US to the proposal 
is not surprising.
 
 
 
A question could be raised at this juncture: would developed countries have responded the 
same way if the subject matter of the inventions involved animal genetic resources pertaining 
to the livestock industry? Arguably for animal inventions, the proposal of developing 
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countries would be considered more favourably by developed countries. As already discussed 
in chapter 1, the shortage of productive breeding stock and fish seed, the risk of livestock and 
aquatic diseases and the constraints of animal and fish feed are problems for the global 
livestock industry. In the production of transgenic livestock animals, the genetic resources 
could come from any country, not limited to developing countries. Therefore, for example, in 
research to produce a transgenic cow which can stand extreme weather condition, scientists 
from South Africa may need the genetic material of a cow from the US. In terms of the 
developed transgenic animal, the transgenic Atlantic Salmon is perhaps the best example of a 
clear trans-boundary movement of genetic material from the donor salmon (originating from 
the Pacific Ocean) to the host salmon (which originates from the Atlantic Ocean). While in 
the latter instance it may be quite difficult to exactly identify the provider of the genetic 
resources, in both examples, the disclosure requirements should become important to both 
developed and developing countries since each is a potential provider of animal genetic 
materials.
183
 
 
Nevertheless, the implementation of the requirements is not without problems. On the 
disclosure of origin or source of genetic materials, the ability to fulfil the requirement would 
depend on the ability to trace these two things. The „source of origin‟ has been said to mean 
the country from where the applicant received the genetic material, whereas the „country of 
origin‟ is the country to which the genetic resource is indigenous.184 While to disclose the 
information as to the former seems manageable, since an applicant would know where the 
genetic resources are obtained from, the latter may be more problematic. Before a genetic 
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resource is involved in a modern biotechnological application such as genetic engineering to 
produce transgenic livestock animals, the product of the original source may be the result of 
years of breeding processes. According to the FAO,
185
 farm animal resources (and the genetic 
diversity they represent) have developed over 12,000 years of domestication as a result of 
selection by human communities and adaption to new environments and environmental 
challenges. Largely involved in the process is a practice which is prevalent in livestock 
breeding, namely the trans-boundary movement of the resources. As a result, an animal 
genetic resource which is found in country „A‟ may not be indigenous to that country. Yet in 
another instance, the resource may originate from many countries. Therefore, to be accurate 
on the „country of origin‟ of a genetic resource involved in an animal invention may be 
challenging to a patent applicant.
186
 Apart from this, the difficulty in identifying the true 
providers of animal genetic resources would also make it problematic to facilitate the prior 
informed consent requirement and to ensure that the deserving parties would benefit from the 
potential commercial gains. The challenge in detecting commercial gains from the use of the 
genetic resources itself is another hurdle in ensuring that the provider countries could claim 
their benefit.
187
 Related to this, specifically on the disclosure of a benefit-sharing agreement 
in a patent application, the implementation is not always easy since the agreement, if any, 
would be in terms of contractual agreements between private parties. The unveiling of 
information, such as disclosure of ownership information and consent from the provider 
countries, pertaining to the agreement may be subject to various contractual conditions 
making it costly and burdensome for an applicant.  
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While the implementation of the requirements may seem theoretically achievable, problems 
as to the practical side of it may be the reason why the requirements are still subject to on-
going debates. Therefore, due to the challenges illustrated above, arguably the disclosure 
requirements should be introduced within the TRIPs Agreement possibly by amending 
Article 29. This would encourage patent applications to include additional information as to 
the source and country of origin. This approach is more realistic for developing countries in 
pursuing their interest (which arise from the CBD) within the WTO framework where the 
concept of forum shopping is a major hurdle. Albeit with lesser weight in terms of 
international enforcement, it offers a greater prospect for the requirements being introduced 
within national patent laws, hence global acceptance in the long run. Otherwise, a stronger 
option which ties the disclosure requirements to the enforcement aspect has been suggested 
by critics,
188
 which is by utilising Article 62. The provision allows the imposition of 
reasonable procedures and formalities which need to be complied with by patent applicants, 
in the light of national laws of relevant Signatories, in order to acquire patent rights in those 
countries.
189
 The only condition is that the procedures shall not run contrary to the principle 
of the TRIPs Agreement which prohibits the provisions which amount to denial of patents to 
inventions which fulfil the patentability criteria.
190
 As such, it has been suggested that the 
disclosure requirements be made as conditions for enforcement of the granted patent.
191
 
Following these approaches, it is argued that the interest under the CBD should not have 
deterred developing countries from considering the grant of patent protection to animal 
inventions. In this way, the transfer of technology, investment, and economic development all 
remain possible to be achieved. 
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This section has shown two things. Firstly, notwithstanding the diverse arguments of 
developed countries (that the exclusion of animal inventions is unnecessary) and developing 
countries (that all life forms are unpatentable) during the review of Article 27.3(b), the 
flexibility to construe the meaning of the term „animals‟ and the subject matter of the 
exclusion remains. This is pertinent and necessary given the difference in the socio-economic 
levels of the Signatories to the TRIPs Agreement, and national economic interests of the 
negotiating countries. In particular, the flexibility relating to the exclusion will allow 
developing countries to shape the application of the provision in accordance with their 
national requirements and technological development. Secondly, while the issues involved in 
the review of Article 27.3(b) have not yet been resolved, they are pertinent to be considered 
by a Signatory which intends to implement the flexibility. This is because, implications 
arising from issues such as access and transfer of technology and disclosure requirements will 
influence the decision of whether or not to allow patent to animal inventions within national 
patent law. The following section identifies the options which a Signatory may have when 
interpreting the exclusion of animal inventions. 
 
4.  The Future: a way forward for interpreting the exclusion of animal inventions 
within national patent law 
 
In the absence of any specific resolution to the issues relating to the patentability of animal 
inventions in the review of Article 27.3(b), Signatories to the TRIPS Agreement (including a 
developing country such as Malaysia) have the right to determine how the exclusion of 
animal inventions within their national law is to be construed. Due to the flexibility, any 
approach that a country may choose should not be criticised by other countries merely 
because it interprets the aspect differently. A Signatory may develop its own interpretation 
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based on any approach it thinks fit. Nevertheless, an assessment of existing interpretations by 
other Signatories within the international patent law framework is arguably the most 
appropriate approach that a Signatory could opt for. This will ensure that any interpretation 
that is made corresponds with international practice. For the purpose of this thesis, two 
approaches will be examined and assessed: (1) the permissive approach as modelled by the 
interpretation of Article 53(b) of the EPC; and (2) the restrictive approach as modelled by the 
interpretation of s2 of the Canadian Patent Act 1985.  
 
5.  Conclusion 
 
The TRIPs Agreement was negotiated where there was no international agreement as to the 
patentability of animal inventions. As this chapter has shown the basis and purpose of the 
exclusion within the TRIPs Agreement is not explicitly explained. Nevertheless, it is clear 
that the introduction of the exclusion into the TRIPs Agreement was based on proposals from 
the negotiating countries, which derived from existing patent provisions within their national 
patent laws. On the one hand, developed countries, which principally allow patent protection 
to animal inventions, proposed broad protection of living matter to secure their intellectual 
property interests worldwide. On the other hand, developing countries suggested the 
exclusion of such material due to various national needs and constraints, in particular, their 
economic and technological development. Faced with this difference of views, the most 
practical way to ensure that an agreement between the countries on the protection of animal 
inventions could be achieved in the TRIPs Agreement was to allow these countries to 
continue practising the policy which underpinned their national patent laws. This has led to 
the flexibility to exclude the inventions under Article 27.3(b) at the end of the Uruguay 
Round Meeting.  
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The review of Article 27.3(b) which started just four years after the TRIPs Agreement came 
into effect, demonstrates that the flexibility which was adopted as a „compromised solution‟ 
is still a subject of much disagreement between developed and developing countries. The 
second round of the negotiations has seen how, on the one hand, developed countries, in their 
concerted effort to pursue their economic interests globally, have argued that the exclusion 
should be deleted. Underpinning this view was that its retention would undermine R&D 
activities, hence affecting the progress of technology and economy. On the other hand, 
developing countries argued that all life forms should be unpatentable for being discoveries 
rather than inventions. Unless and until a decision as to the deletion of the exclusion of 
animal inventions under the review of Article 27.3(b) is achieved, the status quo
192
 remains. 
Signatories retain an option either to exclude animal inventions or include them within their 
national patent system. Notably, the TRIPs Agreement is not prescriptive in terms of what the 
meaning of „animals‟ is and how the exclusion under Article 27.3(b) should be interpreted: 
either narrowly or broadly. Therefore, for Signatories which have the exclusionary provision 
under their national patent laws, the flexibility would allow them to interpret the exclusion in 
tandem with various national policies and economic interests which they intend to pursue.  
 
The scope of the review of Article 27.3(b) was broadened when developing countries argued 
that the need for the retention of the exclusion is to be linked to the implications of patenting 
biotechnological inventions to technology transfer and the conservation of biodiversity. It has 
been emphasised that allowing patents for biotechnological inventions which are mainly 
developed by the experts in developed countries would amount to the recognition of 
misappropriation of genetic resources, without appropriate economic return to them as 
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providers of the genetic resources. This contention is underpinned by the provisions of the 
CBD which aim to regulate the utilisation of genetic material for global sustainable 
development. So far, issues relating to Article 27.3(b) under the review process remain 
unresolved. Nevertheless, their assessment would inform the relevant Signatories of the 
various advantages, disadvantages and implications for their economic development should 
they decide to implement any policy measures proposed therein. In the context of the thesis, 
this chapter highlights that in order to assist with the interpretation of the exclusion of animal 
inventions under a national patent law it is pertinent for the relevant Signatories to the TRIPs 
Agreement to firstly identify their interest and ability in utilising animal biotechnology 
applications to enhance the development of livestock industry and economic development. 
This enables them to decide whether or not allowing patent to animal inventions will assist 
them in pursuing their national requirements.  
 
A key issue in the review process is the patentability of life forms. This chapter contends that 
animal inventions can be patentable for being able to fulfil the patentability criteria. 
Nevertheless, strengthened patent protection for biotechnological inventions (including 
animal inventions) in developing countries has been criticised for hindering the transfer of 
technology as the technology would become expensive due to their licensing. This would 
eventually limit access to the technology. This chapter argues that while the problem of 
licensing may be circumvented by not allowing patent to animal inventions, the socio-
economic implications for developing countries are more crucial. In this respect, it is 
important to note the widely accepted economic rule that technology-developed countries 
(mostly developed countries) are unlikely to invest in R&D in countries which lack patent 
protection. The transfer of technology is subject to the same rule. Intrinsically, this arises 
from the importance to recoup the investment put into developing a biotechnological 
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invention, including animal invention. While animal biotechnology applications have been 
applied in developing countries to increase the production of livestock products, widely they 
are still at the research stage. Being users and importers of the technology, it is important for 
developing countries which have the technological ability to absorb knowledge from 
technologically-developed countries to consider allowing patent protection to animal 
inventions. The protection would attract the transfer of technology and investment into 
developing countries‟ R&D activities pertaining to animal livestock. Eventually, this will 
assist the countries to secure the supply of livestock products to meet the growing demands 
from the population.  
 
Another central aspect of the review process pertains to the proposal that mandatory 
disclosure of the source and country of origin of genetic resources involved in animal 
inventions be introduced under Article 27.3(b). This aims to ensure transparency of 
commercial gains arising from the use of genetic resources from provider countries (mostly 
developing countries). While the conditions will economically benefit livestock breeders 
which may have contributed toward improving particular breeds involved in scientific 
research, its implementation is not without problems. Mainly, the challenges will come from 
the condition to precisely identify the „country of origin‟ of the relevant animals and 
disclosure of ownership information. Due to the practice of the trans-boundary movement of 
livestock animals, the requirements may pose an unnecessary burden on a patent applicant, 
hence discouraging innovation. Consequently, it is suggested that the disclosure aspect is to 
be encouraged by amending Article 29 of the TRIPs Agreement, rather than be made 
mandatory under Article 27.3(b). While of lesser weight in terms of international 
enforcement, it provides a better opportunity for the requirements be introduced in national 
patent laws, in the light of the political ramifications of the review process. Attaching the 
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disclosure requirements to the enforcement of a granted patent is another option for 
developing countries to consider. Besides meeting the requirement under Article 27.3(b) that 
inventions which fulfil patent criteria should be granted patents, the option realises the 
interests of developing countries under the CBD and contributes to their economic growth. 
 
While there is no fixed rule on how the exclusion of animal invention in national patent law 
is to be interpreted, arguably the examination and assessment of current international 
interpretation is the most practical way of dealing with this issue. In this way, any decision on 
how the exclusion should be construed can be justified in a more robust way. Consequently, 
this thesis will work on two international models of interpretation namely; the permissive 
approach which has been adopted by the European patent system and the restrictive approach 
which has been adopted by the Canadian patent system. Detailed analysis of these approaches 
will be made in chapters 4 and 5, respectively. However, before that, the next chapter will 
examine the Malaysian exclusionary provision which is s13(1)(b) of the Patents Act 1983. 
The discussion will include its legislative history and the application of the exclusion so as to 
understand the intention of the legislature, the country‟s expectations from the provision and 
current legal development of the same. In the context of the research questions, the chapter 
identifies the lack of legal development and clarity within the Malaysian patent law, which 
ultimately justify this research. 
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CHAPTER THREE 
 
THE EXCLUSION OF ANIMAL VARIETIES UNDER SECTION 13(1)(b) OF THE 
MALAYSIAN PATENTS ACT 1983:  
LEGAL DEVELOPMENT AND APPLICATION 
 
1. Introduction 
 
Malaysia is one of developing countries which exclude animal varieties under national patent 
law. In the light of the flexibility to interpret the exclusion under Article 27.3(b) of the TRIPs 
Agreement, it becomes relevant and important to ask the question: how should the exclusion 
be applied? This is in the context of the country‟s international obligations under Article 27.1 
of the same Agreement, which requires inventions that fulfil the patent qualification criteria 
be patentable. Nevertheless, there is a scarcity of materials which have discussed how 
Malaysia should interpret the exclusion. This is not surprising as a similar situation can be 
observed at the international level where, apart from Europe and Canada, the question of how 
a Signatory, which has adopted the exclusion, should deal with the implementation of the 
exclusion is very rarely discussed. The most probable reason leading to this may be that a 
situation has not yet arisen which requires the exclusionary provision to be interpreted either 
by national patent offices or judicial authorities of the relevant Signatories to the TRIPs 
Agreement. Yet as already shown in chapter 2, there have been significant discussions within 
the WTO on issues relating to the exclusion of animal inventions. It has been further 
concluded in that chapter that any international development on the exclusion is relevant to 
be considered by a Signatory in applying its exclusionary provision. But, before that, the 
relevant Signatory should be clear of what is intended from the exclusionary provision within 
its national patent law.  
 
138 
 
This chapter offers an understanding of s13(1)(b) of the Malaysian Patents Act 1983 which 
contains the exclusion of animal varieties and explains how the country has been dealing with 
the exclusion. It identifies the gap within the Malaysian patent law (which this thesis seeks to 
fill), and in the context of international patent law, it highlights the legal provision of a 
Signatory to the TRIPS Agreement, and its development. For these purposes, this chapter 
contains five sections. Section 2 gives a background to the country‟s patent law. It discusses 
the basis and purpose of the introduction of the Malaysian Patents Act 1983 by highlighting 
the problems encountered by the country which, prior to the Act, had diverse legislations 
regulating national patent laws in different regions. It explains how the Malaysian Patents Act 
1983 tried to solve the problems. Section 3 focuses on the exclusion of animal varieties under 
s13(1)(b). It explores the legislative history of the provision in order to appreciate the basis 
and purpose for having the exclusion under the legislation. The section also assesses if the 
intended meaning of the term have been made clear by the legislature. Section 4 looks at the 
current application of the exclusion in Malaysia. In particular, the discussion focuses on the 
handling of applications involving animal inventions by the MyIPO, and the extent to which 
the term „animal varieties‟ have been considered by the office. Section 5 ends the chapter. 
  
This chapter will show that there is very minimal development of the exclusion within the 
Malaysian patent law, and so its legal position is vague. In the context of the thesis, the 
uncertainty will hamper the various efforts of the government to exploit animal 
biotechnology applications to develop its livestock industry (identified in chapter 1). The 
ambiguity would also deter foreign investments and technology transfer which are essential 
for the same purpose (identified in chapter 2). Conversely, a clear position of the law assists 
Malaysia to pursue its economic interests more effectively. Owing to this, it will be argued 
that this thesis is pertinent and timely.  
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2. The Malaysian Patents Act 1983: basis and purpose of introduction 
 
Malaysia is made up of two regions: Peninsular Malaysia (which consists of eleven states)
1
 
and East Malaysia (which consists of two states).
2
 The present Malaysian patent law 
originated from the English system where during the colonial era, a patent system, based on 
the English patent system, was introduced in Malaysia. The aim of such a system was mainly 
to protect the commercial interests of foreign manufacturers (particularly the British) who 
were involved in primary local industries such as tin and gold mining, rubber, palm oil and 
mineral oil extraction and refining.
3
 As a result, prior to 1983, the country‟s patent law was 
governed by three pieces of patent law legislation.
4
 The Registration of United Kingdom 
Patents Act 1951 (Revised 1978) governed the law in Peninsular Malaysia, the Registration 
of United Kingdom Patents Ordinance (Chapter 125) covered Sabah and the Registration of 
United Kingdom Patents Ordinance (Chapter 61) was in force in Sarawak.
5
 This was based 
on a re-registration system where any inventor who would like to have their inventions 
protected would have to apply for a patent in the UK and then apply to register it in Malaysia 
within three years of the date of the grant in the UK.
6
  This system had two major problems: 
(1) as the examination and search process would be conducted in the UK Patent Office, the 
whole process toward granting a patent, took a considerable time and incurred high costs. 
                                                          
1
  Perlis, Kedah, Pulau Pinang, Perak, Selangor, Melaka, Negeri Sembilan, Johor, Pahang, Kelantan and 
Terengganu. 
2
  Sabah and Sarawak. 
3
  L.H. Gee, A study of the historical development of the Malaysian patents system in A. Firth (ed), The 
prehistory and development of intellectual property systems (London: Sweet and Maxwell, 1997) 84. 
4
  Prior to 1983, patent protection via various sources had existed for many years in different component states 
of Malaysia. Depending on the status of the component states then (either the Straits Settlement or the 
Federated Malay States or the Unfederated Malay States), protection granted to inventors originated from 
sources such as English Statute, Indian legislation and indigenous legislations. See further details in L.H. 
Gee, ibid. 116-120. 
5
  These three statutes, together with the Patents (Rights of Government) Act 1967 which provided for the 
rights of the Government in the legislation relating to patents and for matters incidental thereto, were 
repealed by s89 of the Patents Act 1983 (Act 291). 
6
  I.M. Abdul Ghani Azmi, Patent law in Malaysia: cases and commentary (Sweet and Maxwell, 2003) 15. 
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This was an obstacle to inventors in getting their inventions patented; and (2) the separate 
laws governing each of the regions caused administrative difficulties, as inventors had to 
register their inventions in each region in order to obtain protection in the whole of 
Malaysia.
7
  
 
Between the 1980s and the mid-1990s, the Malaysian economy experienced a shift from an 
agricultural to an industrial basis. Among the most important, for the latter, are the local 
automotive
8
 and manufacturing industries. The introduction of the Malaysian Patents Bill 
1983 was intended mainly to support this shift in economic focus. One of the issues that 
quickly became apparent to the legislature is the importance of protecting technical 
inventions created by local inventors in order to encourage innovations. The unsatisfactory 
re-registration system, which was prevalent within the country‟s patent system,9 was seen to 
be a hindrance to the country‟s aspirations.  
 
The Malaysian Patents Bill 1983 was drafted after consideration of the patent laws of a 
number of countries, which included the UK, Australia, Sri Lanka, Thailand and Japan. In 
addition, the views of the WIPO, whose function includes the promotion of the protection of 
IPRs throughout the world, were also considered.
10
 For instance, in November 1982, several 
expert missions from the WIPO, including consultants from Sweden and the US visited 
Malaysia to advise the government on the establishment of the new patent system.
11
 The 
Malaysian Patents Act 1983 consolidates the diverse legislations that governed the patent law 
                                                          
7
  Malaysian Hansard, HR vol 1 cols 7767-7768 (25 July 1983). 
8
  For instance, DRB-HICOM, is one of Malaysia‟s leading corporations which play an integral role in the 
country‟s effort toward industrialisation. It was established in 1979 to support the production of national 
vehicles. See USF-HICOM, http://www.usf-hicom.com.my/about_usf.html (Accessed: 29 July 2010). 
9
  Malaysian Hansard, n 7 above, col 7768. 
10
  ibid. Speech by Mr Oo Gin Sun, Deputy Minister of Trade and Industry. 
11
  WIPO, Review of regional project activities in 1981/1982 (1983) Industrial Property in Asia and the Pacific, 
3. 
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of Malaysia into a statute. In addition to the introduction of a centralised registration 
mechanism, the new legislation introduced many new provisions with the aim of clarifying 
various aspects of patent law
 12 
and giving better protection to inventors. For instance, the old 
legislations only provided basic provisions such as procedures for filing an application at the 
then UK Patent Office, commencement and duration of rights, and powers of the High Court 
in case of disputes. In contrast, the new patent law provides detailed provisions with respect 
to (among other aspects) the meaning of an invention, the patentability criteria of an 
invention, a list of non-patentable inventions, licences, infringement, offences, and 
enforcement. 
 
In furtherance of the country‟s newly developed industrial sectors, participation in the 
international patent law arena was seen by the government to be a necessary step. It was the 
intention of the government to become a member of international conventions and 
organisations relating to patent rights, which include the Paris Convention, the PCT and the 
WIPO. Membership of these (all of which have since been achieved),
13
 was considered to be 
of benefit to Malaysian inventors, where their interests could be secured globally, due to the 
internationalisation and harmonisation role played by such Conventions and Organisations.
 14
 
 
This section has explained the general purpose of the Malaysian Patents Act 1983. Similar to 
other patent laws worldwide, its introduction within the Malaysian legal system aims at 
encouraging innovation by providing protection to local and foreign inventors. The next 
section investigates the basis and purpose of the exclusion of animal varieties by examining 
the legislative history of s13(1)(b) in order to see if the intention of the legislature was clearly 
                                                          
12
  Malaysian Hansard, n 7 above, cols 7769-7770. 
13
  Malaysia became the Member State of the Paris Convention 1883 on 1 January 1989, the WIPO on January 
1989 and the Patent Co-operation Treaty 1970 on 16 August 2006.  
14
  Malaysian Hansard, col 7941 (26 July 1983). 
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made. As the following section will demonstrate, there was very little attention given to the 
exclusion by the legislature during the parliamentary debates, hence rendering the purpose 
and subject matter of the exclusion unclear. 
 
3.  The exclusion of animal varieties under the Malaysian Patents Act 1983 
 
Section 13 provides for „Non-patentable inventions‟. Sub-section (1)(b) states: 
 
(1)  Notwithstanding the fact that they may be inventions within the meaning of 
section 12, the following shall not be patentable: 
 . . . 
(b) plant or animal varieties or essentially biological processes for the 
production of plants or animals, other than manmade living micro-
organisms, micro-biological processes and the products of such 
micro-organism processes; 
. . . 
Provided that this paragraph shall not apply to products used in any such 
methods.
15
 (emphasis added) 
 
This provision has been included in the Malaysian Patents Bill 1983 since it was tabled in the 
Malaysian Parliament (in 1983), and adopted when the Act came into effect in 1986. It 
should be noted that even though there was a shift in the country‟s economy focus from the 
agricultural to the industrial sector, the former remains one of the country‟s key sources of 
income. In terms of Malaysia‟s biotechnology industry, even though it was not yet developed 
when the Malaysian Patents Act 1983 was drafted, the government‟s commitment to develop 
the industry was evidenced by the creation of the National Biotechnology Committee in 1984. 
The function of the Committee, among others, was to advise the government on policy issues 
in research, funding and incentives to industries, to monitor new developments in 
                                                          
15
  Section 13(1)(b) has been amended only once since its promulgation via the Patents (Amendment) Act 1986 
(Act A648) where the word „may be‟ replaced the previous word „are‟. See Appendix 3 for s12. 
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biotechnology and to facilitate R&D between research institutions and industry.
16
 The 
emphasis on the development of the industry, particularly agricultural biotechnology, was 
explicitly made by the government in the Sixth Malaysia Plan (1991-1995).
17
 In the context 
of the aspiration of the government, it is important that two questions relating to the exclusion 
under s13(1)(b) be understood: (1) the origin of the exclusion; and (2) its basis and purpose. 
 
Materials from secondary sources that would enable a precise conclusion to be made as to the 
origin of such an exclusion in the Malaysian patent law are very scarce. Nevertheless, an 
inference for this purpose can be made from two sources mentioned in the parliamentary 
debates of the Malaysian Patents Bill 1983. The first relates to the five countries‟ patent law 
legislations which were considered by the legislature. An inspection of the legislations, 
disclosed the fact that only the UK Patents Act 1977, the Sri Lanka Code of Intellectual 
Property Act of 1979
18
 and the Thailand Patent Act 1979 exclude „variety of animal‟ or 
„animals‟ from patent protection.19 The position in Australia and Japan at all material times 
was very different in that no provision that excludes living matter from patent protection can 
be found in the respective Patents Act 1952
20
 and Patents Act 1959.
21
 However, in view of 
the fact that Malaysia was once a colony of the British, and that the Malaysian patent system 
                                                          
16
  J. Komen and G. Persley, „Agricultural biotechnology in developing countries: a cross-country review‟, 
ISNAR Research Report, 1993, 6. The National Biotechnology Committee was succeeded by the National 
Biotechnology Working Group in 1991. 
17
  ibid. 
18
  WIPO, „Exclusions from Patent Protection: Memorandum of the International Bureau of WIPO‟, Document 
HL/CE/IV/INF/1 (30 May 1988). 
19
  Patent Act B.E 2522 of 1979 was amended by Patent Act (no.2) B.E 2535 (1992) and Patent Act (no.3) B.E 
2542 (1999). See Patent Act B.E 2522 of 1979 which is available at: 
http://www.asianlii.org/th/legis/consol_act/pa199991/ (Accessed: 20 July 2009).  
20
  Attorney General‟s Department, Australian law online, http://152.91.38.99/html/histact/0/261/top.htm 
(Accessed: 20 July 2009). The Australian Patent Office‟s practice was to allow patents for processes 
producing non-human animal varieties and the products of such processes. Even though no patents have 
been granted for non-human animal varieties, it was understood that patent protection should be available for 
such inventions on the same general principles as it is available for micro-organisms and plant varieties. See 
WIPO, n 18 above.  
21
  Article 32 of the Japan Patent Act 1959 provides for general exclusion: „Any invention that is liable to injure 
public order, morality, public health shall not be patented‟. See WIPO, n 18 above. See also discussion in 
section 2.2.1 of chapter 2. 
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originated from the English patent system, it is possible to conclude that the reason for such 
an exclusion being included in the Malaysian Patents Act 1983 was the presence of a similar 
provision in the UK Patents Act 1977. The second source which might have influenced the 
introduction of the exclusion in the Malaysian Patents Act 1983 was the WIPO‟s Revised 
Model Law for Developing Countries on Inventions (WIPO Model Law),
22
 where s112 also 
excluded animal varieties from patent protection.
23
  
 
Yet another insight comes from the parliamentary proceeding of the Malaysian Patents Bill 
1983 itself where a question was raised by one of the Ministers as to the rationale for 
excluding plants and animals from patent protection.
24
 In response to this question, three 
reasons were mentioned by the Minister who tabled the Bill: (1) that they were considered as 
natural developments; (2) that the exclusion was available in other countries‟ patent law 
legislations, and  (3)  that  the  provision  was  one  which  was  normally  available in patent 
laws of other countries.
25
 The last two of the reasons suggested the fact that to have a similar 
exclusion in the Malaysian Patents Act 1983 was deemed necessary by the legislature to 
ensure that the Malaysian patent law is in line with those of other countries. In addition, it is 
the government‟s intention to become a member of the Paris Convention.  It is important in 
this convention that every contracting state should give national treatment in terms of patent 
protection to foreign citizens.
26
 Therefore, the approach taken by Malaysia, to bring its patent 
law as close as possible to the provisions of international patent law, is expected.  
 
                                                          
22
  WIPO, WIPO Model Law for Developing Countries on Inventions, Volume 1: Patents (Geneva, 1979) 19. 
Section 12 of the Malaysian Patents Act 1983 on the meaning of the term „invention‟ is similar to the Model 
Law for Developing Countries on Inventions.  
23
  ibid. 
24
  Malaysian Hansard, HR vol 1col 7916 (26 July 1983). 
25
  ibid. col 7943. These three reasons were generally stated without any authority being given to support the 
contention. 
26
  Article 2 of the Paris Convention requires each Member State of the Convention to provide national 
treatment to foreign citizens with regard to patents, industrial designs, trademarks and trade names. 
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The brief answer during the parliamentary debate of the Malaysian Patents Bill 1983 which 
reasoned the statutory exclusion of animals from national patent protection would inevitably 
lead to a question: what was the extent of the legislature‟s awareness and the information 
available, as to the ability of scientific technologies to create animal inventions? In this 
respect, it is important to consider the international patent law scene with regard to scientific 
developments in biotechnology. Modern biotechnology had begun in the 1970s where 
technology such as genetic engineering has been used to modify living organisms to obtain 
certain intended characteristics.
27
 Nevertheless, as far as the issue of the patentability of 
living organisms was concerned, it came to prominence only in 1980 due to the ground-
breaking decision of the US Supreme Court in the case of Diamond v Chakrabarty.
28
 Since 
such international developments in patenting animal inventions were at a very early stage, it 
is doubtful if there was much information on the scientific technologies available to the 
Malaysian legislature when the Malaysian Patents Act 1983 was drafted and debated. 
Otherwise, the parliamentary debates would have disclosed some of the scientific 
developments considered by the legislature, and their views on the issue. In the light of this 
situation, the first reason given by the Minister seems to suggest that it was the legislature‟s 
understanding that as animals are products of nature or naturally occurring, they are 
unpatentable under s13(1)(b). It is worthy of note that during the debate of the Malaysian 
Patents Bill 1983 there was a proposal that patent protection be allowed for animals and 
plants in view of the then existing innovative ideas of local scientists to produce some types 
of plants which were able to produce better quality yields.
 29
 Nevertheless, the proposal does 
not appear to have been discussed or explained further. As a result, it is more probable to 
conclude that the issue of patentability of animal inventions was then not appropriately 
considered by the legislature, hence the rationale for having the exclusion in the Malaysian 
                                                          
27
  See footnote 12 in chapter 1. 
28
  See discussion in section 2.2.1 of chapter 2. 
29
  Malaysian Hansard, n 24 above, ibid. 
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Patents Act 1983 and the actual intended subject matter of the exclusion remains 
ambiguous.
30
 
 
A key point which determines the subject matter excluded under s13(1)(b) is the intended 
meaning to the term „animal varieties‟. Notwithstanding the assumption that the exclusion of 
animal varieties was adopted in accordance with similar provisions of the UK Patents Act 
1977 and the WIPO Model Law, to conclude what could be the intention of the Malaysian 
legislature as to the meaning of the term is not an easy task. A question that may be asked is: 
can an inspection of the language of the Malaysian Patents Act 1983 shed some light? In 
Malaysia, the texts of all Acts will normally be prepared in two versions, which are in 
English and the national language, Malay. In this context, it is relevant to note that s13(1)(b) 
of the Malay version of the Malaysian Patents Act 1983 states the exclusion as ‘berbagai 
jenis binatang’, which in direct English translation is stated as „variety of animal‟. According 
to s6 of the National Language Act 1963/1967,
31
 the text (of a legislation) in the national 
language is to be considered as the authoritative text. The provision states: 
 
The texts of all Bills and Acts of Parliament shall be in the national language and in 
the English language, the former being authoritative unless the Yang di-Pertuan 
Agong
32
 otherwise prescribed generally or in respect of any particular law or class 
of laws. 
 
                                                          
30
  There is a difference in this respect with Singapore‟s patent law (the country is a neighbour of Malaysia). 
The Singaporean‟s Patents Act 1994 does not exclude animal inventions from patent protection, albeit the 
provisions on patentability closely followed the scheme of the English Act. Most importantly, this decision 
was made due to the recognition by the Select Committee of the promise of developments in biotechnology. 
In this regard, while noting the exclusion of variety of animals under the s1(3)(b) of the UK Patents Act 
1977, the Select Committee clearly reasoned out that non-human animal varieties should not be excluded 
from patent protection as the right „provides an incentive for people to invest and innovate.‟ On the possible 
application of biotechnology on human beings, the Committee firmly stated that the issue was preferably to 
be handled through the list of matters not considered as inventions „as such‟ under s13(2) of the Act. See 
detailed discussion on the position of genetically engineered life forms in Singapore in G.W.S. Shun, Mus 
Musculus and Homo Sapiens: murine metaphysics and the Canadian Supreme Court (2003) Singapore 
Journal of Legal Studies, 38-79. 
31
  Act 32. Available at: http://www.agc.gov.my/Akta/Vol.%201/Act%2032.pdf (Accessed: 8 April 2011). 
32
  Yang di-Pertuan Agong is the Head of State of Malaysia. 
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As a result, based on s6, the Malay term ‘berbagai jenis binatang’ is the authoritative text for 
the exclusion. Nevertheless, whichever may be the authoritative text (English or Malay), the 
choice of the term „animal varieties‟ and therefore, the subject matter of the exclusion were 
not raised or discussed during the parliamentary debates of the Malaysian Patents Bill 1983. 
In fact, the brief proceedings demonstrated that no importance was given to these aspects. 
Therefore, the language of the exclusionary provision is similarly not able to resolve the issue. 
Yet it can at least be concluded at this juncture that the terms, in both the English and Malay 
version of the Malaysian Patents Act 1983, should carry the same meaning and refer to the 
same subject matter, whatever the terms could mean. 
 
Irrespective of the lack of clarity in the purpose and intended subject matter of the exclusion 
at the time of the tabling of the Malaysian Patents Act 1983 (in 1980s) as demonstrated in 
this section, it should be noted that the exclusion has been retained, even though various 
amendments have been made to the Act since it came into effect.
33
 While one might argue 
that such a situation may be created by the „dormant‟ nature of the exclusion as there is not 
yet any issue that has been raised by any parties so far, a counter-argument that the retention 
indicates its importance is equally reasonable. For this reason, the following section will look 
at the application of the exclusion in the Malaysian patent law so far. This allows an 
assessment of whether there has been a conclusive approach adopted by Malaysia in 
exercising the flexibility under Article 27.3(b) of the TRIPs Agreement, or if there is an area 
to which this thesis can, theoretically and practically, contribute. 
 
 
 
                                                          
33
  The Patents Act 1983 has been amended five times since it came into effect; in 1986(A648), 1995(A863), 
2001(A1088), 2003(A1137) and 2006 (A1196). 
148 
 
4.  The current application of the exclusion in Malaysia 
 
Similar to other patent offices throughout the world, one of the aims of the MyIPO is to 
provide an efficient administrative system to encourage greater creativity and exploitation of 
intellectual property.
34
 It is indicated
35
 that, from 1986 to January 2010, the MyIPO received 
thirty-two applications (relating to the production of antibodies) for patent protection 
involving what the Organisation termed „transgenic animals‟. 36  These include transgenic 
mice and transgenic cattle. Thirteen of these applications involved claims to patent the 
transgenic animals as products. Such applications were received from international countries 
such as the US, the UK, Sweden, Cuba, Thailand and Finland.
37
 So far, nine claims have been 
refused. Two of the claims were refused based on s31(1) of the Patents Act 1983
38
 for being 
contrary to public order or morality.
39
 Seven others were refused due to other administrative 
grounds such as the absence of a response from applicants and non-payment of required 
fees.
40
 There were however, three claims relating to antibodies involving animal inventions, 
which have been allowed.
 41
 According to the office‟s practice, patents will be granted for 
                                                          
34
  Intellectual Property Corporation of Malaysia, Corporate information, http://www.myipo.gov.my/en/about-
myipo.html (Accessed: 8 April 2011). 
35
  Personal communication with an official of the MyIPO dated 29 January 2010. 
36
  According to the MyIPO, „transgenic animal‟ is: „an animal that has been genetically engineered using 
recombinant DNA techniques to make animals with new characteristics. Transgenic animals are produced by 
adding one or more genes to an animal genome, using a process called transformation‟. 
37
  Personal communication with an official of the MyIPO dated 3 May 2010. 
38
  Personal communication with an official of the MyIPO dated 21 January 2010.  
39
  Personal communication with an official of the MyIPO dated 5 May 2010. For s31(1) see Appendix 3. The 
provision has been included in the Act via Patents (Amendment) Act 2000 (Act A1088) so as to comply with 
the minimum requirement under Article 27.3(b) of the TRIPs Agreement. The question of whether an 
invention is contrary to „public order or morality‟ is currently determined by a patent examiner in the MyIPO. 
Personal communication with an official of the MyIPO dated 5 May 2010. Since many applications of 
modern biotechnology are in the field of agricultural food and pharmaceuticals which involve public interest, 
it has been argued by Abdul Ghani Adzmi that the determination of what constitutes „morality‟ should be 
shouldered by a special Ethics Committee (which should comprise of parties involved in the process 
standards, halal certification and religious bodies) rather than solely entrusted to the patent office. This could 
gain public confidence in the products of biotechnology. See I.M. Abdul Ghani Azmi, Patenting whilst being 
ethical (2009) International Islamic University Malaysia (IIUM) Law Review, 499. There is not yet any 
decision made by the Malaysian courts to determine the test for „public order‟ or „morality‟ within the 
Malaysian patent law. 
40
  Personal communication with an official of the MyIPO dated 5 May 2010. 
41
  Personal communication with an official of the MyIPO dated 19 January 2010. 
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inventions involving animal materials such as genes and plasmids provided they fulfil the 
patentability criteria.
42 
 
According to the MyIPO, the term „animal varieties‟ in s13(1)(b) is defined based on the 
practice of European countries‟.43 Therefore, the term is understood to carry the meaning of: 
 
[a]ny of various groups of animals ranking below a species (subspecies). Therefore, 
in the taxonomic hierarchy, „variety‟ clearly appears below the category of 
„species‟. That category is in turn defined as a category of biological classification 
ranking immediately below the genus or subgenus, comprising related organisms 
or populations potentially capable of interbreeding, and being designated by a 
binomial that consists of the name of a genus followed by a Latin or latinized 
uncapitalized noun or adjective agreeing grammatically with the genus name. Thus, 
examples of species include Mus musculus (M. musculus), M. abbottii, and M. 
caroli; and M. musculus, for instance, is further subdivided into subspecies such as 
M. musculus domesticus and M. musculus bractianus. „Genus‟ itself is defined as a 
category of biological classification ranking between the family and the species, 
comprising structurally or phylogenetically related species or an isolated species 
exhibiting unusual differentiation, and being designated by a Latin or latinized 
capitalized singular noun. An example of a genus would thus be Mus (Mice).
44
 
 
This is clearly an adoption of the meaning given by the Technical Board of Appeal (TBA) of 
the EPO in the Harvard/Onco-mouse case.
45
 Although the MyIPO has continued to handle 
applications involving animal inventions, and the above meaning, an in-depth examination of 
the exclusion is arguably crucial for at least four reasons. Firstly, the discussion in section 2 
has disclosed the fact that the derivation, intended meaning and subject matter, of the 
exclusion, within the Malaysian patent law, are not at all clear.
46
 Secondly, the meaning of 
                                                          
42
  Personal communications with an official of the MyIPO dated 4 December 2009 and 4 March 2010. Under 
Chapter IV, paragraph 3.1 of the MyIPO Guidelines for Patent Examination, genes which are discovered to 
exist in nature may be patentable if a technical effect is revealed. Plasmids which fall under the term „micro-
organism‟ under paragraph 3.3 of the same Chapter are also patentable. See MyIPO Guidelines for Patent 
Examination, http://www.myipo.gov.my/files/PT_Guidelines.pdf (Accessed: 24 December 2009). 
43
  Personal communication with an official of the MyIPO dated 29 January 2010. 
44
  ibid. 
45
  The decision is discussed in detailed in sub-section 3.2 of chapter 4. 
46
  The Malaysian Biotechnology Corporation has similarly identified that while the Malaysian Patents Act 
1983 recognised some exclusions, the current position as to the patenting of biotechnological inventions in 
Malaysia is still vague. Therefore, a request has been made that in the light of the increasing demands for the 
protection of inventions, the Act is reviewed and amended to include clearer provisions and provide 
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the term „animal varieties‟ and therefore the subject matter excluded under s13(1)(b) has not 
yet been tested by the Malaysian courts. Thirdly, so far, there is no formal interpretation to 
the term „animal varieties‟ has been made by the patent office.47 Finally, it is important that 
the meaning of the term be clarified, should a grant or rejection of patents to animal 
inventions under s13(1)(b) be deemed relevant to be applied by the MyIPO in the future. In 
addition, it is pertinent to note that under s88 of the Malaysian Patents Act 1983, an 
aggrieved party to the decision or order by the Registrar (of the MyIPO) or the Corporation is 
given recourse for an appeal to the High Court. Due to these reasons, this thesis is timely and 
its findings will fill the vacuum mentioned. The thesis may also provide some input to the on-
going efforts by the MyIPO to review and amend the Malaysian Patents Act 1983, Malaysian 
Patent Regulations 1986,
48
 and the Organisation‟s Guidelines for Patent Examination, where 
issues relating to transgenic animals are also being considered.
49
  
 
5.  Conclusion 
 
It has been shown in this chapter that the exclusion of animal varieties was included under 
s13(1)(b) of the Malaysian Patents Act 1983, mainly due to the country‟s intention to 
participate in the international patent scene. Among the earliest steps adopted by the country 
to place itself within the international intellectual property (including patent) rights 
framework, was the application to become a member of the international IPRs-related 
conventions, treaties and organisations such as the Paris Convention, PCT and the WIPO. 
                                                                                                                                                                                    
direction to the issue. See Malaysian Biotechnology Corporation, Patent protection in Malaysia – a basic 
information guide, http://www.biotechcorp.com.my/wp-
content/uploads/2011/11/downloads_aboutmalaysia/IP_Booklet_Patents_V1.pdf (Accessed: 5 March 2012) 
9. 
47
  Personal communication with an official of the MyIPO dated 19 January 2010. So far, no application to 
patent the Harvard Mouse has been filed in the MyIPO. 
48
  PU(A) 327/86. Available at MyIPO, http://www.myipo.gov.my/acts/Patent%20Regulations%201986-.pdf 
(Accessed: 6 April 2012). 
49
  Personal communication with an official of the MyIPO dated 4 March 2010. 
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Another important reason for having the exclusion in the Malaysian Patents Act 1983 was to 
ensure that the national patent law is in line with other countries‟ patent legislations. 
However, the meaning of the term „animal varieties‟ under s13(1)(b) is unclear. This is due to 
the lack of consideration given by the legislature to the needs and implications of the 
exclusion. The parliamentary debates and the language of the exclusionary provision offer 
little assistance with these uncertainties. 
 
The presence of the exclusion of animal varieties under the Malaysian Patents Act 1983 
should not be concluded as depicting the country‟s pessimistic position toward innovations. 
This is because, currently, there is a gap in terms of its application within the Malaysian 
patent law. The MyIPO has not thoroughly considered the exclusion because s13(1)(b) has 
not been applied in any patent applications involving transgenic animals filed with the patent 
office. More importantly, the Malaysian courts have not construed the exclusion.  
 
The basis and purpose of introducing the Patents Act 1983 in Malaysia, was to give 
protection to inventors (local and international) for the enhancement of the country‟s 
economy and ultimately the socio-economic interests of the population. While originally 
introduced with the aim of supporting the country‟s shift of economy from agriculture to 
industrial (mainly automotive and manufacturing) the purpose of the Malaysian Patents Act 
1983 can be concluded to be similarly applicable to other types of industry, which become 
equally important as the country‟s economy develops. Malaysia‟s biotechnology industry 
(including agricultural or livestock) is one of these, as it is one of the industries which the 
government has been aiming to develop since the time the Malaysian Patents Act was 
introduced in 1983.  
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In the absence of the clear intention and direction from the legislature as to how the exclusion 
of the term „animal varieties‟ is to be construed, the door is wide open for Malaysia to 
determine its application, either broadly or narrowly, as seemingly allowed under Article 
27.3(b) of the TRIPs Agreement. This thesis proposes to fill the gap by proposing which one 
is the most practical for Malaysia to adopt. Nevertheless, since the exclusion relates to animal 
inventions, it is only logical that any interpretation of the exclusionary provision should 
consider the area in which the inventions are applied in a relevant Signatory‟s economic 
activities, as any decision would heavily affect the interest of the public. As far as Malaysia is 
concerned, the problems of its livestock industry in securing a food supply for the population 
(as identified in chapter 1) should be the main consideration. With this guiding principle in 
mind, the next chapter will examine the European-wide permissive approach. The discussion 
will include a legislative examination of Article 53(b) of the EPC, the analysis of relevant 
legal cases and an assessment of the implications of the approach on the livestock industry. 
With regard to the whole thesis, the chapter will show that the permissive approach promotes 
animal biotechnology applications relating to livestock animals. As a result, the production 
and quality of the livestock products will be enhanced.  
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CHAPTER FOUR 
 
THE PERMISSIVE APPROACH FOR PATENTING ANIMAL INVENTIONS   
AND ITS IMPLICATIONS ON THE LIVESTOCK INDUSTRY:  
THE EUROPE PERSPECTIVE 
 
1. Introduction 
 
Together with developed countries such as the US and Japan, the EU has made rapid 
advances in the field of biotechnology. According to the 2010 World Intellectual Property 
Indicators,
1
 the largest number of patent applications in the field of biotechnology originated 
from the US (10,769) followed by the European Member States (4,299) and Japan (2,827). 
While the three are considered the key players in the international patent law scene,
 2
 the EU 
has adopted a different approach to its economic competitors by having the exclusion of 
animal varieties under Article 53(b) of the EPC.
3
 Notwithstanding the exclusion, which might 
suggest that the continent is a less-attractive place for investment in biotechnology compared 
to its main competitors,
4
 the EU has put considerable effort into diminishing the „negative‟ 
                                                          
1
  WIPO, World Intellectual Property Indicators 2010: Foreign-oriented patent families by field of technology, 
http://www.wipo.int/ipstats/en/ (Accessed: 9 April 2011) 60. The top fifteen countries of origin which were 
involved are Austria, Australia, Canada, China, Switzerland, Germany, Finland, France, Italy, Japan, 
Republic of Korea, the Netherlands, Sweden, the UK and the US. 
2
  China is among the top three intellectual property offices (apart from the US and Japan) which account for 
60% of the total patent applications filed worldwide. See WIPO, WIPO IP facts and figures 2011, 
http://www.wipo.int/export/sites/www/ipstats/en/statistics/patents/pdf/wipo_pub_943_2011.pdf (Accessed: 
26 October 2011). However, in terms of patent applications in the field of biotechnology, according to the 
World Intellectual Property Indicators 2010, only 238 applications originated from China.  
3
  Similar to the EU, under Article 25(4) of the Patent Law of the People's Republic of China 1984, animal 
varieties are excluded from patent protection. See WIPO, 
http://www.wipo.int/wipolex/en/text.jsp?file_id=178664 (Accessed: 31 October 2011). However, within the 
international patent law framework, it is not yet clear how China would interpret the exclusion. See for 
instance, C. Smith, A practical guide to Chinese patent law (2005) 29 Seton Hall Legislative Journal, 2, 643-
664; K. Geng, Should China provide intellectual property protection for genetically modified animals? (2003) 
23 Northwestern Journal of International Law and Business, 467-486. 
4
  There are no similar exclusionary provisions under the 35
th
 Title US Code and Japan Patent Act 1959. See 
detailed discussion in sub-section 2.2.1 of chapter 2. See also J. Straus, The present state of patent systems in 
the European Union: as compared with the situation in the United States and Japan (Luxembourg: Office 
for Official Publications of the European Communities Stationery Office, 1997) 45.  
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perceptions. In particular this has been implemented through its biotechnology policies, 
legislative framework and decisions of the EPO as demonstrated here.  
 
The EPC was drafted with the Strasbourg Convention as its predecessor, albeit with a 
different purpose (discussed in section 2 below). Despite the existence of these treaties, the 
EU was concerned with differences in the implementation aspects.
5
 Mainly they were about 
the interpretation of the term „invention‟, the patentability criteria, and the nature of excluded 
subject matter, which were left with the patent offices and national courts of the Member 
States.
6
 As stated by the Commission White Paper on completing the Internal Market
7
 in 
1985 such differences „have a direct and negative impact on intra-Community trade and the 
ability of enterprises to treat the Common Market as a single environment for their economic 
activities.‟8 As a result, the EU proposed to have a supplementary document which was 
meant to provide the Member States with a better understanding and application of the EPC‟s 
provisions. This led to the adoption of the EU Biotechnology Directive
9
 which aims at 
clarifying provisions of the EPC. For instance, as regards the exclusion of animal varieties, 
Recital 29 and Article 4(2) of the EU Biotechnology Directive explain that inventions 
concerning animals are patentable „if the technical manipulation of the invention is not 
restricted to a particular animal variety‟.10 Whether or not these provisions have actually 
                                                          
5
  G. Kamstra, M. Döring, N. Scott-Ram, A. Sheard and H. Wixon, Special report: patents on biotechnological 
inventions: The E.C Directive (Sweet and Maxwell, 2002) 2. 
6
  ibid. 
7
  Previously known as „Common Market‟. 
8
  G. Kamstra et al, n 5 above, ibid. 
9
  The EU has no direct influence on the operation of the EPC or the EPO. Thus, the Directive at the outset will 
not bind Member States of the EPC. Having the EPC and the Directive in place (which are issued by 
different administrative bodies), problems might arise for a state which is both a contracting state to the EPC 
and a member state of the EU. If there is a conflict between the provisions of the two texts, the EPO is under 
no obligation to comply with the provisions of the Directive. This anticipated problem has however been 
resolved by the Administrative Council of the EPO with the incorporation of the Directive‟s provisions into 
the Implementing Regulations to the EPC (Rule 26 to 29; previously Rule 23b to 23e under the EPC 1973). 
The incorporation ensured harmonisation between the two texts. The Implementing Regulations to the 
Convention on the Grant of European Patents is available at: EPO, http://www.epo.org/law-practice/legal-
texts/html/epc/1973/e/ma2.html (Accessed: 22 August 2011).  
10
  For the provisions, see Appendix 6. 
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clarified the meaning of the term „animal varieties‟ and therefore, the subject matter excluded 
under Article 53(b), will be seen in section 3 of this chapter. 
 
As already explained in the Introduction chapter, the term „permissive approach‟ refers to the 
ease with which an inventor may obtain patent protection for animal inventions (as products) 
in the EPC Member States, notwithstanding the explicit exclusion of animal varieties under 
Article 53(b). This chapter assesses the approach and identifies how permissive it is. It also 
examines the impact of the approach to the livestock industry and other applications of 
animal biotechnology. Consequently, the chapter is divided into five sections. Section 2 
begins with a legislative overview of Article 53(b) so as to understand the intended meaning 
of the term „animal varieties‟, and the basis, purpose and subject matter of the exclusion. This 
identifies the permissive approach adopted by the EPO in interpreting the exclusion. The 
importance and influence of Article 2(b) of the Strasbourg Convention to Article 53(b), on 
which the current law rests, will also be examined. Reliance will be mainly placed upon the 
preparatory working papers (travaux preparatoires)
11
 of the two conventions. Despite both 
being Conventions for the European patent laws, it is observed that the exclusion is framed in 
a different manner in each Convention: Article 53(b) of the EPC requires Member States to 
exclude the subject matter, whereas Article 2(b) of the Strasbourg Convention permits 
Member States to do the same. In the light of the different nature of the exclusions, and also 
the flexibility for Signatories to the TRIPs Agreement to exclude animal inventions under 
Article 27.3(b) (identified in chapter 2), an account of the reasons behind the distinction in 
the relevant provisions will be made. Section 3 examines the narrow interpretation of the 
term „animal varieties‟ in the light of judicial interpretation and legal commentary. Mainly, 
                                                          
11
  French expression. Travaux preparatoires are the official record of negotiations, often useful in clarifying 
the intentions of a treaty or other instrument. As from 4 April 2011, the record relating to Article 53(b) is 
available online at the EPO website, http://www.epo.org/law-practice/legal-texts/archive/epc-
1973/traveaux.html?update=law (Accessed: 6 April 2011). 
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this focuses the analysis on the cases of Harvard/Onco-mouse and Leland Stanford/Modified 
Animals,
12
 which have underlined various important principles pertaining to the exclusion of 
animal inventions under the European patent law. The discussion includes the facts of the 
case and decisions of the various Boards of the EPO. Central to this section is an analysis of 
leading critics‟ views so as to assess the feasibility of their previous arguments on the 
interpretation by the EPO. The section also examines the reasons underpinning the 
permissive approach to appreciate its broader stance to the importance of patent protection of 
animal inventions. Section 4 assesses the impact of the permissive approach on the livestock 
industry. The chapter is concluded by section 5.  
 
As regards the whole thesis, this chapter deals with the first model of interpretation and its 
practical implications from which Malaysia could learn in deciding how it should apply its 
exclusionary provision which is in pari materia
13
 with Article 53(b). Malaysia is not a 
Member State of the EPC. Nevertheless, as the country‟s patent law originated from the UK‟s 
patent system, the permissive approach would be relevant for the Malaysian patent office and 
courts
14
 to consider because it is the same approach which would be adopted by the UK‟s 
courts when interpreting the exception in the UK Patents Act 1977.
15
 Although decisions of 
foreign judicial authorities are not legally binding on the Malaysian courts, they are of highly 
persuasive value if they were decided by courts with a similar common law background. 
Decisions of this nature have often been followed by national courts when Malaysia‟s law is 
                                                          
12
  Leland Stanford/Modified Animals [2002] EPOR 2.  
13
 Latin expression which means: „of the same matter or on the same subject‟. See http://legal- 
dictionary.thefreedictionary.com/pari+materia (Accessed: 7 April 2011). 
14
  I.M. Abdul Ghani Azmi, Research on human embryos and stem cells: weaving ethical and religious 
concerns into the framework of patent law in Malaysia in P.L.C. Torremans (ed), Intellectual property and 
human rights: enhanced edition of copyright and human rights (Wolters Kluwer, 2008) 510-512. 
15
  Paragraph 3(f) of Schedule A2 of the Patents Act 1977. See Appendix 9 for the provision. 
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unclear.
16
 Findings of this chapter will form a basis for various conclusions that will be laid 
down in the Discussion and Conclusion chapter.  
 
2. The exclusion of animal inventions under the European patent laws 
 
The main concepts of European substantive patent law were established by the Strasbourg 
Convention
17
 under the aegis of the Council of Europe (COE). The Convention
18
 laid down 
general rules for the adoption of national laws. It dealt principally with conditions relating to 
the patentability of inventions and attempted to define the prerequisites for patent protection, 
namely novelty, inventive step and industrial application.
19
 The initiative to create a patent 
convention for the EU
20
 was inspired by the broader aim to create a Common Market where 
trade barriers among the Member States of the then European Economic Community (EEC)
21
 
                                                          
16
  See for instance S.S. Syed Ahmad, Malaysian legal system (Lexis Nexis: 2007) 155; A. Ibrahim and A. 
Joned, The Malaysian legal system (Kuala Lumpur: Dewan Bahasa dan Pustaka, 1995) 133. The Federal 
Court in the case of DG of Inland v Kulim Rubber Plantations Ltd [1981] 1 MLJ 214 commented on the 
effect of decisions of other countries‟ courts on the interpretation of legislation which are in pari materia 
with Malaysian legislation. The court held that those decisions, although not binding, should be paid due and 
proper attention by the Malaysian courts. In fact, judgements of courts of foreign jurisdictions have never 
been lightly treated or refused unless the Malaysian courts could successfully distinguish or hold them as per 
incuriam. Per incuriam is a Latin expression which means: „through lack of care‟. See http://legal-
dictionary.thefreedictionary.com/ (Accessed: 30 May 2011). 
17
  Work on patents under the era of the COE started in 1949. See D. Thompson, The draft Convention for a 
European Patent (1973) 22 International and Comparative Law Quarterly, 52. The Convention was signed 
on 27 November 1963 and came into effect on 1 August 1980. 
18
  The Convention was largely based on the preparatory work undertaken by Scandinavian countries (Denmark, 
Norway, Sweden and Finland) in preparation for a Nordic patent law. See M. Singer and D. Stauder, 
European Patent Convention: a commentary: Vol. I (Sweet and Maxwell, 2003) 64. The Nordic patent law 
came into force on 1 January 1968. It was the result of close collaboration between the joint government-
appointed committees of Denmark, Norway and Sweden which had been working since 1950 on an 
assignment to present a system of Scandinavian patents and to propose the legislation necessitated thereby. 
See The Joint Scandinavian Patent Committees, „The Preliminary Report by the Joint Scandinavian Patent 
Committees: Draft Patent Law and Extracts from the Explanatory Notes‟ (25 March 1971) 1. 
19
  See D. Thompson, n 17 above, 53. 
20
  The initiative was taken in November 1959 by the Secretaries of State of the six member states of the Rome 
Treaty, which had established what was then called the EEC. The EEC was established on 1 January 1958. 
See G. Oudemans, The draft European Patent Convention: a commentary with english and french texts 
(London: Stevens & Sons Limited, 1963) 1. 
21
  Belgium, France, Germany, Holland, Italy and Luxembourg. 
158 
 
were to be removed in order to promote a single market for community trade.
22
 Through the 
unified patent system, the EU aspires to compete economically with the US and Japan. 
 
The EPC specifically aims to establish a system of law, common to the Member States, for 
the granting of European patents for invention.
23
 Thus, when compared to the Strasbourg 
Convention, the EPC has a broader aim, which is to harmonise
24
 the patent systems of the 
Member States for the granting of patents for innovation. The two important provisions under 
the European patent law which provide for matters which are to be excluded from patent 
protection are Article 2(b) of the Strasbourg Convention and Article 53(b) of the EPC. As 
regards the exclusion of animal inventions, Article 2(b) of the Strasbourg Convention 
provides: 
 
The Member States shall not be bound to provide for the grant of patents in respect 
of: 
 
Plant or animal varieties or essentially biological processes for the production of 
plants or animals; this provision does not apply to micro-biological processes and 
the products thereof. (emphasis added) 
 
In turn, Article 53(b) of the EPC states: 
 
 European patents shall not be granted in respect of: 
plant or animal varieties or essentially biological processes for the production of 
plants or animals; this provision shall not apply to microbiological processes or the 
products thereof. (emphasis added) 
 
                                                          
22
  K. Haertal, European Patent Convention: english translation by Volker Vossius (C.Heymanns, 1981) 2. 
23
  Article 1 of the EPC. 
24
  The terms „harmonisation‟ and „unification‟ have been frequently used by commentators when discussing 
the development of the European patent laws. According to Cataldo, by underlining the rules governing 
patent application and examination procedures the EPC played both the roles of harmonising and unifying 
the European patent law. On the one hand, the unification is achieved by having a set of granting rules under 
the Convention, whereas the harmonisation is achieved when the rules are later adopted by the national 
patent laws of the Member States, creating a uniform granting system for European patents. See V.D. 
Cataldo, From the European patent to a community patent (2002) 8 Columbia Journal of the European Law, 
19-35. 
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Before the legislative examination of the exclusion under Article 53(b), the following sub-
section will examine the main reasons underpinning the manner in which the above 
exclusions are formed, and its comparison with Article 27.3(b) of the TRIPs Agreement. This 
provides an understanding of why the exclusion is framed in a different manner by framers of 
each patent law treaty. 
 
2.1 The exclusion of animal inventions under the European patent laws and the TRIPs 
Agreement: a comparison 
 
While Article 2(b) and Article 53(b) are similar in terms of materials which are to be 
excluded by Member States of each Convention, the former prescribes the exclusion of 
animal varieties in an optional manner in contrast to the mandatory nature of the latter. In 
turn, in comparison to the TRIPs Agreement, it is important to note the similarity between 
Article 2(b) and Article 27.3(b)
 25
 where each allows their Member States and Signatories 
either to grant, or not to grant, patent protection to animal inventions. Conversely, Article 
53(b) and Article 27.3(b) are different where the former imposes a mandatory obligation on 
its Member States, whereas the latter is worded in a permissive manner. It is pertinent to 
consider why these differences arose.  
 
The permissive nature of Article 2(b) and Article 27.3(b) arises from the common feature of 
the Strasbourg Convention and the TRIPs Agreement, respectively. Each treaty regulates 
national patents, only to the extent of establishing basic principles for substantive patent law 
such as the patent qualification criteria and the period for patent protection. The individual 
Contracting State maintains its discretion either to grant patent protection, or not, to animal 
                                                          
25
  For Article 27.3(b), see Appendix 4. 
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inventions. Nevertheless, where a State decides to grant a patent under its national patent law, 
it is obliged to adhere to the requirements underlined by these parent treaties.
26
 
 
In contrast, the mandatory nature of the exclusion under Article 53(b) is due to the function 
of the EPC in regulating the grant of European patents.
27
 The Convention governs the patents 
which an inventor could apply for via a single application,
28
 and if granted, will create a 
bundle of national patents as if it had been granted by the local granting offices
29
 and 
enforceable through the national courts.
30
 Thus, as it is the EPC which underwrites the 
granting procedures for the European patent, it is only reasonable that it imposes a uniform 
system. The mandatory obligation to exclude animal inventions under Article 53(b) is an 
example of the EPC attempting to achieve parity among the Member States in terms of the 
implementation of the EPC provisions. Given that the granting of European patents is 
regulated by the EPC, the function of the national courts is then only to determine the validity 
or infringement of rights of the granted patent.  
 
The importance of the mandatory obligation also arises from the fact that, while the EPC does 
not oblige the Member States to bring their national laws into conformity with it, most have 
amended their national laws to achieve such uniformity.
31
 This is due to the various legal 
                                                          
26
  For detailed discussion see J. Pila, Article 53(b) EPC: a challenge to the Novartis theory of European patent 
history (2009) 72 The Modern Law Review, 3, 442. 
27
  Article 1 of the EPC. 
28
  However, in practice, an applicant has an option to file a series of applications in each of the EPC Member 
State countries in which the relevant invention is intended to be protected, and claim priority of an 
application through priority provisions. See Articles 87 to 89 of the EPC; L. Bently and B. Sherman, 
Intellectual property law (Oxford University Press, 2009) 372; H. MacQueen, C. Waelde and G. Laurie, 
Contemporary intellectual property: law and policy (Oxford University Press, 2007) 415-417. 
29
  Articles 2(2) and 64(1) of the EPC. 
30
  Article 64(3) of the EPC; L. Bently et al, n 28 above, 330; H. MacQueen et al, n 28 above, 368. 
31
  See G. Tritton, Intellectual property in Europe (London: Sweet and Maxwell, 1996) 53-54; G. Paterson, The 
European patent system: the law and practice of the European Patent Convention (Sweet and Maxwell, 
1992) 3. For instance the UK Patents Bill 1977 was drafted to bring the UK patent law into compliance with 
the provisions of the EPC. The UK Patents Act 1977 replaces the Patents Act 1949.
  
See M. Victoria (ed), 
The Patents Act 1977: Queen Mary College Patent Conference Papers (London: Sweet and Maxwell, 1978) 
3; Committee to Examine the Patent System and Patent Law, The British patent system: Report of the 
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requirements imposed on the Member States by the Convention.
32
 Allowing a permissive 
exclusion of animal inventions under Article 53(b), which in turn, would be adopted by the 
national patent laws, would invite Member States to dispute the granting or refusal of the 
European patent by the EPO. This arises from the power of national courts to interpret the 
permissive obligation differently. Eventually, this would lead to greater challenges in 
achieving the uniformity of the European patent laws. 
  
This sub-section has explained that the way in which the exclusion of animal inventions is 
framed in the European patent laws and the TRIPs Agreement, depends on the function of 
each treaty. In essence, treaties such as the Strasbourg Convention and the TRIPs Agreement 
which underline the European or international substantive aspects of patent law (such as the 
patentability criteria) grant the flexibility for Member States and Signatories to either allow 
patents on animal inventions or otherwise. This is due to the right of the individual Member 
State and Signatory to decide on the patentability of the inventions according to national 
intellectual property policies. Conversely, the treaty which regulates the granting of patents 
for its Member States, such as the EPC, imposes compulsory exclusion to ensure consistency 
in the taking up of the exclusion. Nevertheless, in those countries and regions where the 
exclusion is adopted it is how the exclusion is interpreted which allows permissiveness to 
arise. 
 
The next sub-section focuses on the exclusion of animal varieties under Article 53(b). The 
discussion investigates four aspects: (1) the basis of the exclusion; (2) the intended meaning 
of the term „animal varieties‟; (3) the intended purpose for the exclusion; and (4) the intended 
                                                                                                                                                                                    
Committee to Examine the Patent System and Patent Law (London: Her Majesty‟s Stationery Office, 1970) 
xvii. 
32
  For instance, Articles 2 and 64 of the EPC, respectively, require that a Member State must ensure that the 
European patent has the same effect and is subject to the same conditions, and that the same rights are 
conferred, as would be conferred by a national patent granted by the relevant State. 
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subject matter of the exclusion. For these purposes, the preparatory working documents of 
Article 53(b) of the EPC and Article 2(b) of the Strasbourg Convention will be examined. It 
will be shown that, except for the first aspect, the last three of these are unclear. Nevertheless, 
as to the subject matter of the exclusion, it is apparent that the framers intended to exclude 
from the patent system only inventions which do not involve technical intervention. In terms 
of the thesis, the discussion is important to facilitate an understanding of the legislative 
background of the exclusion under Article 53(b) which is in pari materia with s13(1)(b) of 
the Malaysian Patents Act 1983. 
 
2.2 The legislative examination of the exclusion of animal varieties under Article 53(b)  
 
The exclusion of animal varieties, in the work of the EEC Patents Working Party (PWP), was 
influenced by the Strasbourg Convention, which in turn aspired to the harmonisation of 
European patent law. Administratively this situation was due to at least two reasons: (1) the 
majority of Member States of both Conventions are the same, making it understandable that 
both Conventions should contain similar provisions in order to maintain consistency in the 
implementation of the European patent law; and (2) a number of the members of the 
Committee of Experts on Patents of the Council of Europe of the Strasbourg Convention 
(Committee of Experts) were also leading figures in the PWP. They include G. Finniss (who 
was the Rapporteur-General of the Committee of Experts and Chairman of the PWP), M. 
Haertel (who was the German expert in the Committee of Experts and President of the PWP), 
B. van Bentham (the expert for Holland in both Committees) and M. Rosciani (the expert for 
Italy in both Committees).
33
 For these reasons, the tendency to have the exclusion in the EPC 
                                                          
33
  The Working Group for Patents was nominated in the beginning of 1960 and is composed of: K. Haertel 
(President), F. Froschmaier (Secretary), J. de Reuse, J. Degavre, P. Verlinden (Belgium), P. Fressonnet, R. 
Gajac, J. Roller (France), K. Pfanner, R. Singer, O. Bossung (Germany), B. van Bentham, G. van Exter 
(Holland), M. Roscioni, F. Nunziata, R. Briganti (Italy), A. de Muyser (Luxembourg), H. Sünner, J. Lannoy, 
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(as in the Strasbourg Convention) and the use of similar wording are to be expected, rather 
than for the framers to „reinvent the wheel‟, drafting a new provision.  
 
2.2.1 Basis of the exclusion and meaning of the term „animal varieties‟ 
 
Article 12 of the first preliminary draft Convention relating to a European patent law (which 
came into being in 1961) provides that: „European patents shall not be granted in respect of 
inventions relating to the production of or a process for producing a new plant variety or a 
new animal species.‟34 Nevertheless, „processes of a technical nature are not excluded‟.35 The 
draft provision discloses that there was a distinction between the terms used by the framers of 
the EPC to represent the exclusion in contrast to the corresponding provision in the 
preliminary draft of the Strasbourg Convention (which was also drafted in March 1961). The 
former used the term „new plant variety or a new animal species‟, while the latter used the 
term „new plant or animal species‟. The early use of different terms for plant (variety) and 
animal (species) in the draft of the EPC suggested that there was an understanding among the 
framers of the EPC of the terms that were appropriate for each category of exclusion. 
Nevertheless, as the negotiations developed, and during the process of finalising the terms to 
be used, the Chairman of the PWP reminded the Committee that the wording of Article 12 
was not to be altered too much.
36
 Otherwise, they would have to inform the COE, since the 
text of the Strasbourg Convention which similarly excluded plant or animal varieties
37
 had 
                                                                                                                                                                                    
J.P. Petitbon, E. Ciasca (European Atomic Energy Committee - Euratom), R. Knöpfle (European Coal and 
Steel Cummunity – S.A.C.C), J. Dieu, P. Pujade, J.P. Lauwers, Miss M. Kapten (European Economic 
Community – E.E.C). See G. Oudemans, n 19 above, 1. 
34
  PWP, „Comments on the First Preliminary Draft Convention Relating to a European Patent Law of 14 March 
1961‟, Document IV/2071/61-E, section 13, 3. 
35
  ibid. 
36
  PWP, „Proceedings of the 5th Meeting of the Patents Working Party held at Brussels from 2-18 April 1962‟, 
Document 3076/IV/62-E (22 May 1962) section 4, 137. 
37
  In the then paragraph 2(2) of the draft Council of Europe Convention. See COE, „Memorandum by the 
Secretariat on the Meeting held at Strasbourg from 7
th
 to 10
th
 November 1961‟, Document EXP/Brev (61) 8 
(13 December 1961) 16. 
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been submitted to the governments of the negotiating countries.
38
 Consequently, the PWP 
decided to adopt the expression used in Article 2(b) of the Strasbourg Convention.
39
  
 
The discussion concerning Article 53(b) revealed that the reason for having the exclusion in 
the EPC arose from the need for consistency with Article 2(b). In particular, this is due to the 
recognised need for the framers of the EPC and the Strasbourg Convention to work in „co-
operation‟, so as to ensure that the aim for the creation of an Internal Market would not 
prejudice the work of the COE which aims at establishing the basic principles of European 
substantive patent law.
40
 This motivation was also observed by critics
41
 who stated that the 
identical wording of (the then) Articles 9 to 14
42
 of the draft of the EPC and the draft of the 
Strasbourg Convention was chosen in order to ensure that, once both Conventions were 
adopted, there should be no discrepancy between these basic provisions.
43
 Others
44
 made 
similar observations about the adoption of Article 53 of the EPC based on Article 2 of the 
Strasbourg Convention where it was said that „Article 53 was adopted without further 
discussion as to its purport‟. 
 
Notwithstanding the clear need for consistency between Article 53(b) and 2(b), the 
preparatory working documents for the Strasbourg Convention do not provide any reason for 
the adoption of the term „plant or animal varieties‟ (a change from the term „new plant or 
                                                          
38
  PWP, n 36 above, ibid. 
39
  ibid. 138. 
40
  COE, „Report by the Committee of Experts to the Committee of Ministers on the meeting held at The Hague 
from 28 November to 2 December 1960‟, Document CM (60) 150 (2 December 1960); J. Pila, n 26 above, 
442. 
41
  See G. Oudemans, n 20 above, 21. 
42
  Article 9: patentable inventions; Article 10: Exceptions to patentability; Article 11: Novelty; Article 12: 
Non-prejudicial disclosures; Article 13: Inventive step; Article 14: Industrial application.  ibid. 
43
  ibid. 
44
  E. Armitage CB and I. Davis CB, Patents and morality in perspectives (London: Common Law Institute of 
Intellectual Property, 1994) 24. The former was closely involved in the preparatory work on the Strasbourg 
Convention and the EPC.  
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animal species‟, previously used in the preliminary draft of the Convention).45 Arguably, the 
discussion on the protection of new plant varieties which took place alongside the work on 
the unification of the substantive aspects of the European patent law, could have contributed 
to the change of terms adopted. This is evidenced by the similarity of phrase used to define 
the protectable subject matter.
46
 The discussion, which finally led to the adoption of the 
UPOV Convention, gave specific protection to plant varieties which were considered not 
appropriate to be protected by the patent regime.
47
 In the negotiations over Article 53(b), the 
PWP made an explicit reference to the Convention where the debate on the terms „new plant 
variety‟ and „new animal species‟ arose in its first meeting. A delegate48 questioned the use of 
the term ‘nouvelles espêces animales’ (which could be translated as: new animal species). He 
was of the opinion that the exclusion of new animal species would not cover any new animal 
breeds.
49
 In response to this, the PWP decided „to wait and see what terminology would 
shortly be adopted in the UPOV Convention before changing those terms‟.50 
 
It can be observed that the term „plant or animal varieties‟ under the EPC was adopted by the 
PWP only four months after the adoption of the UPOV Convention which provides a sui 
generis protection to plant varieties. Intrinsically, the term „plant varieties‟ was chosen as the 
most appropriate for the exclusion of plants in the EPC. As regards the term „animal 
varieties‟, in the absence of an equivalent legal instrument relating to animals, the term used 
to represent the exclusion is most likely to have been influenced by the term „variety‟ when 
applied to plants. Given that the term „variety‟ was already being used in the discussion 
                                                          
45
  COE, „Report of the meeting on 16 and 17th March 1961‟, Document EXP/Brev B (61) 3 (24 March 1961) 6. 
The change was due to proposals that were received from the Working Group and the Drafting Committee. 
See COE, „Proposal by the Working Group‟, Document EXP/Brev/Misc (61) 13 (8 November 1961); COE, 
„Proposal of the Drafting Committee‟, Document EXP/Brev/Misc (61) 14 (9 November 1961). 
46
  See comment in J. Pila, n 26 above, 453. 
47
  Plants which are novel, distinct, uniform and stable. 
48
  Mr. De Reuse, an expert from Belgium. See PWP, „Proceedings of the 1st Meeting of the Patents Working 
Party held at Brussels from 17-28 April 1961‟, Document IV/2767/61-E (3 May 1961) section 6, 45. 
49
  PWP, ibid.  
50
  ibid. 
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surrounding plant variety protection, its use, and the extension to animals, which appears in 
the same draft provision, might have seemed both obvious and logical. 
 
2.2.2 Purpose of the exclusion 
 
The purpose of the exclusion of animal varieties from the patent regime was neither explicitly 
discussed nor raised in the negotiating process of Article 53(b) and 2(b). It has been 
highlighted in the negotiation of Article 2(b) that novel plant inventions
51
 should be excluded 
from the patent system as the potential monopoly would raise issues of public interest. 
Further, there was disagreement among negotiating countries as to the concept of „industrial 
character‟52 that should be attached to agricultural inventions.53 In the same context, it can 
only be assumed that animal varieties are excluded for the same reason. Nevertheless, despite 
the specific prerequisites and concept for plant varieties under the UPOV Convention, critics 
have asserted that the conceptual exclusion for plant varieties under the EPC should be 
extended to animal varieties. For instance, it has been stated that:  
 
                                                          
51
  Terms such as „vegetable novelties‟, „vegetable species‟, „plant varieties‟ and „plant species‟ were used 
interchangeably to represent novel plant inventions in communications among delegates of participating 
countries. While there was no specific meaning attached to the term „novel plant inventions‟, the early 
discussion of the Committee of Experts on Patents of the Council of Europe which started with a 
comparative study made by the Secretariat General of the Committee with regard to new horticultural 
products might shed some light as to the nature of products which were under discussion. Therefore, the 
terms used by the delegates may cover fruits, vegetables, flowers and ornamental plants. In the context of 
patent protection, the term „novel plant inventions‟ may be intended for any plant products which may be 
patentable as they were new in the patent law sense of novelty, rather than those which are naturally 
occurring. 
52
  Industrial applicability is one of three granting criteria for patent protection beside novelty and inventiveness. 
Industrial applicability means an invention must be able to be used in an industry. For an inventor to be able 
to claim protection for his invention he needs to show that the invention has a technical character which 
exhibits useful purpose in solving a technical problem. While processes in agricultural activities may be 
easily understood to be able to fulfil this criterion, participating countries of the Strasbourg Convention 
varied in opinion whether the end products per se could have an „industrial‟ method of operation to solve a 
technical problem. 
53
  COE, „Report of the French Delegation on the Unification of European Laws in respect of Patents‟, 
Document EXP/Brev (57) 3 (13 May 1957) 5. 
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[t]he extension of the exclusion to animal varieties was a logical consequence 
because to accord protection to a corresponding category of animals whilst 
refusing protection to a certain category of plants (variety) would be deemed 
anomalous.
54
 (emphasis added) 
 
Similarly, it has also been contended
55
 that the extension was logical for the possible creation 
of a similar sui generis system to plant varieties for animal breeds that may take place in the 
future.
 Notwithstanding these arguments, it seems possible to argue that the critics‟ 
conclusions are difficult to appreciate, as there is no equal or alternative Convention which 
provides for the protection of animal varieties (including its concepts). While it is appropriate 
for plant varieties to be excluded from patent protection due to the availability of an 
alternative protection, there were no calls for protection of any kind to be provided for animal 
inventions. Therefore, it can only be surmised that the reason animal varieties were excluded 
under Article 53(b) was because of some sense of the need for completeness.   
 
The lack of consideration for the purpose of excluding animal inventions from the European 
patent laws may be further explained by two reasons based on the negotiation of Article 2(b) 
of the Strasbourg Convention: (1) in comparison to novel plant inventions, which were 
handled differently in most of the negotiating countries, thus requiring a decision on suitable 
protection,
56 
the need for legal protection for novel animal inventions had not yet developed. 
Nevertheless, the negotiating countries had no objection to the patenting of processes 
                                                          
54
  E. Armitage CB et al, n 44 above, 14. See also observation by M.W. Tvedt, Patent protection in the field of 
animal breeding (2007) 57 Acta Agriculturae Scand Section  A, 108. 
55
  O. Mills, Biotechnological inventions: moral restraints and patent law (Ashgate, 2005) 27. 
56
  COE, „Draft Minutes of the Fourth Meeting held at Strasbourg on 10th July 1952‟, Document EXP/Brev (52) 
PV 10 prov (11 July 1952). The comparative study by the Secretariat General of the Committee of Experts 
disclosed that there was no national legislation of the participating countries which made express provision 
for the patenting of novel plant inventions. For instance, France at that time provided an inventor of novel 
plant inventions with a limited protection outside the patents legislation through the decree of 16 November 
1932 for certain kinds and species of plants. See COE, „Draft Official Report of the Meeting of 6th July 
1951‟, Document CM/WP/IV (51) PV 8 (7 July 1951); COE, „Criteria of Novelty and Patentability‟, 
Document CM/WP/IV (51) 9. 
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involving animals for agricultural reasons.
57
 However, there seems to have been no reason for 
the framers to seriously consider the idea that patents might be granted for novel animal 
inventions as products;
58
 (2) apart from this, plant varieties and animal species may be seen 
as sharing a similar characteristic; they are living organisms which are of agricultural 
relevance, hence, important to the public. In view of the absence of a specific concept for 
animal varieties, a separate discussion for this issue might be seen as premature or 
unnecessary by the Meeting. Yet their exclusion under Article 2(b) may be considered as 
justified by the framers should issues relating to their legal protection arise in the future. 
 
2.2.3 Subject matter of the exclusion 
 
A pertinent issue arising from the non-definitive meaning of the term „animal varieties‟, 
concerns the subject matter of the exclusion. The intended meaning and, therefore, the subject 
matter which the framers intended to exclude for the term „animal varieties‟ remained 
indefinite. However, looking at the whole provisions of Article 53(b) and 2(b), a relevant 
conclusion can be reached. The framers of both provisions had made it clear from the 
negotiations that processes of a technical nature, although being applicable to animals, are 
patentable.
59
 In evidence, the drafts of Article 53(b) and 2(b) clearly stated that „essentially 
                                                          
57
  Such as methods of rearing animals. See COE, „Reply to questionnaire drawn up by the Bureau of the 
Committee of Experts of the Council of Europe, from the point of view of the German legislation‟, 
Document EXP/Brev (53) 1 (12 January 1953) 3; COE, „Reply to questionnaire drawn up by the Bureau of 
the Committee of Experts of the Council of Europe from the point of view of legislation in Norway‟, 
Document EXP/Brev (53) 9 (7 April 1953) 2. 
58
  COE, „Reply to questionnaire drawn up by the Bureau of the Committee of Experts from the point of view 
of the French legislation‟, Document EXP/Brev (53) 4 (10 February 1953) 3-4; J. Pila, n 26 above, 453-454. 
59
  COE, „Observations and proposals of the German experts on the unification of general conditions of 
patentability‟, Document EXP/Brev (56) 8 (26 October 1956) 2. See also PWP, n 34 above, section 13, 6. It 
was stated in the document that: „Even if protection of new plant varieties and processes for producing new 
plants is excluded under European patent law, European patents will still have to be granted for processes 
which, while being applicable to plants, are of a technical nature, e.g, processes for producing new plants by 
irradiation of the plants themselves or of the seed with isotopes‟. As regards new animal species, it was 
stated that the comments for new plant varieties „also apply mutatis mutandis to the patentability of new 
animal species‟. Mutatis mutandis is a Latin expression which means: „the necessary changes‟. See 
http://legal-dictionary.thefreedictionary.com/Mutatis+mutandis (Accessed: 10 April 2012). 
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biological processes for the production of plants and animals‟, can (or should) be excluded 
from patent protection whereas „micro-biological processes and the products thereof‟ are not 
bound by the exceptions.
60
 In other words, the framers of the provisions only intended to 
exclude from the patents system inventions involving no technical intervention which would 
render it eligible for patent protection. However, the question which remained concerns the 
lack of legal protection for „animal varieties‟ (as products) as compared to plant varieties. In 
this, whether or not animal inventions are unpatentable under the European patent law, will 
be seen in the next section. 
  
Based on the examination of the preparatory working papers of the Strasbourg Convention 
and the EPC, this sub-section has shown three things: (1) the work of the draft of the EPC 
which ran parallel with the final stage of the Strasbourg Convention shows that the latter 
influenced the former in terms of the basis of, and the terminology used to represent, the 
exclusion. Essentially, this was to ensure consistency between the two European patent law 
treaties so that the objective for the creation of an Internal Market was not prejudiced; (2) the 
purpose of the exclusion under both Conventions was not explicit. Apart from the assumption 
that it is based on the importance of agricultural products to the public, the exclusion of 
animal varieties is arguably a complement to the exclusion of plant varieties; and (3) although 
what exactly was intended to be excluded by the term „animal varieties‟ under Article 53(b) 
is unclear, it can be concluded that inventions with technical intervention, albeit relating to 
animals, are to be protected under the European patent law. 
 
                                                          
60
  COE, „Report of the Committee of Experts to the Committee of Ministers on the meeting held from 
Strasbourg from 14
th
 to 17
th
 May 1963‟, Document CM (63) 101 (27 May 1963) 10; Intergovernmental 
Conference for the Setting Up of a European System for the Grant of Patents, „First Preliminary Draft of a 
Convention Establishing a European System for the Grants of Patents‟, Document BR/88/71 (15 February 
1971) 12. 
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Notwithstanding these conclusions, it is important to note Articles 31 and 32 of the Vienna 
Convention on the Law of Treaties 1969 (Vienna Convention)
61
 which laid down the 
convention in international law. According to the provisions, if the relevant treaty or 
Convention fails to provide a definition, „then the ordinary meaning of that term should be 
used, in the context and in the light of the object and purpose of the Convention‟.62 In the 
absence of a definitive meaning for the term „animal varieties‟ as shown in this sub-section, it 
is significant to see how the EPO, being the granting office of European patents, has defined 
the term and shaped the application of the exclusion.  
 
Under the European patent law, biotechnological inventions, as with other types of invention, 
should be patentable provided the patent qualification criteria under Article 52(1) of the EPC 
are met. Article 3 of the EU Biotechnology Directive reiterates this principle where it clearly 
states that the fact that an invention involves living organisms is not a bar to its patentability. 
With these general principles as a pillar, the exclusion of animal varieties under Article 53(b) 
has been narrowly applied by the EPO.
63
 The Harvard/Onco-mouse and Leland 
Stanford/Modified Animals are two important decisions of the EPO which directly address the 
issues of the patentability of animal inventions, and so the next sub-section will focus on 
them.
64
 Brief facts of the cases will first be discussed, followed by an analysis of the 
decisions of the EPO in the context of critics‟ views about the decisions.  
                                                          
61
  Available at: http://untreaty.un.org/ilc/texts/instruments/english/conventions/1_1_1969.pdf (Accessed: 27 
May 2011). 
62
  M. Adcock and M. Llewelyn, Micro-organisms, definitions and options under TRIPS, Paper prepared for a 
discussion meeting hosted by the Quaker UN Office (Geneva) and the International Centre for Trade and 
Sustainable Development, 23 November 2000, 4. See also the EPO‟s statement in the case of EISAI G5/83 
(Second medical indication). Available at EPO, http://www.epo.org/law-practice/case-law-
appeals/recent/g830005ep1.html (Accessed: 31 May 2011). 
63
  G. Kamstra et al, n 5 above; M.W. Tvedt, n 54 above. 
64
  A line of decisions of the Harvard/Onco-mouse case has been widely discussed within the European patent 
law jurisprudence on the exclusion of biotechnological inventions. They explain extensively several legal 
considerations on the patentability of animals. Nevertheless, the Leland Stanford/Modified Animals case is 
no less important in underlining the European patent law policy on the subject matter. This is because, unlike 
the onco-mouse which was held patentable by being an animal genetically modified at the molecular level, 
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The discussion will show that the use of taxonomic definitions confirmed by the TBA in the 
Onco-mouse II to justify the patentability of animal inventions under the European patent law 
is not free from challenge. However, the isolated category approach which underpins the 
narrow interpretation aiming at the grant of patent protection to animal inventions, would 
eventually promote inventive efforts and technological advancement. In terms of the research 
questions, the analysis contained in the next section (which is based on the final decision of 
the Harvard/Onco-mouse case)
65
 informs Malaysia (and other countries with the same 
exclusion) of two things: (1) how permissive is the European-wide approach; and (2) which 
of the leading critics‟ views (all of which were based on the earlier decisions of the 
Harvard/Onco-mouse case) could still stand or have been otherwise refuted. The analysis of 
the latter would serve as a pertinent guide to Malaysia as the implications of the critics‟ 
arguments for the progression of scientific R&D involving animal inventions, will be 
concluded.  
 
3. The narrow interpretation for the exclusion of animal varieties under Article 53(b) 
of the EPC 
 
3.1 The Harvard/Onco-mouse and Leland Stanford/Modified Animals: facts and issues 
for determination  
 
Both cases have straight forward facts and issues for determination. The Harvard/Onco-
mouse case involved a European patent application filed by Harvard University for two types 
                                                                                                                                                                                    
hence altering the whole genome of the animal, and, therefore, should have easily fulfilled the patentability 
qualifications, the Leland Stanford/Modified Animals decision held that chimeric (simply means: hybrid) 
animals which are altered at the neonatal stage (hence should have been more difficult to prove novelty) are 
also patentable under the European patent law. 
65
  The decision of Transgenic Animals/Harvard, T 315/03, Decision of Technical Board of Appeal, 6 July 
2004. 
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of patents: (1) process patents; and (2) product patents. The claims for the main process 
patent were for a method for producing a transgenic mouse, for which the process involved 
the alteration of the genetic sequence of the mouse by the injection of onco-genes (cancer-
inducing genes) to develop cancer tumours. The mouse would then be used for testing new 
anti-cancer drugs. The product claim was for the transgenic mouse itself.
66
 Patents relating to 
the process to create the mouse, cell cultures and plasmids associated with the transgenic 
mouse were allowed.
67
 Therefore, the issue for the EPO to decide was whether the genetically 
engineered mouse fell within the term „animal varieties‟ in Article 53(b) and therefore, was 
unpatentable.  
 
As regards the Leland Stanford/Modified Animals case, the patentee produced an immuno-
compromised
68
 human-animal chimera (hybrid) mouse. The mouse was produced using 
tissues from aborted human foetuses and children below three years old, for the purpose of 
modelling HIV-1 infections. The issue before the Opposition Division (OD) was whether the 
patent granted to the proprietor for „a chimeric non-human mammalian‟ was valid. One of the 
oppositions to the patent was that the subject matter involved contravened Article 53(b) for 
being animal varieties. 
 
The Harvard/Onco-mouse case was the first case where the EPO was required to determine 
the excluded subject matter under Article 53(b). While the case was also decided by the 
Examining Division (ED) (in 1989 and 1992) and by the OD (in 2001), the ratio decidendi
69
 
                                                          
66
  Harvard V 0004/89, Examining and Opposition Division, Official Journal of the EPO 1989, 451, paragraph 
3. 
67
  ibid. 
68
  Means: a health condition where an organism suffers from „an incapability to develop a normal immune 
response, usually as a result of disease, malnutrition, or immunosuppressive therapy‟. See 
http://www.thefreedictionary.com/immunocompromised (Accessed: 19 August 2011). 
69
  A Latin expression which means: „the ground or reason of decision; the legal principle upon which the 
decision in a specific case is founded‟. See http://legal-dictionary.thefreedictionary.com/ratio+decidendi 
(Accessed: 19 April 2011). 
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of the case was laid down by two decisions of the TBA (in 1990, sometimes referred to as the 
Onco-mouse I; and in 2004, sometimes referred to as the Onco-mouse II).
70
 Intrinsically, this 
is due to the hierarchy of the decision-making within the EPO, which afford primacy to the 
decisions of the Technical Board in this context. The analysis in the next sub-section will use 
the Onco-mouse II decision as a focal point with the support of the decision of the Leland 
Stanford/Modified Animals case (where relevant).  
 
3.2 The decision of the Onco-mouse II: an analysis  
 
The EPC has three versions, namely English, French and German, which, according to 
Article 177(1) of the EPC, are equally authentic. Consequently, the exclusionary terms under 
Article 53(b) are represented differently: „animal varieties‟ in English, ‘races animales’ in 
French and ‘Tierarten’ in German (the three terms). Each of the versions of Article 53(b) 
contains a reference to the terms „animal varieties‟ and „animals‟; ‘races animales’ and 
‘animaux’; and, ‘Tierarten’ and „Tiere’; in the same provision.71 Therefore, the TBA in the 
Onco-mouse I was of the view that the framers intended the former (of each term) to have a 
narrower meaning than the latter. Ultimately, the Board decided that under Article 53(b) the 
framers intended that only certain categories of animals should be excluded and not animals 
per se.
72
 Underpinning the decision is the principle that as Article 53(b) is an exception to the 
general rule of patentability under Article 52(1) it should be narrowly construed.
73
 Notably, 
                                                          
70
  The Onco-mouse II decision was the result of the opposition to the patents granted by the Examining 
Division in 1992, where the issue of whether the onco-mouse should be patentable as it constitutes „animal 
varieties‟ under Article 53(b) was again raised. Seventeen Notices of Opposition were filed against the 
granted patent. See Onco-mouse/Harvard, Decision of the Opposition Division 7 November 2001, Official 
Journal of the EPO, October 2003, 473, at 474. 
71
  Harvard T 0019/90, Technical Board of Appeal, Official Journal of the EPO 1990, 476, paragraph 4.2. 
72
  ibid. paragraph 4.6. 
73
  See further discussion about the legal principle in H. Holzapfel and G. Werner, Interpreting exceptions in 
intellectual property law in Wolrad Prinz zu Waldeck und Pyrmont, M.J. Adelman, R. Brauneis, J. Drexl and 
R. Nack (eds), Patents and technological progress in a globalized world (Berlin: Springer, 2009). 
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the rule was adopted by the long-held decisions of the Boards of the EPO in some earlier 
cases involving plant varieties such as Lubrizol/Hybrid Plants.
74
  
 
In both the Harvard/Onco-mouse and Leland Stanford/Modified Animals the granted patents 
were held to be valid as the claims are not caught by the exclusion of animal varieties under 
Article 53(b). How did the EPO define the term „animal varieties‟ (in the light of the three 
different terms), hence, reaching the conclusion? Before analysing the decisions, it is 
pertinent to appreciate the salient principles underlined by the Onco-mouse II, to which the 
discussion now turns. 
 
3.2.1 Salient principles of the Onco-mouse II 
 
In reference to the Merriam-Webster OnLine Dictionary,
75
 the Onco-mouse II
76
 has discussed 
the taxonomic classifications for the terms „variety‟, „race‟ and „species‟ as below.  
 
„Animal variety‟ is defined as:  
any of various groups of animals ranking below a species (sub-species).  
 
„Animal race‟: 
an actually or potentially interbreeding group within a species; also a taxonomic 
category (as a sub-species) representing such a group. 
 
„Animal species‟: 
a category of biological classification ranking immediately below the genus or sub-
genus, comprising related organisms or populations potentially capable of 
                                                          
74
  [1990] EPOR 173, at paragraph 6. This principle should be distinguished from the broad construction 
adopted in the cases involving human embryonic and human embryonic stem cells which have been 
specifically excluded from patentability under Rule 28(c) and Rule 29(1) of the Implementing Regulations to 
the EPC. The issue has been discussed in the lead case of WARF/Stem Cells [2009] EPOR 1; Decision of the 
Board of Appeal 3 November 2008 T 1374/04, and the earlier case of Edinburgh Patent case European 
patent (EP) no 0695351; Opposition Division‟s Interlocutory Decision of 21 July 2003. Underpinning the 
broad construction, as stated by the EBA in paragraph 28 of the WARF decision, was „the concern of the 
framers to prevent misuse in the sense of a modification of human embryos and one of the essential 
objectives of the whole Biotechnology Directive to protect human dignity.‟   
75
  Understandably the Board was specific about the source of classification that they adopted as there is more 
than one standard adopted in the science of animal taxonomy. 
76
  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 11.6. 
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interbreeding, and being designated by a binomial that consists of the name of a 
genus followed by a Latin or Latinized uncapitalized noun or adjective agreeing 
grammatically with the genus name. 
 
In turn, the decision has discussed the definition below for „genus‟: 
 
a category of biological classification ranking between the family and the species, 
comprising structurally or phylogenetically related species or an isolated species 
exhibiting unusual differentiation, and being designated by a Latin or latinized 
capitalized singular noun.
77
 
 
These definitions are based on the taxonomic classification of the animal kingdom where 
each category (taxon) denotes the categorisation of an individual animal (and its relatives), 
into groupings based on their inheritable characteristics or traits (such as animals with or 
without backbones, hot or cold blooded, and two-legged or four-legged). Known as a 
reproductive community or an ecological unit or a genetic unit, species is the lowest category 
in the classification rank.
78
 It refers to a population of animals which can breed and produce 
viable offspring.
79
 The Onco-mouse II exemplified species „to include Mus musculus (M. 
musculus), M. abbotti and M. caroli; and M. musculus can be further sub-divided into sub-
species such as M. musculus domesticus and M. musculus bractianus.‟80 Animals are treated 
as sub-species and given sub-specific names if different populations within a species can be 
shown to differ consistently from other populations.
81
 It is also important to note that genus is 
preceded by five other higher theoretical categories: family, order, class, phylum and 
Kingdom.
82
 Therefore, a full animal taxonomic classification (based on the definitions 
discussed in the Onco-mouse II) can be illustrated as Diagram 1 below (with a demonstration 
                                                          
77
  ibid. 
78
  E. Mayr, Principles of systematic zoology (New York: McGraw-Hill Book Company, 1969) 23; W.H. 
Johnson, L.E. Delanney, E.C. Williams and T.A. Cole, Principles of zoology (Holt, Rinehart and Winston, 
1969) 274. 
79
  ibid. 
80
  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 11.6. 
81
  R. Freeman, Classification of the animal kingdom (London: English Universities Press Ltd, 1972) 3. 
82
  G.G. Simpson, Principles of animal taxonomy (London: Oxford University Press, 1961) 3; E. Mayr, n 78 
above. 
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for the taxonomic classification of the species of house mouse i.e Mus musculus or M. 
musculus). 
 
KINGDOM    Animalia 
       
 
 
PHYLUM         Mollusca  Chordata
83
 
 
  
 
CLASS        Cephalopoda
84
   Reptilia      Mammalia 
 
 
 
ORDER         Teuthida    Carnivora       Rodentia
85
 
 
 
   
FAMILY              Sciuridae (squirrels)      Muridae
86
 
 
 
   
GENUS        Rattus (rats) Mus (mice) 
 
 
 
SPECIES     M. musculus    M. abbotti
87
   M. caroli 
(Tierarten)                (house mouse)           (Ryukyu mouse)
88
 
 
 
 
Sub-species      M. musculus domesticus   M. musculus bractianus 
(races animales/variety) 
 
Diagram 1: The full taxonomic classification of Mus musculus (house mouse)
89
 
                                                          
83
  Vertebrates animal. See http://www.thefreedictionary.com/Chordata (Accessed: 9 May 2011). 
84
  Includes squid, cuttlefish, octopus and squid. See Taxonomy of the Cephalopods, 
http://www.molluscs.at/cephalopoda/taxonomy.html (Accessed: 5 October 2011). 
85
  Animal characterised by large incisors, adapted for gnawing or nibbling. See 
http://www.thefreedictionary.com/rodent (Accessed: 9 May 2011).  
86
  The family includes mice and rats, gerbils, whistling rats and relatives. See 
http://www.globalspecies.org/ntaxa/115756 (Accessed: 9 May 2011).  
87
  According to the International Union for Conservation of Nature and Natural Resources (IUCN), Mus 
abbotti is a synonym of Mus musculus. See IUCN, Red list of threatened species, 
http://www.iucnredlist.org/apps/redlist/details/13972/0 (Accessed: 2 November 2011). 
88
  Also known as Ricefield Mouse. ibid. 
89
  The diagram is adopted from Figure 6 of Warren Jones‟s „Taxonomic Classification‟ with modification 
based on the Onco-mouse II decision as regards the placement for the taxon of Rodentia, Mus (mice) and 
downwards.  See A. Warren-Jones, Patenting rDNA: human and animal biotechnology in the United 
Kingdom and Europe (Oxford: Lawtext Publishing, 2001) 114. Albeit the difference (where, in Figure 6 she 
reduces some taxa to lower ranks; such as by placing Mus under species; Rodentia under genus and 
downwards) her analysis on the subject matter remains relevant for consideration as taxonomic classification 
is an inexact science where classification of animals to a particular category is quite subjective depending on 
the knowledge of the taxonomist. The most important point to bear in mind is that the taxonomic 
classification is a system which relies on inheritable characterisation of an animal. 
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The Diagram demonstrates two important points: (1) A species is a group of animals which 
are grouped together in a genus due to shared general inheritable characteristics, but which 
are divided further into sub-species (or further sub-specific categories) due to more specific 
characteristics (arising, for example, from a common geographical location); and (2) the 
terms „animal varieties‟ (variety), ‘races animales’ (race) and ‘Tierarten’ (species) adopted 
under Article 53(b) are taxonomically not equal to each other. The categories of „race‟ and 
„variety‟ come below the category of „species‟ for being sub-species. Notwithstanding the 
latter point, the Onco-mouse II
90
 has confirmed that a definition by reference to taxonomical 
rank „was the most appropriate so that it would be consistent with the position to plant 
varieties and in the interests of legal certainty‟. According to the TBA, the definition would 
enable an assessment under Rule 27(b) of the Implementing Regulations to the Convention 
on the Grant of European Patents (Implementing Regulations to the EPC) which states inter 
alia that „if the technical manipulation of the claimed subject matter is not limited to a 
particular animal variety, the claims do not fall within the exclusion‟.91 Therefore, adopting 
the principle underlined by the Enlarged Board of Appeal (EBA)
92
 in the case of 
Novartis/Transgenic Plant,
93
 the Onco-mouse II
94decided that: „[a] patent should not be 
granted for a single animal variety (or species or race, depending on which language text of 
the EPC is used) but can be granted even if varieties may fall within the scope of its claim.‟95 
                                                          
90
  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 11.5. 
91
  The principle simply means, while animal varieties are not patentable in Europe, if an invention is not 
restricted to a particular variety of animal, the exclusion does not apply. For example, if an invention 
involves genetically engineering a gene construct for expressing an enzyme into a mammary gland of a pig, 
but the technical manipulation of the invention can be applied to different varieties of pigs or different 
mammals (not to a particular variety of pig), then the invention would not be deemed an animal variety, thus 
not barred from patentability. 
92
  The EBA is a higher rank of decision-making panel than the TBA within the EPO. 
93
  G 01/98 [2000] EPOR 303; T 1054/96 [1999] EPOR 123. The EBA in its decision held that a claim will not 
be excluded from patentability where specific plant varieties are not individually claimed.  
94
  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 11.8. 
95
  ibid. In the context of animal, the principle simply means, a single animal variety (in terms of the taxonomic 
classification) is not patentable. However, where (for example) patent is granted to a gene which is contained 
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This principle has been similarly adopted by the OD in the case of Leland Stanford/Modified 
Animals,
96
 and will be further discussed in sub-sections 3.2.2 and 3.3 below.  
 
One of the aspects which the TBA (in Onco-mouse I) had directed the ED to consider was to 
determine the common meaning of the three terms.
97
 Nevertheless, an examination of the 
decision of the ED identifies that the Division did not reach this point. Rather, the 
patentability of the claimed transgenic mouse was generically decided by looking at the terms 
used in the specification of the claims filed by the applicant to describe the invention.
98
 As a 
result, the Division simply held that, „as the claims referred to the invention as „mammals‟ 
and „rodents‟, which were taxonomically higher than „species‟, „race‟ and „variety‟, the 
transgenic mouse was not caught by Article 53(b)‟.99 The decision suggested that a common 
meaning for the three terms is not attainable. Yet, the ED reversed its earlier decision which 
refused the applicant‟s claim. While the subject matter excluded under Article 53(b) appears 
to have been decided by the Onco-mouse I through the generic approach adopted by the ED, 
hence suggesting an explicit distinction between patentable and unpatentable animal 
inventions, what remains vague from the decision is: what precisely is excluded?  
 
In response to the generic approach of the Onco-mouse I, Vossius,
100
 Beyleveld and 
Brownsword,
101
 and Warren-Jones
102
 have offered their views on the excluded subject matter 
                                                                                                                                                                                    
in an animal variety, the patent covers the animal with that gene contained within it. For example, according 
to Diagram 1, an applicant cannot claim patent to M. musculus domesticus, but if a patent is granted to a 
gene contained in the mouse, it is covered by the patent. 
96
  Leland Stanford/Modified Animals, n 12 above, paragraph 42.  
97
  Harvard T 0019/90, n 71 above, paragraph 4.3.  
98
  Harvard V 0006/92, Examining and Opposition Divisions, Official Journal of the EPO 1992, 589, paragraph 
2; A. Warren-Jones, n 89 above, 117. 
99
  Harvard V 0004/89, n 66 above, paragraph 2. 
100
  V. Vossius, Patent protection for animals; Onco-Mouse/Harvard (1990) 12 European Intellectual Property 
Review, 7. 
101
  D. Beyleveld and R. Brownsword, Mice, morality and patents (London: Common Law Institute of 
Intellectual Property, 1993). 
102
  A. Warren-Jones, n 89 above. 
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actually intended under Article 53(b). Sub-section 3.2.2 below will analyse their arguments 
which are pertinent to this thesis for two reasons: (1) the Onco-mouse II has confirmed most 
principles underlined in the previous Harvard/Onco-mouse decisions (which were the basis 
of the critics‟ arguments); and (2) therefore, any points and arguments that the critics have 
considered and advocated are relevant in the current analysis of the Onco-mouse II. 
 
3.2.2 An analysis of the Onco-mouse II in the light of the leading critics‟ arguments and the 
EU Biotechnology Directive 
 
The Onco-mouse II affirmed that taxonomic definition is the most appropriate approach to 
define the term „animal varieties‟ (where Vossius and Warren-Jones are proponents of this 
principle). It is important to firstly appreciate the meaning of the term in the science of 
animal taxonomy in order to see if the TBA decision to adopt the taxonomic definition is 
firmly supported by scientific definition. While intrinsically, the meaning of the term should 
have come from the EU Biotechnology Directive, unfortunately, it fails to define the term. 
Article 4(1) of the Directive simply repeats the wording of Article 53(b), whereas Recital 29 
and Article 4(2),
103
 and Rule 27(b) of the Implementing Regulation to the EPC
104
 do not help 
much in clarifying the meaning of the term. Due to this deficiency, the definition provided by 
the decisions of the EPO, and the views of experts in the field of animal taxonomy and critics 
of the exclusion under Article 53(b) become particularly important.  
 
The ED and OD in the cases of Harvard/Onco-mouse
105
 and Leland Stanford/Modified 
Animal,
106
 respectively, admitted that the meaning of the term is not clear. Similarly, critics 
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  See Appendix 6. 
104
  See Appendix 7. 
105
  Harvard V 0004/89, n 66 above, paragraph 2. 
106
  Leland Stanford/Modified Animals, n 12 above, paragraph 42. 
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from the field of animal taxonomy observed that the term „variety‟ is either not commonly 
used by taxonomists or used in a subjective manner. The subjectivity of the definition for the 
term arises from the differences in views of taxonomists in classifying variants of species.
107
 
In this respect, discussion on lower categories of animals focuses on species which is the 
most defined category in animal classification. While being recognised as the only 
subdivision of species by Linnaeus
108
 and the early taxonomists,
109
 it has been strongly 
urged
110
 that the term „variety‟ be abandoned due to the absence of a clear and defined 
meaning for it. The term was said
111
 to simply denote „anything that deviated from the ideal 
type of the species‟. The unclear scientific definition for the term „variety‟ has also been 
observed by some other critics. Their arguments range from: (1) the term is „more vague for 
animals than for plants and that the use of the term in natural science is less defined‟; 112 and 
(2) the term is challenging both from the areas of active breeding and legal definition.
113
 
 
Focusing on the appropriateness of the usage of terminology for the three terms, rather than 
assessing the excluded subject matter intended by the ED, Vossius
114
 argued some important 
points. According to him, the choice of the word „variety‟ indicates the framers‟ intention not 
to exclude animals per se from the patent system, but rather only certain category of animals. 
Otherwise the framers would have used the term „animals‟ to represent the exclusion. He 
argued, this interpretation corresponds with the ethos of the EPC which aims at promoting the 
                                                          
107
  R. Freeman, n 81 above, 3. 
108
  Linnaeus was a botanist who produced the system of classification of living organisms in the 18
th
 century 
and his system still forms a basis of animal taxonomy today. See for instance, R.T. Schuh, Biological 
systematic: principles and applications (Ithaca: Cornell University Press, 2000) 3; E. Mayr, n 77 above; G.G. 
Simpson, n 82 above, 16. 
109
  E. Mayr, n 78 above, 346. 
110
  G.G. Simpson, n 82 above, 178. 
111
  E. Mayr, n 78 above, 346. 
112
  R. Teschemacher, Patentable subject matter under the European Patent Convention (EPC) in the field of 
biotechnology and disclosure and manner of claiming of biotechnological inventions before the European 
Patent Office, Paper presented in the Symposium on the Protection of Biotechnological Inventions, 1987, 
89-115. 
113
  M.W. Tvedt, n 54 above, 107. 
114
  V. Vossius, n 100 above, 252. 
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development of science by giving incentives to inventors for a limited period of time to 
encourage them to innovate.
115
 Therefore, he further argued that the decision of the ED which 
held animals per se as unpatentable (in the first instance of its decision) was wrong.
116
 
Notwithstanding this view, he admitted that the three terms do not have the same meaning as 
regards „the scientifically recognised definition in biological usage‟,117 making them unequal 
to each other. The term „variety‟ carries a different meaning from the term „species‟ and 
„race‟. The last two of these refer to populations of animals produced through 
interbreeding.
118
 Therefore, being a group of animals which is subject to natural conditions, 
he asserted that they are not suitable subject matter for patents.
119
  
 
In agreement with the views of the taxonomists, Vossius further asserted that the term 
„variety‟ simply denotes structural and physical variations (such as in colour, size or shape 
due to ecological, environmental or geographical factors) from a species or sub-species.
120
 
While acknowledging the fact that the term could be a precise one to describe „new kinds of 
animals‟ and individuals, he was of the view that the term „strain‟ or „breeding stock‟ are the 
most appropriate terms to describe a uniform group of animals which are genetically altered 
through modern biotechnology methods (arguably this refers to transgenic animals as 
well).
121
 As a result, he concluded that the three terms should not be synonymously used 
under Article 53(b), and proposed that the terms be changed to: „animal species‟, ‘espèces 
animales’ and ‘Tierarten’, for consistency purposes.122 In essence, Vossius‟s main argument 
is that Article 53(b) only excludes animals which are produced through traditional breeding, 
                                                          
115
  ibid. 
116
  ibid. 
117
  ibid. 251. 
118
  ibid. 
119
  ibid.  
120
  ibid.  
121
  ibid.   
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  ibid. 254. 
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but not animals which could fulfil patent qualification criteria. Due to the inconsistent 
taxonomic definition of the term „variety‟ as demonstrated here, the Onco-mouse II decision 
to adopt the taxonomic definition is arguable. Nevertheless, since this definition has been 
adopted by the TBA, the more important question is therefore: is the decision, which only 
excludes from patent protection claims that relate to species, justifiable? Pertinent issues 
relating to this question will be analysed here.  
 
Two conclusions can be made from the earlier-mentioned statement in the Onco-mouse II 
that: „A patent should not be granted for a single animal variety (or species or race, 
depending on which language text of the EPC is used)‟. Firstly, the TBA has tried to equate 
the three terms irrespective of their different taxonomic classification. Secondly, the Board 
left open the question about the precise meaning of the terms used in each of the official 
languages. Therefore, it is possible to conclude that based on the TBA decision, theoretically 
(due to the linguistic usage), species, variety and race are at the same level of taxonomic 
classification, hence, are unpatentable. This approach corresponds to the three versions of the 
EPC which provides that species or race or variety is to be excluded under each of the three 
official languages of the Article 53(b). However, due to the TBA‟s non-definitive meaning 
for the three terms, on a practical level, it is unclear if the term „race‟ and „variety‟ would 
have similar taxonomic meaning as „species‟.  
 
In this respect, the Onco-mouse II coincides with Warren-Jones‟s 123  isolated category 
construction which she advocated in response to the Onco-mouse I. The construction states 
that if the exclusion is intended to cover a particular category within the animal taxonomic 
classification, only that category is unpatentable. Therefore, if species is the standard, 
                                                          
123
  A. Warren-Jones, n 89 above, 115. The meaning, application and implication of the construction are detailed 
in her work. 
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theoretically, only claims which relate to the category of species are caught by Article 53(b), 
whereas claims which relate to other categories (sub-genus upwards and sub-species 
downwards) are patentable. However, on a practical level, the construction leads to the 
unpatentability of species downwards, whereas patent protection can still be obtained for sub-
genus upwards.
124
 This is because, taxonomically, by excluding species, sub-species and 
below (which are the genetic variants) are also excluded.  
 
Notwithstanding the practical implications which may arise from the isolated category 
construction mentioned here, the Onco-mouse II appears to have decided that only the 
theoretical application of the isolated category construction can be adopted whereas its 
practical application is no longer possible. In evidence, the TBA has taken a stance in the 
decision that transgenic animals (such as the Onco-mouse) are to be classified as sub-species. 
In this, the TBA has explicitly stated that it is not sufficient for mice which inherited a certain 
characteristic due to the insertion of a cancer-gene to its genome to be called a new 
species.
125
 This point has been earlier discussed by Warren-Jones
126
 who argued that 
transgenic animals are taxonomically classified as sub-species, in contrast to the creation of 
chimera which produce animals that are sufficiently distinct from the original animals for 
them to be categorised as a new species. In the hierarchy of taxonomic classification, she 
describes the former as „moving downwards‟, in contrast to the latter which was said to 
„move sideways‟.127 The TBA did not explain the reason which underpins its classification. 
Nevertheless, the classification by the Board and Warren-Jones, and the argument by the 
latter about the categorisation of transgenic animals are logical. The relevant novel trait 
within transgenic animals as a result of genetic manipulation amounts to genetic variation 
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  ibid. 
125
  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 13.3.1. 
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  A. Warren-Jones, n 89 above, 116. 
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  ibid. 
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from their parent animal (species). Therefore, it is justified for the transgenic animals to be 
classified as sub-species due to the distinct inheritable characteristic. However, they are not 
as sufficiently distinct as chimera because the latter is an animal which contains at least two 
genetically different groups of cells originating from different animals. This enables the 
creation of a new species.  
 
Two other possible options of construction explored by Warren-Jones
128
 are the „top down‟ 
and „bottom up‟ approaches. According to the „top down‟ construction, if a category is 
selected to represent the intended exclusion, animal inventions from the top of the taxonomic 
classification downwards to the selected category are unpatentable. The categories below the 
selected level are patentable. If the category of species is selected as a standard, animal 
inventions which fall in the category of Kingdom down to the selected category are 
unpatentable. Those which fall in the category of sub-species and below are patentable. 
Conversely, the „bottom-up‟ construction means if a category is selected, animal inventions 
from the bottom of the taxonomic classification up to the selected category are unpatentable. 
Those which fall above the selected category are patentable. Again, if species is the selected 
category, animal inventions which fall in the category of sub-category of sub-species (sub-
sub-species) up to species are unpatentable. Those which fall under sub-genus upwards are 
patentable.
129
 The three-constructions proposed by Warren-Jones can be illustrated in Table 2 
below. 
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  ibid. 115-116. 
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  ibid. 
185 
 
 
 
The isolated category 
construction 
 __________________ 
Kingdom 
_____________________ 
. 
. 
_____________________ 
Species  
_____________________ 
. 
. 
_____________________ 
Sub-sub-species 
_____________________ 
 
 
The „top down‟ construction 
 
__________________ 
Kingdom    
_____________________ 
. 
. 
_____________________ 
Species  
_____________________ 
. 
. 
_____________________ 
Sub-sub-species 
_____________________ 
 
 
The „bottom up‟ construction 
 
__________________ 
Kingdom 
_____________________ 
. 
. 
_____________________ 
Species           
_____________________ 
. 
. 
_____________________ 
Sub-sub-species 
_____________________ 
 
    
                                      Key:            Unpatentable animal taxonomic category(ies) 
                                                         for each construction (species as the standard) 
 
 
 
Table 2: The Warren-Jones three-proposed-constructions for interpreting  
the exclusion of animal inventions under Article 53(b) of the EPC 
 
Arguably, the Onco-mouse II has limited the feasibility of adopting both the „top down‟ and 
„bottom up‟ constructions. As regards the „top down‟ construction, theoretically and 
practically, it would amount to the exclusion of broad categories of animals since higher 
categories which consist of large numbers of animals are involved. In addition, having the 
category of Kingdom to fall within the construction would amount to the unpatentability of 
animals per se from the European patent law. This contravenes the policy of narrow 
interpretation as underlined by the Onco-mouse I. Further, as identified by Warren-Jones,
130
 
the construction would negate all the three versions of the EPC which require lower 
categories of animals to be unpatentable rather than the higher categories. Moving on from 
this, the „bottom up‟ construction would appear to be more in line with the Onco-mouse II 
decision where lower categories of animal taxonomic classification are excluded.
131
 
Therefore, the three official languages of the EPC are satisfied. However, in the context of 
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the decision, arguably the adoption of the construction is no longer possible because the 
Onco-mouse II only allows the exclusion of species. 
 
The TBA‟s approach to equate the three terms, hence adopting the isolated category approach 
resolves some problems left by the Onco-mouse I. Nevertheless, more generally, the 
approach is not without implications. On the one hand, by leaving the languages to split 
across two taxons, the Onco-mouse I demonstrates an indefinite classification of animal 
inventions. The Onco-mouse II resolves this problem by deciding that the inventions are to 
fall under the category of sub-species (rather than species, that are naturally occurring 
animals). On the other hand, the isolated category approach may raise some issues due to a 
number of potential arguments by an applicant. Firstly, the approach appears to put 
paramount importance on linguistic evaluation. This would lead to easy circumvention of the 
exclusion through skilful drafting as the only condition is that a claim for patent protection 
should not mention the categories of „species‟, „race‟ and „variety‟. Secondly, as only species 
are excluded, an applicant may try to argue that an animal invention falls under higher 
categories of animals in the taxonomic classification, and claim those higher categories. 
Arguments in favour of the attempt would include that: (1) it serves as a time-saving 
approach.
132
 By allowing an applicant to claim higher categories, an inventor could avoid 
filing an application with a long (maybe endless) list of various species of animals upon 
which the method claimed can be applied. While this may be seen as a trivial technical issue, 
undoubtedly it would help an applicant with the administration aspect of his claim;
133
 and (2) 
it could prevent easy circumvention by competitors where an inventor might unintentionally 
                                                          
132
  ibid. 127. 
133
  The only conditions for patent claims under the EPC are that the claims must relate to one invention or group 
of inventions, and be clear and concise, and be supported by description. See Articles 82 and 84 of the EPC 
respectively. 
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leave out any species of animals (which are similarly applicable to the claimed method) from 
the list in the specification.
134
  
 
These two advantages are difficult to refute, but some disadvantages may equally surface 
from the same arguments. For instance, an inventor who genetically manipulates a house 
mouse (a species) may try to claim the order of rodentia which includes various families such 
as canidae (dogs), felidae (cats), ursidae (bears) and many others, by alleging that the 
teaching
135
 is similarly applicable. Apart from this, a few orders may also be claimed, 
including primates (mammals which include humans, apes and monkeys), insectivores 
(insect-eating mammals) and carnivores (flesh-eating mammals). At most, the inventor may 
want to claim mammals as a class or even chordata as a phylum, being the higher categories 
where the relevant house mouse is taxonomically grouped. In the case that the claimed 
method is not actually applicable to such a broad category of animals, the implication of this 
would be the monopolisation of animal genetic resources and materials by a small number of 
applicants who are financially able to venture into new inventions. Eventually, the rights of 
other researchers who may require other types of genetic materials as starting materials for 
their research (apart from the one actually developed by the applicant, but which has been 
broadly claimed) would be prejudiced. This contention corresponds with the ethos of patent 
law which disallows inventors‟ claims for protection over and above the legal rights that they 
                                                          
134
  A. Warren-Jones, A mouse in sheep‟s clothing: the challenge to the patent morality criterion posed by 
“Dolly” [1998] European Intellectual Property Review, 447. 
135
  The term „teaching‟ under the patent law refers to the enablement disclosure that an applicant should make 
in the specification filed with an application. The description should allow a person skilled in the art to 
repeat the invention based on the information disclosed. See L. Bently et al, n 28 above, 362-363; W. 
Cornish and D. Llewelyn, Intellectual property: patents, copyright, trade marks and allied rights (London: 
Sweet and Maxwell, 2007) 238-241. 
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are entitled to. Nevertheless, in practice, this concern has been safeguarded by requiring an 
applicant to include an enabling disclosure in the application.
136
 
 
Beyleveld and Brownsword hold opposite views from Vossius and Warren-Jones. According 
to them, as there is no precise definition for the term „variety‟, the generic meaning for the 
term should be adopted.
137
 They argued that this approach would assist in achieving the 
common meaning of the three terms and avoid the allegation that the EPC is not able to be 
treated as a single Convention (due to diverse scientific meaning of the three terms).
138
 The 
generic meaning of the term „variety‟ is taken by Beyleveld and Brownsword to mean „types 
of animals in general‟ or „classifications within the Animal Kingdom‟.139 Based on the latter 
definition, their assessment of animal classification initially covers the category of Kingdom 
downwards to sub-species,
140
 but was later extended to sub-sub-species (which they termed 
as „informal specific category‟).141 Therefore, they argued that under Article 53(b) animal 
varieties in the generic sense (all animals) are unpatentable. Yet, they qualify this argument 
by a recognition that since „taxonomic classification is defined strictly in terms of genetically 
transmissible (germ line) gametes features‟, what is excluded are only animals with germ-line 
modification rather than animals with somatic alteration.
142
 Due to their distinction between 
germ-line and somatic alteration, it is possible to conclude that they hold the view that the 
Onco-mouse is not patentable.  
 
                                                          
136
  This principle underpins the requirement of Article 84 of the EPC. National patent laws such as s14(5) of the 
UK Patents Act 1977 contain similar provision. See arguments on this point in Onco-mouse/Harvard, 
Decision of the Opposition Division 7 November 2001, n 70 above, 483 and 495-496. 
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  D. Beyleveld et al, n 101 above, 15. 
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  ibid. 16, at footnote 36. 
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Zoological Nomenclature 1961. See D. Beyleveld et al, n 101 above, 4, at footnote 11.  
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  ibid. The critics are of the view that due to the recognition that while post 1961, the term „variety‟ was not 
recognised in scientific usage, the field treated it as an „infra-subspecific category informally‟.  
142
  ibid. 18-19. 
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Beyleveld and Brownsword‟s argument of generic meaning and, hence, the exclusion of 
animals per se is reasonable given the non-definitive intention of the framers of the EPC of 
what is to be excluded under Article 53(b). Nevertheless, the Onco-mouse II has refuted their 
arguments both on the meaning of the term „animal variety‟ and the subject matter of the 
exclusion under Article 53(b) because the contention runs contrary to the principle of narrow 
exclusion (affirmed by the decision). In addition, by also accepting the meaning of „animal 
variety‟ to mean taxonomic classification of animal Kingdom and extending the exclusion to 
sub-sub-species, Beyleveld and Brownsword have qualified their arguments on the generic 
meaning of the term and the excluded subject matter. This is because, based on their final 
estimation of the taxonomic definition of the term „variety‟, it would amount to suggesting 
that the indefinite categories below sub-sub-species are patentable. However, the reason why 
only these taxonomic categories are distinctively deemed patentable is unclear. 
 
A distinction between animal inventions which involve germ-line modification (unpatentable) 
and those which are somatically altered (patentable), as argued by Beyleveld and 
Brownsword, has no parallel with the Onco-mouse II. One of the reasons for the absence of 
this assessment in the decision would have been the understanding that it is obvious that only 
animals whose germ-line is altered could be protected under patent law. It has been argued by 
Warren-Jones
143
 that Beyleveld and Brownsword‟s assessment would lead to an unnecessary 
emphasis and reliance on the stage at which the alteration is made, rather than the ability of 
the end result to fulfil patent qualification criteria. If Beyleveld and Brownsword‟s estimation 
is put into context, for instance, a mouse whose germ-line is altered at no later than the 8-cell 
stage (such as the onco-mouse) is not patentable, whereas if it is altered at the stage after the 
germ-line cells have fully differentiated, the same subject-matter will be patentable. The 
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distinction is arguable because principally, germ-line alteration (which involves the 
manipulation of a lineage of cells from which gametes are derived) should be more likely to 
produce novel animal inventions as required by patent law than mere somatic alteration. This 
arises from the inheritable characteristics that could be passed on to the offspring from the 
process of germ-line alteration rather than non-inheritance of the manipulated traits by 
progeny through somatic alteration.
144
 Consequently, Beyleveld and Brownsword‟s argument 
on this point contradicts the general understanding of characteristic inheritance and the Onco-
mouse II. In addition, their conclusion that products of germ-line alteration are unpatentable 
is not supported by other conditions for exclusion under Article 53(b). In this regard, apart 
from animal varieties, the only other exception from patentability under the provision is an 
„essentially biological process‟. In contrast, the provision explicitly provides that 
„microbiological processes and products‟ derived from the process are patentable. These 
principles and contention will be further elaborated here. 
 
3.2.3 Essentially biological process and microbiological process 
 
The word „essential‟ rather than „pure‟ in the phrase „essentially biological process‟ 
demonstrates that a pure biological process is clearly beyond patentability. Yet under the 
European patent law „essentially biological processes‟ are not per se unpatentable. Specific 
conditions are provided by Article 2(2) of the EU Biotechnology Directive and Rule 26(5) of 
the Implementing Regulations to the EPC. The provisions state: „a process for the production 
of animals is essentially biological if it consists entirely of natural phenomena such as 
                                                          
144
  Nevertheless, germ-line alteration cannot be regarded as being fundamentally different where somatically-
altered animals are subsequently cloned. This means that, while the trait may not be inherited through the 
natural reproductive process, but through cloning, it has the effect of retaining the trait over even more 
generations than inheritance would. In this way, the cloned animals should be able to obtain patent 
protection if the patent prerequisites are met. This distinction was not made in Beyleveld and Brownsword‟s 
work. 
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crossing or selection.‟ This condition intrinsically brings microbiological processes such as 
genetic engineering outside the exclusion of an „essentially biological process‟. A similar 
conclusion could be achieved for breeding methods such as artificial insemination and super-
ovulation due to the involvement of technical processes beyond mere human intervention in 
arranging the mating of animals for nature to take its course. 
 
The meaning of „essentially biological process‟ within Article 53(b) has also been dealt with 
by some cases of the EPO. While all the cases involve plant varieties, the principles have 
been similarly applicable to cases of animal inventions due to the Onco-mouse II
145
 ruling on 
the extension. The test for an „essentially biological process‟ was first underlined in the case 
of Lubrizol/Hybrid Plants
146
 where in order to escape the exclusion, human intervention must 
go beyond the trivial level and its impact on the result must be decisive. The PGS/Glutamine 
Synthetase Inhibitors
147
 case confirmed and further clarified this principle where the TBA 
ruled that a process for the production of plants comprising at least one essential technical 
step, which cannot be carried out without human intervention and which has a decisive 
impact on the final result, falls outside the exception. However, in the latest ruling of the 
EBA for appeals to the cases of Plant Bioscience/Broccoli
 
and State of Israel/Tomatoes,
148
 it 
was held inter alia
149
 that the requirements underlined by the cases of Lubrizol and PGS were 
no longer the determining factor for the exclusion of an „essentially biological process‟ under 
Article 53(b).
150
 In the context of its application to animal inventions, the relevant ruling of 
the EBA can be summarised in two principles: (1) The exclusion of an „essentially biological 
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  Transgenic Animals/Harvard, T 315/03, n 65 above, paragraph 11.4. 
146
  Lubrizol/Hybrid Plants, n 74 above. 
147
  PGS/Glutamine Synthetase Inhibitors [1995] EPOR 357, reason point 28. 
148
  Essentially Biological Processes, G2/07 and G1/08 [2011] EPOR 27. The former is an appeal from the 
Technical Board of Appeal, T 83/05, while the latter is an appeal from the Technical Board of Appeal, T 
1242/06. 
149
  Latin expression which means: „among other things‟. See http://www.thefreedictionary.com/inter+alia 
(Accessed: 9 April 2012). 
150
  Essentially Biological Processes, n 148 above, 27. 
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process‟ is not saved by a step of a technical nature which enables or assists the performance 
of the steps of sexually crossing the whole genomes of animals or of subsequently selecting 
animals, irrespective of the extent of the role played by the technical work in the final result; 
(2) However, if an „essentially biological process‟ contains within it a step which introduces 
or modifies a trait in an animal causing novel characteristics, so that the introduction or 
modification of the trait is not the result of sexually crossing the whole genomes of animals 
or of subsequently selecting animals, then the process escapes the exclusion under Article 
53(b). Based on these principles, it appears now that the breeding methods such as artificial 
insemination and super-ovulation (mentioned earlier), which are otherwise patentable under 
Article 53(b), could no longer enjoy the right.
 
It is because the methods merely assist the 
normal reproduction process without directly introducing or modifying any traits in the 
resulting animals.
151
 
 
The phrase „microbiological process‟ is defined under Rule 26(6) of the Implementing 
Regulations to the EPC as „any process involving or performed upon or resulting in 
microbiological material‟.152 Its patentability can be appreciated by the involvement of a 
technical process which warrants legal protection. It is also pertinent to note that the 
patentability of products of microbiological processes and their offspring (provided they 
retain the essential identity of the transgenic animals) has been acknowledged by Article 8 of 
the EU Biotechnology Directive.
153
 Intrinsically, this is because the process of genetic 
                                                          
151
  Warren-Jones has argued before, that these breeding methods are mere alternatives to „natural‟ reproduction 
process, and thus should not sufficiently qualify to be protected as „essentially biological process‟ under 
Article 53(b). See A. Warren-Jones, n 89 above, 122-123. 
152
  However, a strict reading of this definition may raise an issue because there are many „macro‟ biological 
materials (such as the Onco-mouse and Leland Stanford modified mouse) which have been similarly 
produced through the process. 
153
  Article 8(1) provides: „the protection conferred by a patent on a biological material possessing specific 
characteristics as a result of the invention shall extend to any biological material derived from that biological 
material through propagation or multiplication in an identical or divergent form and possessing those same 
characteristic.‟ In turn, Article 8(2) states: „the protection conferred by a patent on a process that enables a 
biological material to be produced possessing specific characteristics as a result of the invention shall extend 
193 
 
engineering and resulting animals can qualify under the exception to Article 53(b). The 
alteration at the microbiological level is capable of altering the hereditary material, and hence 
of having a decisive impact on the final result. In this, it is pertinent to note Beyleveld and 
Brownsword‟s154 view that while transgenic animals fall within the term „animal varieties‟ 
under Article 53(b), the ED should have considered whether the animals (and the processes 
and the products of genetic engineering, generally) are „microbiological process or the 
products thereof‟ under the same provision. This demonstrates their view that genetically 
modified animals are appropriate subject matter to be protected under the exception to the 
„animal variety‟ exclusion.155 Therefore, if the above principles on essentially biological and 
microbiological processes are applied to their conclusion on the unpatentability of products of 
germ-line alteration, their assessment is arguable.
156
 Germ-line alteration constitutes a 
microbiological process and products derived from it (such as the Onco-mouse) constitute 
products of the process, and therefore, are patentable.  
 
This sub-section has shown that the TBA‟s approach in the Onco-mouse II which equates the 
three terms: (1) clarifies and responds to the criticism arising from the Onco-mouse I which 
dealt with the patentability of the Onco-mouse by adopting a generic approach based on the 
wording of the claims; and (2) resolves the linguistic ramifications surrounding the three 
official languages of Article 53(b) which pose a long-term challenge to the patentability of 
animal inventions under the European patent law. Nevertheless, as the meaning of the three 
equated terms is not resolved by the Board, the decision may be challenged as mainly aiming 
                                                                                                                                                                                    
to biological material directly obtained through that process and to any other biological material derived from 
the directly obtained biological material through propagation or multiplication in an identical or divergent 
form and possessing those same characteristics.‟ 
154
  D. Beyleveld et al, n 101 above, 19-20. 
155
  A. Warren-Jones, n 89 above, 122. 
156
  However, given that Beyleveld and Brownsword‟s assessment was made before the Boards of Appeal had 
considered the point on essentially biological and microbiological processes, and that subsequently their 
construction of the law was not taken up by the Boards, their analysis cannot be said to be wrong. It is 
simply that they did not accurately predict the approach eventually adopted on the issue. 
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at the granting of patent without appropriately considering the implications for the meaning 
of the three terms in the context of taxonomic classification. The analysis has also shown how 
permissive the European-wide approach is by identifying that transgenic animals (including 
livestock) would be patentable for being classified as sub-species. In this, claims to sub-
species would be excluded only where the terms „variety‟ or „race‟ adopt the German 
meaning of species. The principles relating to the exclusion of „essentially biological 
processes‟ provide further evidence of the permissiveness of the approach. As the European 
patent law currently stands, the involvement of a microbiological process in the production of 
animals, in whatever percentage and irrespective of its decisive impact on the end result, 
would render the claims to products derived from there as patentable. This reiterates the 
principle that the European patent law excludes only non-technical processes. Others, which 
can fulfil the patent qualification criteria, albeit relating to animals, are widely open to patent 
protection. 
 
Moving on from here, it is crucial to have a broader understanding of why the Onco-mouse II 
has confirmed the patentability of the Onco-mouse, despite an explicit exclusion of animal 
varieties under Article 53(b). This is the aim of the next sub-section which examines the 
rationale underpinning the permissive approach. It will be shown that the economic 
importance of patents requires that animal inventions, which are capable of fulfilling the 
patent prerequisites, are not to be left legally unprotected.  
 
3.3 The rationale for the Onco-mouse II narrow interpretation  
 
It has already been mentioned in sub-section 3.2.1 that the Onco-mouse II adopts the 
principles underlined by the decision of the Novartis/Transgenic Plant. In essence, while 
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animal varieties are not patentable under Article 53(b), the rules are: (1) where technical 
manipulation is not confined to a particular animal variety, the invention is patentable; and (2) 
patent granted to a genetic material contained in an animal variety covers the host animal, 
even if it is an animal variety.
157
 It is argued that underpinning the isolated category approach 
and the extension of principles relating to the exclusion of plant varieties to animal varieties 
is a broader recognition of the economic need to protect animal inventions which can fulfil 
the patent prerequisites. Plant varieties are excluded from the patent regime due to the non-
involvement of technical intervention in the patent law sense. However, an alternative sui 
generis protection is available under the UPOV Convention in the event that they meet the 
required qualifications. Unfortunately, animal varieties (even where they fulfil patent 
qualification criteria) will be left without any legal protection if the Onco-mouse II decides 
that the subject matter is not patentable, because there is no alternative protection available to 
date. While the sui generis system (equal to plant varieties) for the animal breeding sector has 
been the subject of much discussion,
158
 the establishment of an efficient system has not 
widely materialised because of problems including: (1) the concept is not easily defined; (2) 
the difficulty in identifying the key characteristics of the subject matter; and (3) the rationale 
for the protection of „animal varieties‟ (when in animal breeding, the protection is said to be 
more relevant for „breeds‟).159  
 
 
 
                                                          
157
  See explanation of the rules in footnotes 91 and 95. 
158
  See for instance M.W. Tvedt, S.J. Hiemstra, A.G. Drucker, N. Louwaars and K. Oldenbroek, Legal aspects 
of exchange, use and conservation of farm animal genetic resources, Fridtjof Nansens Institut (FNI) Report 
1/2007, 29-30; S. Biber-Klemm, and M. Temmerman, Rights to animal genetic resources for food and 
agriculture: notes from an interdisciplinary workshop, Working paper No 2010/05, 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1652166 (Accessed: 31 March 2011) 81.  In relation to 
the legal protection for animal genetic resources (i.e breeds) it has been raised in the workshop that one of 
the important issues which require careful consideration is whether the sui generis system or other forms of 
protection includes the scope and duration of protection, and the extension of the protection to the progeny. 
159
  ibid.  
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In some countries such as India
160
 and the Czech Republic,
161
 the sui generis system of 
protection of animal genetic resources is in place, as an alternative, due to the unpatentability 
of animals as such. In these countries, the criteria required for new animal breeds resemble 
plant varieties under their sui generis system of protection. Nevertheless,
 
it is observed that so 
far the system only covers administrative aspects such as the registration and documentation 
of new and improved breeds and strains (of poultry, fish and animals developed by selective 
breeding by farmers, researchers or communities). There is not yet any provision in the 
relevant guidelines or legislation on pertinent aspects such as the infringement of the rights 
granted under the system and intended benefit-sharing arising from the use of the animals.
162
  
 
The economic importance of patent protection relating to animal inventions in the EU has 
long been expressly stated. For instance, in 1988, in the Meeting of the Committee of Experts 
on Biotechnological Inventions and Industrial Property, a delegate from the Netherlands said:  
 
in view of the cost of biotechnological research and development, improved legal 
protection was necessary and, in these circumstances, it was understandable that 
the EPO had tried to limit the scope of the restriction in the EPC concerning plant 
and animal varieties.
163
  
 
                                                          
160
  P.J. Singh, Sui generis protection of animal genetic resources: An initiative by the Indian Council of 
Agricultural Research (ICAR) in S. Biber-Klemm et al, n 158 above, 67-68. In India, the guidelines for the 
registration and documentation of new and improved breeds are contained in Guidelines for Registration of 
Livestock and Poultry Breeds. See National Bureau of Animal Genetic Resources, India, 
http://www.nbagr.res.in/guidelines.html (Accessed: 21 May 2011). 
161
  M. Temmerman, The patentability of animal genetic inventions. Pt.1, NCCR International Trade:  
Stocktaking paper no. 2006/4, 66-67. In the Czech Republic, the protection for new animal breeds is 
provided under the Law on the Legal Protection of New Varieties of Plants and Breeds of Animals. 
Available at: http://www.wipo.int/wipolex/en/text.jsp?file_id=126145 (Accessed: 21 May 2011). 
162
  ibid.; P.J. Singh, n 160 above, 67-68. 
163
 WIPO, „Industrial Property Protection of Biotechnological Inventions: Report adopted by the Committee of 
Experts‟, Document BiOT/CE/IV/4 (28 October 1988) 3. 
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The TBA in the Onco-mouse I
164
 observed a similar economic need to protect animal 
inventions, in view of the absence of alternative protection, when it highlighted three 
important points for the ED to consider:  
 
(1) the presumed intention of the framers of the Strasbourg Convention and EPC in 
the context of changes of circumstances (scientific development) since the law was 
adopted; (2) the need to appropriately balance the interests of inventors in this field 
which sought reasonable protection for their intellectual labours and the interests of 
society to exclude animal inventions from the patent regime; and (3) the need to 
seriously consider the non-availability of alternative protection for animal 
inventions in the event that the patent is not allowed to relevant inventions.
165
  
 
In recognition of these principles, the absence of appropriate legal protection for animal 
inventions would have been seen by the EPO as able to prejudice the interest of inventors to 
create inventions for the benefit of the public and the large amount of investment put in by 
investors to develop the relevant inventions.  
 
This sub-section has shown that economic motivation for protecting animal inventions under 
the patent system has influenced the EPO to interpret the exclusion of animal varieties under 
Article 53(b) narrowly. The next section examines the EU animal biotechnology applications 
relating to livestock animals so as to identify its importance and development. In addition, the 
impact of the permissive approach on the livestock industry will be assessed. The discussion 
will show that the EU puts much emphasis on the importance of animal biotechnology 
applications which is largely at the research stage. Notwithstanding public pessimism towards 
animal biotechnology food, the potential of the technology to contribute to the sustainable 
development of the livestock and fisheries industries has driven the active research in the 
field. Patent protection which is available to transgenic livestock animals (through the 
                                                          
164
  Harvard T 0019/90, n 71 above, paragraph 4.7.  
165
  ibid. This statement appears to give a clear „indication‟ to the ED to revise its decision which refused to 
grant patent to the onco-mouse in the first instance of its decision. 
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decision of the Harvard/Onco-mouse) will enhance the progress of the technology. This will 
realise the demand of the population for animal protein-based products. In terms of the 
research questions, the discussion informs Malaysia about the advantages and disadvantages 
of adopting the European-wide permissive approach in interpreting its exclusionary provision, 
in the light of the problems and needs of the country‟s livestock industry (identified in 
chapter 1).  
 
4. The implications of the permissive approach on the livestock and fisheries (and 
aquaculture) industries: an assessment 
  
Biotechnology is a developing discipline in the EU with an extremely robust market.
166
 For 
instance, there was an increase of 15% in global revenue to $60 billion in 2006, compared to 
2005.
167
 In reviewing its strategy on „Life Science and Biotechnology‟, the EU launched the 
„Eight Technology Platforms‟ in the area of life sciences and biotechnology in order to 
develop and foster public-private partnerships at European level.
168
 One of the areas under 
consideration is animal breeding and reproduction.
169
 Under the Seventh Framework 
Programme (started in 2007) €2 billion is dedicated to supporting research on food, 
agriculture and fisheries, and biotechnology.
170
 This is a significant increase in the amount of 
investment compared to the Sixth Framework Programme (2002 to 2006) where €756 million 
                                                          
166
  EPO, Biotechnology in European patents – threat or promise?, http://www.epo.org/news-
issues/issues/biotechnology.html (Accessed: 20 April 2011). 
167
  ibid. 
168
  Europa, Life sciences and biotechnology – a key sector for Europe‟s competitiveness and sustainability, 
Press Release, 11 April 2007, 
http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/07/130&format=HTML&aged=1&langua
ge=EN&guiLanguage=en (Accessed: 19 May 2011). 
169
  ibid. Other areas are (1) innovative medicines initiatives; (2) nanomedicine – nanotechnologies for medical 
applications; (3) plant genomics and biotechnology; (4) industrial biotechnology under the sustainable 
chemistry technology platform; (5) food for life; (6) global animal health; and (7) forestry and biofuels. 
170
  ibid. 
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was allocated to fund projects in various fields including animal biotechnology.
171
 As regards 
the livestock industry, one of the reasons for the investment could have been the explicit 
recognition that the technology would relieve Europe from being heavily dependent on 
imports of animal feed due to the shortage of land for growing animal feeds.
172
 In this respect, 
the growth in publication activities in a biotechnological sector is one way to indicate the 
importance of the sector to a particular country.
173
 The higher the growth the more important 
the sector is. In the EU, publication activities in animal biotechnology grew about 0.08% for 
the period between 1995 and 2000. Although placed behind environmental (0.59% growth) 
and industrial (0.2% growth) biotechnologies, animal biotechnology appears to be more 
important to the EU, if compared to plant biotechnology which has lost considerable 
importance (-0.15% growth) for the same period.
174
 
 
Similar to the situation worldwide, there has been no commercial application of animal 
biotechnology to livestock animals and marketing of the products in the EU Member 
States.
175
 Nevertheless, it is pertinent to note that several Member States have been applying 
various molecular breeding methods to improve livestock production. Methods adopted by 
Member States include embryo sexing, transgenetics and cloning.
176
 It is shown in a study 
that twenty four country reports indicate the use of molecular technologies: marker assisted 
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  ibid. 
172
  Europa, Biotechnology and Europe - The speech of Peter Mandelson (Europe Trade Commissioner) on the 
European biotechnology info day, 14 June 2007, Speech/07/397, 
http://europa.eu/rapid/pressReleasesAction.do?reference=SPEECH/07/397&format=HTML&aged=0&langu
age=EN&guiLanguage=en (Accessed: 19 May 2011). 
173
  T. Reiss, S. Hinze and I.D. Lacasa, Performance of European Member States in biotechnology (2004) 
Science and Public Policy, 31, 5, 351-352. 
174
  ibid. 
175
  United States Department of Agriculture (USDA) Foreign Agricultural Service, Animal Biotech Policy and 
Research in the EU, Global Agricultural Information Network (GAIN) Report, 14 September 2009, 
http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Biotechnology%20-
%20GE%20Animals_Berlin_EU-27_9-1-2009.pdf (Accessed: 23 September 2011). 
176
  D. Pilling, R. Cardellino, M. Zjalic, B. Rischkowsky, K.A. Tempelman and I. Hoffmann, The use of 
reproductive and molecular biotechnology in animal genetic resource management – a global overview 
(2007) Animal Genetic Resources Information, 40, 7-8. See also FAO, The state of capacities in animal 
genetic resources management: reproductive and molecular biotechnology, 2007, 
ftp://ftp.fao.org/docrep/fao/010/a1250e/a1250e.pdf  (Accessed: 17 December 2010) 269-271. 
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selection is used in commercial animal production in eight EU countries and eleven Member 
States specify the implementation of molecular distancing studies.
177
  
 
Many public and private institutions in the EU Member States are currently conducting 
research on biotechnologies relating to livestock animals.
178
 Some of the initiatives will be 
discussed here to demonstrate the situation in the EU. At the regional level, the European 
Animal Disease Genomics Network of Excellence for Animal Health and Food Safety 
(EADGENE) was established with the aim of co-ordinating a genomics approach to host-
pathogens interactions in domestic animals.
179
 For this purpose, it co-ordinates activities of 
fifteen partners from ten European countries
180
 by bringing together expertise which focuses 
on research including the investigation of the interaction of Salmonella (pathogen) in pigs 
and poultry (hosts), E.coli (bacteria) in cattle, mastitis in cattle, goats and sheep, and 
Infectious Salmon Anaemia (ISA) and Infectious Pancreatic Necrosis viruses in Atlantic 
salmon and rainbow trout.
181
  
 
At national level, in the UK, for example, active research on genetics and genomics with 
regard to livestock animals is on-going at the Roslin Institute of the University of 
Edinburgh
182
 and ARK-Genomics.
183
 Research undertaken in the former institution includes 
the identification of genes involved in immune response aiming at preventing infection and 
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  ibid. The countries include Croatia and Czech Republic. 
178
  I. Cassar-Malek, B. Picard, C. Bernard and J.F. Hocquette, Application of gene expression studies in 
livestock production systems: a European perspective (2008) 48 Australian Journal of Experimental 
Agriculture, 704. 
179
  EADGENE, http://www.eadgene.info/ (Accessed: 3 October 2011). 
180
  The fifteen partners which work together under EADGENE are: INRA, France; Wageningen University, the 
Netherlands; Animal Sciences Group Lelystad, the Netherland; Institute for Animal Health, United Kingdom; 
Roslin Institute, University of Edinburgh; Faculty of Agricultural Sciences, University of Aarhus, Denmark; 
Liege University, Belgium; Ljubljana University, Slovenia; Cordoba University, Spain; Norwegian School 
of Veterinary Science, Norway; Research Institute for the Biology of Farm Animals, Germany; Parco 
Techologico Padano, Italy; European  Forum of Farm Animal Breeders, the Netherland; University of 
Copenhagen, Denmark; Institute for Pig Genetics, the Netherlands. 
181
  ibid. 
182
  The Roslin Institute, University of Edinburgh, http://www.roslin.ed.ac.uk/ (Accessed: 3 October 2011). 
183
  ARK-Genomics, http://www.ark-genomics.org/ (Accessed: 3 October 2011). 
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controlling disease in livestock animals such as chicken and cattle, and the investigation of 
the use of genomics to improve productivity and product quality in sheep. The latter 
institution is a high-technology laboratory which plays a role as a collaborative centre for 
functional genomics
184
 in farm animals (such as chickens, pigs, cattle and sheep).
185
 In France, 
the French National Institute for Agricultural Research (INRA)
186
 is a leading European 
public agricultural research institute. As regards livestock animals, it has been carrying out 
research in improving fertility in dairy cows and identifying genetic determinism of 
tenderness of bovine meat. Studies at the Institute focus on a wide range of animals including 
cattle, pigs, chickens, sheep, trout, goats, and ducks. Rodents (mice and rats) and the Medaka 
fish are used as models for genetic studies.
187
 This evidence is an indication of other Member 
States‟ R&D activities, demonstrating the priority given to the animal biotechnology 
industry.
188
 Genomic research is intrinsically expensive and complicated. Therefore, research 
carried out by the institutions mentioned here is supported by public funding and involves 
collaborative projects with, and industrial support from, private companies. For instance, 
research at the EADGENE is funded by the EU, and the Roslin Institute‟s is mainly funded 
by the Biotechnology and Biological Sciences Research Council (BBSRC). Other funders for 
the Roslin Institute include the Department for Environment, Food and Rural Affairs 
(DEFRA), the EU, the Medical Research Council, the Food Standards Agency, the Wellcome 
Trust, the Meat and Livestock Commission, Pfizer Ltd and British United Turkeys Ltd.
189
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  Means: „the branch of genomics that determines the biological function of the genes and their products‟. See 
http://www.thefreedictionary.com/functional+genomics (Accessed: 3 October 2011). 
185
  The Roslin Institute, University of Edinburgh, n 182 above. 
186
  INRA, http://www.international.inra.fr/the_institute/a_brief_overview (Accessed: 2 October 2011). 
187
  ibid. For other projects involving genomics research relating to livestock animals in the EU, see Sustainable 
Animal Breeding (SABRE), an integrated project including thirty-three leading animal research groups 
which focussed on three aspects of sustainable development of livestock: mammary gland, digestive system 
and fertility, http://www.sabre-eu.eu/ (Accessed: 3 October 2011). 
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  While very little research of this nature appears to take place in countries such as in Finland, Sweden, Spain 
and Austria, research involving genetically engineered animals in other sectors such as medical and 
pharmaceutical research is actively carried out in these countries. See USDA Foreign Agricultural Service, n 
175 above. 
189
  See The Roslin Institute, University of Edinburgh, n 182 above. 
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Many analyses
190
 have described the attitude of the Europeans as: very positive toward 
medical and environmental biotechnologies; neutral toward agricultural biotechnology; but 
negative toward GM food
191
  and the cloning of animals (and its products). As evidence for 
the last of these, the latest EU barometer survey has shown that public support for GM food 
and the cloning of animals for food is declining due to the perception that the products have 
no benefit and the concern that the products are unnatural and unsafe for consumption.
192
 In a 
research project, under the Sixth Framework Programme, spanning nine Member States of 
the EU,
193
 participants perceived „safe beef‟ as „beef which is not harmful to consumers‟ 
health‟ and that lean beef is considered to be the healthiest type.194 Notably, the research 
found that the focus group participants „supported the development of technologies that can 
make beef healthier and guarantee eating quality.‟ Nevertheless, only procedures which are 
considered not invasive are acceptable and these include: (1) the application of muscle 
profiling in beef production; (2) marinating by injection for improved healthiness (nutritional 
                                                          
190
  G. Gaskell and J. Jackson, A comparative analysis of public opinion: Canada, the USA and the European 
Union, in First impressions: understanding public views on emerging technologies, prepared by Genome 
Prairie GE3LS team as the University of Calgary, funded by the Canadian Biotechnology Secretariat, 
http://epe.lac-bac.gc.ca/100/200/301/cbs-scb/first_impressions-e/Iu199-4-2005E.pdf#page=64 (Accessed: 29 
September 2011); S. Bonny, How have opinions about GMOs changed over time? The situation in the 
European Union and the USA (2008) CAB Reviews: Perspectives in agriculture, veterinary science, 
nutrition and natural resources, 93, 1-17; M. Canavari, F. Tisselli, R.M. Nayga Jr and R. Scarpa, Italian 
consumer acceptance of nutritionally enhanced GM food,  Paper prepared for presentation at the 
International Association of Agricultural Economists 2009 Conference, 1-16. 
191
  For the purpose of the EU barometer survey, „GM food‟ refers to „the use of modern biotechnology in the 
production of foods, for example to make them higher in protein, keep longer or change the taste.‟ See G. 
Gaskell, N. Allum, M. Bauer, J. Durant, A. Allansdottir, H. Bonfadelli, D. Boy, S. de Cheveigné, B. Fjaestad, 
J.M. Gutteling, J. Hampel, E. Jelsøe, J.C. Jesuino, M. Kohring, N. Kronberger, C. Midden, T.H. Nielsen, A. 
Przestalski, T. Rusanen, G. Sakellaris, H. Torgersen, T. Twardowski and W. Wagner, Biotechnology and the 
European public (2000) 18 Nature Biotechnology, 935, http://www.ask-force.org/web/Discourse/Gaskell-
Biotechnology-European-Public-2000.pdf (Accessed: 29 September 2011). Arguably the meaning of GM 
food covers livestock products which are produced through modern biotechnological methods.  
192
  The 2010 Eurobarometer on the life sciences (2011) 29 Nature Biotechnology, 2, 113-114; European 
Commission, Europeans and biotechnology in 2010: winds of change? 
http://ec.europa.eu/public_opinion/archives/ebs/ebs_341_winds_en.pdf (Accessed: 29 September 2011) 38-
44. This has been the trend as observed by commentators since the third EU barometer survey in 1996. See 
George Gaskell et al, ibid.  
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  France, Germany, Spain, the United Kingdom, Belgium, Denmark, Germany, Greece and Poland. 
194
  W. Verbeke, F.J.A. Pérez-Cueto, M.D. de Barcellos, A. Krystallis and K.G. Grunert, European citizen and 
consumer attitudes and preferences regarding beef and pork (2010) Meat Science, 84, 287. 
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aspect); (3) marinating by injection for improved eating quality (a combination of tenderness, 
flavour and juiciness); (4) and marinating by submerging for improved eating quality.
 195
 
Processing technology such as injecting substances (such as enzymes) into muscle meat was 
considered invasive, thus rejected by participants.
196 
While this illustration would inevitably 
demonstrate a pessimistic view of the EU consumers, it could not lead to a conclusion that 
the EU consumers totally refuse animal biotechnology food; either because of the high risk of 
the technology used or that the products are unsafe for consumption. If the conclusion is true, 
one would expect wide consumption of organic foods including livestock products as organic 
meat and poultry among the EU consumers. Unfortunately, this has not been the case. 
Pertinent factors appear to be the high price and the uncertain characteristics of such 
products.
197
  
 
Arguably, information and knowledge are two more important factors in determining 
consumers‟ acceptance.  In evidence, there have been important findings, from research on 
consumers and new technologies, that perception and consumers‟ confidence could be 
improved by increased communication about food safety, the risks and benefits of novel food 
products, and label information.
198
 In this respect, empirical research has disclosed that EU 
consumers notably want to be informed of how new technologies can bring benefits (such as 
health, taste, tenderness) for livestock products for their consumption.
199
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foods (2011) 28 International Journal of Research in Marketing, 167-180. One of the reasons for this is the 
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Based on this discussion, it seems less likely that animal biotechnology food would be easily 
approved by the EU consumers. Nevertheless, with concerted effort by the EU and food 
industries to provide consumers with information on the benefits of the relevant technologies, 
it is anticipated that their confidence in, and acceptance of, the products would increase. In 
fact, various efforts have been implemented by the EU to gain public confidence to accept 
GM food in order to ensure that the products can be commercially marketed. Of particular 
importance is having the relevant legislations and regulations involving GMOs in place.
200
 
 
It has been identified
201
 that while aquaculture is an important alternative to the decreasing 
fish stock supply from the open sea, a long time is required for the industry to close the gap 
left by the decline in supply.
202
 Moreover, as already identified in chapter 1, challenges to the 
livestock and fisheries industries, such as a shortage of productive breeding stock and fish 
seed, livestock and aquatic diseases, and constraints in the supply of animal and fish feed are 
global problems. As far as the EU is concerned, the BSE crisis (1996), Foot-and-Mouth 
                                                          
200
  The legislations include: (1) Directive 2001/18/EC on the deliberate release into the environment of GMOs 
which applies to two types of activities: the experimental release of GMOs into the environment (for 
example, in field test) and the placing on the market of GMOs for example the cultivation, importation or 
transformation of GMOs into industrial products; (2) Regulation (EC) No 1829/2003 on the placing on the 
market of GMO food and feed or food and feed products containing or consisting of GMO; (3) Regulation 
(EC) 1946/2003 on trans-boundary movements of genetically modified organisms which governs 
unintentional trans-boundary movements of GMOs as well as exports of GMOs to third countries; (4) 
Directive 90.219/EEC as amended by Directive 98/81/EC on the contained use of genetically modified 
microorganisms (GMMs); and (5) Regulation (EC) No 1829/2003 (amending Directive 2001/18/EC) 
concerning the traceability and labelling of genetically modified organisms and the traceability of food and 
feed products produced from GMOs. See Europa, Questions and answers on the regulation of GMOs in the 
European Union, MEMO/07/117, 26 March 2007, 
http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/07/117 (Accessed: 29 September 2011) 2. 
201
  Europa, The Common Fisheries Policy (CFP), 
http://ec.europa.eu/fisheries/documentation/publications/pcp2008_en.pdf (Accessed: 8 November 2011). 
202
  In particular, the EU has identified that overfishing contributes to the decrease of total catch from open sea. 
The problem has led to the current effort by the EU to reform its fishing policies which have been argued as 
failing to achieve sustainable fish stocks. Factors leading to overfishing include the size and power of fishing 
fleets compared to fish stock, and the weakness of the Total Allowable Catches (TACs) policy imposed by 
the EU under the Common Fisheries Policy. The latter quota policy which limit catches of each fishing fleet 
has lead to dead fish been discarded by fishermen back to the sea in order to avoid the limit. In spite of 
resolving the problem of fish stock depletion, the practice has been identified as leading to other issues 
including threat to eco-system. See Europa, A fisheries policy for the future, 
http://europa.eu/rapid/pressReleasesAction.do?reference=IP/11/873&format=HTML&aged=0&language=E
N&guiLanguage=en (Accessed: 8 November 2011).  
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disease (2000) and avian influenza (2005) have similarly disturbed its animal production and 
economy.
203
 For instance, the BSE outbreak caused the EU an estimated cost of €92 
billion.
204
 Notably, the livestock disease crisis has resulted in decreased beef production, and 
consumption and demand from consumers in the EU for the period between 1985 and 
2000.
205
 In this respect, climate change has been identified by critics
206
 as another factor 
which has a high potential to affect the industry as parasites and pathogens survive the 
changes in temperature and humidity.
207
  
 
Irrespective of the public‟s pessimism toward animal biotechnology food, the active research 
on the application of biotechnology to livestock animals in the EU can be concluded as being 
motivated by the various challenges to the livestock and fisheries industries shown here. This 
can be further understood in the context of the OECD-FAO latest projection that the growth 
in the consumption of meat in the EU will be 7% by 2020,
208
 which would lead to a decrease 
to the exports from the Union.
209
 Apart from that, the on-going research appears to be 
underpinned on the pertinent scientific opinions on the safety of biotechnological products for 
human consumption. Notably, the European Food Safety Authority (EFSA)
210
 has adopted 
                                                          
203
European Commission, Agricultural statistics: main results 2008-2009, 
http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-ED-10-001/EN/KS-ED-10-001-EN.PDF 
(Accessed: 27 September 2011) 100; T. Garnett, Meat and dairy production and consumption, 2007, 
http://www.miljopunkt-valby.dk/det-gor-vi-old/ressource-forbrug/klimatildes-kokken/tg-fcrn-livestock-
final-6-nov.pdf (Accessed: 29 September 2011) 28. 
204
  FAO, The state of food and agriculture: livestock in the balance, 2009, 
http://www.fao.org/docrep/012/i0680e/i0680e.pdf  (26 November 2010) 78. 
205
  M. Zjalić, A. Dimitriadou and A. Rosati, Beef production in the European Union and the CAP reform: an 
overview of situation and trends (2006) Stočarstvo (Professional paper) 3, 183-184.  
206
  B. McKelvey and G. Marshall, Food supply – can we meet the demand? (2007) Journal of the Royal 
Agricultural Society of England, 168, 3. 
207
  ibid. 
208
  OECD-FAO, Agricultural Outlook 2011-2020, http://www.agri-outlook.org/dataoecd/2/36/48184304.pdf 
(Accessed: 27 September 2011) 137. 
209
  ibid. 141. 
210
  EFSA, Scientific opinion of the scientific committee: Food safety, animal health and welfare and 
environmental impact of animals derived from cloning by somatic cell nucleus transfer (SCNT) and their 
offspring and products obtained from those animals, 15 July 2008, 
http://www.efsa.europa.eu/en/efsajournal/doc/767.pdf (Accessed: 12 March 2012); European Food Safety 
Authority, Update on the state of play of animal cloning, 14 September 2010, 
http://www.efsa.europa.eu/en/efsajournal/doc/1784.pdf (Accessed: 12 March 2012) 2. 
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the view that animal cloning poses no increased risk to food consumption. This is based on 
scientific evidence that there is no indication of difference between meat and milk of clones 
and their progeny compared to those from conventionally bred animals.
211
 At the national 
level, a similar view has been recently published by the UK Food Standard Agency 
(UKFSA).
212
 
 
An argument may be raised about the potential of the permissive approach to enhance the 
livestock industry due to the absence of a commercial market for transgenic livestock animals 
so far. Nevertheless, it is equally possible to contend that there will be a potential market for 
the products in the near future if current developments (worldwide) relating to efforts to 
commercialise animal biotechnology food is analysed. An important example is the persistent 
effort by Aqua Bounty Technologies, the US biotechnology firm to obtain the USFDA 
approval for their transgenic salmon, and the University of Guelph, Canada to obtain 
approval from Health Canada (HC) for their Enviropig.
213
 Logically, these efforts should 
have been underpinned by the potential to market these products and the optimism that 
consumers will accept the products. Based on this evidence, it is argued that the market for 
animal biotechnology food is imminent.
214
  
 
The narrow interpretation given to the exclusion of animal inventions under Article 53(b) of 
the EPC would render transgenic animals for food patentable in the EU. Therefore, in the 
light of the potential demand for animal biotechnology food demonstrated here, the narrow 
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  ibid. 
212
UKFSA, Meat and milk from cloned animals, 7 December 2010, 
http://www.food.gov.uk/news/newsarchive/2010/dec/boardcloning (Accessed: 8 April 2012). 
213
 Although the Enviropig is developed mainly for its environmental-friendly feature. The Canadian regulatory 
framework for animal biotechnology food is further discussed in section 2 of chapter 5. 
214
  H.P.S. Kochhar, G.A. Gifford and S. Kahn, Regulatory and biosafety issues in relation to transgenic animals 
in food and agriculture, feeds containing genetically modified organisms (GMO) and veterinary biologics in 
H.P.S. Makkar and G.J. Viljoen (eds), Applications of gene-based technologies for improving animal 
production and health in developing countries (Springer, 2005) 496. 
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interpretation will enhance the progress of animal biotechnology applications and the 
livestock industry. The necessary legal protection for the resulting animal inventions 
encourages the scientists to be more innovative by creating livestock and fisheries products 
which meet the demands of the population. This is made possible through the motivation 
from investors to contribute to the growth of the technology due to the sense of security that 
their investment in the R&D activities would be recouped.
215
 The Onco-mouse II decision 
which upheld the patentability of transgenic animals allows an inventor to claim what he 
actually invented (through genetic alteration, in a laboratory). As a result, this enhances the 
technology involved, and the livestock industry further. 
 
5. Conclusion 
 
The work of the Strasbourg Convention was to establish the substantive aspects of European 
patent law. In turn, the work of the EPC was coordinated with it in order to ensure that the 
creation of a Common Market was not prejudiced by having differing provisions governing 
patentable inventions. The result of this was the parity of the exclusion of animal varieties 
from patent protection in both, Article 2(b) of the Strasbourg Convention, and Article 53(b) 
of the EPC. This chapter has shown that the adoption of the term „animal varieties‟ under 
Article 2(b) and Article 53(b) is due to the sense of completion with the exclusion of plant 
varieties in the same provisions. The absence of a specific concept for novel animal 
inventions at the time of the drafting of the Conventions influenced the adoption of the term 
„animal varieties‟ in parallel to the term „plant varieties‟ without a specific meaning and 
concept intended by the framers to the former. The exclusion of plant varieties from the 
patent regime is backed by the establishment of a specific concept for the materials which 
                                                          
215
  The transgenic salmon has been patented by Aqua Bounty Technologies. See Europe scorns “supersalmon” 
as GM battle widens, http://uk.reuters.com/article/2011/04/22/food-salmon-idUKLDE73K1EU20110422 
(Accessed: 10 November 2011). 
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warrant its protection under the sui generis system of protection. While some critics have 
argued that the exclusion of animal inventions should have shared similar ground, its 
acceptance seems difficult due to the absence of an equal concept for them so far. In this, the 
indefinite meaning to the term „animal varieties‟ eventually led to unclear subject matter of 
the exclusion under Article 53(b). Nevertheless, it is at least clear from the preparatory 
working papers of the provision that under the European patent system, only inventions 
which involve no technical intervention are unpatentable.  
 
The absence of a clear intention of the framers as to the meaning of the term „animal varieties‟ 
and the subject matter excluded under Article 53(b), have not deterred the EPO from 
applying the exclusion, hence determining the two aspects. Underpinning the EPO 
interpretation is the convention under international law as underlined by Article 31 and 32 of 
the Vienna Convention. The provisions require that in the absence of meaning to a term in a 
treaty or convention, their determination should be based on the object and purpose of the 
convention. The European patent laws were drafted with a clear objective in mind, namely 
the creation of a Common Market where a uniform patent system among the Member States 
was seen as an important strategy for the EU to compete with its major economic competitors 
(the US and Japan). This aim has broadly influenced the EPO to construe the exclusion of 
animal varieties under Article 53(b) of the EPC narrowly. Specifically, the interpretation is 
underpinned by the economic importance of patents that any inventions (including animal 
inventions) which could fulfil the patent qualification criteria should be given the necessary 
legal protection. The Onco-mouse II which decides on the patentability of animal inventions 
under the European patent law adopts these principles. 
 
209 
 
The Onco-mouse II confirmed the Onco-mouse I where the exclusion to patentability under 
Article 53(b) is to be narrowly construed and the taxonomic approach is the most appropriate 
approach to determine the patentability of animal inventions. The Onco-mouse I held that 
while species (Tierarten) and sub-species (races animales and variety) are within two 
different taxonomic categories, both are not patentable. The Onco-mouse II clarifies this 
position by deciding that the categories are of the same taxonomic level. The decision arises 
from the approach of the TBA which equates the three terms under the three official 
languages of the EPC to the term „species‟. As a result, it was decided that genetically 
engineered animals are classified as sub-species for being genetic variants of species, hence 
patentable.  
 
While the equation clearly shows the intention of the TBA to grant patent to animal 
inventions and resolve the long-problematic issue of excluded subject matter under Article 
53(b), it has opened another gap as to whether or not the term „race‟ or „variety‟ now has the 
same taxonomic meaning with the term „species‟. This issue arises from the Board‟s action in 
leaving open the precise meaning of the terms used in each of the official languages. 
Eventually, animal inventions are widely entitled to patent protection under the European 
patent law because the exclusion would not take effect unless a particular claim mentions the 
excluded categories or if sub-species adopt the meaning of the German term „species‟. This 
demonstrates how permissive the European-wide approach is. The permissiveness is further 
evidenced by the narrow interpretation to the exclusion of „essentially biological processes‟ 
under Article 53(b). As the European patent law now stands, the process is patentable 
irrespective of any degree of involvement of a microbiological process and the impact of the 
process to the final result.  
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This chapter has shown that animal biotechnology applications are important to the EU as a 
tool to support the sustainable development of its livestock and fisheries industries, hence, 
meeting the growing demand from the population. This explains the significant amount of 
effort and investment in the on-going R&D activities relating to livestock animals, 
notwithstanding the pessimistic opinions from consumers toward animal biotechnology food 
and the absence of their current commercial market in the EU. In particular the motivation 
comes from the potential market for animal biotechnology food where public acceptance 
could be nurtured by appropriate information and knowledge of the benefit of the food. 
Patent protection for animal biotechnology food is pertinent to promote the technology 
involved. The permissive approach serves this objective by attracting investments from 
public and private institutions due to the patentability of the products. In the long run, this 
stimulates and advances the relevant R&D activities in the EU.  
 
As regards the previous critics‟ views analysed in this chapter, Warren-Jones precisely 
predicted the Onco-mouse II decision through her isolated category construction, amid the 
non-definitive decision of the Onco-mouse I as to the subject matter of the exclusion of 
animal varieties under Article 53(b). In the context of the function of a legal provision, her 
construction would allow an effective development of the technology as it elevates the 
unnecessary difficulties with linguistic issues of Article 53(b), but rather focuses on the 
aspiration for a patent system which aims at encouraging research and innovation. Therefore, 
in the context of the implications of the isolated category approach on the livestock industry, 
it can be concluded that the approach is pertinent for the progress of scientific research 
involving livestock animals. On the other hand, Beyleveld and Brownsword‟s arguments on 
the generic meaning of the term „animal varieties‟, and, their argument for the exclusion of 
all animals in general under Article 53(b) has been refuted by the Onco-mouse II. The 
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construction would leave animal inventions legally unprotected. Bearing in mind that there is 
not yet an efficient sui generis system of legal protection for animal inventions, the 
construction would result in the refusal of investors to support relevant R&D activities which 
are known-to-be expensive, complicated and time consuming. Equal assessment for 
Vossius‟s arguments is quite difficult as he did not advocate any approach on how the matter 
excluded under Article 53(b) should be determined. This is owing to his focus which was 
limited to analysing the appropriateness of the usage of the three terms in each of the official 
language of the EPC in the context of the biological meaning of the terms. Nevertheless, his 
conclusion that Article 53(b) should be narrowly construed as the three terms do not amount 
to the exclusion of animals per se from patent protection appears to have been confirmed by 
the Onco-mouse II.  
 
The legislative background of Article 53(b) of the EPC is similar to s13(1)(b) of the 
Malaysian Patents Act 1983 (as identified in chapter 3) where the intended meaning of the 
term „animal varieties‟, the purpose, and the subject matter of the exclusion are unclear. 
Irrespective of the deficiencies, the EU has demonstrated that the exclusion should have been 
construed in the light of the intention of the patent system which is to enhance innovation and 
the economic development of a given country. As a non-Member State to the EPC, Malaysia 
is not legally bound by the European-wide permissive approach. Nevertheless, the approach 
remains an option for the MyIPO and Malaysian courts to consider (through its potential 
adoption by the UK courts) in their attempt to interpret the similar exclusion. Whether or not 
the permissive approach should be adopted by Malaysia (in the light of the problems and 
need of its livestock industry) will be determined in the Discussion and Conclusion chapter 
after the restrictive approach is examined in the next chapter. The chapter covers the 
examination of the Canadian political perspective and government‟s policy toward animal 
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patenting, and an assessment of the restrictive approach adopted by the judicial authorities. 
Also included is an analysis of the implication of the restrictive approach on the livestock 
industry. As regards the research questions the chapter identifies a Signatory‟s (to the TRIPs 
Agreement) different way of interpreting the exclusion of animal inventions, while not 
having an exclusionary provision in its national patent law, and the implications arising from 
it. 
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CHAPTER FIVE 
 
THE RESTRICTIVE APPROACH FOR PATENTING ANIMAL INVENTIONS,  
AND ITS IMPLICATIONS ON THE LIVESTOCK INDUSTRY:  
THE CANADIAN PERSPECTIVE 
 
1. Introduction 
 
The previous chapter demonstrated how the permissive approach in Europe assists the 
development of the livestock industry by stimulating investment. This chapter examines the 
approach adopted under the Canadian patent system which is vastly different to the approach 
of the EPO. The difference will allow suggestions be made to Malaysia on the range of 
possibilities available to it when construing s13(1)(b) of its Patents Act 1983. Canada has 
been a Member State of the WTO since 1 January 1995.
1
 Therefore, similar to other Member 
States, the country is expected to provide for a minimum standard of patent protection for 
biotechnological inventions under Article 27.1 of the TRIPs Agreement. Section 2 of the 
Canadian Patent Act 1985
2
 broadly defines the term „invention‟ as: 
 
any new and useful art, process, machine, manufacture or composition of matter, or 
any new and useful improvement in any art, process, machine, manufacture or 
composition of matter. 
 
The five categories of invention in the provision: „art, process, machine, manufacture or 
composition of matter‟, suggest a broad range of subject matter which could be protected 
under the Act. Ironically, during the last three decades the Canadian Intellectual Property 
Office (CIPO) and judicial authorities have made a distinction between biotechnological 
inventions which are patentable (as products) and those which are not. Under the patent law 
                                                          
1
  WTO, Members and observers, http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm (Accessed: 
13 October 2011). 
2
  Patent Act, R.S.C, 1985, c.P-4. 
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of the country, only lower life forms such as micro-organisms, yeasts, moulds, fungi, bacteria, 
viruses or protozoa are patentable. This has been ruled by the Commissioner of Patents in the 
case of Re Application of Abitibi Co. (Abitibi).
3
 However, the same rule is not applicable for 
higher life forms (including animals and plants) since they are considered as neither 
„manufacture‟ nor „composition of matter‟ within the meaning of the term „invention‟ under 
s2.
4
 This principle has been explicitly underlined by the Supreme Court in the precedent case 
of Harvard Mouse.
5
 Thus, as a reminder of the Introduction chapter, the term „restrictive 
approach‟ used in this thesis refers to the unpatentability of animal inventions under the 
Canadian patent law, notwithstanding the absence of express statutory exclusion.  
 
In order to facilitate comparison with the discussion in chapter 4 on the European-wide 
permissive approach, this chapter follows the same format: it explores how Canada has 
interpreted the term „invention‟ leading to the unpatentability of animal inventions and 
identifies how restrictive it is. The chapter also assesses the implications of the adopted 
approach on the livestock industry. To achieve these aims, this chapter is divided into five 
sections. Section 2 identifies Canada‟s attitude toward animal inventions. This permits 
identification of any change of policy adopted by the country, between the time when 
biotechnology was newly developed and the current position where the technology has 
proved its potential to produce useful products for the enhancement of life and the economy. 
Section 3 analyses the relevant principles of law which underpin the decisions of the 
Commissioner of Patents and the Supreme Court
6
 for not allowing patent protection to animal 
                                                          
3
  Decision of the Chairman, Patent Appeal Board, Canada dated 18 March 1982, to the application from the 
Abitibi Company of Toronto. Available at: CIPO, http://brevets-patents.ic.gc.ca/opic-
cipo/comdec/eng/decision/933/summary.html?query=933+%3cin%3e+comdecnumber&start=1&num=10  
(Accessed: 4 May 2010); (1982) 62 C.P.R (2d) 81 (Pat. App. Bd). 
4
  The meaning of „lower life form‟ and „higher life form‟ is elaborated further in sub-section 3.1.2 below. 
5
  Harvard College v Canada (Commissioner of Patents) [2003] 5 LRC 330. 
6
  These are the lead-decision-making bodies in patent cases in Canada. 
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inventions. This is followed by section 4 which assesses the implications of the restrictive 
approach on the livestock industry. Section 5 concludes the chapter. 
 
Canada‟s approach is relevant for Malaysia for two reasons: (1) while the Canadian Patent 
Act 1985 has no statutory exclusion of animal varieties (as is the case under the Malaysian 
Patents Act 1983), the decision to exclude animal inventions implies a different approach to 
interpreting the exclusions to „animal varieties‟; and (2) as Canada is a commonwealth 
country (similar to Malaysia), the approach becomes relevant for historical reasons. As the 
EPO interpretation, the Canadian Supreme Court decisions are not binding on Malaysian 
judicial decisions. Nevertheless, based on the principle of judicial precedence, they represent 
a persuasive authority for potential cases before the Malaysian courts where the patentability 
of animal inventions would be in issue.  
 
2.  Canada‟s attitude toward animal inventions 
 
It has been a long-argued debate whether patent law is able to promote innovation.
7
 However, 
progress in the field of science and technology depends largely on the economic value of 
patents where vast amounts of investment could be secured from their licensing to research 
and academic institutions. Notably, patents have been used as a principal criterion by venture 
                                                          
7
  It has been observed patents have a positive impact on the increase of investments and R&D spending, hence, 
advancing economic growth. See K.E. Maskus, Intellectual property rights and economic development (2000) 
32 Case Western Reserve Journal of International Law, 471- 506. In the recent report to the UK 
Government, it has been identified that while IPRs are paramount as „risks and costs are a disincentive to 
innovate‟, proliferation of the use of IPRs can increase IP transaction costs and block new (small and young 
innovative) firms from competing in markets. See an independent report by Professor Ian Hargreaves in I. 
Hargreaves, Digital opportunity: a review of intellectual property and growth, May 2011, 
http://www.ipo.gov.uk/ipreview-finalreport.pdf (Accessed: 13 February 2012) 1-130. The review‟s 
recommendations include that the UK government works to ensure that patents are not extended into sectors 
such as non-technical computer programs and business methods without clear evidence of benefit.  
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capital firms when evaluating funding requests from biotechnology firms.
8
 Firms which 
consider investing in local R&D activities have also put emphasis on the strength of local 
patent protection.
9
 Canadian patent law originates from this basic purpose of patents as 
clearly underlined in the preamble of the Canadian Patent Act 1826:
10
 
 
[w]hereas it is expedient for the encouragement of Genius and of Arts in this Province 
to secure exclusive right to the Inventor of any New and Useful Art, Machine, 
Manufacture, or Composition of Matter …11 
 
Notwithstanding the seemingly broad objective of the Canadian patent law, the country has 
adopted a pessimistic stance since the time when the patentability of living organisms became 
an international issue. This contention finds support from some pertinent evidence, including: 
(1) the country‟s political perspective; (2) the regulatory framework pertaining to animal 
biotechnology food; and (3) the opinion of Canadian consumers. These three aspects are 
elaborated here.  
 
During the negotiations of the Uruguay Round Meeting of the TRIPs Agreement, Canada 
argued that it was not reasonable to oblige all governments to extend patents to an area such 
as multi-cellular life forms.
12
 More strongly, the country raised the view that „multi-cellular 
life forms or processes for producing new multi-cellular life forms should not be 
patentable‟. 13  This initial view is consistent with the attitude of the country to date in 
regulating animal biotechnology food. Article 15 of the Cartagena Protocol advocates, that 
                                                          
8
  J. Niosi, Biotechnology in J. Niosi, Canada’s regional innovation systems: the science-based industries 
(McGill-Queen‟s University Press, 2005) 45.   
9
  K.E. Maskus, n 7 above, 484. 
10
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 40. See also G. Asher, The 
development of the patent system in Canada since 1767 (1965) 43 Canadian Patent Reporter, 60. 
11
  ibid. 
12
  GATT, „Proposal by the Nordic Countries for the Negotiations on Standards and Principles for Trade-related 
Aspects of IPRs‟, Document MTN.GNG/NG11/W/36 (10 July 1989) 1-2. 
13
  GATT, „Synoptic Tables Setting Out Existing International Standards and Proposed Standards and 
Principles‟, Document MTN/GNG/NG11/W/32/Rev.2 (2 February 1990) 86. 
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Signatories should conduct risk assessments concerning the implications of LMOs.
14
 It is 
already identified in chapter 1 that this obligation covers transgenic livestock animals and 
their products.
15
 Canada is not a party to the Protocol,
16
 and, therefore has no legal obligation 
to implement the various provisions of the document relating to „the safe transfer, handling 
and use of LMOs resulting from modern biotechnology that may have adverse effects on 
human health and environment‟. 17  Nevertheless, it is worthy of note that the Canadian 
Biotechnology Strategy 1998
18
 (the Strategy) was formed with a similar aim, namely „to 
ensure that the benefits of biotechnology are realised in a way that protects health, safety, and 
the environment‟.19 This is meant to be achieved through high regulatory standards.20  
 
As regards the regulation of livestock animals produced through modern biotechnology and 
their products, the Strategy underlines that the country‟s existing legislative and regulatory 
bodies are to regulate the subject matter.
21
 Therefore, the animals and products, which are 
considered as „novel‟,22 come under the purview of Environment Canada (EC) and Health 
                                                          
14
  See discussion in sub-section 3.2 of chapter 1. 
15
  ibid. 
16
  However, Canada ratified the CBD on 4 December 1994. See CBD: List of parties, 
http://www.cbd.int/convention/parties/list/ (Accessed: 13 February 2012). 
17
  Article 1 (Objective) of the Cartagena Protocol.  
18
  The Strategy broadens the 1983 initial Canadian Biotechnology Strategy by framing general framework and 
various broad goals to develop the biotechnology industry, and is meant to be implemented by main 
departments of the federal government. See Government of Canada, Biostrategy: the 1998 Canadian 
Biotechnology Strategy, http://www.biostrategy.gc.ca/english/View.asp?pmiid=520&x=535 (Accessed: 15 
February 2012) 15; Canadian Biotechnology Advisory Committee (CBAC), Toward a Canadian action 
agenda for biotechnology: a report from the CBAC (CBAC, 2006). 
19
  ibid. 
20
  ibid. 
21
ibid.; CFIA, Regulating agricultural biotechnology in Canada: an overview, 
http://www.inspection.gc.ca/english/sci/biotech/reg/bioage.shtml (Accessed: 15 February 2012). 
22
  CFIA, Animal biotechnology, http://www.inspection.gc.ca/english/anima/biotech/bioteche.shtml (Accessed: 
15 February 2012). „Novel food‟ means: (a) a substance, including a microorganism, that does not have a 
history of safe use as a food; (b) a food that has been manufactured, prepared, preserved or packaged by a 
process that (i) has not been previously applied to that food, and (ii) causes the food to undergo a major 
change; and (c) a food that is derived from a plant, animal or microorganism that has been genetically 
modified such that (i) the plant, animal or microorganism exhibits characteristics that were not previously 
observed in that plant, animal or microorganism, (ii) the plant, animal or microorganism no longer exhibits 
characteristics that were previously observed in that plant, animal or microorganism, or (iii) one or more 
characteristics of the plant, animal or microorganism no longer fall within the anticipated range for that plant, 
animal or microorganism. See HC, Division 28, Part B.28.001, of the Food and Drug Regulations (Novel 
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Canada (HC), with support from the Canadian Food Inspection Agency (CFIA). In Canada, 
livestock animals produced through modern biotechnology need to undergo a two-tier 
assessment.
23
 First, developers who intend to manufacture, import or sell the animals in 
Canada need to apply for approval to the EC and HC which are jointly responsible for 
assessing the impact of the animals on the environment and human health (including the 
safety of people working with the animals).
24
 Then, the products are assessed on the basis of 
the products‟ intended end use. For example, if the transgenic livestock animals or fish are 
intended to be used as food, the HC will be in charge of the assessment relating to food 
safety.
25
 In these assessments, the CFIA assists in matters pertaining to animal health.
26
 
Except for the detailed procedures for assessment, it is observed that the regulatory 
framework  which  is  applicable in Canada is similar (in terms of aspects which are regulated  
 
                                                                                                                                                                                    
Foods) http://www.hc-sc.gc.ca/fn-an/consult/_novel_foods/consultation_appendix-annexe1-eng.php 
(Accessed: 15 February 2012). 
23
  CFIA, Animals and animal products derived through modern biotechnology: roles and responsibilities of the 
Government of Canada, http://inspection.gc.ca/animals/veterinary-biologics/guidelines-forms/animal-
biotechnology/eng/1334783323017/1334783436055 (Accessed: 15 February 2012); H.P.S. Kochhar and B.R. 
Evans, Current status of regulating biotechnology-derived animals in Canada – animal health and food safety 
considerations (2007) Theriogenology, 67, 194.  
24
  ibid. HC co-administers the Canadian Environmental Protection Act (CEPA) 1999 with respect to human 
health. The Department of Fisheries and Oceans (DFO) is involved in the environmental assessment and 
notification involving requests to develop fish using modern technology for commercial purposes under the 
New Substances Notification Regulations (Organisms). Notification is to be sent to the EC for full 
assessment of potential impacts on the environment. The EC administers the assessments under the CEPA 
and the New Substances Notification Regulations (Organisms) 2005. Both the Act and Regulations are 
available at: Department of Justice, http://laws-lois.justice.gc.ca/PDF/C-15.31.pdf and http://laws-
lois.justice.gc.ca/PDF/SOR-2005-248.pdf, respectively (Accessed: 7 March 2012). The Regulations provide 
for notification and assessment of processes for living organisms. The scope includes „certain new livestock 
animals (and their progeny)‟ such as cattle modified to increase milk or meat production and fish modified 
for growth enhancement. Nevertheless, the 2005 Regulations only provide broad aspects of information 
required in respect of the organisms (such as taxonomic name of the species and description of modification 
made to the organisms). Efforts on the details of notification and assessment involving organisms other than 
micro-organisms for confined or full release in the environment has not been finalised. See EC, Review of 
the New Substances Notification Regulations (Organisms), http://www.ec.gc.ca/subsnouvelles-
newsubs/B59FB284-AC16-448C-A343-
9A5F0E1E57F4/NSNR%28O%29%20Phase%20II%20consultation%20-%20EN.pdf (Accessed: 7 March 
2012); EC and HC, New substances: review of the new substances notification regulations (organism) – 
background and update, http://biosafety.icid.com/en/files/presentations/Review-New-Substances-
Notfication-Regulations.pdf (Accessed: 7 March 2012). 
25
  ibid. 
26
  ibid. 
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and assessed)
27
 to that in the EU,
28
 Australia and New Zealand.
29
 
 
Historically, efforts toward developing regulations, risk assessments and guidelines for 
transgenic animals (including fish and aquatic animals) and animal biotechnology food in 
Canada started in 2001, where the Royal Society of Canada (RSC)
30
 recommended to the HC, 
EC and CFIA that „approval of new transgenic organisms for environmental release, and for 
use as food or feed, should be based on rigorous scientific assessment of their potential for 
causing harm to the environment and human health.‟31  In an immediate response to the 
recommendation, the Canadian Government promised that the HC would develop and publish 
guidelines for the safety assessment of novel foods derived from the animals.
32
 Unfortunately, 
after more than a decade of „efforts‟33 there is still no clear indication when the document will 
                                                          
27
  Which are the safety of the food for human health and environment. See S.J. MacLaughlin, Food for the 
twenty-first century: an analysis of regulations for genetically engineered food in the United States, Canada 
and the European Union (2003) 14 Industrial International and Comparative Law Review, 1, 375-407; H.P.S. 
Kochhar, G.A. Gifford and S. Kahn, Regulatory and biosafety issues in relation to transgenic animals in food 
and agriculture, feeds containing genetically modified organisms (GMO) and veterinary biologics in H.P.S. 
Makkar and G.J. Viljoen (eds), Applications of gene-based technologies for improving animal production 
and health in developing countries (Springer, 2005) 478-498. 
28
  For instance, in the EU, foods produced from cloned animals fall under Regulation (EC) No 258/97, being 
considered as novel foods. They must be subjected to a safety evaluation before they can be legally marketed. 
European Commission, Novel foods and novel food ingredients, 
http://ec.europa.eu/food/food/biotechnology/novelfood/index_en.htm (Accessed: (12 March 2012). 
29
  GM foods derived from animals which are entering the Australian and New Zealand food market must 
comply with Standard 1.5.2 - Food Produced Using Gene Technology 1998 (a joint standard between the 
two countries). Section 1 of the Standard imposes a pre-market approval system to ensure that GM food is 
equally safe to conventionally produced foods. Section 2 provides for labelling requirements. See P. Brent, 
D. Bittisnich, S. Brooke-Taylor, N. Galway, L. Graf, M. Healey and L. Kelly, Regulation of genetically 
modified foods in Australia and New Zealand (2003) 14 Food Control, 409-416.  
30
  RSC, Elements of precaution: recommendations for the regulation of food biotechnology in Canada, January 
2001, http://www.rsc.ca//files/publications/expert_panels/foodbiotechnology/GMreportEN.pdf (Accessed: 
15 February 2012). 
31
  ibid. x, paragraph 7.1. 
32
  HC, Action Plan of the Government of Canada in response to the Royal Society of Canada Expert Panel 
Report, titled „Elements of precaution: recommendations for the regulation of food biotechnology in Canada‟, 
23 November 2001, http://www.hc-sc.gc.ca/sr-sr/pubs/gmf-agm/RSC_response-reponse_SRC-eng.php 
(Accessed: 15 February 2012). 
33
  This includes: (1) obtaining inputs from national experts consultations; and (2) considering the FAO/WHO 
Expert Consultation on Genetically Modified Animals which include advice on making GM animals safer 
from the outset by wise selection of breeding goals and the use of post-market surveillance to gather 
information relating to the beneficial and adverse effects of GM food. The latter consultation document is 
available at: FAO, ftp://ftp.fao.org/docrep/fao/006/y5316E/y5316E00.pdf (Accessed: 15 February 2012). 
See also Progress Reports, in response to the Royal Society of Canada Expert Panel Report, from January 
2002 to June 2005, which are available at HC, Reports and publications: biotechnology, http://www.hc-
sc.gc.ca/sr-sr/pubs/biotech/index-eng.php (Accessed: 15 February 2012). 
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be ready for implementation. The latest Progress Report published by the HC states that the 
relevant agencies are still working on the guidelines.
34
 In this respect, it can be observed that, 
while the Guidelines for the Safety Assessment of Novel Foods
35
 have already provided 
information required for novel foods derived from plants and micro-organisms, so far, only 
the remark „under development‟ appears under the heading of „Novel Foods Derived from 
Animals‟ of the Guidelines.36 
 
The HC‟s seemingly continued commitment conflicts with an important policy 37 published 
by the authority itself. As early as 2003, the authority explicitly prohibited the sale of cloned 
animals derived from the somatic cell nuclear transfer (SCNT) technique through the Food 
Directorate Interim Policy on Foods from Cloned Animals. The Policy states:  
 
[f]oods produced from livestock developed using SCNT and the progeny of such 
livestock to be captured under the definition of „novel food‟ in the Food and Drug 
Regulations in that they have been obtained by a reproductive technology which 
has not previously been applied to generate animals that would be used to 
manufacture foods (meat, eggs, milk, etc) and which may result in a major change 
in these foods. 
 
… 
 
Developers producing cloned animals through SCNT must, therefore, not sell the 
products or by-products of any cloned animals or their progeny in the human food 
supply in Canada unless they have been subjected to the pre-market safety 
assessment required of novel foods.
38
  
 
 
 
                                                          
34
  HC, Progress Report: June 2005 - Action Plan of the Government of Canada in response to the Royal 
Society of Canada Expert Panel Report, http://www.hc-sc.gc.ca/sr-sr/pubs/gmf-agm/prog-rep-rap_06_2005-
eng.php (Accessed: 15 February 2012).  
35
 HC, Guidelines for the Safety Assessment of Novel Foods, June 2006, http://www.hc-sc.gc.ca/fn-
an/legislation/guide-ld/nf-an/guidelines-lignesdirectrices-eng.php (Accessed: 15 February 2012). 
36
  ibid. 
37
 HC, Food Directorate Interim Policy on Foods from Cloned Animals, http://www.hc-sc.gc.ca/fn-
an/legislation/pol/pol-cloned_animal-clones_animaux-eng.php (Accessed: 15 February 2012). 
38
  ibid. 
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In addition, the Policy states: 
 
As there is currently insufficient data to guide the pre-market safety assessment of 
these products, developers who wish to use SCNT technology for producing 
livestock are requested to withhold novel food notification until requirements are 
determined and guidance is available.
39
  
 
The Interim Policy appears to cover only food from cloned animals. A question may arise as 
to whether the Policy similarly covers transgenic livestock animals and their products which 
are meant for human consumption. Cloning is not genetic engineering per se as it does not 
involve direct manipulation of DNA
40
 (thus has been described as „an indirect means of 
creating biotechnological products‟).41 However, the process offers the opportunity to create 
genetically engineered (or transgenic) animals such as the production of cattle from cells 
lacking the gene for the prion protein responsible for BSE disease.
42
 Therefore, it can be 
concluded that the Policy also covers genetically engineered (transgenic) livestock animals 
and their products.  
 
The Policy demonstrates the unequal treatment given by the Canadian Government to animal 
biotechnology food compared to their conventional counterparts. To date the Interim Policy 
has not been revised. It should be noted that Canada has been involved in international 
forums such as CODEX Alimentarius
43
 where issues of animal biotechnology food are 
involved. Nevertheless, the country refrains from taking an official position on the regulation 
                                                          
39
ibid.; A.L. van Eenennaam, Is livestock cloning another form of genetic engineering? 
http://agribiotech.info/details/Alison%20-%20cloning%20March%208%20-%2003.pdf (Accessed: 26 April 
2012) 4-5.  
40
  ibid. 
41
  A. Warren-Jones, Patenting rDNA: human and animal biotechnology in the United Kingdom and Europe 
(Oxford: Lawtext Publishing, 2001) 11-16. 
42
  A.L. van Eenennaam, n 39 above, ibid. 
43
  An international organisation established by the FAO and WHO, which develops food standards and 
guidelines. 
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of animal biotechnology food, due to the absence of any definitive and comprehensive stance 
on the regulation of the products.
44
 
 
Some public surveys prepared for, or undertaken by, the Canadian Government disclose 
consumers‟ pessimism toward GM animals and fish as food products. In a recent survey 
undertaken for Industry Canada,
45
 it was reported that Canadians are most supportive of the 
development of GM animals for medical purposes (such as cloned animals for bio-medical 
research). However they are less supportive of non-health applications such as animals with 
uniform quality of meat or dairy products. Of paramount concern are the risks from 
consuming the products. As regards the impact of some applications of technology, 58% of 
the respondents were opposed to the genetic modification of animals; 54% to fish and 50% to 
food.
46
 The public survey also identified that genetic modification of fish is not an area of 
technology that many Canadians are aware of, leading to significant concerns with the idea 
that GM fish are being imported to Canada.
47
 In an earlier survey,
48
 while consumers 
generally accepted that patent protection was necessary in the field of biotechnology to 
encourage innovations, different perceptions were discovered in terms of the purpose and 
object of patents. Patenting is more acceptable to the consumers in the context of human 
health and environmental applications compared to agricultural applications (including 
altered cows with increased milk production).
49
 While similar concern has also been observed 
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  USDA Foreign Agricultural Service, Canada biotechnology – GE plants and animals: agricultural 
biotechnology annual report, Global Agricultural Information Network (GAIN) Report, 8 August 2010, 
http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Biotechnology%20-
%20GE%20Plants%20and%20Animals_Ottawa_Canada_08-05-2010.pdf (Accessed: 15 December 2011) 22. 
45
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49
  ibid. 4. 
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among European consumers,
50
 it should be noted that the HC has explicitly underlined that 
one of the aspects that it will consider, in reaching a final policy decision concerning the 
foods derived from cloned animals and their progeny, is public opinion.
51
 Therefore, in the 
case of Canada, the negative views of consumers have largely influenced the regulatory 
agencies‟ attitude. This eventually causes the minimal progression of the relevant guidelines. 
 
This section has shown that animal inventions could be patentable in Canada in two aspects: 
(1) the general meaning for the term „invention‟ under s2 of the Canadian Patent Act 1985; 
and (2) the absence of statutory exclusion under the legislation. Yet this is not the case. The 
country has adopted the view that animal inventions are not patentable subject matter since 
the TRIPs Agreement was negotiated. This negative attitude corresponds with the country‟s 
lack of interest in developing the regulatory framework for biotechnology-driven livestock 
animals, and their products. Consumer reluctance to support the products contributes to the 
situation.  
 
The next section assesses the approach to animal patenting within Canada‟s patent law. For 
this purpose, the section is divided into two sub-sections. The first part analyses pertinent 
legal principles in the Harvard Mouse decision which adopted a restrictive interpretation to 
the term „invention‟. The reasoning of the Supreme Court‟s decision will be compared and 
contrasted with: (1) the patent authorities‟ 52  and lower courts‟ 53  decisions; and (2) the 
decisions in the cases of Abitibi and Pioneer Hi-Bred Ltd. v Canada (Commissioner of 
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  See discussion in section 4 of chapter 4. 
51
  HC, Report of stakeholder comments on proposed revisions to Health Canada‟s guidelines for the safety 
assessment of novel foods derived from plants, microorganisms and Health Canada‟s responses to these 
comments, http://www.hc-sc.gc.ca/fn-an/consult/novel-nouveaux/index-eng.php (Accessed: 16 February 
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Patents) (Pioneer-Hi Bred).
54
 The two are leading cases on biotechnological patents within 
Canadian jurisprudence, which involve a micro-organism and a plant, respectively. It will be 
argued that the Supreme Court decision to refuse a patent to the GM mouse for not being an 
invention lacks legal reasoning. This part will also demonstrate that the restrictive approach 
adopted by the judicial authority conforms to the country‟s pessimistic policy toward animal 
inventions as earlier shown in this section. The second part is devoted to an analysis of the 
case of Percy Schmeiser and Schmeiser Ltd v Monsanto Canada Inc. and Monsanto 
Company (Percy Schmeiser).
55
 The case is particularly important in identifying whether there 
has been any change in approach to animal patenting in Canada. It will be contended that 
notwithstanding the Percy Schmeiser decision, the Supreme Court is consistent in its 
restrictive approach where animal inventions are unpatentable. Nevertheless, as a result of the 
decision, patented genes and cells contained in the animal gives the patentee the right to 
exclude others from dealing with the transgenic animal. The latter principle represents a 
puzzling aspect of Canadian patent law. The analysis is important to the research questions 
for two reasons: (1) it identifies, and informs Malaysia about the restrictive approach adopted 
by Canada; and (2) it further identifies whether or not the decision to hold a GM animal as a 
non-invention is legally justified in the context of the broad meaning of the term „invention‟. 
 
3.  The legal approach to animal patenting in Canada  
 
In chapter 4 it was demonstrated that the European-wide permissive approach relies on 
whether or not an animal invention falls within the term „animal varieties‟ under Article 53(b) 
of the EPC. The discussion in this section will demonstrate that the invention faces a more 
fundamental hurdle under Canadian patent law, by first having to qualify as an „invention‟ 
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  [1989] 1 SCR 1623; [1987] 3 FC 8. 
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  [2004] 1SCR 902; [2004] SCC 34; [2003] 2 F.C. 165; [2002] FCA 309; [2001] FCT 256. 
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under s2. The facts of the Harvard Mouse in Canada are similar to those discussed in sub-
section 3.1 of chapter 4, and thus will not be reprised here. As for the position in Europe, 
various claims for process patents, cell cultures and plasmids were allowed in the first 
instance by the Commissioner of Patents.
56
 Therefore, the question which was the subject of 
appeal to the Supreme Court was whether a transgenic mouse is an invention under s2.  
 
3.1 The Harvard Mouse in Canada: an analysis of the Supreme Court’s decision  
 
For the purpose of analysis, the following sub-sections deal with two pertinent aspects which 
formed the refusal of the Supreme Court to grant patent protection to the Harvard Mouse: (1) 
the words, scheme and object of the Patent Act, versus the intention of the legislature; and (2) 
the non-qualification of the GM mouse as an „invention‟ under any of the categories under s2.  
 
3.1.1  The words, scheme and object of the Canadian Patent Act 1985, versus the intention 
of the legislature 
 
Section 2 and its relation to the intention of the legislature were perceived differently by the 
majority and minority (of the panel of judges) in the Harvard Mouse. In the US case of 
Diamond v Chakrabarty, the majority advocated the principle that the term „invention‟ within 
the context of patent law should be broadly interpreted to cover any invention that fulfilled 
the patentability criteria. The majority in the Harvard Mouse refused to adopt this view in 
interpreting the same term under s2. In the US, the principle was achieved based on the 
interpretation of the Congressional Committee Reports accompanying the US Patent Act 
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  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 123. 
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1952.
57
 The majority in the Harvard Mouse argued that the adoption of the five categories 
under s2 clearly indicates that a certain limit was intended by Parliament.
58
 Otherwise, the 
term would have been defined as „anything new and useful made by man‟.59 The majority 
was not convinced that the existing Canadian Patent Act 1985 is broad enough to cover 
higher life forms within the patent scheme, since there was no indication of such an intention 
from Parliament.
60
 Moreover, the patenting of higher life forms raises unique concerns and 
involves public interest issues which require explicit direction from the legislature.
61
 
Conversely, the minority argued that due consideration should be given to the central purpose 
of patent law. Since the law aims to encourage innovation, any invention which fulfils the 
patent qualification criteria should be patentable, irrespective of the fact that it may be a 
living being. The fact that an invention involves a living being should not per se exclude it 
from patent protection, as this would undermine the aim of the creation of the patent law 
itself which is meant to encourage human ingenuity.
62
 It will be shown in the following 
analysis that the majority‟s restrictive interpretation of the intention of Parliament and the 
term „invention‟ shows a lack of legal reasoning. 
 
Firstly, while refusing to adopt the broad meaning of the term „invention‟, the majority 
recognised that the purpose of patent law and the broad intention of Parliament are to 
encourage innovation by the grant of patent.
63
 This explicit recognition should have led to a 
view that the term is to be broadly construed, and hence a patent should be allowed to a 
subject matter which could meet the relevant prerequisites. There are two other reasons which 
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  ibid. paragraph 157. 
58
  ibid. paragraph 158. 
59
  ibid.  
60
  ibid. paragraph 155. 
61
  ibid. 
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  ibid. paragraph 1(iii). 
63
  ibid. paragraph 158. N. Siebrasse, Comment on Monsanto Canada Inc. v Schmeiser (2004) Canadian Bar 
Review, 3. 
227 
 
support this contention: (1) the Canadian courts have tended to consider UK cases when 
interpreting Canada‟s patent law, due to the fact that Canada was once a colony of the UK.64 
Therefore, being a commonwealth country, Canada has a system of law derived from English 
law. While the EPO decisions are not binding upon national courts, the UK courts are, in 
principle, constrained to adopt the permissive interpretation adopted by the EPO (through the 
decision of the Harvard/Onco-mouse case)
65
 when construing the exclusion of animal 
inventions contained in the UK Patents Act 1977.
66
 In evidence, the UK highest courts have 
recently stressed the importance of the UK courts following the decisions of the EPO (on the 
same issues) so as to ensure parity of interpretation of the EPC among the Member States.
 67
 
Consequently, based on the principle of precedence, the EPO cases (which would be 
indicative of UK jurisprudence) would have persuasive value to Canada; and (2) the 
definition of what constitutes an „invention‟ under the Canadian patent statute was modelled 
upon the US Patent Act 1793.
68
 Notably, the majority in the Harvard Mouse conceded this 
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  P. Krishna and M. Perry, Making sense of mouse tales: Canada life form patents topsy-turvy (2001) 23 
European Intellectual Property Review, 4, 199; M. Kamber, Coming out of the maze: Canada grants the 
Harvard Mouse Patent (2003) Washington International Law Review, 779. 
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  For the UK provision, see Appendix 9.  
67
  The House of Lords in the case of Kirin-Amgen Inc v Hoechst Marion Roussel [2005] RPC 9; [2004] UKHL 
46 (which involved product-by-process claims) held that the UK courts should follow the EPO decision. 
Later, in the case of Conor Medsystems Inc v Angiotech Pharmaceuticals Inc [2008] RPC 28; [2008] UKHL 
49, the same court held that the UK courts should follow on general principles, but will diverge in 
application. Lord Hoffmann, delivering the court‟s judgement, notably held at page 720: „A European patent 
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should be uniformity in the way the national courts and the EPO interpret the EPC.‟ In the recent case of 
Human Genome Sciences Inc v Eli Lilly and Company Limited [2012] RPC 6; [2011] UKSC 51, the 
Supreme Court held that the UK courts could decline the EPO decisions only where they considered that the 
decisions had taken the law in an inappropriate direction, misapplied previous EPO jurisprudence or failed to 
take a relevant argument into account.  
68
  J.D. Morrow, Patentable subject matter: emerging technologies in G.F. Henderson (ed), Patent law of 
Canada (Toronto: Carswell, 1994) 24. Despite being a colony of France and the UK (until its confederation 
on 1 July 1867), the country‟s patent legislation has, since the first statute dealing with patents in 1823, been 
modelled upon the US law. This was due to the availability of the US patent statute which was enacted in 
1790, in comparison to the UK‟s patent statute which was only codified in statutory form in 1852 (even 
though the Statute of Monopolies was enacted much earlier in 1624). See H. Fisher and R.S. Smart, 
Canadian patent law and practice (Toronto: Canada Law Book Company Limited, 1914) 3. For detailed 
discussion about the development of the Canadian Patent Act, see O.M. Biggar, Canadian patent law and 
practice: with special reference to the differences between the law and practice in Canada and in Great 
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fact.
69
 It is pertinent to note that apart from the dropping of the words „or discovers‟ which 
still remain in the US Patent Act, the meaning of the term „invention‟ under the current 
Canadian Patent Act 1985 is essentially the same as that of the country‟s Patent Act 1869.70 
This legislative background explains the similarity between s2 of the Canadian Patent Act 
1985 and §101 35 USC.
71
 Therefore, in view of: (1) the alleged inexplicit direction from the 
Canadian Parliament; (2) the influence which the UK permissive approach would have on 
Canada; and (3) the adoption of the meaning „invention‟ from the US Patent Act,72 it is 
difficult to appreciate the distinctive approach adopted by the majority in the Harvard Mouse 
in interpreting the term „invention‟ narrowly.  
 
The different view adopted by the Supreme Courts, in the US and Canada, to interpret the 
meaning of the term „invention‟, demonstrates that the decision whether to allow a patent for 
animal inventions largely depends on how judicial authorities perceive the issue.
73
 The 
majority
74
 in the Harvard Mouse notably stated that: (1) „patenting higher life forms would 
involve a radical departure from the traditional patent regime‟; and (2) „it is unlikely that 
Parliament would choose the Patent Act as it currently exists as the appropriate vehicle to 
protect the rights of investors in this type of subject matter‟.75 In the alleged absence of clear 
intention from the legislature, this statement inevitably reflects the different attitude toward 
animal patenting adopted by the Canadian judicial authorities. 
 
                                                                                                                                                                                    
Britain and the United States (Toronto: Burroughs & Company (Eastern) Limited Law Publishers, 1927) 2-3; 
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  For §101 35 USC, see footnote 52 of chapter 2. 
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  J.A. Lèger, Patent infringement: back to good sense in G.F. Henderson, n 68 above, 263. 
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  T. Scassa, A mouse is a mouse is a mouse: a comment on the Supreme Court of Canada‟s decision on the 
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Commonwealth Law Journal, 1, 117. 
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  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 1. 
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  ibid. 
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Secondly, the majority‟s reasoning amounts to requiring Parliament to state precisely that, 
animal inventions are included in the definition. Arguably a patent legislation would not be 
able to provide a detailed list of all subject matter which would amount to inventions, thus 
covered by the statute. The legislation is meant to lay down substantive provisions for the 
purpose of encouraging innovation and rewarding an inventor,
76
 rather than dealing with the 
minute details. It is the duty of the Court to interpret the relevant provision based on 
applicable legal principles. It is important at this juncture to reiterate the fact that Article 
27.3(b) of the TRIPs Agreement only allows Signatories to exclude „animals‟ and „essentially 
biological processes‟ from the patent regime.77 However, products of microbiological process 
are to be patentable.
78
 Similar principles are provided in Article 8(2) of the EU 
Biotechnology Directive. Notably, Article 8(1) of the Directive provides that offspring of 
transgenic animals (which inherit the relevant novel traits) fall within the scope of protection 
of the European patents.
79
 These leading patent law texts do not prevent an animal obtained 
through technical intervention from being an „invention‟. Moreover, as already highlighted in 
chapter 2, even in the absence of explicit provision on the patentability of animal inventions, 
the inventions have been held to be patentable in many countries (such as the US and 
Japan).
80
 
 
Thirdly, it is pertinent to note that the rules under Article 27.3(b) of the TRIPs Agreement, 
that only an „essentially biological process‟ is not to be protected whereas products of 
microbiological process are to be granted patents are similarly provided under Article 1709 of 
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the North American Free Trade Agreement (NAFTA),
81
 to which Canada is a Signatory. 
Therefore, it must fulfil its international obligation under both Agreements. It is already 
identified in chapter 4 that the EPO cases (including the Harvard/Onco-mouse) have been 
decided along these principles of Article 27.3(b). In contrast, arguably Canada has failed to 
observe its international obligation, both under Article 27.3(b) and Article 1709, by refusing a 
patent to the Harvard Mouse (which is a product of microbiological process). 
 
This contention finds further support from the inconsistency of the Canadian Supreme Court 
decisions. In Pioneer-Hi Bred, the appellant (Pioneer Hi-Bred) claimed a patent for a new 
line of soybean variety which was achieved through: (1) selection and crossing of the parent 
plants; and (2) development of a pure line by selective reproduction.
82
 The Supreme Court 
recognised two types of genetic engineering, hence highlighting the difference between them 
in the case. In essence, the Court was of the view that while hybridisation (crossing different 
species or varieties) involves human intervention, the process does not alter the actual rules 
of reproduction, which remains to follow the laws of nature. This first type of genetic 
engineering falls short of patent protection. Conversely, patent law only grants protection to 
the second type of genetic engineering which involves an alteration made by human at the 
molecular level, where the modification to the sequence of the genes affects all the hereditary 
material.
83
 Following this distinction, the processes involved in Pioneer Hi-Bred had been 
classified by the Supreme Court under the first category. Therefore, while the Court did not 
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provides: A Party may also exclude from patentability: (b) plants and animals other than microorganisms; 
and (c) essentially biological processes for the production of plants or animals, other than non-biological and 
microbiological processes for such production. Notwithstanding subparagraph (b), each Party shall provide 
for the protection of plant varieties through patents, an effective scheme of sui generis protection, or both.‟ 
See P.C.M. da Costa, NAFTA – The Canadian response or why does the Canadian Patent Act keep changing? 
(1994) 22 AIPLA Quarterly Journal, 66. 
82
  Pioneer Hi-Bred, n 54 above, 6. 
83
  ibid. 11-12. 
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decide on the unpatentability of the new soybean variety based on the processes involved,
84
 
the distinction could have been part of the reasons for the refusal. In contrast, the process to 
obtain the Harvard Mouse explicitly involved the processes described in the second category. 
Consequently, for the majority in the Harvard Mouse to refuse patent protection to the 
transgenic mouse is anomalous. 
 
Related to this, the majority
85
 in its judgement also commented on the Federal Court of 
Appeal which argued that „the language of patent law is to be given wide scope as the 
inventions are necessarily unanticipated and unforeseeable‟.86 Nevertheless, this has been 
countered by an argument of the majority
87
 that while „Parliament would not have foreseen 
the genetically engineered mouse and the modern genetic engineering process to produce it, 
the legislature was well aware of the animal husbandry or breeding which similarly produces 
animals with a new or several new features‟.88 The Supreme Court further observed, that 
„Parliament chose to define the categories of invention using language that does not, in 
common usage, refer to higher life forms‟.89 There is no clarification as to what the Court 
meant by „animals with a new or several new features‟. Bearing in mind that the Canadian 
Patent Act 1985 was passed in the 19
th
 century when the second type of genetic engineering 
(as categorised by the Pioneer Hi-Bred case) was unknown, it is only possible to conclude 
that the „new features‟ referred to by the Court are the result of genetic enhancement through 
traditional cross-breeding. Therefore, the reason why Parliament did not explicitly include the 
resulting animals under the Act is obvious - being the product of traditional cross-breeding, 
                                                          
84
  Rather, the plants were decided to be unpatentable due to the issue of insufficiency of disclosure, ibid. 13. 
85
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 164. 
86
  ibid. 
87
  ibid. 
88
  ibid. 
89
  ibid. Similar argument has been made by Marceau J in the case of Pioneer Hi-Bred. In interpreting the 
limited intention of Parliament he argued that in view of the well established plant breeding when the Patent 
Act was passed, had the legislature intended to include plants within the Act, the words „strain‟, „variety‟ or 
„hybrid‟ should have appeared in the Patent Act. 
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they will eventually fail the qualification requirement under patent law. For this reason, it is 
more probable that the definition of the term „invention‟ has been intentionally left open by 
the Canadian legislature to allow the Court to interpret the patentability of a subject matter 
accordingly, based on relevant legal principles as technology develops. 
 
Fourthly, one of the arguments of the majority
90
 was that the current form of the Canadian 
Patent Act 1985 is unprepared to cover animal inventions, and thus necessary protection 
should come from special legislation.
91
 The argument is underpinned by the passage of the 
Plant Breeders‟ Rights Act 199092 (subsequent to Pioneer Hi-Bred) which grants sui generis 
rights to plants that fulfil the requirements of the UPOV Convention.
93
 The majority
94
 further 
contended that this development showed that the Canadian Patent Act 1985 was not tailored 
to protect plants due to their unique characteristics.
95
 Eventually, the majority
96
 averred that if 
Parliament intends to include animal inventions in the realm of the patent system it has to 
make this explicit by two options: (1) introducing a separate Act which would be more 
suitable to the complex nature of living and sentient beings; or (2) amending the current 
Canadian Patent Act 1985.
97
  
 
It is argued that, while the proposed methods of implementation are in accordance with the 
procedural legal requirements, the refusal of the majority to allow patent to the Harvard 
Mouse based on the development of sui generis protection for plant varieties, shows a lack of 
legal reasoning. The majority should have been able to appreciate that when they formed 
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  ibid. paragraph 192. 
91
  ibid. 
92
  Available at: WIPO, http://www.wipo.int/wipolex/en/text.jsp?file_id=207967 (Accessed: 29 November 
2011). 
93
  That has been argued as a response of Parliament to the refusal of the Supreme Court to allow patent 
protection to a variety of plant in the case of Pioneer Hi-Bred. 
94
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 188. 
95
  ibid.  
96
  ibid. paragraph 189. 
97
  ibid. 
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their decision, there was not yet any legal development toward the establishment of a sui 
generis system of protection for animal inventions in Canada.
98
 Although the two options are 
available to the Canadian Parliament, it is not obliged to adopt them.
99
 As identified by the 
appellant in the Harvard Mouse, Parliament has not made any move toward either of the 
options.
100
 Notably, this has been the position so far in Canada.  
 
Nevertheless, the decision of the majority to refuse patent protection to the Harvard Mouse 
because Parliament has not given its express „blessing‟, cannot be said to be anomalous as it 
corresponds with the principle of separation of power between legislature and judiciary.
101
 
This principle requires that judicial authorities merely interpret and apply the law without 
interfering with policy decisions which fall within the responsibility of the legislature.
102
 In 
fact, the majority
103
 and the minority
104
 had constantly reminded themselves of this judicial 
function in their decision. At this juncture, it is also important to note that the Canadian 
Biotechnology Advisory Committee (CBAC)
105
 had earlier recommended to the Canadian 
Government two things: (1) that higher life forms (including animal inventions) which meet 
the patent qualification criteria should be patentable; and (2) so as to safeguard the public 
interest, three aspects should be included in the Canadian Patent Act 1985: farmers‟ privilege, 
innocent bystanders, and research and experimental use.
106
  
                                                          
98
  This is one of the reasons which motivate the EPO to allow patent protection to the Harvard Mouse. See 
discussion in section 3.3 of chapter 4. 
99
  N. Siebrasse, n 63 above, 6. 
100
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 189.  
101
  K. Kanani, Transgenic animal patents: The Harvard mouse on the Canadian frontier (2002) Canadian 
Intellectual Property Review, 555. The author addresses this approach as judicial minimalism, the problem 
of which, while the court settles cases before it, it leaves many things undecided, thus inviting Parliament to 
deal with the relevant issue through public debate.  
102
  ibid. 
103
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 150. 
104
  ibid. paragraph 1(iii). 
105
  The CBAC is a special committee appointed to advise the Government of Canada on issues relating to 
biotechnology. See CBAC, Patenting of higher life forms and related issues: report to the Government of 
Canada Biotechnology Ministerial Coordinating Committee, June 2002, x.  
106
  ibid. As regards „farmer‟s privilege‟, the report recommended that „farmers are permitted to breed patented 
animals, as long as the progeny are not sold as commercial propagating material or in a manner that 
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The majority
107
 was well aware of these recommendations while deciding the Harvard Mouse 
case. However, in view of the complexity of the three aspects involved in the second 
recommendation, and also of concern about the patentability of human life,
108
 all of which 
require public debate, the majority (as the decision is explicit) chose to leave the issue for 
Parliament to decide. The majority‟s „dormant‟ reaction to the CBAC recommendation is not 
unusual as it has no binding effect on the Court.
109
 In fact, a similar situation is observed 
where the opinion of the European Group on Ethics in Science and New Technologies (EGE) 
that embryonic stem cell lines are patentable (if modified to allow a specific industrial 
application and that the modification process is also patentable) was refused by the OD in the 
case of Edinburgh Patent case.
110
 Nevertheless, refusing legal protection to the transgenic 
mouse, in the absence of special legislation dealing with animal inventions, is not a neutral 
act. Granting a patent to the transgenic mouse is a more neutral act as the Supreme Court did 
not raise any question about its ability to fulfil the patent qualification criteria. In this way, 
the technology will be retained for Parliament to consider before it becomes marketable.  
 
                                                                                                                                                                                    
undermines the commercial value to its creator of a genetically engineered animals‟. „Innocent bystander‟ 
means „the potential liability of farmers who discover genetically modified biological material in their land‟. 
The report recommended that innocent bystanders are protected from claims of patent infringement with 
respect to „adventitious insemination of an animal by a patented animal‟. The issue of innocent bystander 
will be further dealt with in sub-section 3.2 below. As regards „research and experimental use‟, the report 
recommended that for private and non-commercial use, and study, of a patented product or process be 
protected from infringement claims.  
107
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraphs 169-183. 
108
  This issue is beyond the scope of this thesis. 
109
  M. Perry, Life forms patents: the high and the low (2004) 1 Journal of International Biotechnology Law, 22.  
110
  European patent (EP) no 0695351. For instance, the role of the opinion by the EGE on the governance of 
commercial cord blood banking has been studied recently. It was concluded that the expert bioethics 
advisory body has played an important function in influencing policies relating to the matter.  Their opinion 
has been included in policies and guidelines issued by such bodies as the national ethics committees of some 
EU Member States. However, among other issues, it was identified that the body‟s working methods failed 
to involve public participation which is one of the pertinent aspects in the decision of the EU policy. See A. 
Mohr, H. Busby, T. Hervey, and R. Dingwall, Mapping the role of official bioethics advice in the 
governance of biotechnologies in the EU: the European Group on Ethics opinion on commercial cord blood 
banking (2012) 39 Science and Public Policy, 105-117. 
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Finally, one of the implications of the majority‟s argument is that it requires the Canadian 
Patent Act 1985 to be amended as technology develops. Arguably this would impose an 
unnecessary burden on the legislature as technology advances so rapidly.
111
 It has been 
contended
112
 that this is not how technology-specific regulation is introduced in any area such 
as nuclear power or firearms.
113
 Other than that, the argument of the majority can be read as 
requiring the law to precede the technology.
114
 This is detrimental to the development of the 
latter as it would not be possible for law to evolve at, or faster than, the pace of technology.
115
 
In this regard, the minority‟s116 argument that specific indication from Parliament to include 
inventions involving living organisms within the Canadian Patent Act 1985 was not 
necessary since the term „invention‟ is broad enough to cover unanticipated inventions 
(including higher life forms), is more reasonable. Intrinsically, this can be supported by the 
phrase „any new and useful‟ preceding the five categories of inventions in s2.  
 
3.1.2  The non-qualification of a GM animal as an „invention‟ under any of the categories 
under s2 of the Canadian Patent Act 1985 
 
Both the majority and minority in the Harvard Mouse argued that the transgenic mouse could 
only potentially come into the categories of „manufacture‟ or „composition of matter‟ under 
s2. Thus, the reasoning rendered by the Court focussed on these two categories. This 
contention is arguable as it is clear from the wording of s2 that an animal invention can come 
within any of the five categories for it to constitute an „invention‟. For this reason, the 
                                                          
111
  J.D. Morrow, n 68 above, ibid. 
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  N. Siebrasse, n 63 above, 6. 
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  ibid. 
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  ibid.; Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 1 (iii). 
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following analysis considers the potential of the transgenic mouse to fall within any of the 
categories. 
 
As the majority did not consider the terms „art‟, „process‟ and „machine‟ in their judgement, 
the analysis looks into the meaning of the terms discussed elsewhere. The term „art‟ has been 
construed as „a mode, or method, or manner of accomplishing a certain result as distinct from 
the result‟117 whereas the term „process‟ means „a mode, method or operation, by which a 
result or effect is produced by chemical action, by the operation or application of some 
element or power of nature or of one substance to another.‟118 While these constructions align 
the term „art‟ with the term „process‟, it has been emphasised119 that the former term is 
„broader than (but embraces) the latter‟.120  
 
The term „art‟ was given an even broader meaning by the Canadian Supreme Court itself, in a 
leading case prior to the Harvard Mouse, where the meaning of the term „invention‟ was in 
question.
121
 In the case of Shell Oil Company v The Commissioner of Patents,
122
 the appellant 
claimed patents to the discovery of a new use for chemical compounds which he patented 
earlier. In other words, the claim was for a new use of an old compound. In interpreting the 
term „invention‟ broadly, Wilson J stated: 
 
[w]hat then is the „invention‟ under section 2? I believe it is the application of this 
new knowledge to effect a desired result which has an undisputed commercial 
value and that it falls within the words „any new and useful art. I think the word 
‘art’ in the context of the definition must be given its general connotation of 
                                                          
117
  H.G. Fox, The Canadian patent law and practice relating to letters patent for inventions (Toronto: Carswell 
Co, 1969) 16-17. 
118
  ibid. 
119
  ibid. 
120
  ibid. 
121
  N. Siebrasse, n 63 above, 10. 
122
  [1982] 2 SCR 536. 
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‘learning’ or ‘knowledge’ as commonly used in expressions such as „the state of 
the art‟ or „the prior art‟.123 (emphasis added) 
 
The Court
124
 decided the new use is patentable because the appellant‟s new discovery 
amounted to „new and useful art‟ for adding new knowledge of the compound which was not 
known before. While the claims were being opposed for failing the condition of inventive 
step,
125
 the approach adopted by the Court demonstrates the understanding of judicial 
authorities (long before the Harvard Mouse) of the importance of patent protection so as to 
acknowledge the contribution of inventors to the promotion of innovation.  
 
Arguably the Harvard Mouse can be covered by the term „art‟ if the majority appreciates the 
value it contributes to knowledge. Intrinsically, inventions (such as the Harvard Mouse) bring 
with them a breakthrough of knowledge. It should be reiterated that the novelty, 
inventiveness and industrial applicability of the transgenic mouse was not disputed by the 
majority.
126
 This demonstrates an acknowledgement of additional new and useful 
information to the field of invention. In this respect, it has been argued by critics
127
 that the 
Court has a legal duty to „fit the subject matter within the definition of invention by breathing 
life into the bare and sometimes dated, words of patent statutes.‟ 128  It has also been 
identified
129
 that the exclusion of animal inventions from protection under the Canadian 
patent law is judicially created.
130
 Therefore, in order to give effect to the purpose of patent 
law which includes the promotion or disclosure of information and investments, the court has 
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  ibid. 549. 
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  ibid. 
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  ibid. 539. 
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  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 203. 
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  E.A. Crowne-Mohammed, Can you patent that? a review of subject matter eligibility in Canada and the 
United States (2009) Temple International and Comparative Law Journal, 269. 
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to construe the exclusion „narrowly and strictly‟.131 Otherwise the progress of innovation is 
„foreclosed ab initio’.132 The majority in the Harvard Mouse failed to consider the ability of 
the transgenic mouse to constitute an invention under the term „art‟ (which the same court 
found to be broad enough to be construed as „learning‟ or „knowledge‟). This inevitably 
demonstrates the failure of the majority in the Harvard Mouse to appreciate the function and 
uphold the purpose, of patent law. As regards the process of creating the transgenic mouse, it 
easily falls under the term „process‟, or „art‟ (as defined above), and hence is expected to be 
allowed by the CIPO patent examiner in the first instance of the application.  
 
Moving on to the term „machine‟, it has been defined as „the embodiment in mechanism of 
any function or mode of operation designed to accomplish a particular effect.‟133 It includes 
„every mechanical device or combination of mechanical powers and devices that perform 
some function and produce a new result‟. 134  This meaning apparently covers inanimate 
inventions which are mechanical in nature, and therefore, it is appropriate for the majority 
not to consider how the transgenic mouse could fall under the term. 
 
As regards the term „manufacture‟, three definitions had been referred to by the majority in 
the Harvard Mouse: 
 
(1)  The term is defined by the Oxford English Dictionary as:  
 
[t]he action or process of making by hand… The action or process of making 
articles or material (in modern use, on a large scale) by the application of 
physical labour or mechanical power. 
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  E.A. Crowne-Mohammed, n 127 above, 269. 
132
ibid. ‘Ab initio’ is a Latin expression which means: „from the beginning‟. See 
http://www.thefreedictionary.com/ab+initio (Accessed: 30 May 2012). 
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  H.G. Fox, n 117 above, 17. 
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  ibid. 
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(2)  The Le Grand Robert de la langue francaise defines the term „fabrication‟ as: 
 
[Translation] Art or action of manufacturing … The manufacture of a technical 
object (by someone). Manufacturing by artisans, by hand, by machine, 
industrially, by mass production… 
 
(3)  In the Chakrabarty’s case the term was defined as: 
 
[t]he production of articles for use from raw or prepared materials by giving to 
these materials new forms, qualities, properties, or combinations, whether by 
hand-labour or by machinery.
135
 
 
Based on these definitions, the majority
136
 concluded that „the term was commonly 
understood to denote a non-living mechanistic product or process, and that in its vernacular 
sense the term does not include animal inventions‟.137  
 
The argument demonstrates the majority‟s stance that patent protection could only be 
considered for chemical, mechanical and technical inventions. This is inconsistent with the 
ethos of a patent, which is a commercial tool designed to reward an inventor for creating any 
invention (which meets the required criteria) for the benefit of the public. Further, looking 
closely at the definitions of „manufacture‟ referred to by the majority, arguably their 
conclusion has not been precisely achieved. The definitions taken together require three 
things: (1) the process to produce the relevant object should be by hand or the application of 
physical labour or mechanical power; (2) the process should produce a technical object; and 
(3) the object should be produced from raw or prepared materials which have been given new 
forms, qualities, properties or combinations of these. It is argued that the transgenic mouse 
had fulfilled these elements; it has been produced by human intervention when the onco-gene 
was injected into its genome, resulting in a mouse which is predisposed to develop cancer, 
thus making it useful in cancer research. 
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The assessment based on the vernacular meaning of the term demonstrates the Court‟s literal 
interpretation. While this approach accords with the established rule of statutory construction, 
arguably it was not appropriately exercised by looking at the subject matter and modern 
genetic engineering technology, which is at issue. Additionally, it is difficult to appreciate the 
contradicting views of the majority when two facts had been explicitly recognised in their 
decision: (1) that the term „manufacture‟ may be considered to have a very broad meaning; 
and (2) that the mouse may be considered as a „manufacture‟ in an industrial setting.138  
 
With respect to the phrase „composition of matter‟, the majority139 argued that the definition 
of: „… all compositions of two or more substances and … all composite articles‟, as adopted 
in the Chakrabarty case and by the majority in the Federal Court of Appeal, was too broad 
and would cause redundancy to the words „machine‟ and „manufacture‟ which also appear in 
s2.
140
 Therefore, the majority argued that the phrase „composition of matter‟ must be limited 
in some way, and does not include animal inventions such as the transgenic mouse.
141
 The 
majority supported their contention with the principle of statutory interpretation where they 
concluded that the five terms: art, process, machine, manufacture, and composition of matter, 
if read collectively, should be restricted to the same genus.
142
 The majority was of the view 
that animal inventions could not fall within any of the five categories, because the terms 
„machine‟ and „manufacture‟ do not imply a conscious, sentient living matter. Consequently, 
the category of „composition of matter‟ did not cover the transgenic mouse.143 
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The reasoning of the majority for the redundancy of the relevant categories and necessary 
restriction to the same genus is debatable for three reasons. Firstly, patent legislation is 
designed to be as broad as possible precisely because it is meant to catch inventions which 
could not be conceived of when the legislation was put in place. This is what makes patent 
legislation so different from any other type of law where it must regulate what cannot been 
thought of. Consequently, all scientific, engineering, and other advances must fall within one 
category or another because the provision is designed to describe all possible advances. 
Exclusion thereafter relies upon compliance with the patent qualification criteria. In other 
words, it is not justifiable to simply exclude innovation on the basis that it is not a form of 
advancement that the law protects. Secondly, the fact that there may be an overlap between 
the categories does not warrant an argument that a particular category should be understood 
in a restrictive way. It is difficult to appreciate that an invention which may fall into more 
than one category is legally penalised as there is no condition to this effect in the Canadian 
Patent Act 1985. Thirdly, the argument that because the terms „machine‟ or „manufacture‟ do 
not imply living matter,  the category of „composition of matter‟ should not cover a 
genetically engineered mouse is problematic. This is because it amounts to suggesting that all 
the terms should cover the same type of inventions. Arguably it undermines the need and 
importance of each category under s2. 
 
Another pertinent issue which led to the majority‟s conclusion that the transgenic mouse was 
not qualified as „composition of matter‟ arises from the decision of the Commissioner of 
Patents who separated the relevant product patents claim into two phases: (1) the preparation 
of the genetically altered egg; and (2) the development of the embryo in the host mother‟s 
242 
 
womb.
144
 The Commissioner held the embryo to be patentable as the inventor had full control 
over the production, whereas, the transgenic mouse (the end product) was unpatentable 
because laws of nature took control. Underpinning the distinction was the idea that the 
inventor could only consistently reproduce the result of the first, but not the second, phase.
145
 
On appeal, the majority
146
 in the Supreme Court referred to two sources for the definitions of 
the terms „composition‟ and „matter‟, to determine whether or not the transgenic mouse could 
come within the meaning of „composition of matter‟.  
 
According to the Oxford English Dictionary:  
 
„composition‟ means: 
 
[a] substance or preparation formed by combination or mixture of various ingredients; 
and 
 
„Matter‟ means: 
 
[p]hysical or corporeal substance in general... contradistinguishing from immaterial or 
incorporeal substance (spirit, soul, mind), and from qualities, actions, or conditions. 
 
In addition, the Le Grand Robert de la langue francaise defines : 
 
„Composition‟ as: 
 
[a]ction or manner of forming a whole, a set by assembling several parts, several 
elements; and 
 
„Matiére‟ (matter) as: 
 
[Translation] corporeal substance that is perceptible in space and has mechanical 
mass.
147
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Based on the definitions, the majority held that the genetically altered egg would satisfy the 
definition, but the transgenic mouse fails to be covered.
148
 As regards the former, the 
majority
149
 contended that human intervention (through the injecting process) has a direct 
effect on the egg, making it susceptible to cancer, and thus warranted its patentability. 
Conversely, the transgenic mouse was unpatentable because the process for the creation of 
the transgenic mouse involved a complex process of the laws of nature where human 
intervention is no longer required to obtain it.
150
 The decision confirmed the Commissioner of 
Patents‟ findings. Notably, the majority151 asserted that while „the body of the mouse is 
composed of various ingredients or substances, it does not consist of ingredients or 
substances
 
that have been combined or mixed together by a person‟.  
 
Although the majority‟s decision was based on appropriate sources, the wrong decision 
appears to have been reached for a number of reasons. Firstly, it is reasonable that 
dictionaries or linguistic sources give definitions which are broad. It is the duty of the court to 
fit the definitions to the issue at hand. The majority‟s focus on the requirement that the end 
product „should be combined or mixed together by a person‟ demonstrates that the Court‟s 
assessment is addressed to subject matter which is chemical, technical and mechanical in 
nature. Literal application of the definitions to the transgenic animal, with novel 
characteristics obtained through genetic engineering technique, is inappropriate. This is 
because it would be impossible for the transgenic mouse (or even any animal inventions) to 
have been obtained through combining or mixing of ingredients or substances in the way 
chemical, technical and mechanical products are produced. In the context of the transgenic 
mouse, it is argued that the focus of the majority should address a broader meaning that can 
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be achieved from the definitions, such as: a physical matter composed of characteristics 
which are obtained through human effort or technical process. If this more general meaning 
had been the basis of the Court‟s decision, it can be surmised that the transgenic mouse could 
constitute a „composition of matter‟ because it is comprised of the novel trait which was 
developed through human effort and ingenuity. 
 
Secondly, the dividing line between the patentable genetically altered egg, but unpatentable 
end result, is problematic. It is important to be reminded that in the Harvard Mouse the 
alteration to the mouse‟s genome was made no later than its 8-cell stage. This is a very early 
stage of cell division where subsequent cells which develop from the egg (and ultimately 
form the transgenic mouse) would contain the inserted onco-gene. In other words, the 
composition of the egg and the mouse (in terms of the novel traits) is the same. The 
assessment of the majority of the Federal Court of Appeal was that the „onco-gene and the 
fertilised mouse egg are forms of biological matter, which, when combined, constitute a 
„composition of matter‟. When this matter is transferred to the host mother, it produces the 
transgenic mouse. That these constituents remain a „composition of matter‟ within the 
transgenic mouse, and are thus patentable‟,152 appears a convincing argument. Consequently, 
if the majority held that the inventor has full control over the production of the egg, it would 
only be reasonable if they decided that the transgenic mouse is patentable due to the 
biological cycle of life involved.
153
  
 
The fact that the laws of nature are involved in the second phase should not warrant the 
refusal of a patent to the end result. The reasoning of the majority appears inconsistent with 
its own decision to hold the genetically altered egg as patentable. This is because, once the 
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onco-gene is inserted, the egg will further develop to other stages through the biological 
process of cell division which is also outside the control of the inventor.
154
 In addition, the 
distinction made by the majority leads to another difficult question of: where would the 
validity of patent protection of the genetically altered egg cease to take effect? Arguably this 
is a difficult issue which the majority itself failed to address and unnecessarily blurred the 
distinction of the subject matter protected.
155
 Another issue is that the transgenic mouse is the 
product of a process (the microbiological process) which the majority agreed as patentable. 
This reiterates the requirement under Article 27.3(b) of the TRIPs Agreement where the 
resulting product is to be patentable. While the patent law in Canada relies on the broad 
meaning of „invention‟ to determine the patentability of animal inventions (rather than 
adopting the wording of Article 27.3(b)), arguably the majority must give effect to the key 
principle underlined by the TRIPs Agreement. 
 
One of the arguments of the Trial Division of the Federal Court
156
 against the claims for the 
Harvard Mouse was the failure of the inventors to control other characteristics of the 
transgenic mouse including the length of a tail, colour of eyes and texture of fur.
157
 In essence, 
it was averred that the inventors failed the reproducibility test to produce uniform products. 
This is because, unlike the creation of chemical products where the process involved and 
resulting products are known and constant, the creation of transgenic animals relies on 
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modified yeast culture (which it held to be patentable) utilised its natural operation to purify waste from pulp 
plants. See Percy Schmeiser [2004] 1 SCR 902, n 55 above, paragraphs 88 to 91. 
155
  A.D. Morrow and C.B. Ingram, Of transgenic mice and roundup ready canola: the decisions of the Supreme 
Court of Canada in Harvard College v Canada and Monsanto v Schmeiser (2005) 38 University of British 
Colombia Law Review, 1, 211; M. Perry, From Pasteur to Monsanto: approaches to patenting life in Canada 
in Y. Gendreau (ed), An emerging intellectual property paradigm: perspective from Canada (Edward Elgar: 
2008) 79. 
156
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 138. 
157
  ibid. 
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unknown and uncertain factors.
158
 It is pertinent to note that the requirement of 
reproducibility (enablement) under patent law originates from the principle that an invention 
is to be sufficiently disclosed for a person skilled in the art to obtain the invention where the 
described methods are repeated.
159
 The principle aims at ensuring that an inventor is 
commercially rewarded only for the disclosed information which is useful and would work to 
achieve the relevant invention. The robustness of scientific advances relies on this 
requirement as a crucial justifying factor for the monopoly.
160
 There is little doubt that the 
genetic engineering process is not able to produce animal inventions of uniform character as 
chemical products are produced. Nor is this requirement of the principle of reproducibility 
applicable to living matter. The crux of the patent‟s claim for the Harvard Mouse arises from 
the novel traits that it has, namely the susceptibility to develop cancer. In other words, the 
disclosed processes did not promise the attainment of mice with the same length of a tail, 
colour of eyes and texture of fur. Therefore, provided that the relevant characteristic is 
achieved from the disclosed process, the reproducibility criterion can be deemed to have been 
fulfilled.
161
 
 
While the issue of the patentability of lower life forms was not before the Supreme Court in 
the Harvard Mouse, the respondents had questioned the justifiability for the CIPO and courts 
in Canada of allowing patents to lower life forms, but not to higher life forms. The terms 
„lower life forms‟ and „higher life forms‟ are not defined in the Canadian Patent Act 1985. 
Nevertheless, two sources specify what is covered by each term. According to the Canadian 
                                                          
158
  ibid. paragraph 133. 
159
  Section 27.1 of the Canadian Patent Act 1985; S.J.R. Bostyn, A European perspective on the ideal scope of 
protection and disclosure requirement for biotechnological inventions in a harmonised patent system: the 
quest for the holy grail? (2002) The Journal of World Intellectual Property, 1017. 
160
  ibid. 
161
  Rothstein JA in the Federal court of Appeal (majority) decision argued that the inability of the inventor to 
control other named characteristics was irrelevant to the patentability of the transgenic mouse, and otherwise 
highlighted that the sufficiency of disclosure was not an issue in the Harvard Mouse. Harvard College v 
Canada (Commissioner of Patents), n 5 above, paragraph 139. 
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Manual of Patent Office Practice,
162
 „higher life forms‟ cover „animals, plants, seeds, 
mushrooms, fertilised eggs and totipotent stem cells‟, whereas „lower life forms‟ include 
microscopic algae, unicellular fungi (including moulds and yeasts), bacteria, protozoa, 
viruses, transformed cell lines, hybridomas and embryonic pluripotent and multipotent stem 
cells‟.163 The CBAC Report164 defined the former term to include „plants and animals (other 
than single-celled organisms)‟.  
 
The majority approved the distinction between „lower life forms‟ and „higher life forms‟ and 
their distinctive nature of patentability. In response to the arguments of the respondents, the 
majority
165
 stated: „it is easier to conceptualise a lower life form as a „composition of matter‟ 
or „manufacture‟ than it is to conceptualise a „higher life form‟ in these terms‟. 166  This 
statement is inconsistent with some principles in the case of Abitibi. In that case, the Patent 
Appeal Board
167
 adopted the decision of the majority in the case of Chakrabarty, and held 
that a mixed yeast fungal culture (which was modified to digest and purify a certain waste 
product from pulp mills) is patentable.
168
 The Appeal Board underlined an important 
principle, which was not refuted by the majority in the Harvard Mouse, hence arguably 
demonstrating the majority‟s approval of the same. The Appeal Board169 stated:  
 
[i]ts decision will extend to micro-organisms, yeasts, moulds, fungi, bacteria, 
actinomycetes, unicellular algae, cell lines, viruses or protozoa; in fact to all new life 
forms which are produced en masse
170
 as chemical compounds are prepared, and are 
                                                          
162
  Paragraph     17.02.01a     of     the     Manual     of    Patent    Office    Practice.    Available    at:    CIPO,  
 http://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/vwapj/2009-01-01chapitre17-chapter17-
eng.pdf/$file/2009-01-01chapitre17-chapter17-eng.pdf, (Accessed: 28 November 2011). 
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  ibid.  
164
  CBAC, n 105 above, 6. 
165
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 201. 
166
  ibid. 
167
  Re Application of Abitibi Co.  n 3 above. 
168
  The patentability of micro-organisms has not been litigated in Canada since.  
169
  Re Application of Abitibi Co., n 3 above. 
170 A French term which means: „in one group or body; all together‟. See 
http://www.thefreedictionary.com/en+masse (Accessed: 30 May 2012). 
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formed in such large numbers that any measurable quantity will possess uniform 
properties and characteristics.
171
  
 
While uncertain if its decision could be further extended to higher life forms due to their 
more complex nature, the Appeal Board acknowledged that the possibility of them being 
patentable could not be denied. This is provided that the uniformity of characteristics could 
be attained and the prerequisites of patent protection are met.
172
  
 
In this respect, the majority
173
 in the Harvard Mouse agreed with the view of the majority in 
the Federal Court of Appeal that the requirement of being new, useful and non-obvious is 
sufficiently met so long as the transgenic mouse contains the desired feature. In evidence, the 
majority stated that: „If the onco-mouse contains the oncogene, it does not make any 
difference whether its fur is brown or grey‟.174 From this statement, it is possible to argue that 
the majority has accepted that the genetic engineering process (adopted to produce the 
transgenic mouse) is capable of producing results with uniform characteristics as underlined 
by the Abitibi case. Therefore, for the majority to: (1) differentiate between the ability of 
lower and higher life forms to come within the terms „manufacture‟ or „composition of 
matter‟; and (2) argue that it is „far easier to analogise a micro-organism to a chemical 
compound of another inanimate object than it is to analogise a plant or an animal to an 
inanimate object‟, is lack of legal reasoning and contradictory.175  
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  ibid. 
172
  ibid. 
173
  Harvard College v Canada (Commissioner of Patents), n 5 above, paragraph 203. 
174
  ibid. 
175
  M. Perry, n 155 above, 76. Garland and Smordin argued that while the majority made some effort to justify 
the division between the lower life forms which are patentable and higher life forms which are unpatentable, 
they avoided placing a strict line between the two, leaving the task to the Patent Office. S.B. Garland and S. 
Smordin, The Harvard Mouse decision and its future implications (2003) 39 Canadian Business Law 
Journal, 2, 174. 
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This sub-section has challenged the decision of the majority of the Supreme Court. It has 
been shown that the decision to refuse a patent to the Harvard Mouse without express 
direction from Parliament, and the failure to decide that the animal is an „invention‟, was 
achieved with a lack of legal reasoning. It has also been demonstrated that the transgenic 
mouse can constitute an „invention‟ under the categories of „art‟ or „manufacture‟ or 
„composition of matter‟ under s2 of the Canadian Patent Act 1985. More broadly, the analysis 
shows that the decision of the majority corresponds to the restrictive policy adopted by the 
Canadian Government in respect to animal biotechnology food (as identified in section 1).  
 
In the next sub-section, the Supreme Court decision of Percy Schmeiser will be assessed. 
Central to this is an analysis of the ratio of the decision, so as to gauge its implications for 
animal inventions.
176
 It will be argued that, Percy Schmeiser does not change the Harvard 
Mouse. Thus, animal inventions remain unpatentable. However, as transgenic animals can be 
protected through patents of genes and cells contained in the animals, the interests of 
inventors would be adequately protected. Nevertheless, in the instance where the genes and 
cells cannot be patented, the animals are not legally protected. In terms of the research 
questions, the discussion is important to facilitate an understanding of Canada‟s current legal 
approach to animal patenting.  
 
 
 
 
 
                                                          
176
  The relevance of the ratio to animal inventions is due to the broad consideration of the majority to the 
patentability of higher life forms in the Harvard Mouse, where the term „higher life forms‟ has been 
accepted to cover animals and plants. See S.B. Garland et al, ibid. 173; A.D. Morrow et al, n 155 above, 217. 
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3.2 Animal patenting from Harvard Mouse to Percy Schmeiser: Status quo maintained 
or a wind of change?  
 
It is necessary to consider the facts of the Percy Schmeiser case in some details. Monsanto is 
the patent holder of chimeric genes
177
 which confer tolerance of glyphosate herbicides such 
as Roundup and plant cells containing those genes.
178
 Monsanto‟s patents also contained 
claims to: (1) an expression vector;
179
 (2) a plant transformation vector;
180
 and (3) a method 
of regenerating a glyphosate-resistant plant.
181
 Canola seed containing the patented gene and 
cell is marketed in Canada by Monsanto under the trade name „Roundup Ready Canola‟.182 
Schmeiser is a „seed saver‟ where he routinely saves part of his canola harvest for planting in 
future seasons. He never purchased the plants or entered into a licence agreement with 
Monsanto to cultivate the plants.
183
 As his usual practice, he used his 1996 canola seed to 
plant the 1997 crops. While Schmeiser was not a routine user of Roundup in his field, he used 
the herbicide in 1997 and discovered that about 60% of canola survived it.
184
 He kept the 
seed, and used it to plant his entire (1030 acres) crop in 1998.
185
 Through chemical tests of 
the crops in the same year, Monsanto discovered 95-98% of canola in Schmeiser‟s farm was 
Roundup Ready Canola.
186
 Monsanto brought an action against Schmeiser for patent 
infringement. Schmeiser did not deny the presence of the Roundup Ready Canola but argued 
that he never intended to grow the plants.
187
 He also contended that he is an innocent 
                                                          
177
  Means: „a gene that does not exist in nature and is constructed from different species‟. See Percy Schmeiser 
[2004] 1 SCR 902, n 55 above, paragraph 20. 
178
  ibid. page 2. 
179
  Means: „a DNA molecule into which another DNA segment has been integrated so as to be useful as a 
research tool‟. ibid. paragraph 20. 
180
  Which is „used to permanently insert a chimeric gene into a plant‟s own DNA‟. ibid. 19. 
181
  ibid. paragraph 20. 
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  ibid. page 2. 
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  Unlike other five farmers whose farms are adjacent to his farms. ibid. paragraph 60. 
184
  ibid. paragraph 61. 
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  ibid. paragraph 87. 
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  ibid. paragraph 64. 
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  Percy Schmeiser [2001] FCT 256, n 55 above, paragraph 11. 
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bystander as the presence of the patented seed in his farms was due to various possible 
reasons (in 1996). This include cross-field breeding by wind or insects from adjacent farms 
(where Roundup Ready Canola was planted by farmers who were licensees to Monsanto), or 
seed blown from passing trucks, or dropping from farm equipment.
188
 
 
Both the majority
189
 and the minority
190
 concurred that Monsanto‟s patents were valid. 
Therefore, one of the issues
191
 before the Supreme Court was whether Schmeiser had 
infringed Monsanto‟s patent rights under s42 of the Canadian Patent Act 1985192 through the 
„use‟ of the patented genes and cells by planting the Roundup Ready Canola. Schmeiser‟s 
two main defences to the infringement claim were that: (1) the presence of Roundup Ready 
Canola in his crop was not intended;
193
 and (2) he had not sprayed his crop with Roundup, 
thus the invention claimed was not „used‟.194 In a 5-4 decision, the Supreme Court held that: 
 
[t]he appellants‟ saving and planting seed, then harvesting and selling plants that 
contained the patented cells and genes appears, on a common sense view, to constitute 
„utilisation‟ of the patented material for production and advantage, within the meaning 
of section 42 of the Patent Act.
195
  
 
It was further held that: „by cultivating a plant containing the patented gene and composed of 
the cells without licence, the appellants deprived the respondents of the full enjoyment of 
monopoly,‟196 thus infringed the patent rights of the latter.197 The decision is dealt with more 
fully below. 
                                                          
188
  ibid. paragraph 117. 
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  Percy Schmeiser [2004] 1 SCR 902, n 55 above, paragraph 24. 
190
  ibid. paragraph 29 to 131. 
191
  Another issue being the amount of damages to which the respondent was entitled to. ibid. paragraph 7. 
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  Section 42 states: „A patent grants to the patentee the exclusive right, privilege and liberty of making, 
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  ibid. paragraph 49. 
194
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While not the focus of this thesis, some discussion on how plants are protected in Canada 
would be useful in order to identify whether, other than patent protection, there is other 
protection for animal varieties and animal inventions in Canada. It is already identified that 
the Plant Breeders‟ Rights Act 1990 grants a sui generis protection to plant varieties which 
fulfil the requirements (of new, distinct, homogenous and stable) under the UPOV 
Convention. Intrinsically, the legislation does not protect plant inventions produced through 
genetic engineering as the Roundup Ready Canola. Equal Animal Breeders‟ Rights Act is not 
available in Canada. Therefore, as the Harvard Mouse decided that higher life forms are 
unpatentable, both animal varieties and animal inventions have no legal protection in 
Canada.
198
 
 
In terms of animal inventions, critics
199
 have asserted that the Harvard Mouse has left Canada 
at odds with its business counterparts, such as the US, Japan and Europe which allow patent 
protection to animal inventions. Intrinsically this is because inventors are not able to obtain 
the same protection in Canada. Nevertheless, it has also been pointed out
200
 that the result of 
Percy Schmeiser is that „the gap‟ between Canada and its trading partners mentioned here 
„has been minimised‟. Arguably, „the minimisation of gap‟ as identified by the critics is 
reasonable only if one appreciates the issue in terms of practical protection to animal 
inventions per se, rather than legal protection. This contention is elaborated here.  
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  For a comparative analysis of protection of plants and plant variety rights in the US, Europe and Canada, see 
N. Siebrasse, Intellectual property protection for higher life forms: current law and policy (2010) 10 The 
Integrated Assessment Journal, 1, 23-39. 
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  A.D. Morrow et al, n 155 above, 189; K. Sechley, Schmeiser versus Monsanto (2004) 22 Nature 
Biotechnology, 7, 804; C.L. Tape and C.D.M. McCourt, Supreme Court kills Harvard‟s Mouse, 2003 Bio 
Business, 18. 
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  A.D. Morrow et al, ibid, 222.  
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The US and Japan recognise animal inventions as patentable subject matter. Therefore, strict 
comparison between the legal protection of animal inventions in Canada and these countries‟ 
will lead to the conclusion that the gap remains. In terms of Europe, animal inventions are 
patentable notwithstanding the exclusion of „animal varieties‟ under Article 53(b) of the EPC. 
This is because (according to the Onco-mouse II) they are classified as sub-species which are 
not barred from the exclusionary provision.
201
 Animal inventions do not have the privilege of 
being classified in this manner in Canada. Therefore, the assessment similarly refutes the 
suggestion of minimisation of the gap between the legal protection of animal inventions per 
se in Canada and Europe. 
 
The combination of the Harvard Mouse and Percy Schmeiser has created a unique but 
puzzling principle of patent law relating to animal inventions.
202
 This is because, while 
according to the former, animal inventions per se are unpatentable, the latter decided that 
patents to genes and cells give rights to the patentee to exclude others from dealing with the 
transgenic animals. One of the arguments of Schmeiser
203
 was that by deciding infringement 
in favour of Monsanto, the Court implicitly decided that the plants are patentable subject 
matter. This, according to him, runs contrary to the decision in the Harvard Mouse.
204
 Some 
critics
205
 have also argued that the practical result of the Court‟s decision is that „plants (and 
animals) are patentable in Canada provided the genes and cells are claimed.‟206 As these 
contentions revolve around the issue of the subject matter protected, it is important to assess 
the distinctive view of the minority and majority in Percy Schmeiser.  
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  See discussion in sub-sub-section 3.2.2 of chapter 4. 
202
  K. Sechley, n 199 above, 804. 
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  Percy Schmeiser [2004] 1 SCR 902, n 55 above, paragraph 21. 
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  ibid.; W.A. Adams, Confronting the patentability line in biotechnological innovation: Monsanto Canada Inc 
v Schmeiser (2005) Canadian Business Law Journal, 294. 
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254 
 
Monsanto only claims patents to the genes and cells. Upholding the Harvard Mouse decision, 
the minority gave a narrow construction to the claim which is „solely for GM genes and cells 
in the laboratory prior to regeneration‟.207 Therefore, as the protection does not extend to the 
plants, the minority held the view that Schmieser‟s cultivation of the plants containing the 
patented gene and cell does not constitute an infringement.
208
 Conversely, according to the 
majority, the purposeful construction of patent claims in the light of the disclosure and 
specification of the claim „recognises that the invention will be practised in plants 
regenerated from the patented cells, whether the plants are located inside or outside a 
laboratory‟.209 The majority further states that: „whether or not patent protection for the gene 
and cell extends to activities involving the plant is not relevant to the patent‟s validity‟.210 As 
to the right of the patentee to the effective control over the plant, the majority states: 
„according to case law, it is no bar to a finding of infringement that the patented object or 
process is part of or composes a broader unpatented structure or process, provided the 
patented invention is significant or important to the defendant‟s activities that involve the 
unpatented structure.‟211 
 
Some arguments and conclusions can be made based on these opposing views. Firstly, the 
claims made in the Harvard Mouse and Percy Schmeiser are distinct. In the former, the claim 
was to the resulting mouse where the Court had to decide whether or not animal inventions 
per se are patentable. The Court answered this in the negative. In the latter, only genes and 
cells of the canola plants were subject to Monsanto‟s patent claims, hence, the issue of 
infringement of these patented materials. It is an accepted fact that higher life forms consist 
                                                          
207
  Percy Schmeiser [2004] 1 SCR 902, n 55 above, paragraph 139. 
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  ibid. paragraph 160. 
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  ibid. paragraph 19. 
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  Percy Schmeiser [2004] 1 SCR 902, n 55 above, page 4. 
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of cells. Thus, it is not surprising that critics
212
 have argued that it is anomalous for the 
majority to decide that only cells are patentable subject matter. Nevertheless, as the 
patentability of plants per se was not in issue in Percy Schmeiser, the critics‟ suggestion that 
plants per se are patentable based on the ratio of the majority is arguable. This is because, 
intrinsically, infringement can only arise against valid patents (which are the genes and the 
cells).
213
 The absence of a ruling on the patentability of plants per se in Percy Schmeiser 
renders the principle underlined by the Harvard Mouse as the law in Canada, namely that 
plant and animal inventions per se are unpatentable. Accordingly, an applicant is unable to 
claim patents to these inventions. Secondly, it is clear from Monsanto‟s claim that the genes 
and cells are to be used in the creation of glyphosate resistance plants.
214
 Confining the 
subject matter of protection, which can be obtained by an inventor, to the patented genes and 
cells in a laboratory setting is problematic, as it fails to appreciate the intended function of the 
genes. Only a broad construction of the claims will meet the purpose of the invention. 
Consequently, the construction by the majority appears more reasonable in this respect.  
 
In comparison with the European legal position, the principle underlined by Percy Schmeiser 
resembles Article 9 of the EU Biotechnology Directive which states:  
 
The protection conferred by a patent on a product containing or consisting of genetic 
information shall extend to all material, save as provided in Article 5(1), in which the 
product is incorporated and in which the genetic information is contained and 
performs its function.
215
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  N. Siebrasse, n 198 above, 12; E.A. Crowne-Mohammed, n 127 above, 294. 
213
  Sections 54 and 55 of the Canadian Patent Act 1985. 
214
  Percy Schmeiser [2004] 1 SCR 902, n 55 above, paragraph 16-18. 
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This provision explicitly extends the protection of (for example) a patented cell which 
contains a gene to the product which contains the cell. Therefore, while animal inventions per 
se remain not legally protected by patents in Canada, Percy Schmeiser has brought Canada in 
line with Europe in terms of practical protection which may be obtained by an inventor. 
Eventually, as contended earlier, the gap between Canada and its other main trading countries 
(including Europe) is practically minimised. 
 
The Percy Schmeiser decision notably defines what has been characterised as the „innocent 
bystander‟ issue. In this regard, the majority216 underlined four important principles relating 
to infringement of patent rights. Firstly, possession of a patented object or an object 
incorporating a patented feature may constitute „use‟ of the object and thus constitute 
infringement. Secondly, possession, at least in commercial circumstances, raises a rebuttable 
presumption of „use‟. Thirdly, while intention is generally irrelevant to determine the „use‟ 
and hence, infringement, the absence of intention to employ or gain any advantage from the 
invention may be relevant to rebut the presumption of use raised by possession. Finally, a 
patentee cannot obtain any remedy against a non-benefitting infringer.
217
 In the context of 
Percy Schmeiser, by saving, planting and selling canola seed which he knew or should have 
known to be Roundup Ready Canola,
218
 Schmeiser was not an innocent bystander. Moreover, 
the Court found no evidence that Schmeiser had taken any action to remove the „unwanted 
seed‟, once it was discovered in his farm, to rebut the presumption of use.219 Thus, it is right 
for the Supreme Court to find infringement in favour of Monsanto. On appeal, the factor 
which „saved‟ Schmeiser from having to pay the compensation due to Monsanto (as awarded 
                                                          
216
  Percy Schmeiser [2004] 1 SCR 902, n 55 above, page 4. 
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  ibid. 
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by the trial Court)
220
 was the fact that he was a non-benefitting infringer. The Supreme Court 
held that there must be a causal connection between the use of the invention and profits 
identified by the trial Court.
221
 The Court found that the profits that Schmeiser made from his 
sale of the 1998 crops were the same as if he had planted and harvested ordinary canola. This 
is because, there was no evidence that he sprayed the crops with Roundup herbicide to reduce 
weed during that period.
222
 
 
The ratio of Percy Schmeiser is applicable to animal inventions which are equally vulnerable 
of trans-boundary movement from one place to another (as plant inventions). Therefore, 
notwithstanding the puzzling decisions shown earlier, arguably the principles underlined by 
the case would sufficiently protect the interests of an inventor or patentee. In a simple 
illustration, a transgenic bull (containing patented genes which increase milk production, 
belonging to a patentee) may stray from a licensee‟s farm and mate with a non-transgenic 
cow from an adjacent farm, producing a transgenic offspring. Applying the Percy Schmeiser 
decision, the patentee will be entitled to protect his commercial interest against the innocent 
bystander, yet only if the infringer gains any monetary benefit from the use of the offspring. 
Otherwise, while infringement can be established, the patentee will not be able to obtain any 
remedy. In this regard, it appears that through the judgement, Percy Schmesier has preceded 
the Canadian Government in „putting in place‟ the long-recommendation of the CBAC that a 
provision relating to an innocent bystander should be included in the Canadian Patent Act 
1985. 
 
Nevertheless, Percy Schmeiser is not without problems. The decision may create difficulties 
for a patentee to monitor and protect his commercial interests as in the case of trans-boundary 
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movement of animal inventions out of the jurisdiction where patents are granted. As already 
identified in chapter 1, movement of animal inventions may take place for various purposes. 
This includes the movement of transgenic animals for research purposes and from one 
country to another so as to catch up with a sudden decline of local livestock production due to 
disease.
223
 Others include movement for marketing and slaughtering,
224
 and livestock auction. 
In any of these instances a patentee would need to have detailed knowledge of the movement, 
as without it, he will not be able to enforce his commercial rights against the infringers. A 
similar implication arises in the case of change of ownership of the transgenic animals 
without the knowledge of the patentee. In this regard, it is important to note that (for example) 
while the DEFRA of UK
225
 requires keepers of livestock to keep a record of the movement of 
livestock, there have been complaints
226
 that the movement recording system for sheep is 
flawed. This includes the problem with data supplied by farmers to local authorities which 
are in-charge of uploading the data into the Animal Movement Licensing System (AMLS), 
where it took too long, or was no longer being uploaded.
227
 This is because the process is 
done manually, causing extra work.
228
 A more important ramification with the finding of 
infringement (instead of animal inventions per se are held to be patentable) will be where 
claims cannot be made for the genes and cells for lack of complying with the patent 
qualification criteria.
229
 In this instance, inventors may feel insecure in developing animal 
inventions, and investors may refuse to invest in the Canadian animal biotechnology industry. 
This is because the inventions are at risk for being not legally protected. 
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This section has shown that the restrictive approach to animal patenting adopted by the 
Supreme Court in the Harvard Mouse stands as the law in Canada. The latter decision of 
Percy Schmeiser held that patents to genes and cells contained in animal inventions confer 
legal rights to the patentee to control activities relating to the inventions. Nevertheless, it is 
not possible to conclude that there is a wind of change in the Canadian patent law in respect 
of the patent protection available for animal inventions per se. It is because they remain non-
inventions, hence, unpatentable. The decision of the Supreme Court not to allow a patent to 
the Harvard Mouse is arguable because the term „invention‟ under s2 of the Canadian Patent 
Act 1985 is broad enough to cover animal inventions as such. Percy Schmeiser may 
adequately protect a patentee‟s commercial interests through infringement of valid patents to 
genes and cells. However, the decision potentially deters inventors and investors from 
developing animal inventions in Canada, in particular where patent claims to genes and cells 
cannot be guaranteed. 
 
The next section assesses the implications of Canada‟s restrictive approach on the livestock 
industry. Towards this end, the development of animal biotechnology applications in Canada 
is overviewed and put into context. It will be argued that the livestock industry will be 
adversely affected by the approach. The discussion is important to the research questions as it 
identifies two things: (1) the impact of the restrictive approach; and (2) the importance of 
patent protection, in view of a particular country‟s objective to meet the explosion of demand 
of animal-protein based food from the inhabitants. 
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4. The implications of Canada‟s restrictive approach on the livestock industry 
 
Canada is one of the industrialised countries which has been actively pursuing its 
biotechnology sector.
230
 According to the OECD, in 2005, Canada‟s total biotechnology 
R&D expenditure was US$1.4 billion, third after the US (US$25.1 billion) and Germany 
(US$2.35 billion).
231
 Two of the sectors where biotechnology is actively applied in Canada 
are agriculture and aquaculture.
232
 Among the OECD Member Countries, Canada has the 
highest share of biotechnology R&D investment (9%) of agricultural applications.
233
 
Agricultural biotechnology in Canada has been the focus of the province of Saskatchewan.
234
 
Within the Saskatoon Science City,
235
 where the R&D activities on agricultural 
biotechnology are mostly located, molecular techniques have being applied and developed by 
genomics researchers. Nevertheless, it has been identified (in section 2) that the Canadian 
Government remained uncertain of the safety of animal biotechnology food, even after more 
than a decade of efforts to develop the assessment criteria for the products.
236
 As a result, 
unlike plant biotechnology which has been the focus of the Canadian Government (with the 
aim to develop novel crops),
237
 it is observed that less emphasis is given to the animal 
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biotechnology industry.
238
 In evidence, (for example) the R&D activities by Ag-West Biotech, 
a non-profit organisation funded by the province of Saskatchewan whose mandate is „to 
initiate, promote and support the growth of the province‟s agriculture and biotechnology 
industry‟239 focus on plants, pharmaceutical, medical and therapeutic products.240  
 
Yet it cannot be denied that there are some R&D activities relating to livestock animals 
which have been carried out in academic and government institutions in the country. Of note 
is the Enviropig, the GM pig which has been developed by the University of Guelph at 
Ontario. The pig produces the enzyme phytase in its saliva. When the pig consumes animal 
feed, the food mixes with the enzyme, which degrades the phytates which are otherwise not 
digestable in feed grains.
241
 Other than that, the Fisheries and Oceans Canada (DFO)‟s242 
transgenic fish research has produced GM salmon, the strain of which is used to obtain 
information on performance characteristics, fitness parameters and food safety characteristics. 
The information is utilised to assess the impact of transgenic fish on the environment and 
human health.
243
 In addition, animal biotechnology R&D in the Saskatoon Science City 
focuses on: (1) the development of vaccines for livestock animals; (2) genetic services for 
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pure-bred parentage certifications and genetic disease; (3) the development of DNA 
microsatellite markers for parentage testing of llamas, alpacas, elk, sheep, goats and swine; 
and (4) the use of both micro satellites and single nucleotide polymorphisms to assist the 
Canadian livestock industry to improve product lines and gain access to new markets.
244
  
 
The use of the above biotechnology applications relating to livestock animals may 
demonstrate the commitment of the Canadian Government to develop its livestock industry in 
the light of the various factors which may easily influence sustainable production of livestock 
products. In this respect, it is worth noting that similar to the EU (and other countries 
worldwide), the Canadian livestock and fisheries industry was adversely affected by 
problems such as BSE and ISA.
245
 Nevertheless, contrary conclusions can equally be made 
where the animal biotechnology applications (so far adopted by the country) are put into 
context. None is directed toward the addition of benefit to the food that the animal produces 
(such as leaner meat or high quality milk). A more fundamental challenge comes from the 
government policy itself (which explicitly restricts the development and marketing of animal 
biotechnology food) and the undeveloped regulatory framework. So far, no food from 
biotechnology-derived animals have been approved or authorised for sale in Canada.
246
 This 
is not strange given that other countries around the globe (including the European countries) 
have not approved any such products. However, (for example) in Europe the absence of an 
explicit policy which restricts the development and marketing of products obtained from 
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animal biotechnology allows active progression of R&D activities in the field. This is already 
evidenced where the growth of the animal biotechnology industry is supported by clear 
objectives and concerted regional strategies.
247
 Moreover, two aspects will particularly 
support the marketing of the potential products in Europe: (1) the regulatory framework 
relating to the assessment and approval of novel foods derived from animal biotechnology 
which is already in place;
248
 and (2) the EFSA repeated statements that meat and milk from 
cloned animals are just as safe for consumption as their traditionally bred counterparts.
249
 In 
contrast, it is argued that the strict Canadian Government policy and undeveloped regulatory 
framework will hamper the investment which has been spent in animal biotechnology 
industry as the products are not marketable. Consequently, (for example) while an application 
for Enviropig to be approved for food products in Canada has been filed since 2009,
250
 the 
chances of the products reaching the domestic market are negligible. This is because it is 
doubtful that the necessary guidelines for approval will be ready, at least not in the near 
future. 
 
Moving on to the restrictive approach adopted by the Canadian Supreme Court, it pertinent to 
note that the Harvard Mouse decision produced divided criticisms. On the one hand, for 
stakeholders such as scientists, investors and biotechnology companies, the decision has 
failed to uphold what patent law is expected to do: (1) to protect intellectual efforts directed 
at the improvement of the quality of human life through science; (2) to allow biotechnology 
companies to recoup investments spent on the development of an invention; and (3) to 
generate a country‟s economic growth through domestic and international financial 
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support.
251
In evidence, subsequent to the Harvard Mouse, there have been some 
biotechnological companies which asserted that they had had difficulty in raising funds 
abroad because investors were puzzled by the ruling.
252
 On the other hand, while agreeing 
with the expected ramifications for the life-science research and biotechnology in Canada, 
some critics
253
 are doubtful that the industry will be adversely affected by the Harvard Mouse 
decision. This is because Canada has not totally shut its door to allowing patent protection to 
inventions involving animals. This contention was supported by the fact that in the Harvard 
Mouse, claims other than the end product were allowed by the CIPO in the first instance.
254
  
 
In order to assess the weight of these opposing arguments, it is useful to appreciate the 
importance of patent protection to the biotechnology industry. The Canadian biotechnology 
industry is made up of small biotechnology companies
255
 and at the development stage.
256
 Of 
the 470 biotechnology companies in 2007, approximately two-thirds have fewer than twenty 
employees, and one-third have fewer than five employees.
257
 In a survey
258
 involving the 
Canadian biotechnology companies, it has been identified that earlier (start ups) and later 
stage biotechnology companies have different priorities. Start ups companies are generating 
little of product-related revenues and are highly likely to focus on the domestic market.
259
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Consequently, these companies concentrate on funding aspects. Later stage companies which 
were equipped with internal resources converge on retaining and educating employees. 
Nevertheless, notably the survey found that irrespective of the diverse interests, the 
companies at both stages identified protection of patent rights as a key element for success in 
the biotechnology industry where the R&D is known to involve huge investments.
260
 Start 
ups companies require huge investments to develop technology and secure intellectual 
property rights.
261
 Yet the companies struggle to attract investors.
262
  
 
The fact that some transgenic livestock animals have been developed and animal 
biotechnological applications are utilised in Canada will require patent law to support the 
development of the R&D activities which is intrinsically time-consuming and expensive.
263
 
For instance, the R&D on Enviropig has been carried out since 1995
264
 with funding from 
various public and private institutions such as the Agriculture and Agri-food Canada, Ontario 
Ministry of Agriculture, Food and Rural Affairs, Natural Sciences and Engineering Research 
Council of Canada, Rural Economic Development Program of the Ontario Government and 
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Ontario Pork.
265
 Joint funding of animal biotechnology R&D from public institutions and 
private companies as seen here is not exclusive to Canada. The same trend has been identified 
in Europe.
266
 This is not unusual as it has been emphasised
267
 that R&D involving the 
development of products of animal biotechnology cannot be left solely to public funding.
268
 
Two reasons which have been identified are: (1) public funding is often underfunded, 
intrinsically because there are many competing claims; and (2) private research is more 
directly market-based than public research.
269
 Therefore, as private investments are also 
required if the pace of innovation is to accelerate, it has been contended that intellectual 
property protection is necessary.
270
 In the light of these principles, the reaction of investors to 
the Harvard Mouse decision is not surprising.  
 
While patents are territorial in nature (being limited to enforcement in the country of grant), 
the development of a technology often comes down to the broader regulatory environment. 
Nevertheless, critics
271
 have contended that insufficient patent protection in Canada should 
not necessarily have an adverse effect on users‟ willingness to seek patents elsewhere. This is 
because there is a tendency for the Canadians to seek protection in the US because of its 
relative economic size and geographic proximity.
272
 The lack of patent protection in a 
particular country should not be perceived in this way because most stakeholders agree that 
patent protection affects trade in most sectors. 
273
 Overly restrictive policies could result in an 
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outflow of both funds and expertise.
274
 In the long term, the lack of patent protection would 
cause domestic biotechnology companies to suffer due to increased international competition 
for funding and human resource skills.
275
 This could have a dampening effect on the R&D 
activities,
276
 and, eventually, „would leave the country behind in terms of global 
competitiveness in the effort to be an innovative jurisdiction‟.277 Arguably any country which 
lacks patent protection (such as Canada) cannot be immune to this effect.
278
  
 
The contention that the Harvard Mouse adequately protects inventors‟ interest by allowing 
patents to other claims than the resulting animals per se is arguable. The granting of patent 
protection to the end product is important to secure an inventor‟s commercial interest from 
damage by competitors. This is because without any kind of protection to the end product, a 
competitor could simply buy, breed and commercialise a relevant animal invention
279
 while 
leaving the inventor without any remedy. The decision of Percy Schmeiser has responded to 
the reaction of the stakeholders in this respect. Therefore, while animal inventions per se 
remain unpatentable in Canada, the extent of legal protection recognised by the Supreme 
Court through patents of genes and cells would benefit the animal biotechnology, and 
livestock, industry in Canada. Nevertheless, there is a possibility that patent claims to genes 
and cells cannot be made. In this instance, the decision not to allow a patent to animal 
inventions per se where they can: (1) fulfil the patent qualification criteria; and (2) come 
within the broad definition of the term „invention‟ in s2 of the Canadian Patent Act 1985, will 
adversely affect the development of the livestock industry. 
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5. Conclusion 
 
This chapter has shown how Canada deals with the issue of animal patenting in the absence 
of a statutory provision prohibiting the patentability of animal inventions under its patent law. 
Under s2 of the Canadian Patent Act 1985, „any new and useful art, process, machine, 
manufacture or composition of matter‟ may constitute an „invention‟. The patentability of 
animal inventions is seemingly easier to achieve by these broad categories, compared to the 
specific exclusion of animal varieties under Article 53(b) of the EPC. Nevertheless, ironically, 
the Canadian Supreme Court in the precedent case of Harvard Mouse, has adopted a 
restrictive approach where the transgenic mouse (and animal inventions, generally) was held 
to be unpatentable subject matter. Two reasons underpinned this restrictive approach. Firstly, 
that the words and scheme of the current Canadian Patent Act 1985 do not reflect 
Parliament‟s intention to allow patent protection to animal inventions. Secondly, animal 
inventions fail to come within the meaning of the term „manufacture‟ or „composition of 
matter‟ under s2.  
 
In order for the Supreme Court‟s decision to stand, the reasoning should be firmly defended 
according to patent law principles governing the patentability of animal inventions. Through 
various arguments, this chapter has shown that this, unfortunately, is not the case. Section 2 
of the Canadian Patent Act 1985 is modelled from §101 35 USC. There is little doubt that it 
is not necessary that the interpretation of the provisions should reach the same conclusion. 
However, in the light of the alleged inexplicit direction from the Canadian Parliament on the 
patentability of animal inventions, the majority decision in the Chakrabarty case (which 
decided that living matter that fulfils patent prerequisites is an invention within the meaning 
of the term „invention‟ under §101 35 USC) should have been the most persuasive for 
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adoption by the majority in the Harvard Mouse. From another perspective, Canada is a 
commonwealth country whose system of law is derived from English law. As the UK (being 
a Member State of the EPC) would adopt the permissive approach on animal patenting as 
decided by the EPO in the Harvard/Onco-mouse case, it is anomalous that the Canadian 
Supreme Court interpreted the term „invention‟ narrowly and excluded animal inventions 
from the definition. Specifically, this chapter contends that the term „invention‟ under s2 of 
the Canadian Patent Act 1985 is broad enough to cover animal inventions which are capable 
of qualifying as either „manufacture‟ or „composition of matter‟. Underpinning this 
contention is their ability to fulfil the patent qualification criteria (which notably has not been 
refuted by the Supreme Court). In an alternative, while not at all considered by the Supreme 
Court, it has been shown that animal inventions could fall under the term „art‟ under s2 which 
denotes an extensive meaning of „learning‟ or „knowledge‟.   
 
Article 27.3(b) of the TRIPs Agreement allows Signatories to exclude „animals‟ and 
„essentially biological processes‟ from the patent regime. Nevertheless, „microbiological 
processes and products‟ derived from it are patentable. Underpinning this division is the 
aspiration of patent law to protect animal inventions which involve technical intervention and 
meet patent prerequisites. It aims at recognising the inventive effort of inventors in promoting 
innovation. Conversely, products of nature are to be left out of the regime due to the absence 
of human ingenuity. The European-wide permissive approach to animal patenting adopted 
through the case of Harvard/Onco-mouse gives effect to the patent law principles underlined 
by Article 27.3(b). In that, patent protection was allowed to the relevant transgenic mouse 
which was held not to be an animal variety. This chapter has shown that while Canada is also 
a Signatory to the TRIPs Agreement, the decision of the Supreme Court not to allow patent to 
the transgenic mouse (notwithstanding being able to fulfil the patentability criteria, and 
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qualify as a product of microbiological process) runs contrary to the requirement of Article 
27.3(b). Eventually, Canada fails to meet its international obligations. 
 
The restrictive approach to animal patenting adopted by the Canadian Supreme Court 
conforms to government policies. Politically, a strong view was raised during the Uruguay 
Round Meeting of the TRIPs Agreement that animal inventions should not be patentable. The 
pessimistic political view is consistent with the slow development of regulatory framework 
for the assessment and approval of animal biotechnology food which is underpinned by the 
Food Directorate Interim Policy on Foods from Cloned Animals. The Policy restricts the 
development and use of the food due to the absence of pre-market safety assessment of the 
products. To date, the assessment guidelines for novel animal food remained unavailable 
notwithstanding the long period and various seeming efforts undertaken by the government to 
develop the system and documentation. This reflects the government‟s lack of interest to 
promote the use and marketing of the products. Consumers‟ negative perspective towards 
animal biotechnology food has been identified as playing a major role in the strict policy 
adopted by the government. This scenario in Canada is immensely different from the position 
in Europe where the progression of the animal biotechnology sector and the potential 
marketing of livestock products derived from it is supported by many aspects. The absence of 
any restriction allows active R&D activities (including genomics research to improve the 
quantity and quality of livestock products) with huge investment from the EU, public 
institutions and private companies. In addition, the availability of pre-market safety 
assessment facilitates the marketing of the potential products. Of equal importance, the 
decision of the EPO to allow patent protection to animal inventions will enhance innovation 
and investment in the sector. As regards public opinion, it is widely accepted that it is 
pertinent in policy-making decision. However, in terms of whether or not animal 
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biotechnology applications are to be utilised in full for the creation of animal biotechnology 
food so as to ensure sustainable production of livestock products for the population, the 
European-wide permissive approach rightly demonstrates that the opinion should not be the 
decisive factor. Rather, the decision is to be grounded on the myriad of challenges 
underpinning the problem to secure the food supply, which eventually necessitates the 
technology‟s intensive use.  
 
The Harvard Mouse decision has raised divided responses from stakeholders of the Canadian 
biotechnology industry. On the one hand, for the proponents of patent, the decision would 
have a chilling effect on the development of the industry, in particular the R&D activities. On 
the other hand, there have been arguments that the decision would not adversely affect the 
industry as sufficient patent protection could be secured by inventors. This is because, claims 
other than the end product (the transgenic mouse) have been allowed. In this regard, Percy 
Schmeiser appears to be a quick legal response to the criticisms against the Harvard Mouse 
and „remedy‟ the predicted negative implications. However, it should be noted that the 
decision does not change the restrictive approach to animal patenting adopted by the Harvard 
Mouse. Notwithstanding this, the case has underlined an important patent law principle where, 
the use of patented genes and cells embodied in animal inventions amounts to infringement of 
the patent rights of the patentee. Therefore, while animal inventions per se are unpatentable 
in Canada, the findings of the Percy Schmeiser may adequately protect the commercial 
interests of a patentee and investors. Nevertheless, in the event where patents to genes and 
cells cannot be claimed (for not being able to meet the patent qualification criteria) animal 
inventions which are otherwise able to meet patent prerequisites will not be legally protected. 
Consequently, this will hinder inventors from developing animal inventions, and, investors 
from investing, in the animal biotechnology industry. Therefore, unlike the European-wide 
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permissive approach, the restrictive approach is not able to maximise the potential of animal 
biotechnology applications. As a result, it remains challenging for the livestock industry to 
meet the growing demand from the population. The next chapter will conclude the thesis 
where, in the light of the findings, of this chapter, and the four previous core chapters, an 
assessment of both the permissive and restrictive approaches will be made in the context of 
Malaysia. This eventually answers the research questions.  
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DISCUSSION AND CONCLUSION:  
A WAY FORWARD FOR MALAYSIA 
 
Discussion 
 
A patent is meant to recognise the intellectual contribution of an inventor for creating an 
invention which benefits society. However, animals have been explicitly recognised to be 
excluded from the patent regime. As a result, their exclusion is contained in Article 27.3(b) of 
the TRIPs Agreement and other national patent laws (discussed in chapter 2). Nevertheless, 
the meaning of terms used to represent the excluded matter (for example, „animals‟ or 
„animal varieties‟) is not explicit. This creates uncertainty for one of the most pertinent 
aspects of patent law, namely the nature of the patent protection which an applicant is entitled 
to. This thesis focuses on the exclusion of animal varieties in s13(1)(b) of the Malaysian 
Patents Act 1983 which experiences the same ambiguity, and aims to suggest how it can be 
resolved. Towards this end, two research questions were formed at the beginning of the thesis 
(Introduction). In this discussion section the questions are revisited and an assessment is 
made in the context of Malaysia, based on the arguments and conclusions from the previous 
chapters. In essence, the chapter aims to answer the research questions and to suggest a way 
forward for Malaysia, in terms of how it should interpret its exclusionary provision. 
 
The first research question is: how can the exclusion of animal varieties under s13(1)(b) of 
the Malaysian Patents Act 1983 be interpreted?  This thesis has shown that the exclusion can 
be construed either narrowly or broadly. Underpinning the options are two models of 
interpretation which so far have been adopted by countries which are Signatories to the 
TRIPs Agreement, namely the permissive approach (of the European-wide, discussed in 
chapter 4) and the restrictive approach (of Canada, discussed in chapter 5). The TRIPs 
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Agreement plays an important role in the existence of these approaches. Being the „umbrella‟ 
international patent law text, the exclusion of matters relating to animals under Article 27.3(b) 
was formed in a flexible manner (chapter 2). Fundamentally, the provision allows Signatories 
to exclude „animals‟ and „essentially biological processes‟ from patentability. Nevertheless, 
„microbiological processes and products‟ derived from it are patentable. The flexibility is the 
result of negotiations among the Member States of the WTO which have different levels of 
economic and technological development. Most developed countries with strong economic 
and scientific advancement (such as the US, Japan and Australia) urged that the TRIPs 
Agreement provides that animal inventions be explicitly patentable. Intrinsically it aims to 
ensure that the commercial interests of their inventors are secured globally. Conversely, many 
developing countries (for instance, Argentina and Brazil) perceived the inventions as 
products of nature (discoveries), and so argued that they cannot be patented.
1
 Underpinning 
this argument is their lack of ability to benefit from the strengthened patent protection, which 
would eventually benefit their developed counterparts, hence widening the economic gap 
between them.  
 
The flexibility accorded by Article 27.3(b) is pertinent in the context of the international 
obligations imposed by the TRIPs Agreement on its Signatories. Only through flexibility on 
such a contentious issue would negotiating countries agree to the provision, hence securing 
the conclusion of the TRIPs Agreement. Most notably, the flexibility demonstrates that each 
Signatory has the right to determine how the exclusion of animal inventions is to be 
construed and utilised. Yet this thesis argues that for a developing country which includes the 
                                                          
1
  See for instance, GATT, „Communication from Argentina, Brazil, Chile, China, Colombia, Cuba, Egypt, 
India, Nigeria, Peru, Tanzania, Uruguay‟, Document MTN.GNG/NG11/W/71 (14 May 1990) Article 4(1), 8; 
WTO, „Review of the provisions of Article 27.3(b): Summary of issues raised and points made‟, Document 
IP/C/W/369/Rev.1 (9 March 2006) 4; J. Carr, Agreements that divide: TRIPs vs CBD and proposals for 
mandatory disclosure of source and origin of genetic resources in patent applications (2008) 18 Journal of 
Transnational Law and Policy, 1, 131-154. 
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exclusion in its national patent law, there are some pertinent aspects and issues which must be 
considered in interpreting the provision (chapter 2). This is because any interpretation will 
have broader social and economic implications. This contention is further elaborated here in 
the context of Malaysia.  
 
Section 13(1)(b) of the Malaysian Patents Act 1983 and Article 53(b) of the EPC share a 
similar legislative background (chapters 3 and 4). Animal varieties are excluded under both 
patent law texts without clear intention or direction from the framers as to what is the 
meaning of the term „animal varieties‟ itself and, therefore, the subject matter of the 
exclusion. An important lesson that Malaysia can learn from Europe is that, notwithstanding 
the „deficiencies‟, the exclusion has to be construed so as to promote national interests. This 
is precisely the principle which Malaysia should pursue in the light of the flexibility granted 
by Article 27.3(b). While the country can either construe the exclusion of animal varieties 
under s13(1)(b) narrowly or broadly, putting the legal provision in the context of its key 
national interest will assist the country to achieve the interpretation which works in practice.  
 
Similar to other developing countries, food security is a pertinent issue for Malaysia (chapter 
1). In this respect, notwithstanding the shift of economic focus toward industry in the 1980s 
and the mid-1990s, agriculture remains one of the country‟s key economic drivers. Livestock 
animals and fish, and their products, have been an important animal-protein based source for 
Malaysians. The demand for the products from the population is growing as their income 
increases. This trend of consumption differs from that of the population of developed 
countries which focuses on the quality of the products (such as leaner meat and their 
environmental impact). Notwithstanding this, there has been evidence that the population in 
developing countries (including Malaysia) is venturing into the quality aspects of animal-
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protein based food as their knowledge, in particular of health-related issues, advances. The 
production of food in Malaysia has been increasing in tandem with demand. Nevertheless, a 
self-sufficiency level in main livestock products has been identified as Malaysia‟s long-term 
challenge, despite the continued efforts adopted by the government (chapter 1). These include 
the increase of grazing reserves, promotion of good husbandry practice and improvement of 
marketing strategies. The main factors, which have been identified as causing the problem 
and have proved difficult to manage, are the shortage of breeding stock and fish seed; risk of 
livestock and aquatic diseases; and constraints of animal and fish feed.  
 
Animal biotechnology can create products which are not achievable through traditional 
breeding techniques (chapter 1). Most notable are genetic engineering and cloning methods 
which produce optimum yields through the sustainable creation of livestock animals and fish 
(for example), which grow faster and are disease resistant.
2
 The benefits of these scientific 
methods cannot be doubted, but consumers have been very cautious about animal 
biotechnology food.
3
 Concerns relating to the products are mostly associated with the 
implications arising from their consumption for human health and the environment. While 
consumers have the right to be cautious, due to the non-traditional procedures which are 
involved in creating the food, there is ample scientific evidence that they are safe for human 
consumption and for the environment. Most convincing are the views published by the 
international food authorities including the USFDA, EFSA and UKFSA about their safety for 
human consumption, which are underpinned by years of rigorous scientific research (chapter 
                                                          
2
  Other qualities of the animals which have been the focus of the populations of developed countries, and 
would inevitably be followed by Malaysians in the future include: high quality meat; good taste; high 
nutrients; and protection of the environment. 
3
  As a response to animal biotechnology, opponents have argued that consumers should avoid animal products 
altogether, but as identified, it is not clear how many people will feel strongly enough to adopt a vegetarian 
diet in response to the developments in technology. See A. Bruce, Regulation of cloned farm livestock, 
Economic and Social Research Council, 2007, 
http://www.genomicsnetwork.ac.uk/media/Regulation%20of%20Cloned%20Farm%20Livestock.pdf 
(Accessed: 13 March 2012). 
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1). In this respect, the thesis argues that consumers‟ pessimism toward animal biotechnology 
food can be managed through appropriate information and knowledge about the benefits of 
the products. Malaysians‟ perception can also be improved in similar ways (chapter 1).  
 
One of the practices within livestock breeding is the trans-boundary movement of the animals 
for reasons such as to meet a sudden decline of breeding stock in neighbouring countries due 
to livestock diseases, and livestock auction (chapters 1 and 5). A similar practice is relevant 
for their transgenic counterparts, and it causes concern to consumers. The thesis asserts that 
any implications for human health and the environment which arise from the trans-boundary 
movement of the LMOs (including transgenic animals for food) are adequately covered by 
the Cartagena Protocol (chapter 1). The aspect of the Protocol which contributes to this is the 
requirement to subject intended trans-boundary movement of the LMOs to obtaining the prior 
informed consent of the importing Party or notification procedures, and their identification in 
international shipment (chapter 1). Another important feature of the Protocol is that Parties to 
the Protocol may fully utilise the right to impose relevant conditions in national biosafety 
laws so as to reduce potential risks arising from the movement (chapter 1). In addition, patent 
law principle as underlined by the Canadian Supreme Court in the Schmeiser case, which 
holds a benefiting infringer as liable for infringing a patentee‟s right (chapter 5) should have 
also alleviated the consumers‟ unease mentioned here. While the rule stems from a case 
which involves the trans-boundary movement of plant invention, it is similarly applicable to 
animal biotechnology food. 
 
Due to the continued problem of self-sufficiency levels faced by the Malaysian livestock 
industry, it becomes clear that the country cannot continue to depend on current efforts to 
supply animal-protein based food to its population. Assistance is required from animal 
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biotechnology. The promises of the technology have led to the strong aspiration of the 
Malaysian Government to fully utilise the technology to enhance the country‟s food 
production (chapter 1). It aims at the country‟s dependence to imported products, which are 
increasing significantly every year, to be reduced (chapter 1). Broadly, various efforts have 
been made, and incentives offered, by the government in order to support the biotechnology 
sectors. Mainly, it is the increase in government investment, allocated to the industry, which 
amounts to MYR2,021.3 billion in the Ninth Malaysia Plan (2006-2010) compared to 
Malaysian Ringgit MYR574.4 million in the Eighth Malaysia Plan (2001-2005).
4
 There are 
also some other pertinent efforts which are worth mentioning here. One of them is the 
creation of the Agro-Biotechnology Institute Malaysia which „undertakes research, 
development and commercialisation projects pertaining to agriculture biotechnology in co-
operation with various research and higher leaning institutions and industry players‟. 5 
Another notable effort is the granting of BioNexus status which aims to attract foreign 
investments. International and local biotechnology and life science companies which achieve 
the status are eligible for various incentives under the country‟s Bionexus Bill of Guarantees.6 
The incentives include freedom to bring in knowledge workers, eligibility for import duty and 
sales tax exemptions on approved biotechnology equipment and materials, and entitlement to 
strong intellectual property protection.
7
 While these endeavours are not exclusive to the 
                                                          
4
  Biotechnology for Wealth Creation, Chapter 6, The Ninth Malaysia Plan (2006-2010), 
http://www.digitallibrary.my (Accessed: 9 October 2009) 168. MYR is the abbreviation for „Malaysian 
Ringgit‟ which is the currency of Malaysia. 
5
   National Biotechnology Division, Ministry of Science, Technology and Innovation, Malaysia 
http://www.biotek.gov.my/index.php?option=com_content&view=article&id=64&Itemid=63 (Accessed: 21 
April 2012). 
6
  Available at: Malaysian Biotechnology Corporation, Bionexus: A special award for an exceptional group 
http://www.biotechcorp.com.my/bionexus-new/ (Accessed: 21 April 2012). For full details of the Malaysian 
Bill of Guarantees, see Appendix 2. 
7
  ibid. Starting with only seven BioNexus companies in 2006, there were one hundred and thirty five 
companies comprising local and international companies at the end of 2009. Speech of the 5
th
 Prime Minister 
of Malaysia, His Excellency Datuk Seri Abdullah bin Haji Ahmad Badawi, at the official launch of 
BioMalaysia 2006, 6 December 2006,  http://www.pmo.gov.my (Accessed: 20 November 2009); New Straits 
Times, 50 more BioNexus firms in 2 years, 17 November 2009. This BioNexus status has so far continued to 
attract international investment such as from the UK, the US, France, Germany, Italy, Belgium, India, China, 
Japan, Taiwan, Hong Kong, Singapore, Thailand, Australia and New Zealand. It has been reported that the 
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animal biotechnology sector, they are of utmost relevance and important to it, being a 
pertinent sector intended for development in Malaysia and identifying a general commitment 
to this technology. 
 
In the light of the problems which the Malaysian livestock industry is facing and the explicit 
commitment of the government „to provide strong intellectual property protection regime to 
support R&D and commercialisation efforts‟,8 s13(1)(b) has to be construed in a way which 
will ensure that what is expected from the animal biotechnology sector is achieved. In other 
words, the exclusionary provision must play its role in supporting the technology and 
livestock industry. Otherwise, the aspirations, efforts and investment of the government will 
be hampered. This relates to the second research question: which of the permissive or 
restrictive approaches is the most practical for Malaysia to adopt? This thesis argues that 
Malaysia has to adopt the permissive approach if its livestock industry is to be enhanced so as 
to assist the country in meeting the growing demand for animal-protein based products from 
the population. This contention is further supported here.  
 
The permissive approach is underpinned by the importance of patents of animal inventions 
for the development of biotechnology and the economy.
9
 R&D activities for the purpose of 
creating animal biotechnology food are known to be expensive and time-consuming because 
they involve highly skilled workers, modern facilities, and extensive and rigorous research to 
achieve the required output. Within this, investment and technology transfer are two pertinent 
                                                                                                                                                                                    
Bionexus companies, as a group, have substantially contributed to the creation of knowledge workers in 
Malaysia. In 2008, there was a 382% increase of knowledge workers to 1,851 from only 384, in 2007.  
Malaysian Biotechnology Corporation, BiotechCorp Annual Report 2008, http://www.biotechcorp.com.my 
(Accessed: 21 December 2009) 12. 
8
  Which is explicitly underlined in Thrust 7 of the Malaysian National Biotechnology Policy. See Appendix 1. 
9
  The UK Supreme Court has explicitly recognised the importance of patents as an incentive to innovation in 
any sector (not limited to the pharmaceutical industry which is relevant to the case). See Human Genome 
Sciences Inc v Eli Lilly and Company Limited [2012] RPC 6, paragraph 98-99. 
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aspects which are closely related to patents. There has been evidence which shows that 
patents are able to attract FDI (chapter 2), and are being used as a principal criterion by 
venture capital firms to funding requests from biotechnology firms (chapter 5). Intrinsically, 
this is because patents demonstrate the research activities of a given firm. Active research 
would generate more patents, which leads to commercial gain due to their licensing. In the 
context of the thesis, this rule underpins the reluctance of developed countries to invest in the 
R&D activities of countries which lack patent protection for animal inventions (including 
developing countries) (chapter 2). Nevertheless, it has been identified that developing 
countries need to have the relevant technological capacity to adapt the technology to local 
interests (chapter 2).  
 
This thesis contends that allowing patents to animal inventions in accordance with the 
permissive approach will benefit the Malaysian livestock industry, because the country has 
the technological ability in animal biotechnology. In evidence, to date, while only artificial 
insemination is widely applied, other more advanced applications such as gamete and gene 
manipulation for the production of sexed embryos, embryo transfer and embryo 
cryopreservation are already at the research stage in various research and higher learning 
institutions in the country (chapter 1). Although Malaysia has the necessary expertise to use 
the applications, it appears that much knowledge and technologies are still required by local 
scientists to enhance their technological knowledge before they can work independently to 
fully develop the industry. This can be achieved through research collaboration with experts 
from developed countries.  
 
Another important point which has been identified by the thesis is that R&D activities 
involving animal biotechnology also require investment from private companies, as public 
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funding has many competing claims (chapter 5).
10
 Allowing patents to animal inventions 
under the Malaysian Patents Act 1983 will encourage the collaboration which brings together 
the transfer of technology from the technologically developed (which are mostly developed) 
countries to Malaysia and investment from private companies. Strengthened patent protection 
is not to be perceived as only benefiting foreign scientists. Malaysian scientists will similarly 
benefit from it. In this respect, so as to safeguard the sharing of technology of foreign origin 
with local scientists in R&D activities relating to animal biotechnology, and to encourage the 
competition between local scientists and foreign scientists in terms of patent applications, 
conditions similar to those stipulated by § 204 of the USC Bayh-Dole Act 1980
11
 (pertaining 
to the preference of local industry) should be introduced into the Malaysian Patents Act 1983. 
Mainly, the provision stipulates that an invention must be manufactured in the US unless 
there is lack of local capacity.
12
 In this respect, it should be noted that the Malaysian 
Government has been encouraging local scientists and researchers to obtain patents for newly 
developed biotechnological inventions (chapter 1). As a result, many have protected their 
commercial interests through patents for products such as DNA sequence coding for various 
proteins and vaccines and animal feed (chapter 1). Patent protection for animal inventions per 
se widens the subject of patentable matter, and hence encourages them to be more innovative 
in creating animal biotechnology food to fulfil the demand from the population.  
 
                                                          
10
  Some of the pertinent proposals made by the OECD to boost research of agricultural biotechnology are by 
increasing public research investment, reducing regulatory burdens and encouraging private-public 
partnerships. OECD, The Bioeconomy to 2030: Designing a Policy Agenda, 2009, 
http://www.oecd.org/dataoecd/5/24/42837897.pdf (Accessed: 6 May 2012) 6. 
11
  The Act is chapter 18 of 35 USC (the US Patent Act). Available at: USPTO, United States Code Title 35 – 
Patents, http://www.uspto.gov/web/offices/pac/mpep/consolidated_laws.pdf (Accessed: 21 June 2012). The 
Act was introduced so as to allow universities and other research institutions to own and control patents for 
inventions which arise from their scientific research that is funded by the US Government. This incentive 
aims at attracting the private sector to invest in biotechnological inventions, hence, rigorously developing 
and commercialising the relevant inventions. 
12
  ibid. 
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In Europe, the active animal biotechnology R&D activities which are carried out throughout 
the region stems from the optimism that the technology can relieve the region of dependence 
on imported feed, and assist in the sustainable development of its livestock industry (chapter 
4). The activities are funded by both public and private organisations. In addition, the 
regulatory framework to assess the safety of the products derived from the technology is 
already in place. These aspects facilitate the growth of the technology, and ultimately, the 
marketability of the products. The patentability of animal inventions through the permissive 
approach further supports technological development, as the creation of the inventors can be 
legally protected. Conversely, Canada‟s pessimistic view toward animal patenting which has 
been explicit since the issue of animal patenting and was discussed during the Uruguay 
Round Meeting, has a stalling effect on the development of animal biotechnology 
applications in the country (chapter 5). Consequently, in comparison to Europe, the animal 
biotechnology industry has not been the focus of the Canadian Government. It is pertinent to 
note that the country‟s later policies relating to animal biotechnology appear to be consistent 
with its earlier political view. Most notable is the Food Directorate Interim Policy of Foods 
from Cloned Animals which remains in place to date. The Policy contains the specific 
restriction that manufacturers of cloned animals must not sell the products or by-products of 
any cloned animals or their progeny in the human food supply in Canada unless they have 
been subjected to the pre-market safety assessment. Subjecting the production to the 
assessment is most logical given the concerns which consumers may have. However, the 
failure of the Canadian Government to come up with the necessary assessment guidelines 
after more than a decade of planning, demonstrates their reluctance to govern and promote 
animal biotechnology food and relevant technology. Therefore, it is doubted if the products 
of this technology will ever reach the market.  
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It can be concluded from this thesis that the two approaches toward animal patenting 
correspond with a region‟s or a country‟s broader policies and perceptions of animal 
biotechnology. The permissive approach is in line with Europe‟s optimistic policy toward 
animal biotechnology, whereas the restrictive approach is equivalent to Canada‟s pessimistic 
view of the technology. It has been shown that Malaysia has a clear expectation from, and 
direction for, its animal biotechnology industry. Arguably, this corresponds with Europe‟s, 
rather than Canada‟s policies. Consequently, it is only reasonable that Malaysia should adopt 
the permissive approach in order to ensure that the objective it sets forth is achieved. In terms 
of the regulatory framework for assessing the pre-market safety of animal biotechnology food, 
while being an area which has not yet been tested in Malaysia, it should have been covered 
by the existing Biosafety (Approval and Notification) Regulation 2010.
13
  
 
In tandem with this, another marked contrast between the permissive and restrictive 
approaches is the role of consumers‟ opinion towards animal biotechnology food in the 
adoption of each approach. In contrast to the European-wide permissive approach (chapter 4), 
the restrictive approach is also underpinned by the pessimistic attitude of Canadians to the 
use of the products (chapter 5). There is little doubt that public opinion is pertinent in policy-
making decisions, given that the public are the end-users of the technology. However, it has 
been identified by this thesis that the pessimistic view of the public is not necessarily 
informed by scientific evidence (chapter 1). As a matter of fact, opinion could become 
positive if consumers are appropriately and adequately educated about the benefits of the 
                                                          
13
  Section 3 of the Malaysian Biosafety Act 2007 defines „living modified organism‟ „as: „any living organism 
that possesses a novel combination of genetic material obtained through the use of modern biotechnology‟. 
In turn, „modern biotechnology‟ is defined as: „the application of (a) in vitro nucleic acid techniques, 
including recombinant deoxyribonucleic acid (DNA) and direct injection of the nucleic acid into cells or 
organelles; or (b) fusion of cells beyond the taxonomic family, that overcome natural physiological 
reproductive or recombinant barriers and that are not techniques used in traditional breeding and selection.‟ 
These definitions resemble Articles 3(g) and (i), respectively, of the Cartagena Protocol. 
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technology.
14
 It is argued that in the light of the myriad of challenges underpinning the effort 
to attain food security for Malaysians, the permissive approach has rightly demonstrated that 
the decision to either adopt or to reject the technology and products derived from it should be 
based on the potential of animal biotechnology applications to meet expectations, rather than 
be decisively based on opinion of consumers. In addition, as animal biotechnology food is 
subject to a range of regulation
15
 before its use is allowed (chapters 4 and 5), the safety of the 
product cannot be a valid argument for their exclusion from patenting. 
 
The permissive approach aims to ensure that an inventor, whose invention fulfils the patent 
qualification criteria, can be granted patent protection. This rule is the crux of innovation. 
The pertinent aspects of the review of Article 27.3(b) and restrictive approach require 
assessment at this juncture. This thesis asserts that animal inventions are able to fulfil the 
patent qualification criteria. It should be noted that even the Canadian Supreme Court which 
denied patents to the Harvard Mouse did not refute the ability of the transgenic mouse to 
fulfil the criteria (chapter 5). Therefore, there is no doubt that the inventions could be 
patentable. The argument by some developing countries during the review, that animal 
inventions are discoveries (thus should not be patentable) (chapter 2), neglects the basis of 
patent law which only grants protection to animals which do not occur naturally. This rule 
underpins the distinction between the patentable and unpatentable matter under Article 
27.3(b), which recognises that products of nature are not to be patentable, but requires a 
Signatory to grant patents to products of human ingenuity.  
                                                          
14
  See for instance, L.J. Butler, M.M. Wolf and S. Bandoni, Consumer attitudes toward milk products produced 
from cloned cows (2008) 39 Journal of Food Distribution Research, 1, 35; L. Amin, J. Md Jahi, A.R. Md 
Nor, M. Osman and N.M. Mahadi, Uncovering factors influencing Malaysian public attitude towards 
modern biotechnology (2006) 14 Asia-Pacific Journal of Molecular Biology and Biotechnology, 2, 36. 
15
  For instance, Regulation (EC) No 1829/2003 on the placing on the market of GMO food and feed or food 
and feed products containing or consisting of GMO (EU); Directive 2001/18/EC on the deliberate release 
into the environment of GMOs (EU); Standard 1.5.2 - Food Produced Using Gene Technology 1998 
(Australia and New Zealand); and the Biosafety (Approval and Notification) Regulations 2010 (Malaysia). 
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Modern biotechnology applications such as genetic engineering are able to create novel 
animals within patent law. Therefore, animals which fulfil patent qualification requirements 
should be protected. The restrictive approach adopted by the Canadian Supreme Court in not 
allowing patent to animal inventions and the meaning of the term „invention‟, lacks legal 
reasoning and fails the required obligation imposed by Article 27.3(b) (chapter 5). The terms 
„art‟ or „composition of matter‟ or „manufacture‟ under s2 of the Canadian Patent Act 1985 
are broad enough to cover the inventions (chapter 5). In this, so as to give effect to Article 
27.3(b) the Supreme Court had to determine that the transgenic mouse is patentable. 
Alternatively, being a product of a microbiological process (genetic engineering), the 
transgenic mouse should be eligible for patent protection. In the context of Malaysia, the 
adoption of the permissive approach would ensure that the country fulfils its international 
obligation which falls short of the restrictive approach. These are other reasons why the 
permissive approach is advocated for Malaysia.  
 
Malaysia has taken various stances during the review process of Article 27.3(b). Among 
others, that: (1) the flexibility under Article 27.3(b) should be maintained;
16
 (2) the flexibility 
is to be exercised with conditions. Signatories which allow patents on plants and animals, 
should strictly fulfil the criteria under Article 27.1, whereas Signatories which have chosen to 
exclude plants and animals are justified in doing so on the basis that they are discoveries 
rather than inventions;
17
 and (3) Signatories could demonstrate the importance of the CBD 
concepts by enacting national legislation that incorporates the relevant provisions of the 
                                                          
16
  WTO, „Council for Trade-related Aspects of IPRs Minutes of Meeting‟, Document IP/C/M/29 (6 March 
2001) para 204-205. 
17
  WTO, „Council for Trade-related Aspects of IPRs Minutes of Meeting‟, Document IP/C/M/30 (1 June 2001) 
para 179. 
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Convention in order to achieve wider international recognition.
18
 Nevertheless, it is also 
notable that Malaysia has explicitly recognised that patents are important in encouraging 
R&D in biotechnology.
19
 These principles represent the country‟s policies where, while 
intending to utilise animal biotechnology applications to the fullest for its livestock industry, 
the country (being a Signatory to the CBD)
20
 puts equal emphasis on the importance of the 
conservation of biodiversity (including animal resources) for its sustainable development. In 
this respect, the requirement for mandatory disclosure of the source and country of origin of 
animal genetic resources involved in animal inventions is an issue which has also been 
advocated by developing countries during the review of Article 27.3(b) (chapter 2). 
Underpinning the requirement is the prior informed consent of developing countries which 
are widely accepted as producers of genetic resources, and benefit-sharing of profits from an 
invention developed using the genetic resources.  
 
It is pertinent for Malaysia to assess the implications of the proposed mandatory disclosure 
requirements for the progression of animal biotechnology, and its livestock industry. This 
thesis contends that the requirements should be encouraged rather than be made mandatory 
(chapter 2). Underpinning this proposal is the intrinsic problem of identifying the country of 
origin (where the animal genetic resource is indigenous) precisely. It can be too burdensome 
for an applicant (including local innovators) if the granting of patents is conditional upon 
fulfilling this requirement (chapter 2). In the context of the thesis, as farm animals have been 
subject to trans-boundary movement for thousands of years, precise identification appears to 
be almost impossible. The problem in identifying the true providers of the genetic resources 
poses other challenges for an applicant, namely to obtain prior informed consent and ensure 
                                                          
18
  WTO, n 16 above, ibid. 
19
  ibid. 
20
  Malaysia signed the CBD on 12 June 1992, and has ratified the same on 24 June 1994. See CBD, 
http://www.cbd.int/convention/parties/list/ (Accessed: 31 March 2011). 
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that commercial benefits arising from the inventions are equally shared. These hurdles to 
obtaining patents will unnecessarily discourage investment in R&D activities relating to 
livestock animals, and ultimately adversely affect the livestock industry in Malaysia. As an 
alternative, it is proposed that Malaysia considers attaching the disclosure requirements as a 
condition for the enforcement of the granted national patents (in accordance with Article 62 
of the TRIPs Agreement) rather than a prerequisite to obtain patent protection (chapter 2). 
Apart from serving the interests of the country under the CBD (where the obtaining of local 
genetic resources by foreign inventors can be appropriately monitored), it would ensure that 
Malaysia fulfils its obligation to grant patents to animal inventions under Article 27.3(b). 
Similarly, the option would encourage the flow of investment and progress of innovation. 
 
In terms of plant varieties which are similarly excluded under s13(1)(b), it is notable that 
Malaysia has already in place the New Plant Varieties Protection Act 2004
21
 which gives 
intellectual property rights to breeders of a new plant variety. In essence, the Act protects the 
rights of the breeders of plant varieties which fulfil the requirements under the UPOV 
Convention. It is worthy of note that there is not yet a statute which gives sui generis rights to 
animal varieties in Malaysia. Intrinsically this is because the concept of animal varieties 
(equivalent to plant varieties) has not yet been established (not only in the country, but also 
worldwide).
22
 In this regard, the argument which underpins the restrictive approach, that it is 
open for the legislature to enact tailor-made legislation for animal inventions (chapter 5) has 
little foundation. The creation of animal inventions for food purposes is proceeding, and as 
already argued, the inventions are able to fulfil the patentability criteria. Without patent 
protection, they will be left without any legal protection and this will eventually bring social 
                                                          
21
  Act 634. The Act came into force on 1 January 2007, and is available at: WIPO, 
http://www.wipo.int/clea/docs_new/pdf/en/my/my040en.pdf (Accessed: 16 April 2012). 
22
  Although some countries such as India and the Czech Republic have extended the plant varieties concept to 
establish sui generis systems for animal breeders in the countries. See discussion in section 3.3 of chapter 4. 
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and economic repercussions to Malaysia due to the problem of adequately supplying the 
population with animal-protein based food. Conversely, allowing patent protection to animal 
inventions ensures that they are legally protected before any alternative protection (such as 
the sui generis systems) can be established and more importantly, proven to be efficiently 
enforced. The permissive approach explicitly recognises the importance of patents to animal 
inventions and precisely anticipates the implications for its absence, which the restrictive 
approach fails to do.  
 
Another issue relating to the restrictive approach which needs discussion is why patents are 
pertinent to animal inventions per se where process, and other claims relating to the 
inventions (such as cell cultures, plasmids and vectors) have been allowed by the CIPO. 
Patent claims (and protection) need to be broad enough so as to fully cover an inventor‟s 
interests and prevent a competitor from claiming that he does not infringe the patents of the 
original inventor through trivial improvement to the invention.
23
 In this way, patents solve the 
„free-riding‟ problem, and allow the original inventor to recoup the cost of the invention.24 
While patents to process and other claims pertaining to animal inventions give an applicant 
the required protection, the whole end-product is not necessarily protected from trivial 
improvement by competitors. This is unless a provision in national patent law explicitly 
extends the patents granted (for instance) to genetic material for the animals in which it is 
placed.
25
 It is on this basis that patents to animal inventions per se are pertinent. A concern 
with too broad patent protection is that monopoly rights will be concentrated in only a few 
hands, causing a stifling effect on technological development as competitors refuse to 
                                                          
23
  S.J.R. Bostyn, A European perspective on the ideal scope of protection and disclosure requirement for 
biotechnological inventions in a harmonised patent system: The quest for the holy grail? (2002) The Journal 
of World Intellectual Property, 1013. 
24
  ibid. 
25
  For instance, as explicitly provided under Article 8(1) of the EU Biotechnology Directive. For the full 
provision, see footnote 153 in sub-section 3.2.3 of chapter 4.  
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improve the technology.
26
 It is argued that the permissive approach, which allows patent 
protection to animal inventions per se, cannot be taken as allowing too broad a scope of 
protection to an inventor. This is because patent law has already anticipated and safeguarded 
this potential problem through the enablement requirement, which limits an applicant to 
obtaining patents only for claims which can be supported by sufficient disclosure.
27
 It is 
worth noting that this was the fundamental problem with patenting the Harvard Onco-mouse 
in Europe.  
 
The thesis discussed the argument by critics that licensing of patents will cause a barrier for 
technology transfer to developing countries (chapter 2). It is pertinent to put this contention in 
the context of the thesis. As the livestock industry in developing countries is mainly 
dominated by small-scale farmers (generally with limited financial resources), a question 
which may be raised is: how can the breeders benefit from the expensive cost of 
biotechnology? This question is particularly relevant to Malaysia. For instance, in 2008, 
cattle breeders in Malaysia were estimated at 41,838 persons.
28
 The majority of them are 
small-scale breeders, with only 478 commercial and 675 semi-commercial breeders.
29
 Due to 
the nature of their breeding activities, intrinsically small-scale breeders may not be able to 
independently utilise the technology discussed here. Nevertheless, it is premature to conclude 
that the costs of licensing will hinder the utilisation of this technology, and adversely affect 
small-scale breeders in Malaysia. This is because (apart from the widely applied artificial 
                                                          
26
  ibid. 
27
  This is a requirement (for instance) under Article 84 of the EPC; s14(5) of the UK Patents Act 1977.  
28
Department of Veterinary Services Malaysia, Annual Report 2008, 
http://www.dvs.gov.my/web/guest/penerbitan  (Accessed:  25 October 2010). „Commercial‟ and „semi-
commercial‟ breeders are terms generally used in reference to the number and category of livestock breeds. 
For instance, a commercial breeder of poultry breeds 50,000 birds, whereas semi-commercial breeders breed 
fewer than 50,000 but more than 5,000 birds. For cattle breeders, a commercial breeder has 100 cattle, and 
those who have fewer than 100 but more than 40 cattle are considered as semi-commercial breeders. 
Breeders below the semi-commercial category are considered small-scale breeders. Personal communication 
with an official of the Department of Veterinary Services Malaysia dated 1 March 2011. 
29
  ibid. 
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insemination) the more advanced applications (such as embryo transfer and embryo 
cryopreservation) are still in the research stage which is currently undertaken by various 
public research and higher learning institutions (chapter 1). Consequently, the aspect of the 
licensing cost of this technology should be within the management of the institutions (where 
the Malaysian Government has to play its role), rather than becoming the concern of the 
individual breeders. Therefore, any decision not to allow patent protection to animal 
inventions in view of the assumption that licensing impedes the use of the technology is 
unsupportable. 
 
This thesis has shown that the Malaysian Patents Act 1983 comes in two versions, namely 
English and Malay, where each, is a translated version of the other (chapter 3). The 
Malaysian Patents Act 1983 is unique in the sense that the provisions where the patentability 
of animal inventions can be covered, „combines‟ the scheme of Article 53(b) of the EPC and 
s2 of the Canadian Patent Act 1985. Unlike Article 53(b) and s2 which are the sole provisions 
within which the patentability of animal inventions are to be decided (respectively, in Europe 
and Canada), the Malaysian Patents Act 1983 contains both the definition of the term 
„invention‟ (as in the Canadian Patent Act 1985) and the list of „exceptions to patentability‟ 
(as in the EPC). The reproduction of the relevant provisions of the Malaysian Patents Act 
1983 assists to crystallise this point. 
 
Section 12 on the „Meaning of invention‟ states:  
 
An invention means an idea of an inventor which permits in practice the solution to 
a specific problem in the field of technology. 
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In turn, s13 on „Non-patentable inventions‟ provides:  
 
(1) Notwithstanding the fact that they may be inventions within the meaning of section 
12, the following shall not be patentable: 
. . . 
(b) plant or animal varieties or essentially biological processes for the 
production of plants or animals, other than manmade living micro-organisms, 
micro-biological processes and the products of such micro-organism 
processes; 
. . . 
Provided that this paragraph shall not apply to products used in any such methods. 
(emphasis added) 
 
Based on the foregoing reasons and arguments in this discussion section, the permissive 
approach requires that s13(1)(b) be construed narrowly where patents are to be granted to 
animal inventions (provided they fulfil the patent qualification criteria). In this respect, it is 
useful to assess the role which can be played by s12. In comparison with the term „invention‟ 
under s2 of the Canadian Patent Act 1985, s12 appears to be broader as no restriction is 
imposed on the nature of the inventions involved; either animate or inanimate. Under s12, an 
invention does not have to qualify under any specific category of „art, process, machine, 
composition of matter, or manufacture‟ which have been decided by the Canadian Supreme 
Court to exclude animal inventions (chapter 5). In the context of the thesis, animal 
biotechnology food can fit squarely within the term „invention‟ under the provision, as its 
creation is intrinsically the idea of an inventor and is meant to solve the problems of the 
livestock industry. It is thus capable of industrial application in the patent law sense.
30
  
 
From another perspective, the permissive approach appears to be underpinned by the 
purposive interpretation of patent law which intends to encourage innovation. This legal 
principle of interpretation of statutory provision is not foreign or new in the context of the 
Malaysian legal system. It is a principle of law which is clearly provided by the Malaysian 
                                                          
30
  L. Bently and B. Sherman, Intellectual Property Law (Oxford University Press, 2009) 393. 
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Interpretation Acts 1948 and 1967 (Consolidated and Revised 1989)
31
 and has been 
established by the highest court in Malaysia in many cases over time. Section 17A of the 
Interpretation Act explicitly provides: 
 
In the interpretation of a provision of an Act, a construction that would promote the 
purpose or object underlying the Act (whether that purpose or object is expressly 
stated in the Act of not) shall be preferred to a construction that would not promote 
the purpose or object. 
 
This principle has been recently upheld by the Federal Court in case of Tenaga Nasional 
Berhad v Ong See Teong and Anor,
32
 which, referring to s17A stated:  
 
It is thus abundantly clear that what must prevail is a construction that will promote 
the purpose of an Act. ... The literal rule of construction, whatever the 
qualifications with which it is expressed, must give way to a statutory injunction to 
prefer a construction which would promote the purpose of an Act to one which 
would not, especially where that purpose is set out in the Act.
33
  
 
Arguably this legal principle is applicable to the exclusionary provision as s13(1)(b) where 
the meaning of the term „animal varieties‟ and, therefore, the subject matter of the exclusion 
is unclear. The above principle of interpretation makes the purpose of the Malaysian Patents 
Act 1983 crucial. The objective of the Act has only been generally mentioned as „An Act to 
make better provisions in the law relating to patents and for other matters connected 
therewith‟.34 Notwithstanding this, it is pertinent to note that the Malaysian Patents Act 1983 
is enacted to grant protection to inventors in various industries (intrinsically including the 
livestock industry), and is meant to foster the country‟s economic development (chapter 3). 
This objective justifies the adoption of the permissive approach by Malaysia.  
                                                          
31
Act 388. Available at: Commonwealth Legal Information Institute, 
http://www.commonlii.org/my/legis/consol_act/ia1948a1967ar1989425/ (Accessed: 3 June 2011). 
32
  [2010] 2 CLJ 1.  
33
  ibid. paragraph 6. See also the case of Datuk Seri Ahmad Said Hamdan, Ketua Suruhanjaya, Suruhanjaya 
Pencegahan Rasuah Malaysia & Ors v Tan Boon Wah [2010] 3 MLJ 193 (Court of Appeal) where the court 
reiterated the principle of interpretation under s 17A. 
34
  The preamble of the Malaysian Patents Act 1983. 
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Conclusion 
 
In summary, this thesis proposes no amendment to s13(1)(b) of the Malaysian Patents Act 
1983. Through the adoption of the permissive approach, the exclusion of „animal varieties‟ 
contained in the exclusionary provision should be construed narrowly (in line with the 
permissive approach), so as not to exclude transgenic or cloned animals for food purposes. 
Section 12 of the Malaysian Patents Act 1983 on the meaning of the term „invention‟ 
provides support to this interpretation. The adoption of the permissive approach promises the 
enhancement of the Malaysian animal biotechnology sector and ultimately the growth of the 
livestock industry so as to meet the growing demand for animal protein-based food from 
consumers. Of equal importance, the interpretation ensures that Malaysia fulfils its 
international obligations under Article 27.3(b) of the TRIPs Agreement which requires that 
inventions which could fulfil the patent qualification criteria be protected. Nevertheless, so as 
to further clarify the Malaysian legal position on the issue, it is proposed that, the Guidelines 
for Patent Examination of MyIPO introduce two provisions. Firstly, a provision to the effect 
which extends patent protection to an animal invention as a product and not just the process 
of its production. Secondly, a provision to the effect that „notwithstanding that animals are 
involved in an invention it is patentable provided that the patent qualification criteria under 
s11 of the Malaysian Patents Act 1983 are met‟.35 
 
 
 
 
 
                                                          
35
  For full provision of s11, see Appendix 3. 
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APPENDIX 1 
 
 
NATIONAL BIOTECHNOLOGY POLICY (MALAYSIA) 
 
 
Thrust 1: Agriculture Biotechnology Development 
Transform and enhance the value creation of the agricultural sector through biotechnology 
 
Thrust 2: Healthcare Biotechnology Development 
Capitalize on the strengths of biodiversity to commercialize discoveries in natural products as 
well as position Malaysia in the bio-generics market 
 
Thrust 3: Industrial Biotechnology Development 
Ensure growth oppoortinities in the application of advanced bio-processing and bio-
manufacturing technologies 
 
Thrust 4: R&D and Technology Acquisition 
Establish Centres of Excellence, in existing or new institutions, to bring together 
multidisciplinary research teams in co-ordinated research and commercialization initiatives. 
Accelerate technology development via strategic acquisitions. 
 
Thrust 5: Human Capital Development 
Build the nation‟s biotech human resource capability in line with market needs through 
special schemes, programmes and training 
 
Thrust 6: Financial Intrastructure Development 
Apply competitive “lab to market” funding and incentives to promote committed 
participation by academia, the private sector as well as government-linked companies. 
Implement sufficient exit mechanisms for investments in biotech 
 
Thrust 7: Legislative and Regulatory Framework Development 
Create an enabling environment through continuous reviews of the country‟s regulatory 
framework and procedures in line with global standards and best practices. Develop a strong 
intellectual property  protection regime to support R&D and commercialization efforts 
 
Thrust 8: Strategic Positioning 
Establish a global marketing strategy to build recognition for Malaysian biotech and 
benchmark progress. Establish Malaysia as a centre for Contract Research Organizations and 
Contract Manufacturing Organizations 
 
Thrust 9: Government Commitment 
Establish a dedicated and professional implementation agency overseeing the development of 
Malaysia‟s biotech industry, under the aegis of the Prime Minister and relevant government 
ministries 
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APPENDIX 2 
 
 
BILL OF GUARANTEES (MALAYSIA) 
 
 
Freedom of ownership 
 
Freedom to source funds globally 
 
Freedom to bring in knowledge workers 
 
Eligibility for competitive incentives and other assistance  
 
Eligibility to receive assistance for international accreditations and standards  
 
Strong intellectual property (IP) regime 
 
Access to supportive information network linking research centres of excellence 
 
Access to shared laboratories and other related facilities 
 
BiotechCorp as the one-stop agency 
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APPENDIX 3 
 
 
MALAYSIAN PATENTS ACT 1983 (ACT 291) 
 
 
Part IV 
 
Patentability 
 
Patentable inventions 
 
11.  An invention is patentable if it is new, involves an inventive step and is industrially 
applicable. 
 
Meaning of “invention” 
 
12. (1)  An invention means an idea of an inventor which permits in practice the solution 
to a specific problem in the field of technology. 
 
 (2)  An invention may be or may relate to a product or process. 
 
Non-patentable inventions 
 
13. (1)  Notwithstanding the fact that they may be inventions within the meaning of 
section 12, the following shall not be patentable: 
 
(a) discoveries, scientific theories and mathematical methods; 
 
(b) plant or animal varieties or essentially biological processes for the production of 
plants or animals, other than manmade living micro-organisms, micro-biological 
processes and the products of such micro-organism processes; 
 
(c) schemes, rules or methods for doing business, performing purely mental acts or 
playing games; 
 
(d) methods for the treatment of human or animal body by surgery or therapy, and 
diagnostic methods practised on the human and animal body: 
 
Provided that this paragraph shall not apply to products used in any such methods. 
 
 (2)  For the purpose of subsection (1), in the event of uncertainty as to whether the 
items specified therein shall be patentable or not, the Registrar may refer the matter to the 
Examiner for an opinion and the Registrar shall thereafter give a decision as to whether to 
include or exclude such item as being patentable, as the case may be. 
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Novelty 
 
14.  (1)  An invention is new if it is not anticipated by prior art.  
 
(2)  Prior art shall consist of – 
 
(a) everything disclosed to the public, anywhere in the world, by written publication, 
by oral disclosure, by use or in any other way, prior to the priority date of the 
patent application claiming the invention; 
 
(b)  the contents of a domestic patent application having an earlier priority date than 
the patent application referred to in paragraph (a) to the extent that such contents 
are included in the patent granted on the basis of the said domestic patent 
application.  
 
(3)   A disclosure made under paragraph (2)(a) shall be disregarded – 
 
(a)    if such disclosure occurred within one year preceding the date of the patent 
application and if such disclosure was by reason or in consequence of acts 
committed by the applicant or his predecessor in title;  
 
(b)  if such disclosure occurred within one year preceding the date of the patent 
application and if such disclosure was by reason or in consequence of any abuse 
of the rights of the applicant or his predecessor in title;  
 
(c)   if such disclosure is by way of a pending application to register the patent in the 
United Kingdom Patent Office as at the date of coming into force of this Act.  
 
(4)   The provisions of subsection (2) shall not exclude the patentability of any 
substance or composition, comprised in the prior art, for use in a method referred 
to in paragraph 13(1)(d) , if its use in any such method is not comprised in the 
prior art.  
 
Inventive step 
 
15. An invention shall be considered as involving an inventive step if, having regard to 
any matter which forms part of the prior art under paragraph 14(2)(a), such inventive step 
would not have been obvious to a person having ordinary skill in the art.  
 
Industrial application 
 
16. An invention shall be considered industrially applicable if it can be made or used in any 
kind of industry. 
 
( . . . ) 
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Part VI 
 
Application, procedures for grant and duration 
 
( . . . ) 
 
Grant of patent 
 
31. (1)  The grant of a patent shall not be refused and a patent shall not be invalidated on 
the ground that the performance of any act in respect of the claimed invention is prohibited 
by any law or regulation, except where the performance of that act would be contrary to 
public order or morality. 
 
 (2)  Where the Registrar is satisfied that the application complies with sections 23, 29 
and 30, he shall grant the patent and shall forthwith –  
 
(a)  issue to the applicant a certificate of grant of the patent and a copy of the patent 
together with a copy of the Examiner's final report; and  
 
(b) record the patent in the Register.  
 
(2A)  Where two or more persons have separately and independently made the same 
invention and each of them has made an application for a patent having the same priority date, 
a patent may be granted on each application.  
 
(3)  As soon as possible thereafter the Registrar shall -  
 
(a) cause to be published in the Gazette a reference to the grant of the patent; and  
 
(b)  make available to the public, on payment of the prescribed fee, copies of the 
patent.  
 
(4)  The patent shall be deemed to be granted on the date that the Registrar performs 
the acts referred to in subsection (2). 
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APPENDIX 4 
 
 
AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY 
RIGHTS 1994 (TRIPs Agreement) 
 
 
PART II 
 
Standards concerning the availability, scope and use of intellectual property rights 
 
Section 5 : Patents 
 
Article 27 : Patentable subject matter  
 
1. Subject to the provisions of paragraphs 2 and 3, patents shall be available for any 
inventions, whether products or processes, in all fields of technology, provided that they are 
new, involve an inventive step and are capable of industrial application. Subject to 
paragraph 4 of Article 65, paragraph 8 of Article 70 and paragraph 3 of this Article, patents 
shall be available and patent rights enjoyable without discrimination as to the place of 
invention, the field of technology and whether products are imported or locally produced. 
 
2. Members may exclude from patentability inventions, the prevention within their 
territory of the commercial exploitation of which is necessary to protect ordre public or 
morality, including to protect human, animal or plant life or health or to avoid serious 
prejudice to the environment, provided that such exclusion is not made merely because the 
exploitation is prohibited by their law. 
 
3. Members may also exclude from patentability: 
 
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or 
animals;  
 
(b) plants and animals other than micro-organisms, and essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes. However, Members shall provide for the protection of 
plant varieties either by patents or by an effective sui generis system or by any 
combination thereof. The provisions of this subparagraph shall be reviewed four 
years after the date of entry into force of the WTO Agreement.  
  
Article 28: Rights conferred 
 
1. A patent shall confer on its owner the following exclusive rights: 
 
(a) where the subject matter of a patent is a product, to prevent third parties not 
having the owner‟s consent from the acts of: making, using, offering for sale, 
selling, or importing for these purposes that product;  
 
(b) where the subject matter of a patent is a process, to prevent third parties not 
having the owner‟s consent from the act of using the process, and from the acts 
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of: using, offering for sale, selling, or importing for these purposes at least the 
product obtained directly by that process.  
 
2. Patent owners shall also have the right to assign, or transfer by succession, the patent 
and to conclude licensing contracts. 
  
Article 29 : Conditions on patent applicants 
 
1. Members shall require that an applicant for a patent shall disclose the invention in a 
manner sufficiently clear and complete for the invention to be carried out by a person skilled 
in the art and may require the applicant to indicate the best mode for carrying out the 
invention known to the inventor at the filing date or, where priority is claimed, at the priority 
date of the application. 
 
2. Members may require an applicant for a patent to provide information concerning the 
applicant‟s corresponding foreign applications and grants. 
  
Article 30: Exceptions to rights conferred 
 
Members may provide limited exceptions to the exclusive rights conferred by a patent, 
provided that such exceptions do not unreasonably conflict with a normal exploitation of the 
patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking 
account of the legitimate interests of third parties. 
  
Article 31: Other use without authorization of the right holder 
 
Where the law of a Member allows for other use of the subject matter of a patent without the 
authorization of the right holder, including use by the government or third parties authorized 
by the government, the following provisions shall be respected: 
 
(a) authorization of such use shall be considered on its individual merits;  
 
(b) such use may only be permitted if, prior to such use, the proposed user has made 
efforts to obtain authorization from the right holder on reasonable commercial 
terms and conditions and that such efforts have not been successful within a 
reasonable period of time. This requirement may be waived by a Member in the 
case of a national emergency or other circumstances of extreme urgency or in 
cases of public non-commercial use. In situations of national emergency or other 
circumstances of extreme urgency, the right holder shall, nevertheless, be notified 
as soon as reasonably practicable. In the case of public non-commercial use, 
where the government or contractor, without making a patent search, knows or 
has demonstrable grounds to know that a valid patent is or will be used by or for 
the government, the right holder shall be informed promptly;  
 
(c) the scope and duration of such use shall be limited to the purpose for which it was 
authorized, and in the case of semi-conductor technology shall only be for public 
non-commercial use or to remedy a practice determined after judicial or 
administrative process to be anti-competitive;  
 
(d) such use shall be non-exclusive;  
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(e) such use shall be non-assignable, except with that part of the enterprise or 
goodwill which enjoys such use;  
 
(f) any such use shall be authorized predominantly for the supply of the domestic 
market of the Member authorizing such use;  
 
(g)  authorization for such use shall be liable, subject to adequate protection of the 
legitimate interests of the persons so authorized, to be terminated if and when the 
circumstances which led to it cease to exist and are unlikely to recur. The 
competent authority shall have the authority to review, upon motivated request, 
the continued existence of these circumstances;  
 
(h)  the right holder shall be paid adequate remuneration in the circumstances of each 
case, taking into account the economic value of the authorization;  
 
(i) the legal validity of any decision relating to the authorization of such use shall be 
subject to judicial review or other independent review by a distinct higher 
authority in that Member;  
 
(j)  any decision relating to the remuneration provided in respect of such use shall be 
subject to judicial review or other independent review by a distinct higher 
authority in that Member;  
 
(k)  Members are not obliged to apply the conditions set forth in subparagraphs (b) 
and (f) where such use is permitted to remedy a practice determined after judicial 
or administrative process to be anti-competitive. The need to correct anti-
competitive practices may be taken into account in determining the amount of 
remuneration in such cases. Competent authorities shall have the authority to 
refuse termination of authorization if and when the conditions which led to such 
authorization are likely to recur;  
 
(l)  where such use is authorized to permit the exploitation of a patent (“the second 
patent”) which cannot be exploited without infringing another patent (“the first 
patent”), the following additional conditions shall apply:  
 
(i) the invention claimed in the second patent shall involve an important 
technical advance of considerable economic significance in relation to the 
invention claimed in the first patent;  
 
(ii) the owner of the first patent shall be entitled to a cross-licence on 
reasonable terms to use the invention claimed in the second patent; and  
 
(iii) the use authorized in respect of the first patent shall be non-assignable 
except with the assignment of the second patent.  
 
Article 32: Revocation/Forfeiture 
  
An opportunity for judicial review of any decision to revoke or forfeit a patent shall be 
available. 
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Article 33: Term of protection 
 
The term of protection available shall not end before the expiration of a period of twenty 
years counted from the filing date. 
  
Article 34: Process patents – burden of proof 
 
1. For the purposes of civil proceedings in respect of the infringement of the rights of the 
owner referred to in paragraph 1(b) of Article 28, if the subject matter of a patent is a process 
for obtaining a product, the judicial authorities shall have the authority to order the defendant 
to prove that the process to obtain an identical product is different from the patented process. 
Therefore, Members shall provide, in at least one of the following circumstances, that any 
identical product when produced without the consent of the patent owner shall, in the absence 
of proof to the contrary, be deemed to have been obtained by the patented process: 
 
(a) if the product obtained by the patented process is new;  
 
(b) if there is a substantial likelihood that the identical product was made by the 
process and the owner of the patent has been unable through reasonable efforts to 
determine the process actually used.  
 
2. Any Member shall be free to provide that the burden of proof indicated in paragraph 1 
shall be on the alleged infringer only if the condition referred to in subparagraph (a) is 
fulfilled or only if the condition referred to in subparagraph (b) is fulfilled. 
 
3. In the adduction of proof to the contrary, the legitimate interests of defendants in 
protecting their manufacturing and business secrets shall be taken into account.  
 
( . . . ) 
 
PART IV 
 
Acquisition and maintenance of intellectual property rights and related inter-partes 
procedures 
 
Article 62 
1.     Members may require, as a condition of the acquisition or maintenance of the 
intellectual property rights provided for under Sections 2 through 6 of Part II, compliance 
with reasonable procedures and formalities. Such procedures and formalities shall be 
consistent with the provisions of this Agreement. 
2.     Where the acquisition of an intellectual property right is subject to the right being 
granted or registered, Members shall ensure that the procedures for grant or registration, 
subject to compliance with the substantive conditions for acquisition of the right, permit the 
granting or registration of the right within a reasonable period of time so as to avoid 
unwarranted curtailment of the period of protection. 
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3.     Article 4 of the Paris Convention (1967) shall apply mutatis mutandis to service marks.  
4.     Procedures concerning the acquisition or maintenance of intellectual property rights 
and, where a Member's law provides for such procedures, administrative revocation and 
inter partes procedures such as opposition, revocation and cancellation, shall be governed by 
the general principles set out in paragraphs 2 and 3 of Article 41. 
5.     Final administrative decisions in any of the procedures referred to under paragraph 4 
shall be subject to review by a judicial or quasi-judicial authority. However, there shall be no 
obligation to provide an opportunity for such review of decisions in cases of unsuccessful 
opposition or administrative revocation, provided that the grounds for such procedures can be 
the subject of invalidation procedures. 
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APPENDIX 5 
 
 
EUROPEAN PATENT CONVENTION 2010 
 
 
PART II 
 
Substantive patent law 
 
Article 52: Patentable invention 
 
(1)  European patents shall be granted for any inventions, in all fields of technology, 
provided that they are new, involve an inventive step and are susceptible of industrial 
application.  
 
(2)  The following in particular shall not be regarded as inventions within the meaning of 
paragraph 1: 
 
(a)  discoveries, scientific theories and mathematical methods;  
(b)  aesthetic creations;  
(c)  schemes, rules and methods for performing mental acts, playing games or doing   
business, and programs for computers;  
(d)  presentations of information.  
 
(3)  Paragraph 2 shall exclude the patentability of the subject-matter or activities referred 
to therein only to the extent to which a European patent application or European patent 
relates to such subject-matter or activities as such. 
 
Article 53: Exceptions to patentability 
 
European patents shall not be granted in respect of:   
 
(a) inventions the commercial exploitation of which would be contrary to "ordre 
public" or morality; such exploitation shall not be deemed to be so contrary 
merely because it is prohibited by law or regulation in some or all of the 
Contracting States;   
 
(b) plant or animal varieties or essentially biological processes for the production of 
plants or animals; this provision shall not apply to microbiological processes or 
the products thereof;  
 
(c) methods for treatment of the human or animal body by surgery or therapy and 
diagnostic methods practised on the human or animal body; this provision shall 
not apply to products, in particular substances or compositions, for use in any of 
these methods. 
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Article 54: Novelty 
 
(1) An invention shall be considered to be new if it does not form part of the state of the 
art.  
 
(2) The state of the art shall be held to comprise everything made available to the public by 
means of a written or oral description, by use, or in any other way, before the date of filing of 
the European patent application.  
 
(3) Additionally, the content of European patent applications as filed, the dates of filing of 
which are prior to the date referred to in paragraph 2 and which were published on or after 
that date, shall be considered as comprised in the state of the art. 
 
(4) Paragraphs 2 and 3 shall not exclude the patentability of any substance or composition, 
comprised in the state of the art, for use in a method referred to in Article 53(c), provided that 
its use for any such method is not comprised in the state of the art. 
 
(5) Paragraphs 2 and 3 shall also not exclude the patentability of any substance or 
composition referred to in paragraph 4 for any specific use in a method referred to in 
Article 53(c), provided that such use is not comprised in the state of the art. 
 
Article 55: Non-prejudicial disclosures 
 
(1) For the application of Article 54, a disclosure of the invention shall not be taken into 
consideration if it occurred no earlier than six months preceding the filing of the European 
patent application and if it was due to, or in consequence of: 
 
(a) an evident abuse in relation to the applicant or his legal predecessor, or  
 
(b) the fact that the applicant or his legal predecessor has displayed the invention at 
an official, or officially recognised, international exhibition falling within the 
terms of the Convention on international exhibitions signed at Paris on 
22 November 1928 and last revised on 30 November 1972.  
 
(2) In the case of paragraph 1(b), paragraph 1 shall apply only if the applicant states, when 
filing the European patent application, that the invention has been so displayed and files a 
supporting certificate within the time limit and under the conditions laid down in the 
Implementing Regulations. 
 
Article 56: Inventive step 
 
An invention shall be considered as involving an inventive step if, having regard to the state 
of the art, it is not obvious to a person skilled in the art. If the state of the art also includes 
documents within the meaning of Article 54, paragraph 3, these documents shall not be 
considered in deciding whether there has been an inventive step. 
 
Article 57: Industrial application 
 
An invention shall be considered as susceptible of industrial application if it can be made or 
used in any kind of industry, including agriculture.  
306 
 
APPENDIX 6 
 
DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE 
COUNCIL OF 6 JULY 1998 ON THE LEGAL PROTECTION OF 
BIOTECHNOLOGICAL INVENTIONS (EU Biotechnology Directive) 
 
( . . . ) 
 
Recital 29: 
 
Whereas this Directive is without prejudice to the exclusion of plant and animal 
varieties from patentability; whereas on the other hand inventions which concern 
plants or animals are patentable provided that the application of the invention is not 
technically confined to a single plant or animal variety; 
 
( . . . ) 
 
CHAPTER I - Patentability 
 
Article 1  
 
1.  Member States shall protect biotechnological inventions under national patent law. 
They shall, if necessary, adjust their national patent law to take account of the provisions of 
this Directive. 
 
2.  This Directive shall be without prejudice to the obligations of the Member States 
pursuant to international agreements, and in particular the TRIPs Agreement and the 
Convention on Biological Diversity. 
 
Article 2  
 
1.  For the purposes of this Directive, 
(a)  'biological material` means any material containing genetic information and 
capable of reproducing itself or being reproduced in a biological system; 
(b)  'microbiological process` means any process involving or performed upon or 
resulting in microbiological material. 
 
2.  A process for the production of plants or animals is essentially biological if it consists 
entirely of natural phenomena such as crossing or selection. 
 
3.  The concept of 'plant variety` is defined by Article 5 of Regulation (EC) No 2100/94. 
 
Article 3  
 
1.  For the purposes of this Directive, inventions which are new, which involve an 
inventive step and which are susceptible of industrial application shall be patentable even if 
they concern a product consisting of or containing biological material or a process by means 
of which biological material is produced, processed or used. 
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2.  Biological material which is isolated from its natural environment or produced by 
means of a technical process may be the subject of an invention even if it previously occurred 
in nature. 
 
Article 4  
 
1.  The following shall not be patentable: 
 
(a) plant and animal varieties; 
(b) essentially biological processes for the production of plants or animals. 
 
2.  Inventions which concern plants or animals shall be patentable if the technical 
feasibility of the invention is not confined to a particular plant or animal variety. 
 
3.  Paragraph 1(b) shall be without prejudice to the patentability of inventions which 
concern a microbiological or other technical process or a product obtained by means of such a 
process. 
 
Article 5  
 
1.  The human body, at the various stages of its formation and development, and the simple 
discovery of one of its elements, including the sequence or partial sequence of a gene, cannot 
constitute patentable inventions. 
 
2.  An element isolated from the human body or otherwise produced by means of a 
technical process, including the sequence or partial sequence of a gene, may constitute a 
patentable invention, even if the structure of that element is identical to that of a natural 
element. 
 
3.  The industrial application of a sequence or a partial sequence of a gene must be 
disclosed in the patent application. 
 
Article 6 
 
1.  Inventions shall be considered unpatentable where their commercial exploitation would 
be contrary to ordre public or morality; however, exploitation shall not be deemed to be so 
contrary merely because it is prohibited by law or regulation. 
 
2.  On the basis of paragraph 1, the following, in particular, shall be considered 
unpatentable: 
 
(a)  processes for cloning human beings; 
(b)  processes for modifying the germ line genetic identity of human beings; 
(c)  uses of human embryos for industrial or commercial purposes; 
(d) processes for modifying the genetic identity of animals which are likely to cause 
them suffering without any substantial medical benefit to man or animal, and also 
animals resulting from such processes. 
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Article 7  
 
The Commission's European Group on Ethics in Science and New Technologies evaluates all 
ethical aspects of biotechnology. 
 
 
CHAPTER II - Scope of protection 
 
Article 8  
 
1.  The protection conferred by a patent on a biological material possessing specific 
characteristics as a result of the invention shall extend to any biological material derived from 
that biological material through propagation or multiplication in an identical or divergent 
form and possessing those same characteristics. 
 
2.  The protection conferred by a patent on a process that enables a biological material to 
be produced possessing specific characteristics as a result of the invention shall extend to 
biological material directly obtained through that process and to any other biological material 
derived from the directly obtained biological material through propagation or multiplication in 
an identical or divergent form and possessing those same characteristics. 
 
Article 9  
 
The protection conferred by a patent on a product containing or consisting of genetic 
information shall extend to all material, save as provided in Article 5(1), in which the product 
in incorporated and in which the genetic information is contained and performs its function. 
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APPENDIX 7 
 
IMPLEMENTING REGULATIONS TO THE CONVENTION ON THE GRANT OF 
EUROPEAN PATENTS (Implementing Regulations to the EPC) 
 
 
 
CHAPTER 5 – Biotechnological inventions 
 
  
Rule 26: General and definitions 
 
(1)  For European patent applications and patents concerning biotechnological inventions, 
the relevant provisions of the Convention shall be applied and interpreted in accordance with 
the provisions of this Chapter. Directive 98/44/EC of 6 July 1998 on the legal protection of 
biotechnological inventions shall be used as a supplementary means of interpretation. 
 
(2)  "Biotechnological inventions" are inventions which concern a product consisting of or 
containing biological material or a process by means of which biological material is produced, 
processed or used.  
 
(3)  "Biological material" means any material containing genetic information and capable 
of reproducing itself or being reproduced in a biological system.  
 
(4)  "Plant variety" means any plant grouping within a single botanical taxon of the lowest 
known rank, which grouping, irrespective of whether the conditions for the grant of a plant 
variety right are fully met, can be:  
 
(a)   defined by the expression of the characteristics that results from a given genotype 
or combination of genotypes,   
(b)  distinguished from any other plant grouping by the expression of at least one of 
the said characteristics, and  
(c)  considered as a unit with regard to its suitability for being propagated unchanged.  
 
(5)  A process for the production of plants or animals is essentially biological if it consists 
entirely of natural phenomena such as crossing or selection.  
 
(6)  "Microbiological process" means any process involving or performed upon or resulting 
in microbiological material.  
 
Rule 27: Patentable biotechnological inventions 
 
Biotechnological inventions shall also be patentable if they concern:  
 
(a)  biological material which is isolated from its natural environment or produced by 
means of a technical process even if it previously occurred in nature;  
 
(b)  plants or animals if the technical feasibility of the invention is not confined to a 
particular plant or animal variety;  
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(c) a microbiological or other technical process, or a product obtained by means of such a 
process other than a plant or animal variety.  
 
Rule 28: Exceptions to patentability 
 
Under Article 53(a), European patents shall not be granted in respect of biotechnological 
inventions which, in particular, concern the following: 
 
(a) processes for cloning human beings;  
 
(b) processes for modifying the germ line genetic identity of human beings;  
 
(c) uses of human embryos for industrial or commercial purposes;  
 
(d) processes for modifying the genetic identity of animals which are likely to cause them 
suffering without any substantial medical benefit to man or animal, and also animals resulting 
from such processes.  
 
Rule 29: The human body and its elements 
 
(1)  The human body, at the various stages of its formation and development, and the 
simple discovery of one of its elements, including the sequence or partial sequence of a gene, 
cannot constitute patentable inventions.  
 
(2)  An element isolated from the human body or otherwise produced by means of a 
technical process, including the sequence or partial sequence of a gene, may constitute a 
patentable invention, even if the structure of that element is identical to that of a natural 
element.  
 
(3) The industrial application of a sequence or a partial sequence of a gene must be 
disclosed in the patent application.  
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APPENDIX 8 
 
 
CANADIAN PATENT ACT 1985 (PATENT ACT, R.S.C, 1985, c.P-4) 
 
 
Interpretation 
 
Definitions 
 
2. In this Act, except as otherwise provided, 
 
“invention” means any new and useful art, process, machine, manufacture or composition of 
matter, or any new and useful improvement in any art, process, machine, manufacture or 
composition of matter; 
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APPENDIX 9 
 
 
UNITED KINGDOM PATENTS ACT 1977 
 
 
PART 1 
 
New Domestic Law 
 
Patentability 
 
  
1. Patentable inventions  
 
(1)  A patent may be granted only for an invention in respect of which the following 
conditions are satisfied, that is to say -  
 
(a)  the invention is new;  
(b)  it involves an inventive step;  
(c)  it is capable of industrial application;  
(d)  the grant of a patent for it is not excluded by subsections (2) and (3) or section 4A 
below;  
and references in this Act to a patentable invention shall be construed accordingly.  
 
(2)  It is hereby declared that the following (among other things) are not inventions for the 
purposes of this Act, that is to say, anything which consists of -  
 
(a)  a discovery, scientific theory or mathematical method;  
(b)  a literary, dramatic, musical or artistic work or any other aesthetic creation 
whatsoever;  
(c)  a scheme, rule or method for performing a mental act, playing a game or doing 
business, or a program for a computer;  
(d)  the presentation of information;  
 
but the foregoing provision shall prevent anything from being treated as an invention for the 
purposes of this Act only to the extent that a patent or application for a patent relates to that 
thing as such.  
 
(3)  A patent shall not be granted for an invention the commercial exploitation of which 
would be contrary to public policy or morality.  
 
(4)  For the purposes of subsection (3) above exploitation shall not be regarded as contrary 
to public policy or morality only because it is prohibited by any law in force in the United 
Kingdom or any part of it.  
 
(5)  The Secretary of State may by order vary the provisions of subsection (2) above for the 
purpose of maintaining them in conformity with developments in science and technology; 
and no such order shall be made unless a draft of the order has been laid before, and approved 
by resolution of, each House of Parliament.  
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2. Novelty  
 
(1)  An invention shall be taken to be new if it does not form part of the state of the art.  
 
(2) The state of the art in the case of an invention shall be taken to comprise all matter 
(whether a product, a process, information about either, or anything else) which has at any 
time before the priority date of that invention been made available to the public (whether in 
the United Kingdom or elsewhere) by written or oral description, by use or in any other way.  
 
(3) The state of the art in the case of an invention to which an application for a patent or a 
patent relates shall be taken also to comprise matter contained in an application for another 
patent which was published on or after the priority date of that invention, if the following 
conditions are satisfied, that is to say –  
 
(a) that matter was contained in the application for that other patent both as filed and 
as published; and  
 
(b)  the priority date of that matter is earlier than that of the invention.  
 
(4)  For the purposes of this section the disclosure of matter constituting an invention shall 
be disregarded in the case of a patent or an application for a patent if occurring later than the 
beginning of the period of six months immediately preceding the date of filing the application 
for the patent and either -  
 
(a)  the disclosure was due to, or made in consequence of, the matter having been 
obtained unlawfully or in breach of confidence by any person  
 
(i)  from the inventor or from any other person to whom the matter was made 
available in confidence by the inventor or who obtained it from the inventor 
because he or the inventor believed that he was entitled to obtain it; or  
 
(ii)  from any other person to whom the matter was made available in 
confidence by any person mentioned in sub-paragraph (i) above or in this 
sub-paragraph or who obtained it from any person so mentioned because he 
or the person from whom he obtained it believed that he was entitled to 
obtain it;  
 
(b)  the disclosure was made in breach of confidence by any person who obtained the 
matter in confidence from the inventor or from any other person to whom it was 
made available, or who obtained it, from the inventor; or  
 
 (c)  the disclosure was due to, or made in consequence of the inventor displaying the 
invention at an international exhibition and the applicant states, on filing the 
application, that the invention has been so displayed and also, within the 
prescribed period, files written evidence in support of the statement complying 
with any prescribed conditions.  
 
(5)  In this section references to the inventor include references to any proprietor of the 
invention for the time being.  
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(6)  [repealed]  
 
3.  Inventive step  
 
An invention shall be taken to involve an inventive step if it is not obvious to a person skilled 
in the art, having regard to any matter which forms part of the state of the art by virtue only 
of section 2(2) above (and disregarding section 2(3) above).  
 
4. Industrial application  
 
(1)  An invention shall be taken to be capable of industrial application if it can be made or 
used in any kind of industry, including agriculture.  
 
(2) [repealed]  
 
(3) [repealed] 
 
( . . . ) 
 
General provisions as to amendment of patents and applications 
 
( . . . ) 
 
76A. Biotechnological inventions  
 
(1) Any provision of, or made under, this Act is to have effect in relation to a patent or an 
application for a patent which concerns a biotechnological invention, subject to the 
provisions of Schedule A2.  
 
(2)  Nothing in this section or Schedule A2 is to be read as affecting the application of any 
provision in relation to any other kind of patent or application for a patent. 
 
( . . . ) 
 
SCHEDULE A2 (section 76A) 
 
BIOTECHNOLOGICAL INVENTIONS 
 
1.  An invention shall not be considered unpatentable solely on the ground that it concerns-   
 
(a) a product consisting of or containing biological material; or  
(b) a process by which biological material is produced, processed or used.  
 
2.  Biological material which is isolated from its natural environment or produced by 
means of a technical process may be the subject of an invention even if it previously occurred 
in nature.  
 
3.  The following are not patentable inventions -  
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(a)  the human body, at the various stages of its formation and development, and the 
simple discovery of one of its elements, including the sequence or partial 
sequence of a gene;  
(b)  processes for cloning human beings;  
(c)  processes for modifying the germ line genetic identity of human beings;  
(d)  uses of human embryos for industrial or commercial purposes;  
(e)  processes for modifying the genetic identity of animals which are likely to cause 
them suffering without any substantial medical benefit to man or animal, and also 
animals resulting from such processes;  
(f)  any variety of animal or plant or any essentially biological process for the 
production of animals or plants, not being a micro-biological or other technical 
process or the product of such a process.  
 
4.  Inventions which concern plants or animals may be patentable if the technical 
feasibility of the invention is not confined to a particular plant or animal variety.  
 
5.  An element isolated from the human body or otherwise produced by means of a 
technical process, including the sequence or partial sequence of a gene, may constitute a 
patentable invention, even if the structure of that element is identical to that of a natural 
element.  
 
6.  The industrial application of a sequence or partial sequence of a gene must be disclosed 
in the patent application as filed.  
 
7.  The protection conferred by a patent on a biological material possessing specific 
characteristics as a result of the invention shall extend to any biological material derived from 
that biological material through propagation or multiplication in an identical or divergent 
form and possessing those same characteristics.  
 
8.  The protection conferred by a patent on a process that enables a biological material to 
be produced possessing specific characteristics as a result of the invention shall extend to 
biological material directly obtained through that process and to any other biological material 
derived from the directly obtained biological material through propagation or multiplication 
in an identical or divergent form and possessing those same characteristics.  
 
9.  The protection conferred by a patent on a product containing or consisting of genetic 
information shall extend to all material, save as provided for in paragraph 3(a) above, in 
which the product is incorporated and in which the genetic information is contained and 
performs its function.  
 
10.  The protection referred to in paragraphs 7, 8 and 9 above shall not extend to biological 
material obtained from the propagation or multiplication of biological material placed on the 
market by the proprietor of the patent or with his consent, where the multiplication or 
propagation necessarily results from the application for which the biological material was 
marketed, provided that the material obtained is not subsequently used for other propagation 
or multiplication.  
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11.  In this Schedule:  
 
“essentially biological process” means a process for the production of animals and plants 
which consists entirely of natural phenomena such as crossing and selection;  
 
“microbiological process” means any process involving or performed upon or resulting in 
microbiological material;  
 
“plant variety” means a plant grouping within a single botanical taxon of the lowest known 
rank, which grouping can be:  
 
(a)  defined by the expression of the characteristics that results from a given genotype 
or combination of genotypes; and  
 
(b)  distinguished from any other plant grouping by the expression of at least one of 
the said characteristics; and  
 
(c)  considered as a unit with regard to its suitability for being propagated unchanged. 
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